Human Blood Group Systems and Haemoglobinopathies by unknown
Human Blood Group Systems 
and Haemoglobinopathies
Edited by Osaro Erhabor  
and Anjana Munshi
Edited by Osaro Erhabor  
and Anjana Munshi
The past decade has seen remarkable improvements and advances in the fields of 
blood transfusion and hematology, particularly with regards to advances in science, 
technology, method development, quality, standardization, and governance. This 
book provides more evidenced-based insight into the field of blood transfusion and the 
management of hemoglobinopathies.
Published in London, UK 
©  2021 IntechOpen 











Group Systems and 
Haemoglobinopathies
Edited by Osaro Erhabor  
and Anjana Munshi
Published in London, United Kingdom

Supporting open minds since 2005
Human Blood Group Systems and Haemoglobinopathies
http://dx.doi.org/10.5772/intechopen.82992
Edited by Osaro Erhabor and Anjana Munshi
Contributors
Bruna Policiquio, Vivian Gonzaga, Cristiane Wenceslau, Irina Kerkis, Fatima A. Aldarweesh, Jolanta 
Korsak, Anna Piotrowska, Osaro Erhabor, Teddy Charles Adias, Tosan Erhabor, Iwueke Ikechukwu, 
Maria Rios, Emilia Sippert, Evgeniya Volkova, Rocio Aguilar-Quesada, Veronica Valdivieso-Gomez, 
Javier Garrancho-Pérez, Inés Aroca-Siendones, Hassan Njifon Nsangou, Régine Scelles, Vincent Kabwe 
Mulunda-A-Mulunda, Pierre Kouam, Taty Oke Ingwen, Parijat De, Jessica Siew Hua Lee, Kinda Al-
Hourani, Edith Christiane Christianne Bougouma, Sodiomon Bienvenu Sirima
© The Editor(s) and the Author(s) 2021
The rights of the editor(s) and the author(s) have been asserted in accordance with the Copyright, 
Designs and Patents Act 1988. All rights to the book as a whole are reserved by INTECHOPEN LIMITED. 
The book as a whole (compilation) cannot be reproduced, distributed or used for commercial or 
non-commercial purposes without INTECHOPEN LIMITED’s written permission. Enquiries concerning 
the use of the book should be directed to INTECHOPEN LIMITED rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons 
Attribution 3.0 Unported License which permits commercial use, distribution and reproduction of 
the individual chapters, provided the original author(s) and source publication are appropriately 
acknowledged. If so indicated, certain images may not be included under the Creative Commons 
license. In such cases users will need to obtain permission from the license holder to reproduce 
the material. More details and guidelines concerning content reuse and adaptation can be found at 
http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not 
necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of 
information contained in the published chapters. The publisher assumes no responsibility for any 
damage or injury to persons or property arising out of the use of any materials, instructions, methods 
or ideas contained in the book.
First published in London, United Kingdom, 2021 by IntechOpen
IntechOpen is the global imprint of INTECHOPEN LIMITED, registered in England and Wales, 
registration number: 11086078, 5 Princes Gate Court, London, SW7 2QJ, United Kingdom
Printed in Croatia
British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library
Additional hard and PDF copies can be obtained from orders@intechopen.com
Human Blood Group Systems and Haemoglobinopathies




eBook (PDF) ISBN 978-1-83881-969-9
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
5,200+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books









IN D E X E D

Meet the editors
Professor Erhabor Osaro is a Chartered Scientist and fellow 
of the Institute of Biomedical Science of London. He holds a 
Ph.D. in Immunohematology from the Rivers State University of 
Science and Technology, Nigeria. He completed the University 
of Greenwich, UK Specialist Training in Blood Transfusion and 
Laboratory Quality Management System. He holds a Special-
ist Certificate in Transfusion Science Practice from the British 
Blood Transfusion Society (BBTS). He is also an alumnus of Francis Tuttle College 
of Technology in Oklahoma, USA. His teaching experience spans both the African 
continent and Europe. Dr. Osaro is the chair of the equality and diversity working 
group of the BBTS and recipient of the Margaret Kenwright Scientist award from 
the same organization. He is a registered portfolio verifier/examiner for the Insti-
tute of Biomedical Science of London. He has authored five scientific books and five 
book chapters. A well-published contributor with more than 160 published articles 
in the fields of infectious diseases, occupational health, immunohematology, and 
transfusion medicine, Dr. Osaro is also an editorial board member and reviewer for 
several international scientific journals. 
Professor Anjana Munshi, M.Sc, M.Phil, Ph.D., is head of the 
Department of Human Genetics and Molecular Medicine at the 
Central University of Punjab, Bathinda, Punjab, India. She is also 
Dean for the School of Health Sciences and Dean of Research at 
the Central University of Punjab. Her expertise includes stroke 
genetics, hemoglobinopathies, pharmacogenetics, molecular 
cancer biology, epilepsy and bioinformatics. She has published 
125 papers in international peer reviewed journals and contributed to 20 book 
chapters in books published by reputed international publishing houses. She is a 






Inherited Disorders of Hemoglobin and Plasmodium falciparum Malaria
by Edith Christiane Bougouma and Sodiomon Bienvenu Sirima
Chapter 2 39
Sickle Cell Anemia, Representations and Care: Experience of a Brother 
of a Sick Child in Cameroon
by Hassan Njifon Nsangou and Régine Scelles
Chapter 3 59
Investigation and Management of Endocrinopathies in Thalassaemia Major




The Duffy Blood Group System
by Fatima A. Aldarweesh
Chapter 5 91
Post-Transfusion Haemolytic Reactions
by Jolanta Korsak and Anna Piotrowska
Chapter 6 113
Distribution of Clinically Relevant Blood Group Antigens among Nigerians  
and the Management of Rhesus D Negative Pregnancies: Implications for 
Haemolytic Disease of the Foetus and Newborn and Haemolytic Transfusion 
Reactions
by Osaro Erhabor, Tosan Erhabor, Teddy Charles Adias  






Inherited Disorders of Hemoglobin and Plasmodium falciparum Malaria
by Edith Christiane Bougouma and Sodiomon Bienvenu Sirima
Chapter 2 39
Sickle Cell Anemia, Representations and Care: Experience of a Brother 
of a Sick Child in Cameroon
by Hassan Njifon Nsangou and Régine Scelles
Chapter 3 59
Investigation and Management of Endocrinopathies in Thalassaemia Major




The Duffy Blood Group System
by Fatima A. Aldarweesh
Chapter 5 91
Post-Transfusion Haemolytic Reactions
by Jolanta Korsak and Anna Piotrowska
Chapter 6 113
Distribution of Clinically Relevant Blood Group Antigens among Nigerians  
and the Management of Rhesus D Negative Pregnancies: Implications for 
Haemolytic Disease of the Foetus and Newborn and Haemolytic Transfusion 
Reactions
by Osaro Erhabor, Tosan Erhabor, Teddy Charles Adias  





Alternative Immune-Mediated-Based Methods in the Aplastic  
Anemia Treatment
by Vivian Gonzaga, Bruna Policiquio, Cristiane Wenceslau and Irina Kerkis
Chapter 8 167
Harmonized and Quality Sample Handling in Biobank-Supported  
Multicenter Prospective Studies
by Verónica Valdivieso-Gómez, Javier Garrancho-Pérez, Inés Aroca-Siendones  
and Rocío Aguilar-Quesada
Chapter 9 179
Contribution of Biomedical Equipment Management to Better  
Management of Sickle Cell Disease in Africa
by Vincent Mulunda-a-Mulunda, Pierre Kouam and Taty Oke Ingwen
Chapter 10 201
Accuracy of Blood Group Typing in the Management and Prevention  
of Alloimmunization
by Emilia Sippert, Evgeniya Volkova and Maria Rios
Preface
Blood transfusion and hematology are associated with significant advances in 
science and technology. This book provides a comprehensive overview of some 
clinically significant blood group systems, hemolytic blood transfusion reactions, 
and hemoglobinopathies. The aim of this book is to empower biomedical, clinical, 
and allied medical professionals with the tools required for evidenced-based best 
practice in the field of blood transfusion and management of hemoglobinopathies.
Osaro Erhabor,
Professor,
Usmanu Danfodiyo University Sokoto,
Nigeria
Anjana Munshi




Blood transfusion and hematology are associated with significant advances in 
science and technology. This book provides a comprehensive overview of some 
clinically significant blood group systems, hemolytic blood transfusion reactions, 
and hemoglobinopathies. The aim of this book is to empower biomedical, clinical, 
and allied medical professionals with the tools required for evidenced-based best 
practice in the field of blood transfusion and management of hemoglobinopathies.
Osaro Erhabor,
Professor,
Usmanu Danfodiyo University Sokoto,
Nigeria
Anjana Munshi












Edith Christiane Bougouma and Sodiomon Bienvenu Sirima
Abstract
An estimated 300,000 babies are born each year with severe Inherited Disorders
of Hemoglobin (IDH). Despite major advances in the understanding of the molec-
ular pathology, control, and management of the IDH thousands of infants and
children with these diseases are dying due to the accessibility to appropriate medical
care. In addition, as malaria has been the principal cause of early mortality in several
parts of the world for much of the last 5000 years, as a result, it is the strongest
force for selective pressure on the human genome. That is why, in the world, there
is an overlap of malaria endemicity and IDH. Over the past twenty years several
studies have shown that IDH such us hemoglobin and/or red cell membrane abnor-
malities confer resistance to malaria reducing hence the mortality during the first
years of life. This has led to the selection of populations with IDH in malaria-
endemic areas. This may explain the overlap between these two pathologies. This
chapter aims to present the relationship between IDH and malaria susceptibility,
make an overview of the current state of knowledge and the burden of IDH, and
highlight steps that require to be taken urgently to improve the situation.
Keywords: Hemoglobin, Inherited Disorders, malaria, host genetics
1. Introduction
Despite health better care and new strategies of disease control of, mortality
remains high in many countries and worldwide [1]. Malaria is the biggest cause of
childhood mortality in Africa.
In 2018, malaria was the cause of about 405 000 deaths, More than 90% of these
deaths occurred in sub-Saharan Africa [2].
Malaria parasites enter red blood cells during key stages of their life cycle so that
there is no surprise that a change of red blood structures or make-up could affect
malaria infection. Some changes of red blood cells make more resistant to malaria
infection whereas others create the potential for a harmful reaction to certain
antimalarial drugs [3].
Falciparummalaria has had a profound effect on human evolution, evidenced by
the high frequencies of malaria protective mutations observed in populations from
historically malarious regions. This big pressure has resulted in the selection of
many genetic variants that confer protection against severe malaria and reducing
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Human Blood Group Systems and Haemoglobinopathies
The high mortality and widespread impact of malaria have resulted in this
disease being the strongest evolutionary selective force in recent human history,
and genes that confer resistance to malaria [7].
The history of genetics and the study of malaria are much linked. Indeed
Burden of disease due to malaria across much of the world has selected for a series
of traits, including the alleles of genes encoding hemoglobin, red cell enzymes,
and membrane proteins.
Each year more than 7000000 babies born with either a congenital abnormality
and/or a genetic disease, mainly (up to 90%) in low or middle-income countries [8].
About 25% of these births consist of five disorders, two of which, the inherited
disorders of hemoglobin and glucose-6-phosphate dehydrogenase (G6PD)
deficiency, are monogenic diseases [8].
In recent years there has been a major revival in scientific studies interest in the
study of interactions between the inherited hemoglobin disorders and P. falciparum
malaria, work that has been the subject of several extensive reviews [5, 9, 10].
This chapter focuses on IDH that are common enough to be of public health con-
cern particularly those significantly associated withmalaria as summarized inTable 1.
By presenting the relationship between IDH and malaria susceptibility, making
an overview of the current state of knowledge and the burden of IDH, this chapter
outline some of the more important protective genetic variants that have been
identified as far as summarized in the Table 1. The knowledge of our understanding
of the interaction between hemoglobin variants and malaria could give point to
novel preventive and/or therapeutic approaches.
2. Inherited disorders of hemoglobin (IDH) and Plasmodium falciparum
(P. falciparum) malaria
2.1 Brief review of malaria infection
Malaria is a severe infectious disease caused by parasites of the genus Plasmo-
dium. Plasmodium is one of the longest-known parasites, which are transmitted to
humans by a bite of an infected female mosquito of the species Anopheles.
Indeed, after inoculation into a human by a mosquito, the P. falciparum parasites
enter the erythrocytic stage of their life cycle after a brief silent incubation in life
(Figure 2). It is during this time that parasites sequentially invade and egress from
their host RBCs and cause the signs and symptoms of malaria. Hemoglobin is the
oxygen - carrying component and major protein of the RBC [11]. Indeed, the RBC is
essential for the spread of malaria parasites, as summarized in Figures 2 and 3.
Despite progress towards its control of malaria, it is still the most important
parasitic disease and then, one of the world’s worst health problems. In 2018, about
228 million cases of malaria occurred worldwide. Most of these cases (93%) occurred
in African Africa region In the same year malaria was responsible for 405 000 deaths
made up to 67% (272000) of children under 5 years recognized as the most vulnera-
ble group [12]. However, early diagnosis and fast-acting treatment prevent unwanted
outcomes. Until recently it was thought that only four species of malarial parasite
(Plasmodium) especially Plasmodium. falciparum (P. falciparum), Plasmodium.vivax
(P.vivax), Plasmodium. malariae (P.malariae), and Plasmoduim. ovale (P.ovale), have
humans as their natural hosts. But, it has been found that many cases of malaria that
were previously diagnosed as being due to P. malariae infection are in fact due to a
fifth parasite, Plasmodium. knowlesi (P. knowlesi)mostly in Malaysia [13].
It has long been thought that P. falciparum was the only cause of severe malaria
cases and deaths, until the equally destructive, if not worse, the role of P. vivax is
7
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gradually highlighted and established especially in South East Asia and in Latin
America [2, 14–16].
Regarding the relationship between the severity of malaria and host genetics, it
appears that P. falciparum malaria is one of the deadly forms of malaria with a life
cycle including alternatives hosts: a sexual cycle in the insect vector, an Anopheles
mosquito, and a human cycle in a liver stage and an erythrocyte stage. However,
the resistance mechanisms have been described in the sporozoite entry to liver cells
and in the erythrocyte invasion by merozoites (Figures 1 and 3) [17, 18]. Geneti-
cally based resistance is involved in either altering erythrocyte invasion by merozo-
ites, in lowering parasite growth or in impairing merozoite viability after being
released from schizonts [17, 19]. The genetic resistance in the blood stage step has
been extensively documented [12].
There are multiple points in the parasite lifecycle that have impacted host
genetic variation, but the majority of the malaria-protective variants described so
far have various important impacts on the structure and function of the RBC [2].
Figure 1.
The life cycle of the malaria parasite (schematic diagram illustrating life cycles of P. falciparum, involving
Anopheles mosquito and human hosts). Adapted from: Figure from Lopez et al. (2010). [Lopez C, Saravia C,
Gomez A, Hoebeke J, Patarroyo MA: Mechanisms of genetically-based resistance to malaria. Gene 2010,
467:1–12.] and lee et al.(2019) [Wenn-Chyau lee, Bruce Russell, Laurent Rénia sticking for a cause: The
falciparum Malaria parasites Cytoadherence paradigm immu.2019.01444].
8
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P. falciparum malaria is a major cause of mortality and morbidity, particularly in
endemic areas of sub-Saharan Africa [2, 20]. Indeed the disease etiology is variable
and is attributable to environmental factors, parasite virulence and mostly host
genetics [21]. Variations in the severity of P. falciparum infections considered as
different phenotypes include parasitaemia (hyperactive or asymptomatic), severe
malaria anemia and cerebral malaria. Host genetic factors contribute to the
variability of malaria phenotypes [22] and thus, should help to determine some of
the mechanisms involved in susceptibility to P. falciparum infection. Some authors
have summarized common mechanisms by which hemoglobinopathies may
attenuate the pathogenesis of P. falciparum malaria (Figure 2) [11].
The knowledge gained with several studies has produced undisputed evidence
about polymorphisms associated with malaria resistance. Indeed, several gene
mutations and polymorphisms in the human hosts confer survival advantage and
have increased in frequency through natural selection over generations. These
include the classical polymorphisms that cause Sickle Cell Disorders (SCD) and
haemoglobinopathies such as α-thalassaemias and G6PD deficiency and the major
RCB group variants [23]. However, with news technology and experimental design,
other polymorphisms have been identified that include the Dantu blood group
variant, polymorphisms in the red cell membrane protein ATP2B4, and some
variants related to the immune response (Figure 3) [10].
Figure 2.
Common mechanisms by which hemoglobinopathies may attenuate the pathogenesis of P. falciparum malaria.
(A) Restriction of RBC invasion or intraerythrocytic growth, thereby suppressing parasite densities in Vivo;
(B) Interference with parasite-derived mediators of pathogenesis, including those involved in the binding of
parasite-infected RBCs to extracellular host receptors; (C) Modulation of innate host defenses to favor protective,
anti-inflammatory responses over those that drive pathogenic, pro-inflammatory responses; (D) Enhancement of
adaptive cell-mediated and humoral immune responses that clear iRBCs from the blood. Source: Taylor SM,
Cerami C, Fairhurst RM (2013) Hemoglobinopathies: Slicing the Gordian Knot of Plasmodium falciparum
Malaria Pathogenesis. PLOS Pathogens 9(5): e1003327. https://doi.org/10.1371/journal.ppat.1003327. https://
journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003327.
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2.2 Overview of inherited hemoglobin disorders
Inherited hemoglobin disorders include all disorders that are passed down
through families and affect the normal properties of blood in humans. Figure 4
summarizes the general classification IDH.
Hemoglobin disorders can be broadly classified into two general categories [24].
1.Those in which there is a quantitative defect in the production of one of the
globin subunits, either total absence or marked reduction. These are called the
thalassemia syndromes (quantitative disorders of globin chain synthesis/
accumulation: β-Thalassemia and α-Thalassemia
Figure 4.
Flow chart of general classification inherited disorders of Hemoglobin. Note: In this chapter we are interested in
inherited hemoglobin disorders that are common enough to be of public health significance and particularly in
those with a link to malaria (G6PD, α –thal, β-thal, HbS, HbC, HbE). Adapted from table of classification of
hemoglobin disorders from Forget al. (2013). [Forget BG, Bunn HF: Classification of the disorders of
hemoglobin. Cold Spring Harb Perspect Med 2013, 3:a011684].
Figure 3.
Representation of the blood-stage of P. falciparum life cycle in the human host and the malaria-protective
variants that have important roles in the red blood cell (RBC). Image adapted from [1].
10
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2.Those in which there is a qualitative disorders of globin structure defect in one
of the globin subunits: Structural variant of hemoglobin
• Sickle cell disorders: Sickle Cell trait, Sickle cell anemia disease, SC
disease, sickle β-thalassemia disease
• Hemoglobin with decreased stability (unstable hemoglobin variants):
G6PD deficiency
Hemoglobin includes four globin chains:
• fetal hemoglobin (HbF), the main hemoglobin in the fetal period which
has two alpha (α) and two gamma (γ) chains (a2γ2),
• adult hemoglobin (HbA), which increases after birth up to more than
96% of total hemoglobin, has two α and two β chains (α2β2).
Human Hemoglobin genes are located in the α-globin and β-globin gene clusters
in chromosomes 16 and 11. Due to spontaneous mutation, hemoglobin gene variants
are present at low prevalence in all sizeable populations [5].
They fall into two broad groups structural variants that change the amino acid
sequence and produce an unusual hemoglobin, [8] and thalassaemias that lower or
abolish production of globin chains [12].
Morbidity and mortality rates from SCD and β-thalassemia are still very high
and represent an important challenge. Increased understanding of pathophysiolog-
ical aspects has lead to significant improvements in the treatment and prevention of
these diseases [25]. However most hemoglobin gene variants are rare and many are
harmless, but some are common because carriers are less likely than others to die
from falciparum malaria.
We are interested in inherited hemoglobin disorders that are common enough to
be of public health significance and particularly in those with a link to malaria.
2.2.1 Sickle cell disorders
SCD is a group of inherited RBC disorders; it is by far the most common IDH
worldwide. SCD is caused by a variation in the gene that codes for hemoglobin, the
protein in our red blood cells that helps carry oxygen to all parts of the body. The
altered protein found in people with SCD is called hemoglobin S and occurs in
people who have inherited the hemoglobin S (HbS), the red blood cells become hard
and sticky [12].
Hemoglobin S results from an amino acid substitution at the sixth residue of the
β-globin subunit: β6-Glu ! Val. RBCs of persons with HbAS typically have 40%
HbS and 56–58% HbA [24]. The frequency of allele S is up to 0.2 in some parts of
sub-Saharan Africa [26–28]. In equatorial Africa, where malaria is endemic, the
prevalence of HbAS is much higher and can reach over 30% in some populations
because of the survival advantage of HbAS heterozygotes from complications of P.
falciparum malaria. Individuals with HbAS are typically asymptomatic; severe hyp-
oxia is required for them to experience manifestations of SCD, called sickling.
Persons who have inherited the HbS gene from only one parent are Heterozy-
gote for the Sickle gene (AS). They carry the gene certainly, but they usually do not
have the disease and are more tolerant of malaria infection, making them more
likely to survive the disease [12, 29].
SCD is most common in Africa where limited resources and these resources
carefully targeted are often directed towards sectors other than health. However, it
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2.2 Overview of inherited hemoglobin disorders
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Figure 4.
Flow chart of general classification inherited disorders of Hemoglobin. Note: In this chapter we are interested in
inherited hemoglobin disorders that are common enough to be of public health significance and particularly in
those with a link to malaria (G6PD, α –thal, β-thal, HbS, HbC, HbE). Adapted from table of classification of
hemoglobin disorders from Forget al. (2013). [Forget BG, Bunn HF: Classification of the disorders of
hemoglobin. Cold Spring Harb Perspect Med 2013, 3:a011684].
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Representation of the blood-stage of P. falciparum life cycle in the human host and the malaria-protective
variants that have important roles in the red blood cell (RBC). Image adapted from [1].
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• Hemoglobin with decreased stability (unstable hemoglobin variants):
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should be noted that the symptoms of SCD are often serious, substantially reducing
life expectancy and often requiring intensive treatment throughout the patient’s
life.
Hemoglobin C results from a variation in the gene that codes for hemoglobin
(β6-Glu! Lys), the protein in our RBC that helps carry oxygen around the body, It
causes hemolytic anemia, splenomegaly in homozygous state and provides a degree
of protection against malaria infection [12, 26]. Persons with hemoglobin C trait
(Hb AC) are phenotypically normal, with no clinical evident limitations or symp-
toms. However, their heterozygous status, gives them a degree of protection against
developing severe malaria HbC is common in malarious areas of West Africa,
especially in Burkina Faso, the prevalence of HbAC is much higher and can reach
over 21% [26, 28, 30, 31].
HbS and HbC caused by point mutations in the beta-globin gene, offer both
substantial malaria protection. Despite the fact that the blood disorder caused by
homozygosity for HbC is much less severe than that caused by homozygosity for
HbS [9, 12, 26, 32], it is the sickle mutation which has come to dominate many old-
world malarious regions, whilst HbC is highly restricted in its geographical distri-
bution [33]. It is probable that this discrepancy (blood disorder between HbC and
HbS) may be due to sickle cell heterozygotes enjoying a higher level of malaria
protection than heterozygotes for HbC. A probable higher fitness of HbS heterozy-
gotes relative to HbC heterozygotes could certainly have allowed the sickle cell
allele to spread more rapidly. However, observations that carrying either HbC or
HbS enhances an individual’s capacity to transmit malaria parasites to mosquitoes
could also shed light on this hypothesis [32].
Hemoglobin E results from a glutamate to lysine substitution in codon 26 (β26
Glu-Lys and GAG-AAG). Besides being a structural variant, the E variant also
causes the production of an abnormal mRNA with less b-globin being synthesized.
It is synthesized at a slightly reduced rate and has a homozygous phenotype similar
to heterozygous β thalassemia [34].
HbE is the second commonest abnormal hemoglobin after sickle cell hemoglobin
(HbS). HbE is common in South-East Asia, where its prevalence can reach 30–40%
in some parts of Thailand, Cambodia and in Laos [35].
2.2.2 Thalassemia syndromes
The thalassemia syndromes are inherited disorders characterized by absence or
markedly decreased accumulation of one of the globin subunits of hemoglobin.
Individuals with thalassemia disease are not able to make enough hemoglobin,
which causes severe anemia [24].
There is two primary types of thalassemia disease: alpha (α) thalassemias and
beta (β) thalassemia disease. In the α-thalassemias, there is absent or decreased
production of α-globin subunits, whereas, in the β-thalassemias, there is absent or
reduced production of β-globin subunits. Thalassemias affecting the production of
delta (δ)- or gamma (γ)-globin subunits are also been described but are rare and not
clinically significant disorder
2.2.2.1 α-thalassemia
The α-thalassemia syndromes are usually caused by the deletion of one or more
α-globin genes and are sub classified according to the number of α-globin genes that
are deleted or mutated [24].
There is two primary types of α-thalassemia:
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• α+ - thalassemia, in which one pair of the genes is deleted or inactivated by a
point mutation,
• α 0-thalassemia, in which both pairs of genes are deleted or inactivated.
The frequency of a α thalassemia is generally 41% in regions wheremalaria is
prevalent and in some populations, such as in Nepal, parts of India, and Papua New
Guinea, it is over 80% [36]. However, in sub-Saharan African populations, a α-thalasse-
mia frequencies do not exceed 50% despite intensemalaria selection and some authors
[37] suggested that this might occur because of negative epistasis with the S allele.
2.2.2.2 β-thalassemia
The β-thalassemias are characterized by a quantitative deficiency of β-globin
chains, can be sub classified into those in which there is a total absence of normal b-
globin subunit synthesis or accumulation. The βthalassemias are divided into two
main varieties (β0-thalassemia, there is no β-chain production and β+thalassemia,
there is a partial deficiency of β-chain production) [24]. The molecular basis of the
β-thalassemias is very heterogeneous, with over 200 different mutations having
been described [38]. In general, the mutations causing β-thalassemia are point
mutations affecting a single nucleotide, or a small number of nucleotides, in the b-
globin gene. The frequency of carriers of β-thalassemia variants is from 5 to 20% in
some areas, although not as high as the frequency of α-thalassemia variants [39].
2.2.3 Glucose-6-phosphate dehydrogenase deficiency and P. falciparum malaria
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic disorder
that results in impaired enzyme activity.
This X-linked genetic condition is characterized by reduced G6PD enzyme
activity, which can remain asymptomatic. Red blood cells obtain reduced glutathi-
one (GSH) solely from the G6PD/reduced nicotinamide adenine dinucleotide phos-
phate (NADH) pathway [7, 12, 30, 40, 41].
The deficiency makes red cells more susceptible to oxidative haemolysis, this
disease that can cause jaundice in newborn babies and haemolytic anemia (when
red blood cells break up) throughout life. This is, usually caused by an infection or
exposure to certain foods or chemicals [41, 42]. One of the chemicals that can
trigger severe symptoms in people with G6PD deficiency is Primaquine, the only
drug currently available to clear the relapsing life stages of the Plasmodium vivax
parasite from the liver.
G6PD and a number of other human genetic traits including sickle cell anemia
and related haemoglobinopathies are predominantly found in populations living in
malaria endemic countries and have been suggested to provide the host protection
from severe forms of malaria [30, 43–45] and asymptomatic malaria [27].
G6PD deficiency can be common in populations with high levels of malaria
infection, indeed the prevalence is even higher (8%) in malaria-endemic countries
[8]. Malaria control programs need to know this to inform their policies on using
Primaquine as a treatment and as a malaria control measure.
2.3 Epidemiology of inherited hemoglobin disorders and P. falciparum malaria
For a very long time, human beings have interacted with malaria parasites and thus
the parasite has had largely time to adapt and evolve with the human host [40].
Immune processes and genetic traits have contributed to reducing the profligacy of
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the malaria parasite and a wide range of genetic polymorphisms has been developed to
modify the individual response to this disease. Gene mutations involved in suscepti-
bility and resistance to P. falciparummalaria. It has been shown that the severity of
several malaria infections (such as asymptomatic, CM and SMA) varies significantly
between individuals and between populations [5]. Many of the protective variants
identified thus far affect erythrocytes, where the malaria parasite spends a crucial
stage of its life cycle. Several of the best studied mutations affect the globin genes
encoding hemoglobin [46]. Haemoglobinopathies and G6PD deficiency are among the
most common single-gene disorders, which affect RBC stability and integrity [47].
More than 700 abnormal hemoglobin have been described worldwide and more
than 200 million people worldwide have RBC enzyme abnormality [48].
These genetic mutations are major causes of morbidity and mortality around the
world [49]. Sickle hemoglobin and G6PD deficiency are genetically independent,
their loci is located on chromosome 11 for sickle and chromosome X for G6PD
deficiency genes.
Table 1 summarizes the Common Erythrocyte variant that affects malaria
infection particularly P. falciparum malaria.
2.3.1 Sickle hemoglobin (HbS), hemoglobin C (HbC) and P. falciparum malaria
Sickle hemoglobin (HbS) and hemoglobin C (HbC) are both caused by point
mutations in the beta globin gene, and both offer substantial malaria protection.
2.3.1.1 HbS and P. falciparum malaria
Heterozygosity for the sickle mutation (genotype AS) offers considerable pro-
tection against all forms of severe malaria, as well as protection against uncompli-
cated malaria [26, 32, 33] and parasitaemia [26, 32, 50, 51]. The different potential
protective mechanisms that have been proposed and supported for sickle cell
include, the growth of malarial parasites is suppressed in sickle cells [52], the
abnormal display of PfEMP-1 [53], and the acceleration of acquired immunity [54].
It has also been shown that the growth rate of P. falciparum is retarded in HbS
containing erythrocytes under conditions of low oxygen tension in vitro [55]; inhi-
bition parasite growth by [44], miRNAs found more commonly in sickle cell trait
cells than in normal cells inhibit parasite growth [56, 57].
The mechanism of the most strongly protective variant (HbS) against P.
falciparum [1], is very complex. However studies have been shown here are two
plausible mechanisms, which are not mutually exclusive, in suppression of parasite
growing in red cells [55] and enhanced splenic clearance of parasitized erythrocytes
[58]. Furthermore, a study summarized other possible protective effects of HbC.
Indeed effects may result from [59]:
• Impairment of P. falciparum red cell invasion and growth under conditions of
low oxygen tension [39, 55, 59]
• Enhanced removal of parasite-infected red blood cell [39, 58, 59]
• Reduced pathogenicity of P. falciparum infected RBC because of reduced
expression of PfEMP1 [53, 60, 61]
• Improved acquisition of malaria-specific immunity [60, 62–64]
• Inhibition of parasite growth due to oxygen-dependent polymerization [37]
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• Selective sickling of infected sickle trait erythrocytes leading to enhanced
clearance by the spleen. Reduced erythrocyte invasion, early phagocytosis, and
inhibited parasite growth under oxygen stress in venous micro vessels [65].
• Enhancement of innate and acquired immunity [53]
• oxygen-dependent polymerization of HbS is responsible for P. falciparum
growth inhibition [66]
A study with children (between the ages of 2 and 10 years) found that the
protective effect of HbAS against malaria increased from 20% to 56%, which implies
that it enhances or acts in synergy with the acquired immune response [54, 67].
The compromise between risks and benefits allows us to maintain the HbS
polymorphism at allele frequencies of environ 10% in many parts of Africa, despite
the lethal consequences for homozygotes, which provides the most striking known
example of heterozygote advantage in human genetics [9].
• Severe P. falciparum malaria
Some case–control and prospective cohort studies [10, 33, 54, 68–71] indicate that
HbAS is consistently associated with large reductions in the risk of severe malaria.
• Uncomplicated P. falciparum malaria
A comparative studies [33, 44, 71–73] and several prospective studies [5, 26,
37, 74] have shown the reduction of risk in malaria attributable to HbS. In fact, the
HbAS genotype protects against uncomplicated P. falciparum malaria by about 30%
[33, 71]. In addition, this has been further confirmed by some genome-wide associ-
ation studies [70, 71].
• P. falciparum parasitaemia
Cross-sectional studies have reported conflicting data on the prevalence of
P. falciparum parasitemia in asymptomatic HbAS children compared with HbAA
children.
A lower prevalence of parasitaemia in HbAS children was reported in some
studies, [6, 26, 75], when others studies found contrary results of similar prevalence
[72, 76, 77] or of higher prevalence [78, 79].
In these surveys, parasite densities were reported in HbAS children as lower
[6, 62, 76, 79, 80] or similar [27, 78, 81, 82] to those in HbAA children. We can
conclude that HbAS does not consistently protect from P. falciparum parasitaemia.
2.3.1.2 HbC and P. falciparum malaria
A recent meta-analysis concluded that homozygotes for βC (Hb CC) were
strongly protected against severe malaria, and heterozygotes (HbAC) were mildly
protected [10, 33]. It has also been found that both both heterozygotes and homo-
zygotes of HbC are protected against severe malaria [26, 30, 31, 44, 83] but the
protective effect appears to be substantially greater in homozygotes [44].
Although a cohort study in Mali reports an increase in the incidence of clinical
malaria in AC individuals relative to AA [84].
HbC genotypes are not fully elucidated [56], but several mechanisms have been
proposed to explain the malaria protection offered by HbC [32], including abnormal
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Although a cohort study in Mali reports an increase in the incidence of clinical
malaria in AC individuals relative to AA [84].
HbC genotypes are not fully elucidated [56], but several mechanisms have been
proposed to explain the malaria protection offered by HbC [32], including abnormal
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intra-erythrocytic development of the parasite leading to lower P. falciparum repli-
cation rates in subsets of CC erythrocytes [65]; abnormal P. falciparum erythrocyte
membrane protein 1 (PfEMP-1) display, leading to reduced cytoadherence and
possibly reduced parasite sequestration [85], and accelerated acquisition of immu-
nity against malaria [63]. In addition, the protective effect of HbC may result from:
• Increased immune clearance of infected erythrocytes [36, 46].
• Impairment of P. falciparum red cell invasion and growth under conditions of
low oxygen tension [39, 55, 63]
• Improved acquisition of malaria-specific immunity [60, 63, 78]
• Reduced pathogenicity of P. falciparum infected red blood cells because of
reduced expression of PfEMP1 [60, 85, 86] and Reduced cyto-adherence of
infected erythrocyte [30]
• increased immune clearance of infected erythrocytes [28, 36]
• Besides, on observations of reduced parasite cytoadherence abnormal PfEMP1
expression, clustering of erythrocyte band3 protein, and altered surface
topography of the erythrocyte membrane in the presence of HbC, it would
appear that the protective effect of HbC works by increasing the immune
clearance of infected erythrocytes [85, 87, 88].
2.3.1.3 Severe P. falciparum malaria
Compared to healthy children, HbC appears to protect against severe malaria to
a lesser degree than HbS and in proportion to allele frequency [31, 33, 44, 73, 89].
Protection from specific severe malaria syndromes has not been fully investigated in
HbCC; in one study [90] HbAC showed mild protection from cerebral malaria (CM)
and severe malarial anemia (SMA). When compared to children with uncompli-
cated malaria, protection from severe malaria is inconsistent: non-significant pro-
tection is reported from severe malaria in some studies [30, 33, 44, 69] of HbCC and
HbAC, and from SMA in other studies [30, 33, 69] that combined homozygotes
and heterozygotes. Significant protection from CM was reported in one study of
Malian children that combined homo- and heterozygotes [30, 33] Prospective stud-
ies have not reported the incidence of severe syndromes in HbC children. Thus,
convincing evidence for protection from severe malaria owing to HbC derives
largely from few case–control studies. Also, a further strong evidence for overall
protection comes from a recent GWAS, which concluded that for each copy of the
HbC allele, the risk for severe P. falciparum malaria was reduced by 29% [56, 70].
• Uncomplicated P. falciparum malaria
Few studies have reported the risk of uncomplicated malaria associated with HbC.
However some comparative studies [44, 72] and prospective studies have yielded
conflicting results [26, 33, 74, 91]. Further studies are still needed to show the
evidence of protection from uncomplicated malaria afforded by HbCC and HbAC.
• P. falciparum parasitaemia
In most studies cross-sectional surveys with adults and children, HbC has
not been associated with a reduced prevalence of P. falciparum parasitaemia
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[76, 78, 80, 92, 93] or P. falciparum density [76, 78, 80, 94]. The incidence of
asymptomatic parasitaemia did not differ between HbAC and HbAA children in
Mali study [26, 74]. However, in Burkina Study HbAC genotype was associated
with a lower incidence of clinical malaria relative to AA among children. Thus, HbC
does not appear to modify the risk of P. falciparum parasitaemia.
2.3.1.4 HbE and P. falciparum malaria
HbE is an extremely most common structural hemoglobin variant that occurs at
high frequencies throughout Southeast Asia and has reached an allele frequency of
up to 70% in some areas of northern Thailand and Cambodia [52]. It is a β-hemo-
globin variant, which is produced at a slightly reduced rate and hence has the
phenotype of a mild form of β thalassemia [95].
Generally, none of HbS or C variants are present in Southeast Asia and HbE is in
general also absent from populations in which HbS and HbC are present [52].
HbE is an extremely most common structural hemoglobin variant that occurs at
high frequencies throughout Southeast Asia and has reached an allele frequency of
up to 70% in some areas of northern Thailand and Cambodia [34].
AE heterozygotes appear to have protection from invasion into erythrocytes by
P. falciparum malaria [4, 65, 72, 96]. Moreover, the protective effect of HbE may
result from impairment of P. falciparum red cell invasion and growth [96], lower
intra-erythrocytic parasite growth, and enhanced phagocytosis of infected
erythrocytes [28, 96].
When the frequency of HbE is high, some other red cell disorders, such as a-
thalassemia, can be also in high frequency. Although extensive sequence analysis
has not been carried out. [97]. However, the E allele found in China is on the same
haplotype as that found in Thailand [98], suggesting that it does not have a different
origin.
Few studies have been done to characterize the mechanisms of malaria
protection. Three categories of effects are relevant: reduced parasite growth and
development, altered adhesion of parasitized RBCs to endothelium, and impact on
the immune system. In vitro studies of HbEE and HbAE RBCs have found reduced
invasion and growth of HbE [96, 99]. Clearly, more work needs to be done to
answer further questions about the protective impact of HbE.
• Severe P. falciparum malaria
Meta-analysis of few studies [21, 33, 100] that compared the prevalence of HbE
in severe and uncomplicated malaria cases demonstrated no evidence of protection,
though this should be interpreted cautiously given the significant.
Considering heterogeneity of the findings and the highly selected settings of the
studies, more investigations are necessary to conclude on possible protection of HbE.
• Uncomplicated P. falciparum malaria
We have not identified studies that have quantified clearly susceptibility to
malaria by HbE.
• P. falciparum parasitaemia
A cross-sectional study conducted in India reported a significantly lower preva-
lence of P. falciparum parasitaemia in patients with HbE (AE or EE) compared with
patients with HbAA [101].
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the immune system. In vitro studies of HbEE and HbAE RBCs have found reduced
invasion and growth of HbE [96, 99]. Clearly, more work needs to be done to
answer further questions about the protective impact of HbE.
• Severe P. falciparum malaria
Meta-analysis of few studies [21, 33, 100] that compared the prevalence of HbE
in severe and uncomplicated malaria cases demonstrated no evidence of protection,
though this should be interpreted cautiously given the significant.
Considering heterogeneity of the findings and the highly selected settings of the
studies, more investigations are necessary to conclude on possible protection of HbE.
• Uncomplicated P. falciparum malaria
We have not identified studies that have quantified clearly susceptibility to
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• P. falciparum parasitaemia
A cross-sectional study conducted in India reported a significantly lower preva-
lence of P. falciparum parasitaemia in patients with HbE (AE or EE) compared with
patients with HbAA [101].
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2.3.1.5 Hemoglobins S/C and malaria transmission
Some studies suggest that human genetic variation at the β-globin locus can
influence the transmission of malaria. Indeed the same genetic variants that are
protective against infection also showed an association with the intensity of malaria
transmission. Hemoglobin variants C and S protect against severe malaria but their
influence probably on parameters not directly linked to disease severity such as
gametocyte carriage and infection chronicity. Moreover, some studies provided
evidence that hemoglobin variants selected for the protection against malaria might
also have a broader impact on local epidemiology by influencing the frequency of
parasite, including the carriage of gametocytes [3, 32].
2.3.2 Thalassemia (α and β) and P. falciparum malaria
The thalassemias are the most common Mendelian diseases of humans and
constitute a major global health problem [39]. This is a group of clinical
disorders that result from defective production of α- or β-globin chains, which arise
from deletions or other disruptions of the globin gene clusters on chromosomes
11 and 16 [9].
A study in Kenyan children found that both heterozygous and homozygous a1
thalassemia was protective against severe malaria [102], whereas a study in Ghana-
ian children found that heterozygotes were protected [103]. However, a study
conducted in Papua New Guinea, founded the risk of severe malaria (other child-
hood infections) was reduced by 60% in children who were homozygous for α1
thalassemia and to a lesser degree in heterozygotes [104]. The protective mecha-
nism of thalassemia is not well known. Flow-cytometry studies in vitro have shown
that erythrocytes with the thalassemia phenotype show reduced parasite growth
[105] and increased binding of antibodies from malaria-immune [106].
2.3.2.1 α - thalassemia
The distribution of both a and b thalassemia variants seems to correspond
closely to the regions that have historically had high rates of malaria [23] and the
local distribution of these variants also corresponds to endemic malaria [36, 107].
Several studies have shown protection from severe malaria for individuals with a
α-thalassemia, compared with individuals without thalassemia [37, 103, 104]. In
addition, some authors. In a case–control study have shown protection from severe
malaria for a α heterozygotes and homozygotes compared to normal aa/aa genotype
[7, 37]. Overall, it appears that.
many haplotypes that reduce the expression of α-globin provide a selective
advantage in resistance to severe malaria. Indeed some mechanisms have been
proposed to explain the malaria protection offered by α thalassemia:
• Specific protection against malaria-induced anemia [90, 104]
• Reduced pathogenicity through reduced cytoadherence or resetting [108, 109]
• Immunological priming through cross-species immunity between P. vivax and
P. falciparum [94]
• increased phagocytosis of infected variant RBCs by monocytes and Enhanced
antibody binding and subsequent clearance of infected variant RBCs [110, 111]
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• Increased micro-erythrocyte count in homozygotes reduces the amount of Hb
lost for given parasite density, thus protecting against SMA [55, 104, 110, 112]
• Severe P. falciparum malaria
Some studies [90, 102–104] investigated α-thalassaemia showed protection
against severe malaria, malarial anemia and additionally, protection from cerebral
malaria [94].
• Uncomplicated P. falciparum malaria
Several prospective studies have assessed the incidence of uncomplicated malaria
in α-thalassaemic children, with conflicting results. Indeed some studies showed the
incidence of falciparum malaria was higher in α-thalassemia homozygotes and het-
erozygotes [94]; in contrast, other studies, found a lower incidence [37, 113]. How-
ever, other studies have found no protection for both homozygotes and heterozygotes
• P. falciparum parasitaemia
In cross-sectional studies, α-thalassaemia was not associated with the prevalence
of parasitaemia [79, 103, 112, 114, 115]. In prospective study of children conducted
in Papua New Guinea, both α- thalassaemia homozygotes and heterozygotes had
fewer episodes of PCR-detectable parasitaemia than those without α thalassaemia,
[115, 116] though this outcome has not been investigated in other studies.
Finally, there is no evident data to confirm a protective effect of α-thalassaemia
against asymptomatic parasitaemia [112, 114].
2.3.2.2 β–thalassemia
Haldane has explain the very high level of β-thalassemia in some Mediterranean
populations by the ‘malaria hypothesis’ of Haldane [117].
There is ordinarily only one copy of the HBB gene and βþ and β0 thalassemia
showing the reduction and loss, respectively, of the production of functional pro-
tein. Individuals with α-thalassemia major, have profound anemia while Heterozy-
gotes typically have mild anemia, however, symptoms can vary greatly in severity
from having severe anemia to being a symptomless carrier. [118]
Generally, β-thalassemia is more of a public health problem because of this
higher morbidity than α-thalassemia.
Several mechanisms have been also proposed to explain specific protection
against malaria-induced
• Enhanced removal of parasite-infected RBC [45]
• Reduced invasion and growth of P. falciparum parasites [119, 120]
• Reduced pathogenicity through reduced cytoadherence or resetting [121]
• Enhanced antibody binding and subsequent clearance of infected variant
RBCs [110]
• Increased phagocytosis of ring-parasitised variant RBCs [45, 102, 122]
• Severe P. falciparum malaria
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To our knowledge, no studies have investigated the risk of severe malaria in
patients with β-thalassaemia.
• Uncomplicated P. falciparum malaria
A case–control study in Liberia, have showed a low prevalence of β-thalassaemia
in participants with uncomplicated malaria compare to community controls [72].
• P. falciparum parasitaemia
A other study that was done in Northern Liberia, found no differences, although
they did report lower parasite densities in those with β-thalassaemia [46].
2.3.3 Deficiency Glucose-6-phosphate dehydrogenase (G6PD) and P. falciparum
malaria
G6PD deficiency is a common X-linked recessive genetic disorder inherited
from parents. Although, in most cases, G6PD-deficient individuals appear normal,
it can lead to life-threatening anemia in severely G6PD-deficient individuals during
oxidative stress-induced by the consumption of certain foodstuff (fava beans),
legumes, and taking such as particular antimalarial (primaquine and pamaquine),
sulfonamide, sulfamethoxazole, and other drugs and chemicals [123] and also
probably infection with microorganisms [124]. Additionally, some authors show
that G6PD deficiency increases the risk of severe neonatal hyperbilirubinemia,
which can lead to lifetime disability with kernicterus if inadequately treated
[115, 125].
However, there is a big beneficial effect of G6PD deficiency. Some studies have
reported that G6PD deficiency provides resistance against malaria as the malaria
parasite cannot complete its life cycle in compromised G6PD deficient RBC which
have a decrease in life span or because of early phagocytosis of deficient RBC
[126, 127]. Deficient G6PD enzyme activity has been shown to correlate with
protection against severe malaria [43, 89]. Reduced parasite replication in G6PD-
deficient erythrocytes is thought to be the mechanism of protection [128], but the
parasite appears to counter this by manufacturing G6PD itself [129].
The geographical distribution of G6PD deficiency is consistent with evolution-
ary selection by malaria [130], and a hypothesis of positive selection [131–133]. The
results of studies examining the risk of malaria for various G6PD-deficient geno-
types are not consistent. Some authors [43, 134] found in Gambia and Kenya that
the reduction in risk of severe malaria in male hemizygotes was 58% and that the
reduction in risk for heterozygous females was 46%. Other hand, other authors
found that in two populations in Mali, the reduction in risk of severe malaria in
male hemizygotes was also 58%, but no reduction in risk in the female heterozy-
gotes [93]. Some authors [27, 133] found no protective effect for either male
hemizygotes or female heterozygotes. However, a protective effect has been
reported on for females that were found to be G6PD deficient. This finding appears
to be based on the incomplete correlation of genotype and phenotype for G6PD
deficiency in female heterozygotes due to variable inactivation of the two X chro-
mosomes [127].
Several mechanisms have been proposed to explain the malaria protection
offered by G6PD deficiency [45, 127].
• Increased phagocytosis of ring-parasitized variant RBCs due to enhanced
oxidative
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• Increased vulnerability of the G6PD deficient erythrocyte to oxidant stress
causes its protection against parasitization
• Reduced parasite replication in G6PD-deficient erythrocytes
2.4 Global burden of the hemoglobin disorders
Hemoglobinopathies are a group of IDH initially described in the subtropical
regions, they are now spread all around the world. Their high frequency and clinical
severity make them a global health burden mostly in Africa where there is a huge
lack of resources. The measure of the yardstick of under-5 mortality has been used
to assess the broad effect of hemoglobin disorders on health because most affected
children can die in early childhood and most survivors can have a chronic disease.
Some authors show that the disease may be cause of at least 3.4% of deaths in
children aged under 5 years [135]. However, it is very difficult to estimate the
burden especially as inherited disorders affect families and then communities.
Worldwide, over 1% of couples are at risk for IDH most have at least one affected
child. Most affected children could die in early childhood although there are now
better health facilities and medical care.
Although the West African death rate in children aged under 5 years is 18.4%,
This rate is 16.5% for children born to couples, not at risk for sickle-cell disorders,
and 40% for children born to couples who are at risk [135]. Clearly, methods to
assess the health burden of inherited disorders must include also a family
perspective [135].
The burden of disease due to malaria across worldwide vary according to
selected visible traits of major medical importance, including the alleles of genes
encoding hemoglobin. There are several reasons for the extremely high frequency
and uneven distribution of inherited hemoglobin disorders. Natural selection is by
far the most important, because of the frequency of the heterozygote and the
protection against malaria afforded to the homozygotes of thalassemia and HbC,
followed by consanguineous marriages [9, 136]. The epidemiological transition
whereby, owing to improvements of health care services, nutrition, and health
positive social and behavioral factors, babies who would have probably died from
the more severe hemoglobin disorders survive nowadays [39]. Then, the migration
from areas of high frequency of SCD into regions like Europe and the United States
are also cited.
Currently, there are only limited data on the gene frequencies and the number of
births of patients with common hemoglobin disorders, particularly in Africa. Micro
mapping studies involving many different centers in these countries have recently
found that there is remarkable diversity in the frequency of the hemoglobin disor-
ders even over small geographical distances [137–139].
For the future more micro mapping data are then needed to provide an accurate
picture global burden according selective factors distribution [60]. Hemoglobinop-
athies are so common that they provide a convenient model for working out a
genetic approach to the control of chronic childhood diseases. At present, about 250
million people (4.5% of the world population) carry a potentially pathological
haemoglobinopathy gene. Haemoglobinopathy control programs, based on WHO
approaches and recommendations, have been established in different countries in
all WHO Regions and have been successful in the management of the problem by
reducing the burden of the Hemoglobin Disorders [108].
Nowadays effective prevention programs have been carried out successfully in
many developed countries concerning medical care for hemoglobinopathies. The
programs should be extended and followed to African regions where hemoglobin
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male hemizygotes was also 58%, but no reduction in risk in the female heterozy-
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reported on for females that were found to be G6PD deficient. This finding appears
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• Increased vulnerability of the G6PD deficient erythrocyte to oxidant stress
causes its protection against parasitization
• Reduced parasite replication in G6PD-deficient erythrocytes
2.4 Global burden of the hemoglobin disorders
Hemoglobinopathies are a group of IDH initially described in the subtropical
regions, they are now spread all around the world. Their high frequency and clinical
severity make them a global health burden mostly in Africa where there is a huge
lack of resources. The measure of the yardstick of under-5 mortality has been used
to assess the broad effect of hemoglobin disorders on health because most affected
children can die in early childhood and most survivors can have a chronic disease.
Some authors show that the disease may be cause of at least 3.4% of deaths in
children aged under 5 years [135]. However, it is very difficult to estimate the
burden especially as inherited disorders affect families and then communities.
Worldwide, over 1% of couples are at risk for IDH most have at least one affected
child. Most affected children could die in early childhood although there are now
better health facilities and medical care.
Although the West African death rate in children aged under 5 years is 18.4%,
This rate is 16.5% for children born to couples, not at risk for sickle-cell disorders,
and 40% for children born to couples who are at risk [135]. Clearly, methods to
assess the health burden of inherited disorders must include also a family
perspective [135].
The burden of disease due to malaria across worldwide vary according to
selected visible traits of major medical importance, including the alleles of genes
encoding hemoglobin. There are several reasons for the extremely high frequency
and uneven distribution of inherited hemoglobin disorders. Natural selection is by
far the most important, because of the frequency of the heterozygote and the
protection against malaria afforded to the homozygotes of thalassemia and HbC,
followed by consanguineous marriages [9, 136]. The epidemiological transition
whereby, owing to improvements of health care services, nutrition, and health
positive social and behavioral factors, babies who would have probably died from
the more severe hemoglobin disorders survive nowadays [39]. Then, the migration
from areas of high frequency of SCD into regions like Europe and the United States
are also cited.
Currently, there are only limited data on the gene frequencies and the number of
births of patients with common hemoglobin disorders, particularly in Africa. Micro
mapping studies involving many different centers in these countries have recently
found that there is remarkable diversity in the frequency of the hemoglobin disor-
ders even over small geographical distances [137–139].
For the future more micro mapping data are then needed to provide an accurate
picture global burden according selective factors distribution [60]. Hemoglobinop-
athies are so common that they provide a convenient model for working out a
genetic approach to the control of chronic childhood diseases. At present, about 250
million people (4.5% of the world population) carry a potentially pathological
haemoglobinopathy gene. Haemoglobinopathy control programs, based on WHO
approaches and recommendations, have been established in different countries in
all WHO Regions and have been successful in the management of the problem by
reducing the burden of the Hemoglobin Disorders [108].
Nowadays effective prevention programs have been carried out successfully in
many developed countries concerning medical care for hemoglobinopathies. The
programs should be extended and followed to African regions where hemoglobin
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disorders are frequency very high. Indeed this frequency accounts for more than
70% of total hemoglobinopathies in the world [140]. Reducing the incidence of
IDH, better prevention against IDH should remain the major priority of health
services in order to reduce the burden of heamoglobinopathies.
2.5 Global burden of the Malaria
Despite the global awareness with the promulgation of malaria eradication goals,
despite the colossal efforts deployed in many forms: international and bilateral
cooperation, foundations and humanitarian agencies, philanthropic works. Malaria
remains a crucial public health concern within the world in general and in tropical
countries in particular. According to the latest Global Malaria Report, there were
228 million cases of malaria in 2018, of which there were 405,000 deaths. Almost all
of the morbidity and associated lethality, respectively 93% and 94%, occur in Africa
(WMR, 2019) more than 50% of the disease burden of malaria is borne by only 6
countries namely: Nigeria (25%), the Democratic Republic of Congo (12%), Uganda
(5%) and Côte d’Ivoire, Mozambique and Niger (4% each). With 67% of malaria-
related deaths, children under 5 remain the most vulnerable group [2]. These health
consequences of malaria bring with them very important economic and social
tragedies. In some cases, the resulting disruption of family structures has conse-
quences for the family itself and for the whole community over several generations
[141]. The incidence of malaria is inversely proportional to the level of development
of the affected societies. The global distribution of gross domestic product per
capita shows a strong correlation between malaria and poverty. Malaria generates
direct costs (medical care) and indirect costs (loss of productivity linked to disabil-
ities and deaths due to malaria) [141]. The relief of all this sharp and stifled pain
requires strengthening malaria prevention programs and promoting multidis-
ciplinary research on effective and safe antimalarial drugs and vaccines.
3. Discussion
This review confirms that the malaria parasite has co-evolved with its human
host, each struggling for survival. The resulting stigmas appear as polymorphisms of
the human genome. This process resulted in a symbiotic association, conferring to
the host a relative protection against parasitic infection on one hand and allowing
the parasite a greater longevity and proliferation due to host acquired resistance on
other hand About polymorphisms of the proteins of red blood cells conferring an
innate relative resistance to malaria, it is established that with an effect size >80%,
the HbS variant confers the strongest protective effect against severe malaria, while
the α- thalassemia confers a protective effect of about 40% in homozygotes [70, 71].
Other genes such as G6PD deficiency have also been shown to be present at high
frequencies in endemic malaria populations [9, 10, 22, 142]. However, taking into
account the limited mapping specific gene variants of early studies, recent studies
have shown that the significant effects of known candidate genes would explain
only a small fraction of the heritability of malaria [10, 22, 63, 143, 144]. This
indicates that the genetic architecture of susceptibility to malaria is much more
complex and that “missing heritability” could be explained by polygenetic or epi-
genetic effects or by gene–gene and gene–environment interactions [10, 145].
The MalariaGEN consortium has greatly contributed to understanding the cor-
relation between the pathogenesis of malaria and polymorphisms in human RBC.
A better understanding of how changes in RBC physiology affects malaria path-
ogenesis may uncover new strategies to combat the disease. Understanding the
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molecular basis of these polymorphisms may shed additional light on the variation
in human susceptibility to malaria and offer insight into mechanisms of malaria
pathogenesis likewise, a better understanding of red cell membrane structure and
function will offer opportunities for the discovery of new and urgently needed
therapeutic targets for the treatment of malaria.
4. Conclusions
Hemoglobinopathies are among the most common monogenic diseases in
populations. The complexity of their pathophysiological processes, the severity and
diversity of their clinical manifestations reflect the relevance of their scientific
interests. Genetic polymorphisms that affect the structure and production of the β-
or α-chains of hemoglobin are variously associated with protection from a range of
clinical manifestations of P. falciparum infection. The degree of protection con-
ferred by hemoglobinopathies, in general, is greatest against severe malaria, mod-
erate against uncomplicated malaria, and probably absent against asymptomatic P.
falciparum parasitaemia. Therefore, there is a positive relationship between the
frequency of either βC or βS and malaria selection intensity favors.
However, people with hemoglobin disorders could be high-risk groups. Indeed
subjects admitted with malaria are twice more likely to die than those admitted for
other pathologies. The screening and genetic counseling for hemoglobin disorders
should be an intrinsic part of health care in most countries. Health facility’s services
should be designed to provide a foundation for more comprehensive community
genetics services because hemoglobin disorders are commonly a point of entry for
genetic approaches into health systems.
Although information about the precise world distribution and frequency of the
inherited hemoglobin disorders is still limited, there is no doubt that they are going
to pose an increasing burden on global health resources in the future. Increased
knowledge of the biological basis of these diseases would offer significant advances
in their therapeutic management and in the prevention of the occurrence of new
cases. Indeed the high frequency of IDH because of natural selection associated due
to consanguineous marriages in some countries could be reduced through public
awareness campaigns. Improving health care conditions in general and those related
to pathologies associated with IDH would enhance affected children’s survival.
Hemoglobin variants could shape the distribution of malaria parasites in human
populations and their transmission potential. Therefore, the knowledge of our
understanding of the interaction between hemoglobin variants and malaria para-
sites is still being incomplete even if it has improved these last years. Nonetheless,
with the interest in malaria elimination, knowledge on how these prevalent genetic
variants influence parasite distribution and probably cumulative host transmission
potential would be particularly valuable and necessary.
The malaria parasite has co-evolved with its human host in a struggle for their
survival. The scars of this war on the human genome are polymorphisms conferring
an innate resistance to malaria. Regarding relationships between malaria and human
genetic alterations of RBC proteins, it appears that the MalariaGEN studies have
clearly opened new doors to understand the malaria burden on human RBC poly-
morphisms and thus malaria pathogenesis. These new pieces of knowledge will help
to redefine or readjust malaria control strategies.
In fact, despite the complexity of these interactions, hemoglobin variants in
general and hemoglobinopathies, in particular, show a good model and natural
experiment identifying cellular and molecular mechanisms by which P. falciparum
produces morbidity.
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Other genes such as G6PD deficiency have also been shown to be present at high
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account the limited mapping specific gene variants of early studies, recent studies
have shown that the significant effects of known candidate genes would explain
only a small fraction of the heritability of malaria [10, 22, 63, 143, 144]. This
indicates that the genetic architecture of susceptibility to malaria is much more
complex and that “missing heritability” could be explained by polygenetic or epi-
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or α-chains of hemoglobin are variously associated with protection from a range of
clinical manifestations of P. falciparum infection. The degree of protection con-
ferred by hemoglobinopathies, in general, is greatest against severe malaria, mod-
erate against uncomplicated malaria, and probably absent against asymptomatic P.
falciparum parasitaemia. Therefore, there is a positive relationship between the
frequency of either βC or βS and malaria selection intensity favors.
However, people with hemoglobin disorders could be high-risk groups. Indeed
subjects admitted with malaria are twice more likely to die than those admitted for
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should be an intrinsic part of health care in most countries. Health facility’s services
should be designed to provide a foundation for more comprehensive community
genetics services because hemoglobin disorders are commonly a point of entry for
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in their therapeutic management and in the prevention of the occurrence of new
cases. Indeed the high frequency of IDH because of natural selection associated due
to consanguineous marriages in some countries could be reduced through public
awareness campaigns. Improving health care conditions in general and those related
to pathologies associated with IDH would enhance affected children’s survival.
Hemoglobin variants could shape the distribution of malaria parasites in human
populations and their transmission potential. Therefore, the knowledge of our
understanding of the interaction between hemoglobin variants and malaria para-
sites is still being incomplete even if it has improved these last years. Nonetheless,
with the interest in malaria elimination, knowledge on how these prevalent genetic
variants influence parasite distribution and probably cumulative host transmission
potential would be particularly valuable and necessary.
The malaria parasite has co-evolved with its human host in a struggle for their
survival. The scars of this war on the human genome are polymorphisms conferring
an innate resistance to malaria. Regarding relationships between malaria and human
genetic alterations of RBC proteins, it appears that the MalariaGEN studies have
clearly opened new doors to understand the malaria burden on human RBC poly-
morphisms and thus malaria pathogenesis. These new pieces of knowledge will help
to redefine or readjust malaria control strategies.
In fact, despite the complexity of these interactions, hemoglobin variants in
general and hemoglobinopathies, in particular, show a good model and natural
experiment identifying cellular and molecular mechanisms by which P. falciparum
produces morbidity.
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Vaccines are unquestionably the most cost-effective way for malaria control.
The new generation of vaccine delivery systems is increasingly moving towards co-
administration of certain immunostimulants and the use of more than one antigen
in the same system. In any event, the best vaccine should be effective, safe, low
cost, available, and easy to administer.
5. Perspectives
WHO has announced an ambitious goal of global malaria elimination by 2030.
Malaria elimination is possible but will require adaptive and well-managed pro-
grams and the implementation of evidence-based surveillance strategies and strong
national responses, with adequate funding and human resources.
Over the past 20 years, significant progress has been made in the fight against
malaria worldwide, with impressive reductions in transmission in many endemic
regions. However, the successful outcome of the global malaria eradication research
program will depend on the development of new and more effective tools, includ-
ing rapid diagnostic tests, drugs, vaccines, insecticides, and awareness raising.
Nowadays, genetic and genomic knowledge of malaria parasites, vectors (mosqui-
toes), and human hosts are available. These bits of knowledge could and should be
used for the development of the latest generation tools that are more efficient and
secure. The situation is all the more urgent and worrying as there is the emergence
of a resistance of Plasmodium falciparum to the first-line drug, namely artemisinin.
In any event, the development of an effective, safe and operational malaria
vaccine remains the ultimate objective that we must achieve. In this perspective, we
must watch and take into account the genetic variation of the parasite population,
which threatens to undermine our efforts.
A big significant milestone in scientific advancements of the last twenty years
was already the elucidation of the genomes, transcriptomes, and proteomes of many
pathogens, including malaria parasites. These informations give a clearer and more
detailed picture that provides the foundation for new approaches to refine existing
targets as well as to identify new target antigens for the development of more
efficient and effective vaccines, drugs and diagnostic tests. It is clear that further
progress is needed for the development of a malaria vaccine, based on basic
research, in order to identify new target antigens and better understand how dif-
ferent adjuvants will affect balance, sustainability, and the effectiveness of the
responses. To hope for an effective vaccine, emphasis should be placed on mixtures
of antigens combined with potent adjuvants, not only to induce the necessary
effective responses, but also to increase the possibility of inducing at least partial
cross-immunity by including a range of Plasmodium epitopes.
Innovative genome-based vaccination strategies have shown the potential of a
number of pathogens, including malaria. A rational genome-based vaccine design,
allowing the selection of the best possible targets by prioritizing antigens according
to clinically relevant criteria (frequency and magnitude of the clinically relevant
immune response and/or biological function), will overcome the problem of poor
immunogenicity and poor vaccine protection that have undermined the develop-
ment of malaria vaccines in the past 30 years.
The use of gene drive technology could revolutionize ecosystem management.
These emerging technologies with potential global effects are being offered to
researchers and now subject to public discussions regarding environmental and
safety concerns. The relative protection against malaria that heamoglobinopathies
would confer, justify justly that we are still investigating this correlation to deter-
mine all its nature and its power. Despite this relative advantage over the
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manifestations of malaria in subjects with sickle cell trait, gene therapy is a new
approach to healing patients with hemoglobinopathies, which must be popularized.
In this sense, clinical trials are underway with promising results. However, there are
still frontiers to explore that could improve this approach: the stoichiometry
between transgenic hemoglobin and endogenous hemoglobin in relation to the
different genetic mutations of globins; the supply of donor cells, such as the use of
induced pluripotent stem cells (iPSC); and the use of safer gene insertion methods
to prevent oncogenesis.
The overall prospects for malaria elimination are clear, encouraging and the
potential opportunities are endless. Technological discoveries and advances are
happening at an incredibly fast pace. The context of discovery and use of new
technologies makes the eradication of malaria within the reach of the test tube.
However, regardless of the time it will take, we must increase our efforts; intensify
networking, with the financial support and strong political will of our leaders,
especially in Africa where the problem of malaria is the most important.
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Sickle Cell Anemia, 
Representations and Care: 
Experience of a Brother of a Sick 
Child in Cameroon
Hassan Njifon Nsangou and Régine Scelles
Abstract
In Africa, families often with more than one child consult with both modern 
and traditional African medicine to treat their child with sickle cell anemia. This 
research aimed to understand how a child experiences both the medical and tra-
ditional care of his sister. We collected data from an interview and family drawing 
of a young boy growing up with an affected sister in Cameroon. Results showed 
this child persisted to feel as though his sister had fallen victim to a sorcerer and 
that he was at risk of the same fate even after the two of them received traditional 
treatment. He also felt neglected about his suffering because of his sister’s disease by 
hospital professionals that were caring for her. It is therefore necessary to establish 
a support system for affected children and their family by providing a safe space in 
hospitals where they can express and contain their experiences with the disease.
Keywords: sickle cell anemia, care, tradition, modernity, siblings, Cameroon
1. Introduction
Sickle cell anemia is a genetic disease that confronts families with iterative, 
intense and unpredictable crises associated with the physical manifestation on the 
sick child [1] to his death thought to be imminent and inevitable. It is a taboo in 
most sub-Saharan African families [2] where it is difficult to meet unique children. 
Few psychological studies have focused on what happens to children who grow 
up with a sibling with sickle cell disease which is characterized by severe pain, 
frequent hospitalization and early death not to mention the high cost of treatment 
(traditional and medical) for families. However, it is unclear how families live the 
traditional and medical care of the disease.
This article includes an interview and drawing analysis done with a brother 
of a sick child in the context of research whose framework and method will be 
briefly presented. It highlights the way in which a child perceives the healthcare 
of his sister, both by Western medicine professionals and traditional healers—two 
types of care specialists with virtually different processes and goals. It is therefore a 
question of understanding the psychological impact of the concurrent consultation 
of medical and traditional care of a sick child on his brother. The article illuminates 
and questions the simultaneous existence of two sickle cell care systems within a 
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Cameroonian family and tries to understand its effects on a brother of a sick child. 
It shows the complexity of the experiences of children growing up with a sick sib-
ling and its close interweaving with the family experiences as they care for the child. 
The objective is to build on this knowledge to open up the design of care devices 
that better take into account the specificity of the experiences of siblings of children 
with sickle cell anemia.
2. Theoretical consideration
2.1 The sickle cell anemia, a serious and deadly genetic disease
Sickle cell anemia is the most prevalent genetic disease in the world, with 
approximately 500 million individuals with sickle cell traits and 50 million indi-
viduals with the disorder itself worldwide [3]. Originally spread across malaria-
endemic areas such as sub-Saharan African countries, historical migrations linked 
to the slave trade and the recent acceleration of migration flows have gradually 
changed its distribution worldwide [4]. It is found in almost all countries with large 
populations from Africa and regions around the Mediterranean. In France, for 
example, it is a rare disease, but nonetheless the most common genetic disease with 
a prevalence of one child per 1900 births [5].
With a prevalence rate of at least 2% in the general population and an estimated 
mortality rate of more than 70% among children under the age of 5 [6], the African 
continent is most affected by sickle cell anemia. Cameroon is one of the most affected 
countries, with a prevalence of 8.34% in the general population [7]. In sub-Saharan 
Africa, the unavailability of bone marrow transplantation—the only effective treat-
ment for seizures—increases the risk of death in children under 5 years old [8].
The disease is an autosomal recessive pathology transmitted to the child by both 
parents. The presence of abnormal hemoglobin in the blood causes a deficiency in 
the supply of oxygen to various organs in the body by the red blood cells that have 
reduced life cycles. This leads to anemia and chronic, unpredictable pain [4, 9] that 
the patient identifies [1], resulting in multiple expensive hospitalizations and care 
organized by their parents [10] both in the hospital and among traditional healers.
2.2 The sickle cell anemia, a persecution figure of the family group
In the sub-Saharan African cultural context, sickle cell anemia is thought of as an 
“evil” that can attack any member of the family, even after the death of the patient 
[11]. The sick child is immersed in a society structured by traditional taboos, rituals 
and attitudes of which women are custodians [12]. The illness or handicap of the child 
is inscribed in this cultural structure, which gives it meaning and produces effects.
Sickle cell anemia is thought to be a manifestation of the possession of the sick 
child and his family by an evil spirit or bewitchment by a wizard [13]. It can also 
be perceived as a request of the ancestors to repair a transgression of an ancestral 
norm, addressed to the patient’s family [14]. Generally, the mother is designated as 
responsible for this transgression and the overprotection of the sick child, by her 
and by the family members, constitutes a defense allowing them to feel guilt-free 
and to put the child in the family’s history [14] alongside his brothers and sisters.
2.3 The specificities of the medical care of sickle cell anemia in Cameroon
The hospital is a place regularly frequented by sick children and their families. 
Described as the disease of hospitals in several African countries [15], sickle cell 
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anemia makes hospital services a second home for the patient and their families 
around them. The frequency of hospitalizations in Cameroon is estimated to be 
between three and four hospitalizations per month in children under five, between 
five and seven hospitalizations per month in adolescents and two hospitalizations 
per month in adults [16]. The reasons for these hospitalizations are sometimes 
varied in one subject and identical in others. In general, sick children are regularly 
hospitalized for pain attacks, severe anemia and/or chronic complications (stroke 
and heart attacks). Stroke is also a cause of hospitalization for sickle cell patients. 
For the latter, the probabilities of having a stroke before the ages of 20, 30 and 45 
are, respectively, 11, 15 and 24% [17]. In Cameroon, the prevalence of stroke is 
6–7% in patients aged 7 months–35 years [18].
The medical management of patients has undergone an important evolution 
within the past 20 years due to the intensification of available treatments for 
children at risk of severe complications [19]. These treatments consist mainly 
of yoglycurea, transfusion programs and family transplants. Indeed, yoglycan 
significantly reduces the frequency of onset of occlusive seizures, acute thoracic 
syndrome and the degree of hemolysis. The establishment of transfusion programs 
for children detected as at risk of stroke by transcranial Doppler has significantly 
reduced this risk from 11 to 2% [19].
Allogeneic transplantation is currently the only treatment that can cure approxi-
mately 95% of children with sickle cell anemia [8, 20]. This treatment involves 
grafting from a brother or sister of the patient, based on their genetic compatibility 
with hematopoietic stem cells located in the bone marrow of the patient.
Sickle cell anemia is essentially a disease of the south whose treatment is in the 
north. This caricature seems more appropriate to address the lethal nature of this 
pathology in sub-Saharan African countries, including Cameroon, where it remains 
a chronic and orphan disease [21] because of the absence of hematopoietic stem 
cell allograft and the gene editing systems, the only treatments available against 
this disease [8, 9, 22]. Therefore, the therapeutic approach of the disease remains 
curative and focuses on the nature of the crises. The patient is supported in relation 
to the type of crisis he manifests. The primary purpose of medicine, in this case, is 
to alleviate the suffering of the patient by managing the symptoms. Crisis treatment 
incorporates several therapeutic products and postures. Severe attacks (mild pain, 
modeled fever) are often treated at home in collaboration with a doctor or by self-
medication. The patient is advised to rest, drink abundantly and is given an anal-
gesic treatment including acetylsalicylic acid, paracetamol or Di-Antalvic. In case 
of severe attacks involving localized or generalized pain, rest and rehydration are 
recommended. If these measures do not calm the crisis, a transfusion is performed.
The management of anemia, meanwhile, requires a transfusion of phenotyped 
erythrocyte concentrates, leukocyte depleted and filtered. The intervention in cases 
of severe pain attacks is based on the transfusion and/or hydroxyurea of the patient. 
Hydroxycarbamide is the only current attenuator therapy used in the management 
of vaso-occlusive seizures and severe anemias. The price of these products, com-
bined with that of many hospitalizations, is relatively high for most Cameroonian 
families who generally do not have social security [16].
2.4 Balancing between traditional care and medical care
Parents of sick children, supported by the members of their extended families, 
are frequently searching for ways to relieve their suffering. With the advent of 
globalization, they resort to several therapies. The therapeutic route is, in this sense, 
a sort of mosaic between traditional therapies and imported Western and messianic 
therapies. In this way, the traditional therapist, the doctor and the Imam, pastor or 
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priest are consulted at the same time. This system of “round care” [23] is one that 
perfectly summarizes the therapeutic path of most African families in sub-Saharan 
Africa. At each source, they seek the healing of a specific aspect of the child’s 
suffering. The quests for meaning of the child’s illness, ancestral protection and 
reconciliation with the ancestors lead parents to traditional healers. With the priest, 
the pastor or the Imam, families seek the divine therapy to ensure protection from 
God. They usually do this because they yearn for the healing of the child under the 
mercy of God. With the medical doctor, they seek the somatic healing of the child. 
These families are part of a permanent search for identity reconstruction [24, 25]. 
The identities of Africans remain very complex as they continually attempt to find 
their identities, following the effects of globalization [14, 26].
The traditional treatment of sickle cell anemia is based on cultural representa-
tions of this disease that people have. It does not aim to repair physiological disor-
ders. It focuses on restoring social order by reconciling the patient and their groups 
with their social and supernatural environments [14]. This therapy considers the 
sick child as a messenger, a person who talks about the transgressions of ancestral 
norms by a member of his family or the persecution of his family by a wizard. This 
is the reason why parents, uncles, aunts, brothers, sisters and cousins of the patient 
are all also patients of the traditional therapists.
2.5 Cameroonian families oscillating between modernity and tradition
African families have retained certain intrinsic cultural values such as polygamy 
and the maintenance of family life through the births of several children. They have 
also opened up to modernity by gradually applying family planning practices.
In Cameroonian families, the cultural tradition is neither past nor “outdated” 
[14]. The behaviors of the subjects are always marked by identifiable traditional 
elements. These families have neither resisted nor surrendered to modernity. 
These are simultaneously modern and traditional families, not necessarily modern 
or traditional. In Cameroon, there are several types of families; nuclear families, 
extended families, polygamous families, monogamous families, etc. [27]. These 
categories reflect the diversity and complexity of family dynamics in Cameroon, 
and potentially the lives of children confronted by a sick sibling.
2.6 The experiences of the brothers and sisters of sick children
A child’s illness has repercussions on their siblings who experience ambivalent 
feelings towards them. These relate specifically to shame, guilt, love, hatred, com-
plicity, rivalry, anguish and the desire for the death of the sick child [28]. In order 
not to aggravate the suffering of their parents and that of the patient, brothers and 
sisters often attempt to prevent them from suffering [29].
Studies on sickle cell anemia patients indicate the psychological suffering of 
sick children and their parents [9, 14, 30]. The experiences of their siblings are 
often studied from the parents’ stories. Overprotection of the child causes parents 
to progressively neglect caring for their other children [31]. The latter experience 
emotional breakdowns resulting in feelings of rejection, marginalization and exclu-
sion on the part of parents and the extended family [32, 33]. They express jealousy 
towards the patient that they designate as the main person responsible for crises that 
destabilize the family financially and emotionally [34]. They feel guilty for having 
negative thoughts such as jealousy towards the patient; they consider themselves 
“bad siblings” [35]. They experience, at the same time, the desire for the death of 
the patient and the fear of this death [36]. Their experiences are usually influenced 
by parental intrusions in their relationships with the sick child because they are 
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often parented by parents [36]. In the absence of the parents, they are the ones who 
supervise the sick child. Supervision ranges from daily monitoring of treatment 
and observation of medical instructions by the patient [2] to the bodily care of the 
patient and their assistance during hospitalization [37]. This has great implications 
on the sisters of sick children, particularly on girls’ education. In many sub-Saharan 
African societies, the main objective is to bring up girls to be good mothers, thus 
making them the person most likely to take care of children [21].
3. Material and method
3.1 Specificities of the method
The methodology of this research is similar to that presented in a previous 
research [36]. In sub-Saharan African cultures, children who talk to professionals 
about themselves or anything else are supposed to have been given permission by 
their families to do so [38]. It is usually parents who talk to professionals about their 
children, who on their part are obliged to listen and to talk only when adults allow 
it [39]. Talking with children about sickle cell anemia is not easy and it requires the 
researcher to make an alliance with the family. This research, which took place in 
Cameroon worked to get parents to allow their children to talk with the researcher 
about the way they experience the care of their sick brother or sister. In fact, many 
children are not allowed to speak to strangers and to speak only to adults who are 
intimate with the family [40].
The parents signed consent forms concerning the participation of the family and 
children in the research and designated which of their children would participate. 
These children were allowed by their parents to speak with the researcher about 
their family, their sick brother or sister and his/her illness. Indeed they had a mis-
sion to talk to the researcher who informed them about their freedom to participate 
in this research. The method includes an individual interview with each child and a 
drawing, preceded and followed by a group time. Before the interview, the mother, 
in front of the whole family, talks about the relations between her sick child and his 
siblings; the children listen and keep quiet. After the interview and the drawing, the 
adults question the researcher and the participating child about the content of their 
meeting. It is therefore an individual meeting, but it takes place in a group setting 
allowing children to speak as freely as possible.
We report in this article the case of Jules. With Jules, we talked about the 
illness, his relationship with the sick child and the family. In Jules’ interview, there 
is an important place for treatment and its effects on the sick child, on his siblings, 
on his mother and father and on extended family members. This interview was 
done in the absence of the other members of the family whom we asked to leave 
the family room to allow for confidentiality. The interview was followed by the 
drawing session after which the analysis of the drawing was done. The family 
drawing test followed the approach of [41], taking into account the cultural 
referent as advocated by [42]. We asked Jules to draw his family on a sheet. The 
drawing, complementary to the interview allows the child to project on the sheet 
what he thinks and experiences about his family, his sick brother and his place in 
the family.
3.2 Jules and his family
In accordance with the ethical requirements, we gave fictitious first names to the 
persons to guarantee the anonymity and the confidentiality of the meeting.
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priest are consulted at the same time. This system of “round care” [23] is one that 
perfectly summarizes the therapeutic path of most African families in sub-Saharan 
Africa. At each source, they seek the healing of a specific aspect of the child’s 
suffering. The quests for meaning of the child’s illness, ancestral protection and 
reconciliation with the ancestors lead parents to traditional healers. With the priest, 
the pastor or the Imam, families seek the divine therapy to ensure protection from 
God. They usually do this because they yearn for the healing of the child under the 
mercy of God. With the medical doctor, they seek the somatic healing of the child. 
These families are part of a permanent search for identity reconstruction [24, 25]. 
The identities of Africans remain very complex as they continually attempt to find 
their identities, following the effects of globalization [14, 26].
The traditional treatment of sickle cell anemia is based on cultural representa-
tions of this disease that people have. It does not aim to repair physiological disor-
ders. It focuses on restoring social order by reconciling the patient and their groups 
with their social and supernatural environments [14]. This therapy considers the 
sick child as a messenger, a person who talks about the transgressions of ancestral 
norms by a member of his family or the persecution of his family by a wizard. This 
is the reason why parents, uncles, aunts, brothers, sisters and cousins of the patient 
are all also patients of the traditional therapists.
2.5 Cameroonian families oscillating between modernity and tradition
African families have retained certain intrinsic cultural values such as polygamy 
and the maintenance of family life through the births of several children. They have 
also opened up to modernity by gradually applying family planning practices.
In Cameroonian families, the cultural tradition is neither past nor “outdated” 
[14]. The behaviors of the subjects are always marked by identifiable traditional 
elements. These families have neither resisted nor surrendered to modernity. 
These are simultaneously modern and traditional families, not necessarily modern 
or traditional. In Cameroon, there are several types of families; nuclear families, 
extended families, polygamous families, monogamous families, etc. [27]. These 
categories reflect the diversity and complexity of family dynamics in Cameroon, 
and potentially the lives of children confronted by a sick sibling.
2.6 The experiences of the brothers and sisters of sick children
A child’s illness has repercussions on their siblings who experience ambivalent 
feelings towards them. These relate specifically to shame, guilt, love, hatred, com-
plicity, rivalry, anguish and the desire for the death of the sick child [28]. In order 
not to aggravate the suffering of their parents and that of the patient, brothers and 
sisters often attempt to prevent them from suffering [29].
Studies on sickle cell anemia patients indicate the psychological suffering of 
sick children and their parents [9, 14, 30]. The experiences of their siblings are 
often studied from the parents’ stories. Overprotection of the child causes parents 
to progressively neglect caring for their other children [31]. The latter experience 
emotional breakdowns resulting in feelings of rejection, marginalization and exclu-
sion on the part of parents and the extended family [32, 33]. They express jealousy 
towards the patient that they designate as the main person responsible for crises that 
destabilize the family financially and emotionally [34]. They feel guilty for having 
negative thoughts such as jealousy towards the patient; they consider themselves 
“bad siblings” [35]. They experience, at the same time, the desire for the death of 
the patient and the fear of this death [36]. Their experiences are usually influenced 
by parental intrusions in their relationships with the sick child because they are 
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allowing children to speak as freely as possible.
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is an important place for treatment and its effects on the sick child, on his siblings, 
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done in the absence of the other members of the family whom we asked to leave 
the family room to allow for confidentiality. The interview was followed by the 
drawing session after which the analysis of the drawing was done. The family 
drawing test followed the approach of [41], taking into account the cultural 
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the family.
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Aged eleven and a student in fifth grade, Jules is the third child out of five sib-
lings and the older brother of Paulette, his sister with sickle cell anemia. After the 
death of his father, a nurse who had previously worked in his home village, Jules, 
accompanied by his sick sister and his mother emigrated from the village to settle 
in Yaoundé at his elder sister’s home. This sister was a public school teacher. One 
of the reasons for this rural exordium is the medical follow-up of Paulette, eight, 
with sickle cell anemia. She is the second-to-last of the five siblings, three boys and 
two girls. The youngest of two siblings and three boys would probably have died, 
according to Jules’s older sister, following sickle cell anemia crises. In Cameroon, 
sickle cell anemia is not well enough known by all public health professionals and 
some people still do not recognize nor know its symptoms.
Paulette’s illness was diagnosed at the age of seven, when she was first hospi-
talized following an anemic crisis in a hospital in Yaoundé. The unavailability of 
prenatal diagnosis and the non-systematization of neonatal diagnosis of sickle cell 
anemia in Cameroon leads to children being diagnosed relatively late during one of 
their hospitalizations.
Paulette is usually hospitalized between one and two times a month following 
anemia attacks, the main symptom of her illness. Her mother, estimates the average 
duration of each of her hospitalizations to be between 2 and 3 days. During these 
hospitalizations, her older sister and her mother often assist her.
Jules lives with the eldest daughter in the family, his mother, his sick sister and 
his one-year-old niece. The eldest daughter of the siblings is separated from the 
father of her daughter and she is the only child who is a parent herself. Paulette is 
the only sick child and the mother of the family is unemployed. The eldest daughter 
and the second child of the siblings contribute to the financing of Paulette’s care. 
Siblings are therefore a family resource in the financing of care. These first two 
siblings are employed and the last two are students.
4. Results
Paulette’s fits give rise to many hospitalizations.
4.1 The financing of medical care
Jules does not know the cost of Paulette’s medical care. He knows, however, that it is 
his older sister and his paternal uncle who finance this care. He exclaims “Ah! I do not 
know the price. Mom and my older sister do not tell me the price. My older sister pays the 
hospital. There is also my uncle and my brother who also gives the money for the hospital.”
He behaves as though he was forbidden and/or forbade himself from knowing 
or asking adults questions about the cost of his sister’s medical care. However, he is 
grateful for the uncle’s financial support to his mother and older sister. He does not 
mention the involvement of his brother who is a taxi driver in financing the care.
Her older sister and mother usually accompany Paulette to the hospital. This 
elder sister plays both the role of father and sister to Jules and Paulette. She finances 
the care and assists her mother at Paulette’s bedside during hospitalizations. In the 
end, she plays the role of substitute for the deceased father and the mother for the 
sick sister. Her status as the eldest daughter of her siblings demands that she cares 
for her younger siblings, in keeping with the cultural norm that [40] makes the 
eldest son especially, and the eldest sister also, a parental figure for her brothers and 
sisters in African families. Jules specifies, “My sister brings Paulette to the doctors of 
the foundation when the blood reduces.” Therefore, he refers to this sister as a mother 
for both Paulette and himself.
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Jules refers to the fact that the medical professionals at the hospital do not 
care about his family and his siblings. Their interest is in Paulette and the relief of 
her crises. Medical treatment is only given to the patient. Jules feels abandoned, 
forgotten and neglected by these professionals. He says, “they do the remedies only 
to Paulette” which signifies the sentiment of disregard of his own suffering at the 
hands of the professionals in the hospital.
4.2 The attendance at the hospital during crises
Jules refers to the fact that Paulette is usually brought to the hospital during her 
seizures. “When her hands turn white or the eyes start to turn red, it’s because the blood 
is already reducing. When the blood reduces, she becomes very tired and heats a lot. We 
bring her to the hospital.”
The hospital is invested as having a curative function, given in urgency. All of 
this suggests that the family seeks hospital care only after failures of self-medication 
and preventive measures that it would have implemented to avoid or to relieve 
the crises. Obviously, this behavior of the family is an adaptation to the expensive 
nature of healthcare in a context where it is not reimbursed and where health 
insurance is non-existent [16]. This poses the problem of crisis prevention via the 
check-up of children with sickle cell anemia in sub-Saharan Africa, in general, and 
in Cameroon, in particular.
4.3 Recognition of non-effectiveness of crisis treatment in hospitals
Paulette’s seizures are treated in the hospital via transfusions, which relieves 
seizures for a time without eliminating them. Jules evokes the infernal cycle of 
crises, hospitalizations and returns home. He says, “in the hospital, she is given a lot 
of blood. When she takes the blood from the hospital, she comes home. It’s always like 
that for Paulette.” He recognizes the effectiveness of transfusion in relieving crises, 
but temporarily. What arouses him is an anguish of death concerning his sick sister 
“When I see it like that, my body trembles.”
Paulette’s illness is thought of as “a disease of the blood.” Jules knows, therefore, 
that the “affected” blood must be removed from Paulette’s body. “In order for it to 
end, you have to empty all the blood from your body. Like that it will come out with the 
disease.” In his view, this is not what hospital care professionals do because they put 
new blood in the sick child’s body and do nothing about the “bad” blood.
Hospital care professionals are referred to as “responsible” for the chronicity of 
crises. Jules disqualifies them and thinks that they cannot permanently relieve these 
crises. “The people in the hospital just put the blood into the bad blood. That is why the 
disease always comes back. When they put the good blood in their body, the bad blood eats 
up all the good blood, and the disease begins again.” This recognition of the inefficiency 
of hospital care arouses his anger against these professionals whom he designates as 
ineffective against the worsening of his sister’s state of health. It is possible that Jules, 
by this anger, projects on these professionals, his feeling of helplessness concerning the 
crises his sister goes through and the feeling of concomitant guilt. Medical profession-
als can also understand it as a cry for recognition and take into account his experience.
The hospital is designated as responsible for the death of the last daughter of the 
mother, who died from a sickle cell anemia crisis during her hospitalization. “They 
put false blood in her body and she died. It was not necessary to put this blood in her 
body. When they put that blood, she died two days later. We were only called to be told 
that the child is dead, that we should take her body to the morgue.” As a result, Jules 
shows distrust of the hospital, hospital professionals and the handling of crises by 
these professionals whom he designates as responsible for the death of his sister.
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4.4 The traditional healer treats the patient and his family
The traditional healer cares for the sick child, her siblings, her parents and her 
extended family because the illness is considered an ailment of the patient and his 
family.
4.4.1 The care of the sick child
The traditional healer cares for the sick child’s body. The body is thought to be 
possessed by an “evil spirit,” an illness that manifests itself in the patient by chronic 
anemia and the seizures of pains in the back and feet. These symptoms inform the 
traditional healer about the extent of possession and persecution of the sick child’s 
body by wizards. In response to this possession/persecution, the traditional healer 
provides bodily care to the patient.
Jules says that he was wounded on the body. The painful parts of the sick child’s 
body are scarified to allow the therapist to act directly on the evil and to limit the 
destruction of the body by the wizards. He does this by administering a powder 
with magical powers, effective against sorcerers. Therefore, the care of the patient 
has a curative aim of “freeing” the patient from this possession and persecution by 
wizards. Thus, not only is the blood treated here, but also the body too.
4.4.2 Care of the brothers, sisters and the mother
Jules’ mother and his paternal uncle accompanied Paulette to the traditional 
healer. The brothers and sisters, who were absent from the consultation, received 
through the uncle the treatment given by the traditional therapist. Jules refers to 
the fact that his paternal uncle administered on him and his other siblings scarifica-
tions and he applied the powder from the traditional healer. Because the father is 
deceased, the paternal uncle went accompanied his mother and the sick sister to 
the traditional practitioner. This shows the involvement of the extended family in 
traditional care and support for the mother in this process apart from acting as an 
intermediary between the traditional healer and the family. He is also responsible 
for monitoring the application of the traditional medication.
At the requestion of the traditional healer, his paternal uncle scarified Jules just 
as he did to his sister. The treatment was administered orally and via scarification 
of the back. “Even my mother and my older sister ate the same medicine. After eating 
it, the remaining was put in the blood.” Thus, Paulette’s siblings and her mother who 
were considered at risk of becoming, and of being persecuted by witches were also 
subjected to the traditional treatment against sickle cell anemia. The goal of this 
treatment is to protect them against the ailment.
The traditional practitioner, through these treatments, sought to domesticate 
the harm represented by the disease. He did not seek to exclude this evil from the 
family, but to transform it into an entity likely to cohabit in harmony with family 
members. The “bad” blood of the sick child is thus transformed into “good” blood, 
into a blood that is no longer a threat to him or to the family members. This therapy 
does not aim at excluding the “evil” from the family, but to make the ailment an 
entity of the family and to bring the family members to accept it as such [43].
4.5 The experience of traditional treatment
With Jules, there is a before and an after of traditional treatment. An “unse-
cured” pre-treatment period where the threat of contamination by the disease 
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looms, and a more “secure” post-treatment period when the threat is contained by 
receiving traditional treatment.
4.5.1 Treatment reduces feelings of insecurity
Jules thinks of the traditional treatment as a protection against its contamination 
by the disease. Taking this treatment is associated with a reduction of fear regarding 
the disease and possible contamination. He says, “I’m not too scared. Before I was 
very scared. Now, with the remedy in my body, I’m not as afraid as I was before.” It is 
interesting to note that although the fear of his sister’s death has diminished, it still 
lingers in his mind. He experiences his body as less vulnerable and more protected 
against the disease. This indicates that at this point, Jules feels safer with the disease 
and with the wizards.
The receiving of traditional treatment against sickle cell anemia thus helps Jules 
contain the fear and anguish that arises in him because of his sister’s illness. It helps 
him to contain his feelings of persecution by the wizards and the fear of infection 
with the disease even if it does not totally eliminate this fear.
4.5.2 Treatment makes blood bad for wizards
For Jules, the blood of the patient is a dead blood, a blood possessed by the 
wizards. In this sense, “a bad blood” attacks the “good blood” transfused into the 
patient during hospitalizations. According to him, this gives meaning to the chronic 
anemia and the iterative crises of pain that his sick sister experiences.
The traditional treatment is thought by Jules to be effective against wizards. It 
makes the blood of the sick and the non-sick unassailable by wizards. His treat-
ment reduces the feeling of persecution by wizards, even in the event that his sister 
dies. “They will not look for me anymore,” he says. The traditional treatment is thus 
invested as a protection against the attacks of wizards, against the disease and, of 
course, against Paulette’s and his own death.
Jules does not associate the death of a patient with the end of the disease as in 
the case of his mother’s youngest daughter, which preceded that of their father. 
According to him, the disease survives and invests another child or family mem-
ber. This leads Jules to think of himself as the next potential victim of the disease 
in the event of Paulette’s death. “If Paulette dies after her little sister, that means 
we’re going to get another person to kill. If she dies, another person will die. That’s 
what scares me.” Jules has a fear of death concerning his sister. He suffers more 
from this fear of death that he feels threatened by the disease, this “death”. He 
thinks of his sister’s imminent death and, therefore, his infection with the disease 
and his own death.
The administration of the traditional treatment leads Jules to say this about the 
wizards, “it’s over for them, everyone ate the cure, everyone is armored,” and specifi-
cally, “when wizards enter the family they do not leave.” In connection with receiving 
traditional treatment, he says one thing and then contradicts it. He expresses 
ambivalent feelings of protection against and vulnerability to wizards. This sug-
gests that the sense of security against witchcraft remains feeble, as the feelings of 
insecurity were never really eliminated.
4.6 The contribution of the drawing
The drawing was made, after the interview, on the dining table in the living 
room, lit by sunlight.
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4.4 The traditional healer treats the patient and his family
The traditional healer cares for the sick child, her siblings, her parents and her 
extended family because the illness is considered an ailment of the patient and his 
family.
4.4.1 The care of the sick child
The traditional healer cares for the sick child’s body. The body is thought to be 
possessed by an “evil spirit,” an illness that manifests itself in the patient by chronic 
anemia and the seizures of pains in the back and feet. These symptoms inform the 
traditional healer about the extent of possession and persecution of the sick child’s 
body by wizards. In response to this possession/persecution, the traditional healer 
provides bodily care to the patient.
Jules says that he was wounded on the body. The painful parts of the sick child’s 
body are scarified to allow the therapist to act directly on the evil and to limit the 
destruction of the body by the wizards. He does this by administering a powder 
with magical powers, effective against sorcerers. Therefore, the care of the patient 
has a curative aim of “freeing” the patient from this possession and persecution by 
wizards. Thus, not only is the blood treated here, but also the body too.
4.4.2 Care of the brothers, sisters and the mother
Jules’ mother and his paternal uncle accompanied Paulette to the traditional 
healer. The brothers and sisters, who were absent from the consultation, received 
through the uncle the treatment given by the traditional therapist. Jules refers to 
the fact that his paternal uncle administered on him and his other siblings scarifica-
tions and he applied the powder from the traditional healer. Because the father is 
deceased, the paternal uncle went accompanied his mother and the sick sister to 
the traditional practitioner. This shows the involvement of the extended family in 
traditional care and support for the mother in this process apart from acting as an 
intermediary between the traditional healer and the family. He is also responsible 
for monitoring the application of the traditional medication.
At the requestion of the traditional healer, his paternal uncle scarified Jules just 
as he did to his sister. The treatment was administered orally and via scarification 
of the back. “Even my mother and my older sister ate the same medicine. After eating 
it, the remaining was put in the blood.” Thus, Paulette’s siblings and her mother who 
were considered at risk of becoming, and of being persecuted by witches were also 
subjected to the traditional treatment against sickle cell anemia. The goal of this 
treatment is to protect them against the ailment.
The traditional practitioner, through these treatments, sought to domesticate 
the harm represented by the disease. He did not seek to exclude this evil from the 
family, but to transform it into an entity likely to cohabit in harmony with family 
members. The “bad” blood of the sick child is thus transformed into “good” blood, 
into a blood that is no longer a threat to him or to the family members. This therapy 
does not aim at excluding the “evil” from the family, but to make the ailment an 
entity of the family and to bring the family members to accept it as such [43].
4.5 The experience of traditional treatment
With Jules, there is a before and an after of traditional treatment. An “unse-
cured” pre-treatment period where the threat of contamination by the disease 
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looms, and a more “secure” post-treatment period when the threat is contained by 
receiving traditional treatment.
4.5.1 Treatment reduces feelings of insecurity
Jules thinks of the traditional treatment as a protection against its contamination 
by the disease. Taking this treatment is associated with a reduction of fear regarding 
the disease and possible contamination. He says, “I’m not too scared. Before I was 
very scared. Now, with the remedy in my body, I’m not as afraid as I was before.” It is 
interesting to note that although the fear of his sister’s death has diminished, it still 
lingers in his mind. He experiences his body as less vulnerable and more protected 
against the disease. This indicates that at this point, Jules feels safer with the disease 
and with the wizards.
The receiving of traditional treatment against sickle cell anemia thus helps Jules 
contain the fear and anguish that arises in him because of his sister’s illness. It helps 
him to contain his feelings of persecution by the wizards and the fear of infection 
with the disease even if it does not totally eliminate this fear.
4.5.2 Treatment makes blood bad for wizards
For Jules, the blood of the patient is a dead blood, a blood possessed by the 
wizards. In this sense, “a bad blood” attacks the “good blood” transfused into the 
patient during hospitalizations. According to him, this gives meaning to the chronic 
anemia and the iterative crises of pain that his sick sister experiences.
The traditional treatment is thought by Jules to be effective against wizards. It 
makes the blood of the sick and the non-sick unassailable by wizards. His treat-
ment reduces the feeling of persecution by wizards, even in the event that his sister 
dies. “They will not look for me anymore,” he says. The traditional treatment is thus 
invested as a protection against the attacks of wizards, against the disease and, of 
course, against Paulette’s and his own death.
Jules does not associate the death of a patient with the end of the disease as in 
the case of his mother’s youngest daughter, which preceded that of their father. 
According to him, the disease survives and invests another child or family mem-
ber. This leads Jules to think of himself as the next potential victim of the disease 
in the event of Paulette’s death. “If Paulette dies after her little sister, that means 
we’re going to get another person to kill. If she dies, another person will die. That’s 
what scares me.” Jules has a fear of death concerning his sister. He suffers more 
from this fear of death that he feels threatened by the disease, this “death”. He 
thinks of his sister’s imminent death and, therefore, his infection with the disease 
and his own death.
The administration of the traditional treatment leads Jules to say this about the 
wizards, “it’s over for them, everyone ate the cure, everyone is armored,” and specifi-
cally, “when wizards enter the family they do not leave.” In connection with receiving 
traditional treatment, he says one thing and then contradicts it. He expresses 
ambivalent feelings of protection against and vulnerability to wizards. This sug-
gests that the sense of security against witchcraft remains feeble, as the feelings of 
insecurity were never really eliminated.
4.6 The contribution of the drawing
The drawing was made, after the interview, on the dining table in the living 
room, lit by sunlight.
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4.6.1 The complexity of the instructions
Following the instruction “I would like you to draw your family” Jules says he does 
not know how to draw human beings. Regarding his family, he thinks he is too tall 
to be represented on a sheet of paper and he asked for a second drawing sheet. He 
was told that for this drawing, it is recommended that he use a single sheet.
Jules persisted in his request by asking whether he could draw the other people 
on the back of the paper. To this question, the answer was negative. Following these 
requests for clarification of the instructions, he resigned himself to drawing accord-
ing to the rules. This behavior is informative about the limits of family design in this 
context where the family is not limited to the father, the mother and the children. 
It is an extended family leading to the need to (re)think the handover, analysis and 
interpretation of this drawing in a sub-Saharan African context following [42].
4.6.2 The drawing of the extended family
The eldest daughter in the family (“grande soeur,” on the drawing) is the first 
character drawn by Jules, followed by his father (“papa” on the drawing) the second 
character. This can signify in Jules that this sister is the most important person in the 
family because she provides a home near the hospital and money for medical bills. 
She took the role of the father. That can be why the father is then drawn second. 
Mother (“maman” on drawing), older brother (“grand frère Willie” on drawing), 
cousin (“grand frère Hugo” on drawing), maternal uncle and aunt, mother’s aunt, 
paternal aunt, other maternal uncle, cousin mother (“grande soeur Manuella” on 
drawing), her maternal cousin (“petit frère” on the drawing) and her maternal 
grandmother were, respectively, drawn by Jules. All the characters in the drawing 
are real. There are no fictional characters. The drawing is invested as a projective 
support on which Jules illustrates what he lives and thinks about his family in con-
nection with the illness of his sister.
That Jules’s drawing includes his extended family reflects his sense of belonging 
to it and the support it brings to his immediate family in the face of his sister’s illness 
and the successive deaths of his father and youngest sister. It is thus a drawing on 
which is projected the family solidarity surrounding his sister’s illness (Figure 1).
The characters are not very invested by Jules, who drew them in a very minimal-
ist way. It is possible that he wanted to draw all the members of the extended family, 
which would have led him to drawing his characters in a minimalist way on the 
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Moreover, this is the first time that he drew human characters without drawing on 
a predefined model as he often does at school. However, a large part of the sheet 
is empty. The drawing is in the “upper central part” high center of the sheet, in a 
portrait orientation. The drawing location in the upper part of the document can 
signify the escape of the present, the escape towards the unreal and the distance 
from oneself according to [41]. It is therefore possible that this drawing signifies 
Jules’ avoidance concerning his family, which is “inhabited” by death and disease. 
This may justify his lack of drawing.
No character is in contact with others as they do not touch each other. This 
can be interpreted as lack of family support and the isolation of family members 
according to [41]. This interpretation is questionable, however, in a cultural con-
text where affection and support do not necessarily manifest themselves through 
physical contact [26] through touch, caress or hug, for example, thus reflecting the 
complexity of this child’s life.
4.6.3 The elder sister, a father figure
Jules says he drew “these people” in his father’s house, at his father’s funeral in his 
village. Of all these characters, the elder sister (“la grande soeur” on the drawing) is 
designated as the happiest person. This is because, according to Jules, she bought the 
coffin for the burial of his father. The mother is referred to as the least happy person 
in the drawing because “she was crying because she had lost her husband.” The elder 
sister is invested psychologically and symbolically as the father of the family. She is 
the one who provided financial support for the funeral. She is designated as the nic-
est person in the drawing because she looks after her siblings. The fact that Jules first 
drew his older sister might reflect her emotional over-investment. She is invested as 
a mother emotionally and symbolically. The least kind person is the paternal aunt 
(paternal aunt, on the drawing). Jules justifies himself by declaring, “It is they who 
caused the village to be fired. They are mean. They said that mom killed her husband.”
When asked what role he would like to take within the family dynamic in the 
drawing, if he had the opportunity, Jules points to his mother saying, “She is kind. 
As I go to school, she always buys me lunch.” This reveals the mother’s nurturing role in 
the family and invests her as an identification figure.
4.6.4 The absence of Jules on the drawing of a mourning scene
Jules said he had drawn his family members in his father’s house during his 
father’s funeral in his village. This tells us that he is still suffering grieving the 
death of his father. It is possible that Jules represents himself and associates his 
family with death, due to the past deaths of his father and his youngest sister, along 
with the imminent and distressing risk of the death of his sick sister. The family is 
therefore thought to be inhabited by death.
Jules’s absence from the drawing may reflect his avoidance of the family, which 
he associates with disease and death. With this, he avoids living psychologically in 
this family dynamic, where he feels insecure about the circumstances. The sick child 
is also absent from the drawing. This can translate, for Jules, the anguish regarding 
the potential death of his sister. The sick sister is thus excluded from the family 
dynamic, thought of as not making/leaving her because of an illness that makes her 
a “dead” person. It could also be a way of distancing himself from this sister who 
reminds him of the suffering of the family. This absence contrasts with the presence 
of his later father.
The presence of the father in the drawing can explain in Jules the incomplete 
mourning process of this father who is still invested as alive. He remains present 
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Moreover, this is the first time that he drew human characters without drawing on 
a predefined model as he often does at school. However, a large part of the sheet 
is empty. The drawing is in the “upper central part” high center of the sheet, in a 
portrait orientation. The drawing location in the upper part of the document can 
signify the escape of the present, the escape towards the unreal and the distance 
from oneself according to [41]. It is therefore possible that this drawing signifies 
Jules’ avoidance concerning his family, which is “inhabited” by death and disease. 
This may justify his lack of drawing.
No character is in contact with others as they do not touch each other. This 
can be interpreted as lack of family support and the isolation of family members 
according to [41]. This interpretation is questionable, however, in a cultural con-
text where affection and support do not necessarily manifest themselves through 
physical contact [26] through touch, caress or hug, for example, thus reflecting the 
complexity of this child’s life.
4.6.3 The elder sister, a father figure
Jules says he drew “these people” in his father’s house, at his father’s funeral in his 
village. Of all these characters, the elder sister (“la grande soeur” on the drawing) is 
designated as the happiest person. This is because, according to Jules, she bought the 
coffin for the burial of his father. The mother is referred to as the least happy person 
in the drawing because “she was crying because she had lost her husband.” The elder 
sister is invested psychologically and symbolically as the father of the family. She is 
the one who provided financial support for the funeral. She is designated as the nic-
est person in the drawing because she looks after her siblings. The fact that Jules first 
drew his older sister might reflect her emotional over-investment. She is invested as 
a mother emotionally and symbolically. The least kind person is the paternal aunt 
(paternal aunt, on the drawing). Jules justifies himself by declaring, “It is they who 
caused the village to be fired. They are mean. They said that mom killed her husband.”
When asked what role he would like to take within the family dynamic in the 
drawing, if he had the opportunity, Jules points to his mother saying, “She is kind. 
As I go to school, she always buys me lunch.” This reveals the mother’s nurturing role in 
the family and invests her as an identification figure.
4.6.4 The absence of Jules on the drawing of a mourning scene
Jules said he had drawn his family members in his father’s house during his 
father’s funeral in his village. This tells us that he is still suffering grieving the 
death of his father. It is possible that Jules represents himself and associates his 
family with death, due to the past deaths of his father and his youngest sister, along 
with the imminent and distressing risk of the death of his sick sister. The family is 
therefore thought to be inhabited by death.
Jules’s absence from the drawing may reflect his avoidance of the family, which 
he associates with disease and death. With this, he avoids living psychologically in 
this family dynamic, where he feels insecure about the circumstances. The sick child 
is also absent from the drawing. This can translate, for Jules, the anguish regarding 
the potential death of his sister. The sick sister is thus excluded from the family 
dynamic, thought of as not making/leaving her because of an illness that makes her 
a “dead” person. It could also be a way of distancing himself from this sister who 
reminds him of the suffering of the family. This absence contrasts with the presence 
of his later father.
The presence of the father in the drawing can explain in Jules the incomplete 
mourning process of this father who is still invested as alive. He remains present 
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beyond his death; unlike the other daughter who died before him. While the dead 
father remains present (illustrated on the drawing), the sick sister’ s absence from 
the drawing may signify Jules’ avoidance of this sister and therefore, avoidance 
of the threat of death that accompanies her illness. On a psychological level, Jule’s 
drawing may signify that, the living sister is dead, while the dead father remains 
alive. This complexity of Jules’s experiences is illustrated within his drawing.
4.6.5 Friends and other supporters of Jules
Jules perceives the children in the neighborhood as helpers and supporters con-
cerning his sister’s illness. They are friends who support him by protecting his sister 
during games and other interactions with her. “The children do not bother Paulette. 
They go to school and come back together. They do not cause any problems. Even when 
we play together, there are no provocations.” Of course, these friends know that Jules is 
protective of his sick sister. They support him in this way by also protecting her and 
he is grateful for this.
Jules’ friends are curiously absent from the drawing. He differentiates them from 
the members of the family. He does not make them part of his family; and hence their 
absence. In a cultural context where people with whom the subject has special rela-
tionships are considered to be members of their family [14], the absence of friends of 
the drawing is significant. This can tell you that Jules differentiates his friends from 
family members. Therefore, the support provided by the friends does not compen-
sate for his feeling of abandonment by family members. They are considered outsid-
ers and they may have no obligation over his situation. It could also exhibit his need 
for more support from within as the outside support could be a privilege.
4.6.6 The absence of care professionals
Healthcare professionals (hospital and traditional healers) are completely absent 
from the drawing. This absence can translate into their investment by Jules as 
outsiders to the family.
It is also possible that Jules did not draw them because their presence acts as that 
of the disease and, obviously, the risk of contamination and death. This absence can 
indicate a psychological effort to avoid anything that reminds him of the disease. 
In Jules, this absence can refer to the feeling that the traditional therapist does not 
protect him against the idea of possible contamination by the disease. It is possible 
that he did not draw the hospital professionals in order to protect himself against 
the feeling of abandonment by them.
4.6.7 The request for recognition of his experience
At the end of the drawing, Jules handed his drawing to me while smiling and he 
asked me to protect it well because it is very fragile. By a projection mechanism, he 
could be asking me to pay attention to his psychological suffering.
At the end of the meeting, with the agreement of Jules and following the requests 
of his elder sister, we presented the drawing to her and the mother. It is possible 
that Jules found by this means a way to make them understand his experience with 
Paulette’s disease in a family context where talking about the disease remains taboo. 
Particularly moved by finding themselves in the drawing, the elder sister and the 
mother criticized the “non-human” nature of the characters he drew and the absence 
of the use of many colors on the drawing. The elder sister put this in relation to the 
pedagogical approaches used at school, which do not enable children to draw freely.
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5. Discussion
With the exception of the sick child who is named by Jules during the interview, 
parents and siblings are referred to as parents or siblings. The eldest daughter is 
referred to as “my big sister,” the brother who is a taxi driver as “my older brother,” 
the sick sister as “the last daughter of mother,” this is very important as she also died 
of sickle cell anemia. He does not refer to her as ‘sister’ maybe because he wants to 
distance himself from the condition which eventually led to her death, the things he 
fears most, and that have become a part of his family. This shows the specificity of 
his links to his sick sister. Jules refers to her niece as “the daughter of my older sister,” 
thereby differentiating his brothers and sisters from his niece. He referred the father 
and mother as “father” and “mother.”
Four people appear in Jules’s drawing. Referred to in the interview as “my older 
sister,” the eldest daughter is designated on the drawing as “the big sister.” The 
brother who is a taxi driver is, however, named “big brother Willie” on the draw-
ing while he is referred to as “my big brother” in the interview. The father and the 
mother are designated in the drawing by “daddy” and “mother.” However, the father 
is absent from the interview. The absence of the father within Jules’ speech is not 
synonymous with his absence in the psychological universe of the interviewee, as 
he is present on the drawing. This makes the drawing a mediator to speech and a 
complementary tool in the interview.
Not all the people mentioned in the interviews appear in the drawing, and those 
in the interviews are named differently in the interviews. This account for Jules’ 
psychological dynamics concerning his links to family members and the complexity 
of these links.
The valorization of the traditional treatment (as financially expensive for the fami-
lies as the medical treatment) contrasts with Jules persistence of the feeling of insecu-
rity regarding wizards. It suggests that the treatment is not necessarily valued for its 
therapeutic efficacy. In a context where the traditional practitioner is considered as 
the intermediary between the ancestors and the living [44], it is forbidden to devalue 
their treatment. To do so would amount to devaluing the ancestors and running the 
risk of punishment, which could lead to death. The ancestor is incomparable [45] and 
therefore not criticizable. It can be dangerous to criticize the traditional treatment, as 
Jules emphasizes that it “alleviates” the fear and concerns the whole family.
Jules did not mention any consultation with a pastor, a priest or an imam. This is a 
problem in a context where families normally invest religious institutions (churches 
and mosques) to express their suffering and overwhelming misfortune [46]. It is 
possible that Jules, whose family is Christian, avoided talking about the care of his 
sister by the priest or by the pastor to a researcher whose family is of Muslim descent. 
He would have considered it disrespectful to talk about his religion to a researcher 
belonging to another religious denomination. It is also possible that, in not telling 
the researcher about his sister’s consultation with priests or pastors, this young boy 
avoided hitting the researcher’s religious sensitivity. He may not have talked to the 
researcher about this so as not to make him feel uncomfortable during the meeting.
In addition, this study showed that the traditional healer assigns, the uncle 
rather than the mother in the administration and follow-up of the care of the 
children and the family. This can be understood by the fact that the woman is often 
considered by traditional healers, as a being who can reduce the effectiveness of the 
treatment if she were to touch the patient [47]. Consequently, men are more often 
empowered to monitor and to enforce the prescriptions of traditional healers. It 
is also possible that the exclusion of women in this follow-up is motivated by the 
fact that they are considered to be responsible for the transmission of the disease 
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therapeutic efficacy. In a context where the traditional practitioner is considered as 
the intermediary between the ancestors and the living [44], it is forbidden to devalue 
their treatment. To do so would amount to devaluing the ancestors and running the 
risk of punishment, which could lead to death. The ancestor is incomparable [45] and 
therefore not criticizable. It can be dangerous to criticize the traditional treatment, as 
Jules emphasizes that it “alleviates” the fear and concerns the whole family.
Jules did not mention any consultation with a pastor, a priest or an imam. This is a 
problem in a context where families normally invest religious institutions (churches 
and mosques) to express their suffering and overwhelming misfortune [46]. It is 
possible that Jules, whose family is Christian, avoided talking about the care of his 
sister by the priest or by the pastor to a researcher whose family is of Muslim descent. 
He would have considered it disrespectful to talk about his religion to a researcher 
belonging to another religious denomination. It is also possible that, in not telling 
the researcher about his sister’s consultation with priests or pastors, this young boy 
avoided hitting the researcher’s religious sensitivity. He may not have talked to the 
researcher about this so as not to make him feel uncomfortable during the meeting.
In addition, this study showed that the traditional healer assigns, the uncle 
rather than the mother in the administration and follow-up of the care of the 
children and the family. This can be understood by the fact that the woman is often 
considered by traditional healers, as a being who can reduce the effectiveness of the 
treatment if she were to touch the patient [47]. Consequently, men are more often 
empowered to monitor and to enforce the prescriptions of traditional healers. It 
is also possible that the exclusion of women in this follow-up is motivated by the 
fact that they are considered to be responsible for the transmission of the disease 
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to the child [14] and hence as a “stain” in family [4] and a hindrance to traditional 
treatment. In this case, it would be interesting to understand how mothers and 
fathers experience the care of their children with sickle cell anemia by hospital and 
traditional healers.
Jules’s family agreed to participate in the research despite the fact that sickle cell 
anemia remains a taboo subject in African families [2]. It is possible that this family 
invested the research as a means of understanding the experience of the broth-
ers and sisters of the sick child. The researcher can be considered a mediator who 
allows the family to talk indirectly about sickle cell anemia with the sick child and 
his siblings. The parents do not themselves talk with the children about this disease, 
but they prefer that someone else did it. Although this can be a coping mechanism 
due to the guilt they experience regarding the situation, they consider themselves 
as parents who have transgressed a cultural norm whose consequence is the child’s 
illness. This behavior of the parents remains complex. Anyway, the participation of 
the family in this research shows the interest they had in understanding the experi-
ence of all the children in relation to the disease.
This research also allowed Jules to tell the researcher, his family and care profes-
sionals his experience with his sister’s illness despite it being a taboo subject. It has 
therefore d upset the norm or violated the family taboo on sickle cell anemia. It 
would be interesting to understand the impact of Jules and his family’s participation 
in this research on the mother, the sick child and Jules himself.
6. Conclusion
This article presents results similar to those of other works concerning the 
co-existence of traditional and modern representations of sickle cell anemia among 
sub-Saharan African families [9, 36] and their involvement in traditional and 
modern care systems [46]. Finally, Jules knows that in the event of seizures, only the 
hospital (where she is taken only for emergencies) can mitigate them and that there 
is a possibility that the treatment can fail and lead to her death, the brothers and 
sisters are then absent from this care. The traditional healers, meanwhile, intervene 
before crises in order to prevent them before they occur. This intervention protects 
the sick child and their family against the wizards, who are designated as respon-
sible for the attacks and thereby the danger of a possible transmission of the disease 
to the patient’s brothers and sisters.
This research indicates the need for spaces of speech within healthcare 
institutions that can enable families, parents and children to express their experi-
ences with illness and care. It also indicates the need for professionals to take 
these experiences into account. It would therefore be interesting to question the 
experience of the sick child with the side by side existence of two care systems 
within the family.
Acknowledgements





Sickle Cell Anemia, Representations and Care: Experience of a Brother of a Sick Child…
DOI: http://dx.doi.org/10.5772/intechopen.90995
Author details
Hassan Njifon Nsangou1,2* and Régine Scelles2
1 Département de Philosophie-Psychologie-Sociologie, Université de Dschang, 
Cameroon
2 Laboratoire Clipsyd, Université Paris Nanterre, France
*Address all correspondence to: hassannji75@yahoo.fr
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Human Blood Group Systems and Haemoglobinopathies
52
to the child [14] and hence as a “stain” in family [4] and a hindrance to traditional 
treatment. In this case, it would be interesting to understand how mothers and 
fathers experience the care of their children with sickle cell anemia by hospital and 
traditional healers.
Jules’s family agreed to participate in the research despite the fact that sickle cell 
anemia remains a taboo subject in African families [2]. It is possible that this family 
invested the research as a means of understanding the experience of the broth-
ers and sisters of the sick child. The researcher can be considered a mediator who 
allows the family to talk indirectly about sickle cell anemia with the sick child and 
his siblings. The parents do not themselves talk with the children about this disease, 
but they prefer that someone else did it. Although this can be a coping mechanism 
due to the guilt they experience regarding the situation, they consider themselves 
as parents who have transgressed a cultural norm whose consequence is the child’s 
illness. This behavior of the parents remains complex. Anyway, the participation of 
the family in this research shows the interest they had in understanding the experi-
ence of all the children in relation to the disease.
This research also allowed Jules to tell the researcher, his family and care profes-
sionals his experience with his sister’s illness despite it being a taboo subject. It has 
therefore d upset the norm or violated the family taboo on sickle cell anemia. It 
would be interesting to understand the impact of Jules and his family’s participation 
in this research on the mother, the sick child and Jules himself.
6. Conclusion
This article presents results similar to those of other works concerning the 
co-existence of traditional and modern representations of sickle cell anemia among 
sub-Saharan African families [9, 36] and their involvement in traditional and 
modern care systems [46]. Finally, Jules knows that in the event of seizures, only the 
hospital (where she is taken only for emergencies) can mitigate them and that there 
is a possibility that the treatment can fail and lead to her death, the brothers and 
sisters are then absent from this care. The traditional healers, meanwhile, intervene 
before crises in order to prevent them before they occur. This intervention protects 
the sick child and their family against the wizards, who are designated as respon-
sible for the attacks and thereby the danger of a possible transmission of the disease 
to the patient’s brothers and sisters.
This research indicates the need for spaces of speech within healthcare 
institutions that can enable families, parents and children to express their experi-
ences with illness and care. It also indicates the need for professionals to take 
these experiences into account. It would therefore be interesting to question the 
experience of the sick child with the side by side existence of two care systems 
within the family.
Acknowledgements





Sickle Cell Anemia, Representations and Care: Experience of a Brother of a Sick Child…
DOI: http://dx.doi.org/10.5772/intechopen.90995
Author details
Hassan Njifon Nsangou1,2* and Régine Scelles2
1 Département de Philosophie-Psychologie-Sociologie, Université de Dschang, 
Cameroon
2 Laboratoire Clipsyd, Université Paris Nanterre, France
*Address all correspondence to: hassannji75@yahoo.fr
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
54
Human Blood Group Systems and Haemoglobinopathies
[1] Josset-Raffet E, Yi MK, 
Benkerrou M. La trajectoire corporelle 
et psychique de la douleur chez 
l’enfant atteint de drépanocytose. 
Neuropsychiatrie de l’Enfance et 
de l'Adolescence. 2016;64(2):131-
138. Disponible sur: http://www.
sciencedirect.com/science/article/pii/
S0222961716000040 [cité 8 sept 2017]
[2] Bonnet D. Rupture d’alliance 
contre rupture de filiation: Le cas de la 
drépanocytose. In: Dozon J-P, Fassin D, 
éditeurs. Critique de la santé publique: 
Une approche anthropologique. Paris: 
Balland; 2001. pp. 257-280. (Voix et 
Regards)
[3] World Health Organization. Sickle 
cell anaemia. Agenda item 11.4. 59th 
World Health Assembly [Internet]. 
2006. Disponible sur: http://www.
who.int/gb/ebwha/pdf_files/WHA59-
REC1/e/WHA59_2006_REC1 [cité 12 
juin 2012]
[4] Gernet S, Mestre C, 
Runel-Belliard C. Du pays d’origine 
au pays «d’accueil»: Perception 
de la maladie chez 26 familles 
drépanocytaires suivies au CHU de 
Bordeaux. Journal de pédiatrie et 
de puériculture. 2012;25(6):309-
315. Disponible sur: http://www.
em-consulte.com/en/article/771297 
[cité 14 juill 2017]
[5] Njifon Nsangou H, Falck J, Scelles R. 
Culture familiale de la drépanocytose et 
image du corps chez les enfants atteints. 
Annales Médico-psychologiques, revue 
psychiatrique. 2019. Disponible sur: 
http://www.sciencedirect.com/science/
article/pii/S0003448719302999 [cité 3 
déc 2019]
[6] Organisation Mondiale de la Santé. 
Drépanocytose: Une stratégie pour la 
Région africaine de l’OMS: Rapport 
du Directeur régional. OMS. Bureau 
régional de l’Afrique 2011. Disponible 
sur: http://www.who.int/iris/
handle/10665/1727 [cité 7 juill 2017]
[7] Weatherall DJ, Clegg JB. Inherited 
haemoglobin disorders: An increasing 
global health problem. Bulletin of 





o&tlng=en [cité 9 juill 2017]
[8] Pradère J, Drain É, Taïeb O, 
Dutray B, Abbal T, Champion M, et al. 
Le travail de guérison d’une maladie 
chronique de l’enfant: Enjeux, processus 
et vulnérabilités. La Psychiatrie de 
l’Enfant. 2008;51(1):73-124. Disponible 
sur: http://www.cairn.info/revue-la-
psychiatrie-de-l-enfant-2008-1-p-73.
htm [cité 7 juill 2017]
[9] d’Autume C, Cavadini R, Giannica D, 
Drain É, Giraud F, Moro MR, et al. «Le 
sang de mon frère». Expérience de la 
greffe intrafamiliale à travers dessins et 
discours d’enfants drépanocytaires,  
« My brother’s blood ». The experience 
of an intrafamilial transplant through 
drawings and the words of drepanocytic 
children. La Psychiatrie de l’Enfant. 
2015;57(2):355-408. Disponible sur: 
http://www.cairn.info/revue-la-
psychiatrie-de-l-enfant-2014-2-p-355.
htm [cité 12 juill 2017]
[10] Mbassa Menick D, Ngoh F. 
Maltraitance psychologique d’enfants 
drépanocytaires au Cameroun: 
Description et analyse de cas. Médecine 
Tropicale. 2001;61:163-168
[11] Fotso-Djemo J-B. Le regard de l’autre: 
Médecine traditionnelle africaine. Paris: 
Agence de Coopération Culturelle et 
Technique EdSilex; 1982. 447 p
[12] Keita T. Phénoménologie 
traditionnelle de l’enfance en Afrique. In: 
Itoua F, Tettekpoe DA, Traoré A, Keita T, 
References
55
Sickle Cell Anemia, Representations and Care: Experience of a Brother of a Sick Child…
DOI: http://dx.doi.org/10.5772/intechopen.90995
M’Baye M, Kotto E, et al., éditeurs. 
Famille, enfant et développement en 
Afrique. Paris: Uneso; 1988. pp. 99-139
[13] Bonnet D. Au-delà du gène et de 
la culture. Hommes et Migrations. 
2000;1225(1):23-38. Disponible sur: 
http://www.persee.fr/doc/homig_1142-
852x_2000_num_1225_1_3508 [cité 3 
juill 2017]
[14] Tsala Tsala J-P. Familles africaines 
en thérapie : Clinique de la famille 
camerounaise. Paris: Editions 
L’Harmattan; 2009. 268 p
[15] Bouchaud O. Intégrer les 
représentations culturelles dans la prise 
en charge des migrants. La Santé de 
l’Homme. 2007;392:25-27. Disponible sur: 
http://inpes.santepubliquefrance.fr/SLH/
articles/392/03.htm [cité 7 mars 2017]
[16] Ndjiengwe F. Du stigmate physique 
au marquage symbolique: Évolution 
de la construction identitaire dans la 
drépanocytose. In: Lainé A, Bonnet D, 
Keclard L, Romana M, éditeurs. La 
drépanocytose Regards croisés sur une 
maladie orpheline. Paris: KARTHALA 
Editions; 2004. pp. 221-228
[17] Ohene-Frempong K, Weiner SJ, 
Sleeper LA, Miller ST, Embury S, 
Moohr JW, et al. Cerebrovascular accidents 
in sickle cell disease: Rates and risk 
factors. Blood. 1998;91(1):288-
294. Disponible sur: http://www.
bloodjournal.org/content/91/1/288  
[cité 7 juill 2017]
[18] Njamnshi AK, Mbong EN,  
Wonkam A, Ongolo-Zogo P, 
Djientcheu VD, Sunjoh FL, et al. 
The epidemiology of stroke in sickle 
cell patients in Yaounde, Cameroon. 
Journal of the Neurological Sciences. 
2006;250(1):79-84. Disponible sur: 
http://www.sciencedirect.com/science/
article/pii/S0022510X06003327 [cité 7 
juill 2017]
[19] Kamdem A. L’évolution des 
pratiques dans la prise en charge de la 
drépanocytose chez l’enfant. In: 4ème 
symposium international du Réseau 
d’Etude de la Drépanocytose en Afrique 
Centrale (REDAC). Yaoundé; 2013. 
pp. 12-14
[20] Benkerrou M. Place de la greffe de 
cellules souches hématopoïétiques dans 
la drépanocytose. In: 4ème symposium 
international du Réseau d’Etude de la 
Drépanocytose en Afrique Centrale 
(REDAC). Yaoundé; 2013. pp. 30-33
[21] Lainé A. Parents d’enfants 
drépanocytaires face à la maladie et au 
système de soin. [Internet]. Paris; 2007. 
Disponible sur: https://hal.archives-
ouvertes.fr/hal-00326056 [cité 13 juill 
2017]
[22] Drain E, Pradère J, Taieb O, 
Dutray B, Champion M, Bonnet D, et al. 
Processus de guérison d’une maladie 
chronique: La drépanocytose traitée 
par allogreffe de cellules souches 
hématopoïétiques: Principaux résultats 
chez les adolescents. Neuropsychiatrie 
de l’Enfance et de l’Adolescence. 
2008;56(4-5):305-310. Disponible sur: 
http://www.documentation.ird.fr/hor/
fdi:010047377 [cité 4 juill 2017]
[23] Mboussou M. Soigner en rond : 
Sur le front du Partage de l’espace 
thérapeutique en Afrique noire. 
Nervure. 2002;1(15):22-25
[24] Mbassa Menick D. Les représentations 
sociales et culturelles du handicap de 
l’enfant en Afrique noire, Social and 
cultural perceptions of child disability 
in Subsaharian Africa. Perspectives Psy. 
2015;54(1):30-43. Disponible sur: http://
www.cairn.info/revue-perspectives-psy-
2015-1-p-30.htm [cité 7 juill 2017]
[25] Menick DM, Simliwa DK. Nouvelles 
religiosités en Afrique: Des croyants 
à l’épreuve de la folie. Perspectives 
Psy. 2007;46(4):387-404. Disponible 
sur: http://www.cairn.info/revue-
perspectives-psy-2007-4-p-387.htm 
[cité 7 juill 2017]
54
Human Blood Group Systems and Haemoglobinopathies
[1] Josset-Raffet E, Yi MK, 
Benkerrou M. La trajectoire corporelle 
et psychique de la douleur chez 
l’enfant atteint de drépanocytose. 
Neuropsychiatrie de l’Enfance et 
de l'Adolescence. 2016;64(2):131-
138. Disponible sur: http://www.
sciencedirect.com/science/article/pii/
S0222961716000040 [cité 8 sept 2017]
[2] Bonnet D. Rupture d’alliance 
contre rupture de filiation: Le cas de la 
drépanocytose. In: Dozon J-P, Fassin D, 
éditeurs. Critique de la santé publique: 
Une approche anthropologique. Paris: 
Balland; 2001. pp. 257-280. (Voix et 
Regards)
[3] World Health Organization. Sickle 
cell anaemia. Agenda item 11.4. 59th 
World Health Assembly [Internet]. 
2006. Disponible sur: http://www.
who.int/gb/ebwha/pdf_files/WHA59-
REC1/e/WHA59_2006_REC1 [cité 12 
juin 2012]
[4] Gernet S, Mestre C, 
Runel-Belliard C. Du pays d’origine 
au pays «d’accueil»: Perception 
de la maladie chez 26 familles 
drépanocytaires suivies au CHU de 
Bordeaux. Journal de pédiatrie et 
de puériculture. 2012;25(6):309-
315. Disponible sur: http://www.
em-consulte.com/en/article/771297 
[cité 14 juill 2017]
[5] Njifon Nsangou H, Falck J, Scelles R. 
Culture familiale de la drépanocytose et 
image du corps chez les enfants atteints. 
Annales Médico-psychologiques, revue 
psychiatrique. 2019. Disponible sur: 
http://www.sciencedirect.com/science/
article/pii/S0003448719302999 [cité 3 
déc 2019]
[6] Organisation Mondiale de la Santé. 
Drépanocytose: Une stratégie pour la 
Région africaine de l’OMS: Rapport 
du Directeur régional. OMS. Bureau 
régional de l’Afrique 2011. Disponible 
sur: http://www.who.int/iris/
handle/10665/1727 [cité 7 juill 2017]
[7] Weatherall DJ, Clegg JB. Inherited 
haemoglobin disorders: An increasing 
global health problem. Bulletin of 





o&tlng=en [cité 9 juill 2017]
[8] Pradère J, Drain É, Taïeb O, 
Dutray B, Abbal T, Champion M, et al. 
Le travail de guérison d’une maladie 
chronique de l’enfant: Enjeux, processus 
et vulnérabilités. La Psychiatrie de 
l’Enfant. 2008;51(1):73-124. Disponible 
sur: http://www.cairn.info/revue-la-
psychiatrie-de-l-enfant-2008-1-p-73.
htm [cité 7 juill 2017]
[9] d’Autume C, Cavadini R, Giannica D, 
Drain É, Giraud F, Moro MR, et al. «Le 
sang de mon frère». Expérience de la 
greffe intrafamiliale à travers dessins et 
discours d’enfants drépanocytaires,  
« My brother’s blood ». The experience 
of an intrafamilial transplant through 
drawings and the words of drepanocytic 
children. La Psychiatrie de l’Enfant. 
2015;57(2):355-408. Disponible sur: 
http://www.cairn.info/revue-la-
psychiatrie-de-l-enfant-2014-2-p-355.
htm [cité 12 juill 2017]
[10] Mbassa Menick D, Ngoh F. 
Maltraitance psychologique d’enfants 
drépanocytaires au Cameroun: 
Description et analyse de cas. Médecine 
Tropicale. 2001;61:163-168
[11] Fotso-Djemo J-B. Le regard de l’autre: 
Médecine traditionnelle africaine. Paris: 
Agence de Coopération Culturelle et 
Technique EdSilex; 1982. 447 p
[12] Keita T. Phénoménologie 
traditionnelle de l’enfance en Afrique. In: 
Itoua F, Tettekpoe DA, Traoré A, Keita T, 
References
55
Sickle Cell Anemia, Representations and Care: Experience of a Brother of a Sick Child…
DOI: http://dx.doi.org/10.5772/intechopen.90995
M’Baye M, Kotto E, et al., éditeurs. 
Famille, enfant et développement en 
Afrique. Paris: Uneso; 1988. pp. 99-139
[13] Bonnet D. Au-delà du gène et de 
la culture. Hommes et Migrations. 
2000;1225(1):23-38. Disponible sur: 
http://www.persee.fr/doc/homig_1142-
852x_2000_num_1225_1_3508 [cité 3 
juill 2017]
[14] Tsala Tsala J-P. Familles africaines 
en thérapie : Clinique de la famille 
camerounaise. Paris: Editions 
L’Harmattan; 2009. 268 p
[15] Bouchaud O. Intégrer les 
représentations culturelles dans la prise 
en charge des migrants. La Santé de 
l’Homme. 2007;392:25-27. Disponible sur: 
http://inpes.santepubliquefrance.fr/SLH/
articles/392/03.htm [cité 7 mars 2017]
[16] Ndjiengwe F. Du stigmate physique 
au marquage symbolique: Évolution 
de la construction identitaire dans la 
drépanocytose. In: Lainé A, Bonnet D, 
Keclard L, Romana M, éditeurs. La 
drépanocytose Regards croisés sur une 
maladie orpheline. Paris: KARTHALA 
Editions; 2004. pp. 221-228
[17] Ohene-Frempong K, Weiner SJ, 
Sleeper LA, Miller ST, Embury S, 
Moohr JW, et al. Cerebrovascular accidents 
in sickle cell disease: Rates and risk 
factors. Blood. 1998;91(1):288-
294. Disponible sur: http://www.
bloodjournal.org/content/91/1/288  
[cité 7 juill 2017]
[18] Njamnshi AK, Mbong EN,  
Wonkam A, Ongolo-Zogo P, 
Djientcheu VD, Sunjoh FL, et al. 
The epidemiology of stroke in sickle 
cell patients in Yaounde, Cameroon. 
Journal of the Neurological Sciences. 
2006;250(1):79-84. Disponible sur: 
http://www.sciencedirect.com/science/
article/pii/S0022510X06003327 [cité 7 
juill 2017]
[19] Kamdem A. L’évolution des 
pratiques dans la prise en charge de la 
drépanocytose chez l’enfant. In: 4ème 
symposium international du Réseau 
d’Etude de la Drépanocytose en Afrique 
Centrale (REDAC). Yaoundé; 2013. 
pp. 12-14
[20] Benkerrou M. Place de la greffe de 
cellules souches hématopoïétiques dans 
la drépanocytose. In: 4ème symposium 
international du Réseau d’Etude de la 
Drépanocytose en Afrique Centrale 
(REDAC). Yaoundé; 2013. pp. 30-33
[21] Lainé A. Parents d’enfants 
drépanocytaires face à la maladie et au 
système de soin. [Internet]. Paris; 2007. 
Disponible sur: https://hal.archives-
ouvertes.fr/hal-00326056 [cité 13 juill 
2017]
[22] Drain E, Pradère J, Taieb O, 
Dutray B, Champion M, Bonnet D, et al. 
Processus de guérison d’une maladie 
chronique: La drépanocytose traitée 
par allogreffe de cellules souches 
hématopoïétiques: Principaux résultats 
chez les adolescents. Neuropsychiatrie 
de l’Enfance et de l’Adolescence. 
2008;56(4-5):305-310. Disponible sur: 
http://www.documentation.ird.fr/hor/
fdi:010047377 [cité 4 juill 2017]
[23] Mboussou M. Soigner en rond : 
Sur le front du Partage de l’espace 
thérapeutique en Afrique noire. 
Nervure. 2002;1(15):22-25
[24] Mbassa Menick D. Les représentations 
sociales et culturelles du handicap de 
l’enfant en Afrique noire, Social and 
cultural perceptions of child disability 
in Subsaharian Africa. Perspectives Psy. 
2015;54(1):30-43. Disponible sur: http://
www.cairn.info/revue-perspectives-psy-
2015-1-p-30.htm [cité 7 juill 2017]
[25] Menick DM, Simliwa DK. Nouvelles 
religiosités en Afrique: Des croyants 
à l’épreuve de la folie. Perspectives 
Psy. 2007;46(4):387-404. Disponible 
sur: http://www.cairn.info/revue-
perspectives-psy-2007-4-p-387.htm 
[cité 7 juill 2017]
Human Blood Group Systems and Haemoglobinopathies
56
[26] Tsala Tsala J-P. Secret de famille et 
clinique de la famille africaine. Le Divan 
familial. 2010;19:31-46. Disponible sur: 
http://www.cairn.info/revue-le-divan-
familial-2007-2-p-31.htm [cité 9 juill 
2017]
[27] Ekomo Engolo C. Mutations socio-
économiques et conditions de vie des 
ménages ruraux au Cameroun. Revue 
Française de Sociologie. 2001;42(2):281-
294. Disponible sur: https://www.
persee.fr/doc/rfsoc_0035-2969_2001_
num_42_2_5355 [cité 21 mai 2018]
[28] Scelles R. Liens fraternels et 
handicap: De l’enfance à l’âge adulte, 
souffrances et ressources. Toulouse: 
Érès; 2010
[29] Scelles R. Frères et soeurs, complices 
et rivaux. Paris: Fleurus; 2003. 150 p  
(Le métier de parents)
[30] Evans RC, Burlew AK, Oler CH. 
Children with sickle-cell anemia: 
Parental relations, parent-child 
relations, and child behavior. Social 




[cité 14 juill 2017]
[31] Adegoke SA, Kuteyi EA. 
Psychosocial burden of sickle cell 
disease on the family, Nigeria: Original 
research. African Journal of Primary 
Health Care and Family Medicine. 
2012;4(1):1-6. Disponible sur: https://
journals.co.za/content/phcfm/4/1/
EJC133881 [cité 14 juill 2017]
[32] Assimadi JK, Gbadoé AD, 
Nyadanu M. L’impact familial de la 
drépanocytose au Togo. Archives 
de Pédiatrie. 2000;7(6):615-620. 
Disponible sur: http://www.
sciencedirect.com/science/article/pii/
S0929693X00801281 [cité 14 juill 2017]
[33] Burlew AK, Evans R, Oler C. The 
impact of a child with sickle cell 
disease on family dynamics. Annals of 
the New York Academy of Sciences. 
1989;565:161-171
[34] Luboya E, Tshilonda J-CB, Ekila MB, 
Aloni MN. Répercussions psychosociales 
de la drépanocytose sur les parents 
d’enfants vivant à Kinshasa, République 
Démocratique du Congo: Une étude 
qualitative. The Pan African Medical 
Journal. 2014;19. Disponible sur: http://
www.ncbi.nlm.nih.gov/pmc/articles/
PMC4282867/ [cité 14 juill 2017]
[35] Gesteira ECR, Bousso RS, Misko MD, 
Ichikawa CRF, Oliveira PP. Families 
of children with sickle cell disease: An 
integrative review. Online Brazilian 
Journal of Nursing. 2016;15(2):276-290. 
Disponible sur: http://www.objnursing.
uff.br/index.php/nursing/article/
view/5289 [cité 14 juill 2017]
[36] Njifon Nsangou H, Scelles R. 
Drépanocytose et fratrie: Regard croisé 
du vécu d’une sœur et d’un frère d’un 
enfant malade. Journal de Pédiatrie 
et de Puériculture. 2019;32(2):75-
84. Disponible sur: http://www.
sciencedirect.com/science/article/pii/
S0987798319300295 [cité 29 mars 2019]
[37] Souley A. «Emassi»: Discours 
autour de la drépanocytose en milieu 
Haoussa au Niger. In: Lainé A, Bonnet D, 
Keclard L, Romana M, éditeurs. La 
Drépanocytose: Regards croisés sur 
une maladie orpheline. Paris: Karthala; 
2004. pp. 141-169
[38] Anate K. L’imaginaire de la 
communication à travers le concept 
de parole en Afrique et en Occident. 
Communication et organisation. 
2002;22:12-21. Disponible sur: 
http://journals.openedition.org/
communicationorganisation/2773  
[cité 23 août 2018]
[39] Mappa S. Pouvoirs traditionnels 
et pouvoir d’Etat en Afrique: L’illusion 
universaliste. Paris: Karthala Editions; 
1998. 210 p
57
Sickle Cell Anemia, Representations and Care: Experience of a Brother of a Sick Child…
DOI: http://dx.doi.org/10.5772/intechopen.90995
[40] Ortigue MC, Ortigue E. Oedipe 
africain. Plon; 1973
[41] Jourdan C, Lachance J. Le dessin de 
famille: Présentation, grille de cotation, 
éléments d’interprétation. Paris: EAP 
Editions et Applications Psychologiques; 
2000
[42] Tsala Tsala J-P. Test du dessin de 
famille et familles africaines. Le cas du 
Cameroun. Problèmes et méthodologie 
de la recherche. Annales de la Faculté 
des Arts. Lettres et Sciences Humaines. 
1990;VI(1 et 2):201-216
[43] Bello MM, Giannotti A. Renaître en 
pays dendi. Couvade et possession au 
nord Benin. Paris: Le Grand Jardin; 2017. 
164 p
[44] Burguet D. Au fil du récit d’un 
devin-guérisseur. Alliances avec les 
esprits ancestraux et de la nature 
(Vonizongo, Imerina). Études océan 
Indien. 2014;51-52. Disponible sur: 
http://journals.openedition.org/
oceanindien/1560 [cité 13 oct 2018]
[45] Sow I. Les structures 
anthropologiques de la folie en Afrique 
Noire. Paris: Payot; 1978
[46] Mbassa Menick D. Famille, 
Foi, Folie et Soins en Afrique. Une 
pluralité des recours thérapeutiques 
complémentaires. Paris: Paari; 2018
[47] Faye SL. Quand les tradithérapeutes 
ouest-africains soignent l’infertilité 
conjugale à Dakar (Sénégal): 
Recompositions et dynamiques 
entrepreneuriales. Anthropologie & 
Santé Revue internationale francophone 
d’anthropologie de la santé. 2011;3. 
Disponible sur: http://journals.
openedition.org/anthropologiesante/755 
[cité 27 août 2018]
Human Blood Group Systems and Haemoglobinopathies
56
[26] Tsala Tsala J-P. Secret de famille et 
clinique de la famille africaine. Le Divan 
familial. 2010;19:31-46. Disponible sur: 
http://www.cairn.info/revue-le-divan-
familial-2007-2-p-31.htm [cité 9 juill 
2017]
[27] Ekomo Engolo C. Mutations socio-
économiques et conditions de vie des 
ménages ruraux au Cameroun. Revue 
Française de Sociologie. 2001;42(2):281-
294. Disponible sur: https://www.
persee.fr/doc/rfsoc_0035-2969_2001_
num_42_2_5355 [cité 21 mai 2018]
[28] Scelles R. Liens fraternels et 
handicap: De l’enfance à l’âge adulte, 
souffrances et ressources. Toulouse: 
Érès; 2010
[29] Scelles R. Frères et soeurs, complices 
et rivaux. Paris: Fleurus; 2003. 150 p  
(Le métier de parents)
[30] Evans RC, Burlew AK, Oler CH. 
Children with sickle-cell anemia: 
Parental relations, parent-child 
relations, and child behavior. Social 




[cité 14 juill 2017]
[31] Adegoke SA, Kuteyi EA. 
Psychosocial burden of sickle cell 
disease on the family, Nigeria: Original 
research. African Journal of Primary 
Health Care and Family Medicine. 
2012;4(1):1-6. Disponible sur: https://
journals.co.za/content/phcfm/4/1/
EJC133881 [cité 14 juill 2017]
[32] Assimadi JK, Gbadoé AD, 
Nyadanu M. L’impact familial de la 
drépanocytose au Togo. Archives 
de Pédiatrie. 2000;7(6):615-620. 
Disponible sur: http://www.
sciencedirect.com/science/article/pii/
S0929693X00801281 [cité 14 juill 2017]
[33] Burlew AK, Evans R, Oler C. The 
impact of a child with sickle cell 
disease on family dynamics. Annals of 
the New York Academy of Sciences. 
1989;565:161-171
[34] Luboya E, Tshilonda J-CB, Ekila MB, 
Aloni MN. Répercussions psychosociales 
de la drépanocytose sur les parents 
d’enfants vivant à Kinshasa, République 
Démocratique du Congo: Une étude 
qualitative. The Pan African Medical 
Journal. 2014;19. Disponible sur: http://
www.ncbi.nlm.nih.gov/pmc/articles/
PMC4282867/ [cité 14 juill 2017]
[35] Gesteira ECR, Bousso RS, Misko MD, 
Ichikawa CRF, Oliveira PP. Families 
of children with sickle cell disease: An 
integrative review. Online Brazilian 
Journal of Nursing. 2016;15(2):276-290. 
Disponible sur: http://www.objnursing.
uff.br/index.php/nursing/article/
view/5289 [cité 14 juill 2017]
[36] Njifon Nsangou H, Scelles R. 
Drépanocytose et fratrie: Regard croisé 
du vécu d’une sœur et d’un frère d’un 
enfant malade. Journal de Pédiatrie 
et de Puériculture. 2019;32(2):75-
84. Disponible sur: http://www.
sciencedirect.com/science/article/pii/
S0987798319300295 [cité 29 mars 2019]
[37] Souley A. «Emassi»: Discours 
autour de la drépanocytose en milieu 
Haoussa au Niger. In: Lainé A, Bonnet D, 
Keclard L, Romana M, éditeurs. La 
Drépanocytose: Regards croisés sur 
une maladie orpheline. Paris: Karthala; 
2004. pp. 141-169
[38] Anate K. L’imaginaire de la 
communication à travers le concept 
de parole en Afrique et en Occident. 
Communication et organisation. 
2002;22:12-21. Disponible sur: 
http://journals.openedition.org/
communicationorganisation/2773  
[cité 23 août 2018]
[39] Mappa S. Pouvoirs traditionnels 
et pouvoir d’Etat en Afrique: L’illusion 
universaliste. Paris: Karthala Editions; 
1998. 210 p
57
Sickle Cell Anemia, Representations and Care: Experience of a Brother of a Sick Child…
DOI: http://dx.doi.org/10.5772/intechopen.90995
[40] Ortigue MC, Ortigue E. Oedipe 
africain. Plon; 1973
[41] Jourdan C, Lachance J. Le dessin de 
famille: Présentation, grille de cotation, 
éléments d’interprétation. Paris: EAP 
Editions et Applications Psychologiques; 
2000
[42] Tsala Tsala J-P. Test du dessin de 
famille et familles africaines. Le cas du 
Cameroun. Problèmes et méthodologie 
de la recherche. Annales de la Faculté 
des Arts. Lettres et Sciences Humaines. 
1990;VI(1 et 2):201-216
[43] Bello MM, Giannotti A. Renaître en 
pays dendi. Couvade et possession au 
nord Benin. Paris: Le Grand Jardin; 2017. 
164 p
[44] Burguet D. Au fil du récit d’un 
devin-guérisseur. Alliances avec les 
esprits ancestraux et de la nature 
(Vonizongo, Imerina). Études océan 
Indien. 2014;51-52. Disponible sur: 
http://journals.openedition.org/
oceanindien/1560 [cité 13 oct 2018]
[45] Sow I. Les structures 
anthropologiques de la folie en Afrique 
Noire. Paris: Payot; 1978
[46] Mbassa Menick D. Famille, 
Foi, Folie et Soins en Afrique. Une 
pluralité des recours thérapeutiques 
complémentaires. Paris: Paari; 2018
[47] Faye SL. Quand les tradithérapeutes 
ouest-africains soignent l’infertilité 
conjugale à Dakar (Sénégal): 
Recompositions et dynamiques 
entrepreneuriales. Anthropologie & 
Santé Revue internationale francophone 
d’anthropologie de la santé. 2011;3. 
Disponible sur: http://journals.
openedition.org/anthropologiesante/755 
[cité 27 août 2018]
59
Chapter 3
Investigation and Management of 
Endocrinopathies in Thalassaemia 
Major
Kinda Al-Hourani, Jessica Lee Siew Hua and Parijat De
Abstract
A combination of sub-therapeutic chelation and subsequent iron overload are 
regarded as the principal drivers of endocrine dysfunction in thalassaemia. The 
clinical presentation of endocrine complications and their timing of onset can 
be highly variable, in part due to population heterogeneity but also variation in 
chelation strategies. Endocrinopathies commonly associated with thalassaemia 
include: growth delay; pubertal delay; gonadal dysfunction; thyroid disorders; 
parathyroid and adrenal gland impairment; impaired bone metabolism; and type 2 
diabetes mellitus. In this chapter we summarise the main presentations of endocrine 
disorder in thalassaemia, summarising their epidemiology, clinical presentation 
and pathophysiologic basis. Furthermore, we review screening, monitoring and 
treatment strategies, with particular regard to the UK Thalassaemia Society’s 2016 
National Standards.
Keywords: thalassaemia major, beta thalassaemia, endocrinopathy, endocrine 
dysfunction, iron overload, puberty, thyroid, adrenal, diabetes mellitus, bone density
1. Introduction
The inherited haemoglobinopathy thalassaemia major (also known as beta 
thalassaemia major) results from homozygous carriage of mutations at the beta-
globin locus, resulting in defective haemoglobin synthesis and a severe hypochro-
mic, microcytic anaemia. Epidemiologically, the largest incidence of thalassaemia 
major is in the Mediterranean countries and the Middle East, but demographic 
change and international migration have resulted in it posing a global health 
issue. Life expectancy has been radically increased by the advent of combined 
transfusion and chelation therapy, but this regimen is complicated by both citrate 
toxicity and the development of endocrine complications secondary to destructive 
haemosiderin deposition in glandular tissues, particularly during adolescence and 
young adulthood [1]. Pathologic iron deposition is concentrated in cardiac tissue, 
the liver parenchyma and endocrine glands [2], with the development of multiple 
endocrinopathies first being reported by Bannerman and colleagues in 1967 [3]. 
Determining the prevalence and onset patterns of endocrine disease in thalassaemia 
major remains a challenge, despite their high frequency; primarily, this related 
to variation in exposure to chelation therapy, compliance with chelation, and 
improved survival shedding light on new disease phenomena [4–8].
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and review as per 
NICE 9 Key Care 
Processes**
DM: home capillary 
blood glucose as 
per individual 
management plan
• IFG or IGT: fructosamine at 
6-monthly intervals
• Symptomatic hyperglycaemia: 
random plasma glucose ± 




Tests (TFTs)†: free 
TSH, free T3, free T4
• Clinical evidence of thyroid 
dysfunction: random TFTs
Puberty Systematic clinical 











history, no further 
investigations 
indicated





amenorrhoea develop ➔ measure 
LH/FSH/oestradiol. Specialist 
endocrine review advised before 
initiation of hormone replacement.
Growth 6-monthly: height/
weight/height velocity 
from diagnosis to 
attainment of final 
adult height
If concerns regarding growth 
delay: bone age estimation (wrist 
plain radiographs) at 1–2 year 
intervals




Vitamin D level• 6-monthly••: calcium/
phosphate/ALP ➔ 






Key: OGTT: oral glucose tolerance test DM: diabetes mellitus IFG: impaired fasting glycaemia IGT: impaired glucose 
tolerance DKA: diabetic ketoacidosis PTH: parathyroid hormone.
ALP: alkaline phosphatase LH: luteinizing hormone FSH: follicle-stimulating hormone SHBG: sex-hormone binding 
globulin.
*From puberty, or age 10 years if family history of DM.
†From age 12 years.
••From age 12 years.
**NICE 9 Key Care Processes: glycaemic control (via Fructosamine); blood pressure; cholesterol level; retinal 
screening; foot checks; urinary albumin testing; serum creatinine testing; weight monitoring; smoking status check.
‡Including, for female patients, menstrual history; for male patients: history of impotence.
•From age 2 years. UKTS (2016) guidelines recommend ~80 nmol/L optimal target following supplementation.
Table 1. 
Summary of endocrine investigations in thalassaemia major [after UK Thalassaemia Standards, 2016].
Chronic anaemia—and subsequent tissue hypoxia—results in compensatory 
increases in erythropoiesis and gastrointestinal iron absorption. In conjunction 
with regular blood transfusion, these processes conspire to produce massive iron 
deposition in thalassaemia. Iron is regulated exclusively at the level of absorption, 
with no excretory mechanism. Chelation therapies are available, but challenges 
in their administration, including via the parenteral route, and need for regular 
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blood monitoring, hamper their acceptability. The primary endocrine complica-
tions found in thalassaemia, in the order reviewed in this chapter, are: disorders of 
growth; sexual development and fertility; abnormal bone mineralisation; diabetes 
mellitus; hypothyroidism; and hypoadrenalism [9].
We have previously published an online Review of Endocrine Disorders in 
Thalassaemia in 2014 (Open Journal of Endocrine and Metabolic Diseases, 2014, 
4, 25–34). In this book chapter, we have updated all the latest evidence and dis-
cuss current thoughts & details of the multi-system endocrine involvement in 




• Impaired glucose regulation (IFG/
IGT) or Non-insulin treated Diabetes: 
Intensify chelation therapy, consider 
using combination chelation regimens
• Diabetes: Referral to diabetes specialist. 
Managed according to NICE treatment 
targets and recommendations for type 1 
and type 2 diabetes
In patients with symptoms/signs 
of Diabetic Ketoacidosis (DKA) 
who are acutely unwell and plasma 




• Hypothyroidism: thyroxine replacement ✦Hypothyroidism may impair cardiac 
function/rhythm




• Hypogonadism: hormone (oestrogen/
testosterone) replacement
• Females: combined oral contracep-
tive pill (when contraception is also 
required, or “post-menopausal” replace-
ment regime)
✦Specialist endocrine review 
advised before initiation of hormone 
replacement.
Growth • Positive growth hormone stimulation 




• Vitamin D replacement if required
• Bisphosphonates: considered for 
patients with low BMD for age►, fragility 
fractures and/or falling BMD despite 
adequate vitamin D levels
• Denosumab▷: advisable that treatment is 
supervised by a clinical with experience 
and interest in osteoporosis
• Bisphosphonate: should be 
reviewed after a maximum of 
5 years for oral agents and 3 years 
for IV agents. Bisphosphonate 
‘holiday’: is recommended after 




• Adrenal insufficiency: Hydrocortisone 
supplementation
✦Adrenal dysfunction may be 
subacute (during acute illness), 
consider adrenal support, even before 
formal proof of insufficiency is 
available
Key: DM: diabetes mellitus IFG: impaired fasting glycaemia IGT: impaired glucose tolerance DKA: diabetic 
ketoacidosis BMD: Bone Mineral Density GH: growth hormone.
✦Note.
►Z-score < −2.0 if premenopausal or under 50, t-score < −2.5 if post-menopausal or over 50.
▷Anti-RANKL monoclonal antibody.
✥some evidence for GH therapy in childhood only.
Table 2. 
Summary of endocrine treatments in thalassaemia major [after UK Thalassaemia Standards, 2016].
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2. Growth and development in thalassaemia
From the foetal, through to infantile, pre-pubertal period and puberty, children 
with thalassaemia exhibit delayed growth [9]. It is estimated that 20–30% of these 
children and adolescents are affected by growth hormone (GH) deficiency [10]. In 
the remainder of thalassaemic patients without overt growth hormone deficiency, 
provocative testing—for example clonidine or glucagon stimulation tests—suggests 
that peak GH levels are lower than seen in constitutive short stature. Dhouib et al. 
recently showed a 35% incidence of GH deficiency in a Tunisian paediatric cohort 
[11]. Multiple causes for growth failure have been posited. These include features 
directly related to iron overload, including free radical toxicity [12]; damage to 
other endocrine axes, including the GH/Insulin-like growth factor (IGF-1) axis 
[13], pubertal delay and hypothyroidism; and complications of therapy, includ-
ing chelation agent, particularly desferrioxamine, toxicity [14]. Hepatic cirrhosis, 
anaemia and zinc deficiency have also been implicated [15].
The anterior pituitary gland is particularly vulnerable to oxidative stress caused 
by free radicals, with even modest levels of iron deposition, detected by magnetic 
resonance imaging (MRI), disrupting its function [12]. Comparative studies of 
diurnal hormone secretion suggest that the 24-hour profile of GH secretion, and 
the response growth hormone releasing hormone (GHRH, secreted by the arcuate 
nucleus of the hypothalamus), in thalassaemic patients is similar that of children 
with idiopathic short stature [16]. It is posited that thalassaemia major may be 
associated with increased somatostatin tone, with subsequent disruption of GH 
secretion [17].
Thalassaemia major may be characterised by relative growth hormone defi-
ciency, implied by the low levels of serum IGF-1 but normal GH reserve seen in 
patients. The positive therapeutic response seen with exogenous GH supplementa-
tion implies that, at the post-receptor level, this resistance may only be partial 
[18]. Anaemia, ineffecient erythropoiesis and chelation therapy also inhibits linear 
growth in children with thalassaemia major. Desferrioxamine and pathologic iron 
deposition are proposed to disrupt local IGF-1 production and paracrine signalling 
at the growth plate [14], resulting in inhibition of cellular proliferation and mineral 
deposition. Truncal shortening and abnormal body proportions are frequently 
observed, and have been attributed to the disease process itself, compounded by 
iron and desferrioxamine toxicity [18]. Limited evidence is emerging that these 
phenomena may be at least partly contingent on the timing of initiation of chelation 
and its route of administration. Soliman and colleagues reported a cross-sectional 
cohort analysis of beta thalassaemia patients commenced on oral iron chelation 
(OIC) with desferoxamine either before (n = 15) or after (n = 40) attaining final 
adult height. In this small study, pre-pubertal initiation of OIC was correlated with 
increased final adult height, in parallel with a lower overall incidence of endocri-
nopathies and reduced hepatic iron deposition [19].
Karamifar et al. have demonstrated that 62.9% of girls and 69% of boys 
affected with thalassaemia were less than 2SD below the mean for normal height 
[20]. Sharma et al. studied an Indian cohort of beta-thalassaemic children on oral 
desferiprone, of whom 55% were of short stature and 27% had a height z-score 
less than −3 SD. In the subset with height z-score < −3 SD, 17 of 19 patients also 
had severely impaired GH induction in response to dynamic testing with clonidine 
[21]. In one cohort from Germany, 40.6% of patients were defined as being short in 
stature (final adult height < 3rd percentile/below 2 standard deviations [SD] from 
the mean) [22]. Soliman and colleagues replicated this observation, reporting short 
stature (<2SD) in 49% of their thalassaemic patients [23], whereas Borgna-Pignatti 
et al. reported short stature in 37% of their patients [24]. Moayeri et al. showed that 
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62% were less than 2SD and 49% were 3SD below the mean and also confirmed 
decreased growth hormone response to two provocative tests and low levels of 
IGF-1 in a majority of their thalassaemic patients24. Similar reduced responses 
to provocative tests have been reported in studies led by Gulati et al. (51%) and 
Theodiris et al. (20%) [10, 25]. Interestingly, Soliman et al. report that in a small 
sample of adult patients on oral chelation therapy, IGF-1 expression levels did not 
differ significantly between those with normal GH levels and those with GH defi-
ciency, despite significantly lower final adult height in the GH deficient group [19].
Although the results of short term GH therapy are encouraging, the impact 
of treatment on final height of non-GH deficient thalassaemic children remains 
uncertain [18] and often GH produces uncertain clinical response [26, 27]. Ngim et 
al. have undertaken a Cochrane Systematic Review of GH replacement in thalassae-
mia. A single non-randomised trial was eligible, which enrolled 20 Turkish children 
with beta-thalassaemia major, receiving either daily subcutaneous GH or standard 
care. It presented tentative evidence that height velocity may be increased with GH, 
but reported no significant differences in the height standard deviations between 
groups at the study end-point [28]. Most patients lack the pubertal spurt and have 
reduced GH peak amplitude [29], hence responses to recombinant human GH 
therapy is poor when compared with that of children with GH deficiency, idiopathic 
short stature or Turner Syndrome.
The 2016 United Kingdom Thalassemia Society (UKTS) guidelines recommend 
stringent assessment of growth during childhood. This includes recording of height 
(both sitting and standing), weight and height velocity at six-monthly intervals 
until final adult height is attained [30]. Height deficits should prompt referral to 
a paediatric endocrinologist. Plain hand/wrist radiographs at 1–2 year intervals 
until fusion of the epiphyses may aid investigation of faltering height velocity [30]. 
Reduced height velocity, particularly around age 8–12 years, should prompt consid-
eration of both desferrioxamine toxicity and GH deficiency, requiring GH stimula-
tion testing and supplementation if deficient [30].
In contrast to GH deficiency in childhood, GH abnormalities in adults with 
thalassaemia are less well characterised. Recent data from an I-CETA survey 
(International Network of Clinicians for Endocrinopathies in Thalassemia and 
Adolescent Medicine) covering 3314 adult thalassaemia major patients across 
15 international centres, reported a GH deficiency incidence of 3% [31]. The 
discrepancy between this figure and earlier estimates from paediatric cohorts is 
multifactorial. Unlike childhood growth failure, there is no obvious pathological 
correlate of adult growth hormone deficiency to prompt investigation. Adult 
GH deficiency can manifest with neuropsychiatric symptoms; abnormal body 
composition; and cardiac features, including both reduced exercise performance 
[32] and altered myocardial structure [33]. Soliman and colleagues have proposed 
criteria for GH deficiency screening in adults with thalassaemia major. These 
include individuals with high iron loads, short stature (height < −2.5 SDS), low 
serum IGF-1 (< −2 SDS) or existing cardiomyopathy [34]. Given increasing 
survival of patients with thalassaemia major into adulthood, this topic remains in 
need of further investigation.
3. Hypogonadism and puberty in thalassaemia
Sexual immaturity is a profound complication of severe thalassaemia [35]. 
Disruption of the hypothalamic–pituitary-gonadal axis (HPG) may result in 
infertility [36]. While hypogonadism can occur as a result of primary or second-
ary hypogonadism or as a combination of both, multiple studies have shown 
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2. Growth and development in thalassaemia
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deposition are proposed to disrupt local IGF-1 production and paracrine signalling 
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observed, and have been attributed to the disease process itself, compounded by 
iron and desferrioxamine toxicity [18]. Limited evidence is emerging that these 
phenomena may be at least partly contingent on the timing of initiation of chelation 
and its route of administration. Soliman and colleagues reported a cross-sectional 
cohort analysis of beta thalassaemia patients commenced on oral iron chelation 
(OIC) with desferoxamine either before (n = 15) or after (n = 40) attaining final 
adult height. In this small study, pre-pubertal initiation of OIC was correlated with 
increased final adult height, in parallel with a lower overall incidence of endocri-
nopathies and reduced hepatic iron deposition [19].
Karamifar et al. have demonstrated that 62.9% of girls and 69% of boys 
affected with thalassaemia were less than 2SD below the mean for normal height 
[20]. Sharma et al. studied an Indian cohort of beta-thalassaemic children on oral 
desferiprone, of whom 55% were of short stature and 27% had a height z-score 
less than −3 SD. In the subset with height z-score < −3 SD, 17 of 19 patients also 
had severely impaired GH induction in response to dynamic testing with clonidine 
[21]. In one cohort from Germany, 40.6% of patients were defined as being short in 
stature (final adult height < 3rd percentile/below 2 standard deviations [SD] from 
the mean) [22]. Soliman and colleagues replicated this observation, reporting short 
stature (<2SD) in 49% of their thalassaemic patients [23], whereas Borgna-Pignatti 
et al. reported short stature in 37% of their patients [24]. Moayeri et al. showed that 
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62% were less than 2SD and 49% were 3SD below the mean and also confirmed 
decreased growth hormone response to two provocative tests and low levels of 
IGF-1 in a majority of their thalassaemic patients24. Similar reduced responses 
to provocative tests have been reported in studies led by Gulati et al. (51%) and 
Theodiris et al. (20%) [10, 25]. Interestingly, Soliman et al. report that in a small 
sample of adult patients on oral chelation therapy, IGF-1 expression levels did not 
differ significantly between those with normal GH levels and those with GH defi-
ciency, despite significantly lower final adult height in the GH deficient group [19].
Although the results of short term GH therapy are encouraging, the impact 
of treatment on final height of non-GH deficient thalassaemic children remains 
uncertain [18] and often GH produces uncertain clinical response [26, 27]. Ngim et 
al. have undertaken a Cochrane Systematic Review of GH replacement in thalassae-
mia. A single non-randomised trial was eligible, which enrolled 20 Turkish children 
with beta-thalassaemia major, receiving either daily subcutaneous GH or standard 
care. It presented tentative evidence that height velocity may be increased with GH, 
but reported no significant differences in the height standard deviations between 
groups at the study end-point [28]. Most patients lack the pubertal spurt and have 
reduced GH peak amplitude [29], hence responses to recombinant human GH 
therapy is poor when compared with that of children with GH deficiency, idiopathic 
short stature or Turner Syndrome.
The 2016 United Kingdom Thalassemia Society (UKTS) guidelines recommend 
stringent assessment of growth during childhood. This includes recording of height 
(both sitting and standing), weight and height velocity at six-monthly intervals 
until final adult height is attained [30]. Height deficits should prompt referral to 
a paediatric endocrinologist. Plain hand/wrist radiographs at 1–2 year intervals 
until fusion of the epiphyses may aid investigation of faltering height velocity [30]. 
Reduced height velocity, particularly around age 8–12 years, should prompt consid-
eration of both desferrioxamine toxicity and GH deficiency, requiring GH stimula-
tion testing and supplementation if deficient [30].
In contrast to GH deficiency in childhood, GH abnormalities in adults with 
thalassaemia are less well characterised. Recent data from an I-CETA survey 
(International Network of Clinicians for Endocrinopathies in Thalassemia and 
Adolescent Medicine) covering 3314 adult thalassaemia major patients across 
15 international centres, reported a GH deficiency incidence of 3% [31]. The 
discrepancy between this figure and earlier estimates from paediatric cohorts is 
multifactorial. Unlike childhood growth failure, there is no obvious pathological 
correlate of adult growth hormone deficiency to prompt investigation. Adult 
GH deficiency can manifest with neuropsychiatric symptoms; abnormal body 
composition; and cardiac features, including both reduced exercise performance 
[32] and altered myocardial structure [33]. Soliman and colleagues have proposed 
criteria for GH deficiency screening in adults with thalassaemia major. These 
include individuals with high iron loads, short stature (height < −2.5 SDS), low 
serum IGF-1 (< −2 SDS) or existing cardiomyopathy [34]. Given increasing 
survival of patients with thalassaemia major into adulthood, this topic remains in 
need of further investigation.
3. Hypogonadism and puberty in thalassaemia
Sexual immaturity is a profound complication of severe thalassaemia [35]. 
Disruption of the hypothalamic–pituitary-gonadal axis (HPG) may result in 
infertility [36]. While hypogonadism can occur as a result of primary or second-
ary hypogonadism or as a combination of both, multiple studies have shown 
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gonadotropin failure (hypogonadotropic hypogonadism) is the commonest com-
plication [36, 37]. Primary gonadal failure is caused by iron deposition on gonadal 
tissue [37]. Secondary hypogonadism occurs as a result of pituitary gland gonado-
trophic cell iron deposition, as evidenced by GnRH stimulation which demonstrates 
inadequate FSH and LH response [38–40]. Failure of pubertal onset has a very 
high incidence rate, with studies varying between 50–100% [9]. In female patients, 
delayed puberty is defined as a lack of breast development in girls by age 13 and in 
male patients, by a lack of testicular development by age 14 [30].
Delayed puberty in patients with beta thalassaemia major occurs as a result 
of multiple factors. Evidence suggests that the accumulation of excess iron from 
multiple transfusions leads to tissue damage in multiple organs (e.g. the liver, heart, 
endocrine organs), and the presence of free radicals leads to oxidative stress [41]. 
Delays in sexual maturation has been shown to be a result of impaired synthesis of 
leptin caused by the deposition of iron on adipose tissue [42]. Adipose cells response 
to the expression of the ob gene to produce leptin which functions as an indicator to 
instigate puberty. Despite chelation therapy, iron accumulation continues to occur 
in the pituitary, hypothalamus and gonads [43]. The lack of response to gonadotro-
pin releasing hormone in patients with low gonadotropin levels is synonymous with 
hypothalamic and pituitary damage [44].
While MRI assessment of the pituitary gland for iron accumulation has been 
studied with promising results, it is currently not part of routine assessment [45]. In 
terms of growth velocity, patients with thalassaemia were found to have distinctly 
lower or completely absent annual growth rates [46]. Short stature was found in 
up to 20% of such patients [14] and the lack of pubertal growth spurt in puberty, 
whether spontaneous or induced, ultimately adversely affected the attainment of a 
normal final height [18]. Impairment of truncal growth [47] is also compounded by 
disproportionate body ratios and variation in spinal growth. As a result, failure of 
pubertal growth spurt, delayed or absence of sexual development and infertility are 
common sequelae among patients with beta thalassaemia major [36].
Hypogonadism as an endocrine complication in patients with thalassaemia 
major has been reported in multiple studies [36]. A high incidence of hypogonado-
tropic hypogonadism has been found by Chern et al. in their study population [48]. 
A 45% prevalence was found in male patients and 39% in female patients, with an 
overall prevalence of 72%. Of note were significant delays or cessation in develop-
ment of secondary sexual characteristics and the menstrual cycle. These findings 
were reiterated in a cross-sectional study set up in Hong Kong, in which 75% of 
female patients and 62% of male patients were found to have diminished gonadal 
function [13]. In a study conducted of by Saffari et al., hypogonadism was found 
to be the most common endocrine complication. From a study population of 77 
patients, 36 (46.8%) patients were found to have hypogonadism, 28 (36.4%) had 
delayed puberty and in 8 (10.4%) patients there was absence of pubertal progres-
sion [49]. In this study, it was also noted that there was ‘significant correlation 
between bone mineral density and pubertal status (p = 0.001). This study demon-
strates the effects of hypogonadism not only on the reproductive system, but also on 
bone mineral density as well [49].
Failure of puberty was reported by Moayeri et al. in 69% of patients with thalassae-
mia with suppressed FSH and LH levels (73.2% in male patients and 64.8% in female 
patients) [50]. Similar findings were reported in a separate Italian multicentre study, 
which described hypogonadism 47% of female patients and 51% of male patients. 
Hagag et al. demonstrated that in males testosterone levels and testicular volume were 
significantly lower in thalassaemic patients with iron overload [51]. A similar study 
conducted by Hagag et al. in female patients, they showed that FSH, LH and oestrogen 
levels were significantly lower in thalassaemic patients with iron overload [52].
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Pubertal failure has also been described in 73% of male and 42% of female 
patients under the age of 21 years old by Soliman et al. [23]. Similar findings were 
noted by Borgna-Pignatti and colleagues with 67% of males and 38% of females 
experiencing puberty failure [24]. Remarkably, successful conception may still be 
achieved by women who receive adequate chelation therapy.
Bone growth, growth velocity and puberty may be assisted by administration of 
chelation therapy before the commencement of sexual maturation and the use of 
low dose sex steroids in adolescence [9].
Current Standards for the Clinical Care of Children and Adults with 
Thalassaemia UK Guidelines recommend that assessment of gonadal function 
should be done annually throughout adulthood [30]. In men, this would include 
an annual morning testosterone level alongside LH/FSH and SHBG if testosterone 
levels are low. In women, no testing is required in the presence of a normal men-
strual history. However, in the presence of menstrual disturbances, further testing 
(LH/FSH and oestradiol) is recommended [30]. Deficiency should be replaced with 
oestrogen/testosterone while bearing in mind that under-replacement contributes 
to a low bone mineral density. Management is best achieved through a joint multi-
disciplinary consultation between the endocrinologist and thalassaemia team [30].
4. Glucose intolerance and diabetes mellitus
Effective management of patients suffering from homozygous beta thalassaemia 
has led to improved life expectancy and hence manifestations of haemosiderosis 
related complications, notably, disturbances of the exocrine and endocrine function 
of the pancreas [53]. The prevalence of glucose intolerance and diabetes mellitus 
(DM) in patients with homozygous beta thalassaemia has been found to be vari-
able. A retrospective analysis of 92 patients performed by Ang et al. showed that 
diabetes mellitus was one of the most common endocrinopathies with 41% of the 
study population affected [54] while a study conducted by Kanbour et al. reported 
a prevalence of 16.7% for impaired fasting glucose and 12.5% for diabetes mellitus 
[55]. Recently, a meta-analysis conducted by He et al. which included 44 studies 
with 16,605 cases showed that diabetes mellitus was present in 6.54%, impaired 
fasting glucose (IGF) in 17.21% and impaired glucose tolerance (IGT) in 12.46% 
[56]. While the prevalence of glucose intolerance and diabetes mellitus is undoubt-
edly high, many risk factors have also been identified. There was evidence of 
increased risk of diabetes mellitus with co-infection with hepatitis C [55–57], longer 
duration of disease [57–59] and with increased pancreatic iron deposition [58, 60].
Li et al. have found that in addition, patients with diabetes mellitus were charac-
terised by higher ferritin levels, smaller pancreas volume, lower cardiac T2 mag-
netic resonance signal (MRI) than patients without diabetes, and higher prevalence 
of hypogonadism. Interestingly, patients with diabetes were found to be young 
(median age was 22 years [range of 10 to 34 years]) and non-obese (BMI of 20.1 ± 
2.8 kg/m2) [58]. This may explain why the classical association between diabetes 
and increased prevalence of arteriosclerotic cardiovascular disease is not a feature 
in this population [30].
Poor compliance with desferrioxamine therapy (p < 0.05), older age commenc-
ing intensive chelation therapy, liver cirrhosis and severe fibrosis were found to be 
risk factors for glucose intolerance and diabetes mellitus. Risk factors for impaired 
glucose tolerance (IGT) also included male sex [61], poor compliance with desfer-
rioxamine therapy and high hepatic iron concentration.
Current UK guidelines recommend annual monitoring for impaired glucose 
tolerance and diabetes from the onset of puberty, or from the age of 10 years if 
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tissue [37]. Secondary hypogonadism occurs as a result of pituitary gland gonado-
trophic cell iron deposition, as evidenced by GnRH stimulation which demonstrates 
inadequate FSH and LH response [38–40]. Failure of pubertal onset has a very 
high incidence rate, with studies varying between 50–100% [9]. In female patients, 
delayed puberty is defined as a lack of breast development in girls by age 13 and in 
male patients, by a lack of testicular development by age 14 [30].
Delayed puberty in patients with beta thalassaemia major occurs as a result 
of multiple factors. Evidence suggests that the accumulation of excess iron from 
multiple transfusions leads to tissue damage in multiple organs (e.g. the liver, heart, 
endocrine organs), and the presence of free radicals leads to oxidative stress [41]. 
Delays in sexual maturation has been shown to be a result of impaired synthesis of 
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to the expression of the ob gene to produce leptin which functions as an indicator to 
instigate puberty. Despite chelation therapy, iron accumulation continues to occur 
in the pituitary, hypothalamus and gonads [43]. The lack of response to gonadotro-
pin releasing hormone in patients with low gonadotropin levels is synonymous with 
hypothalamic and pituitary damage [44].
While MRI assessment of the pituitary gland for iron accumulation has been 
studied with promising results, it is currently not part of routine assessment [45]. In 
terms of growth velocity, patients with thalassaemia were found to have distinctly 
lower or completely absent annual growth rates [46]. Short stature was found in 
up to 20% of such patients [14] and the lack of pubertal growth spurt in puberty, 
whether spontaneous or induced, ultimately adversely affected the attainment of a 
normal final height [18]. Impairment of truncal growth [47] is also compounded by 
disproportionate body ratios and variation in spinal growth. As a result, failure of 
pubertal growth spurt, delayed or absence of sexual development and infertility are 
common sequelae among patients with beta thalassaemia major [36].
Hypogonadism as an endocrine complication in patients with thalassaemia 
major has been reported in multiple studies [36]. A high incidence of hypogonado-
tropic hypogonadism has been found by Chern et al. in their study population [48]. 
A 45% prevalence was found in male patients and 39% in female patients, with an 
overall prevalence of 72%. Of note were significant delays or cessation in develop-
ment of secondary sexual characteristics and the menstrual cycle. These findings 
were reiterated in a cross-sectional study set up in Hong Kong, in which 75% of 
female patients and 62% of male patients were found to have diminished gonadal 
function [13]. In a study conducted of by Saffari et al., hypogonadism was found 
to be the most common endocrine complication. From a study population of 77 
patients, 36 (46.8%) patients were found to have hypogonadism, 28 (36.4%) had 
delayed puberty and in 8 (10.4%) patients there was absence of pubertal progres-
sion [49]. In this study, it was also noted that there was ‘significant correlation 
between bone mineral density and pubertal status (p = 0.001). This study demon-
strates the effects of hypogonadism not only on the reproductive system, but also on 
bone mineral density as well [49].
Failure of puberty was reported by Moayeri et al. in 69% of patients with thalassae-
mia with suppressed FSH and LH levels (73.2% in male patients and 64.8% in female 
patients) [50]. Similar findings were reported in a separate Italian multicentre study, 
which described hypogonadism 47% of female patients and 51% of male patients. 
Hagag et al. demonstrated that in males testosterone levels and testicular volume were 
significantly lower in thalassaemic patients with iron overload [51]. A similar study 
conducted by Hagag et al. in female patients, they showed that FSH, LH and oestrogen 
levels were significantly lower in thalassaemic patients with iron overload [52].
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Pubertal failure has also been described in 73% of male and 42% of female 
patients under the age of 21 years old by Soliman et al. [23]. Similar findings were 
noted by Borgna-Pignatti and colleagues with 67% of males and 38% of females 
experiencing puberty failure [24]. Remarkably, successful conception may still be 
achieved by women who receive adequate chelation therapy.
Bone growth, growth velocity and puberty may be assisted by administration of 
chelation therapy before the commencement of sexual maturation and the use of 
low dose sex steroids in adolescence [9].
Current Standards for the Clinical Care of Children and Adults with 
Thalassaemia UK Guidelines recommend that assessment of gonadal function 
should be done annually throughout adulthood [30]. In men, this would include 
an annual morning testosterone level alongside LH/FSH and SHBG if testosterone 
levels are low. In women, no testing is required in the presence of a normal men-
strual history. However, in the presence of menstrual disturbances, further testing 
(LH/FSH and oestradiol) is recommended [30]. Deficiency should be replaced with 
oestrogen/testosterone while bearing in mind that under-replacement contributes 
to a low bone mineral density. Management is best achieved through a joint multi-
disciplinary consultation between the endocrinologist and thalassaemia team [30].
4. Glucose intolerance and diabetes mellitus
Effective management of patients suffering from homozygous beta thalassaemia 
has led to improved life expectancy and hence manifestations of haemosiderosis 
related complications, notably, disturbances of the exocrine and endocrine function 
of the pancreas [53]. The prevalence of glucose intolerance and diabetes mellitus 
(DM) in patients with homozygous beta thalassaemia has been found to be vari-
able. A retrospective analysis of 92 patients performed by Ang et al. showed that 
diabetes mellitus was one of the most common endocrinopathies with 41% of the 
study population affected [54] while a study conducted by Kanbour et al. reported 
a prevalence of 16.7% for impaired fasting glucose and 12.5% for diabetes mellitus 
[55]. Recently, a meta-analysis conducted by He et al. which included 44 studies 
with 16,605 cases showed that diabetes mellitus was present in 6.54%, impaired 
fasting glucose (IGF) in 17.21% and impaired glucose tolerance (IGT) in 12.46% 
[56]. While the prevalence of glucose intolerance and diabetes mellitus is undoubt-
edly high, many risk factors have also been identified. There was evidence of 
increased risk of diabetes mellitus with co-infection with hepatitis C [55–57], longer 
duration of disease [57–59] and with increased pancreatic iron deposition [58, 60].
Li et al. have found that in addition, patients with diabetes mellitus were charac-
terised by higher ferritin levels, smaller pancreas volume, lower cardiac T2 mag-
netic resonance signal (MRI) than patients without diabetes, and higher prevalence 
of hypogonadism. Interestingly, patients with diabetes were found to be young 
(median age was 22 years [range of 10 to 34 years]) and non-obese (BMI of 20.1 ± 
2.8 kg/m2) [58]. This may explain why the classical association between diabetes 
and increased prevalence of arteriosclerotic cardiovascular disease is not a feature 
in this population [30].
Poor compliance with desferrioxamine therapy (p < 0.05), older age commenc-
ing intensive chelation therapy, liver cirrhosis and severe fibrosis were found to be 
risk factors for glucose intolerance and diabetes mellitus. Risk factors for impaired 
glucose tolerance (IGT) also included male sex [61], poor compliance with desfer-
rioxamine therapy and high hepatic iron concentration.
Current UK guidelines recommend annual monitoring for impaired glucose 
tolerance and diabetes from the onset of puberty, or from the age of 10 years if 
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there is a family history of diabetes [30]. Screening is carried out with the oral 
glucose tolerance test (OGTT) [30]. However, OGTT compliance is often poor. 
This makes the development of adjunct or alternative screening tests of particular 
interest, as detecting pre-clinical diabetes is crucial because the development of 
clinical diabetes can possibly be slowed down or halted. Pancreatic iron overload 
can be assessed by MRI [62] but does not seem to correlate with siderosis in other 
organs. Currently, the relationship between MRI detectable iron and pancreatic 
beta cell dysfunction is not well characterised and MRI of the pancreas for iron 
deposition monitoring is not used clinically [30, 63]. However, there may be scope 
to use cardiac and liver MRI which already have established protocols, for the pur-
pose of screening for impaired glucose tolerance or diabetes. Ang et al. found that 
abnormal myocardial T2 signal may indicate the development of diabetes mel-
litus and other prediabetic states [54]. Li et al. showed similar findings whereby 
Cardiac T2 MRI values were higher in patients with normal fasting glucose levels 
(P = 0.03) [58]. Kanbour et al. found that patients with very high liver iron 
concentration (LIC) (>30 mg Fe/gm dry liver) were more likely to have a higher 
prevalence of impaired fasting glucose when compared to those with lower LIC 
(p = 0.044) [55]. The use of continuous glucose monitoring (CGMS) in detecting 
glucose intolerance and diabetes mellitus has also been studied, with CGMS found 
to be superior when compared to OGTT (p = 0.012) [64]. El-Samahy et al. studied 
20 beta thalassaemia patients with random blood glucose >7.8 mmol, who then had 
OGTT and CGMS. OGTT detected 6/20 patients (30%) who had impaired glucose 
tolerance and 7/20 (35%) patients who were in the diabetic range, while CGMS 
found that 7/20 (35%) patients had IGT and 13/20 (65%) had frank diabetes mel-
litus [64].
In terms of determining overall glycaemic control, UK guidelines recommend 
that serum fructosamine should be used. Fructosamine is a circulating glycated 
protein which measures overall glucose control in the previous 2–3 weeks. HbA1c 
or glycated haemoglobin should be avoided in thalassaemia as it is unreliable in any 
haemoglobinopathy and also after transfusion [30].
Although inadequate insulin release has been reported by several groups  
[60, 65, 66]. Other aetiologies identified include hyperinsulinemia, reduced 
insulin sensitivity [67] and reduction of hepatic insulin release. A study by Siklar 
et al. suggested that development of insulin impairment occurs prior to insulin 
resistance [68]. Furthermore, autoimmunity results in selective oxidative damage 
to beta cells of the pancreas [68]. Beta cells retain their function up to the later 
stages of the disease [9], however insulin sensitivity was found to be inversely 
related to iron overload and age [69]. Fasting pro-insulin and pro-insulin to 
insulin ratios was found to be considerably elevated and have a positive correla-
tion with hepatic iron [70], however C-peptide levels were found to be inconsis-
tent, thus reflecting fluctuating beta cell function [71, 72]. A reduction in serum 
trypsin and lipase levels were found, alongside regular alpha amylase activity. It 
was also found that the development of other endocrine and cardiac complica-
tions were followed by the onset of diabetes mellitus [73]. A 50% decline beta 
cell function was found to be correlated with glucose intolerance, and beta cell 
function was not entirely recovered even after intensive iron chelation. Moreover, 
high transfusion regimes that were not paired with appropriate iron chelation 
could advance the prevalence of diabetes mellitus further.
The prevalence of abnormal glucose metabolism has gradually increased over 
the last 20 years [55]. Therefore, the topic of glucose intolerance and diabetes 
mellitus in patients with thalassaemia major continues to be of significant clinical 
importance.
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5. Thyroid dysfunction
Thyroid dysfunction is a frequently occurring endocrine complication in 
thalassaemia major [39]. Hypothyroidism occurs either as a results of primary 
gland failure, or insufficient thyroid gland stimulation [74]. Hypothyroidism is 
thought to be a graded phenomenon and many types of hypothyroidism have been 
described: (1) sub-biochemical hypothyroidism: which consists of an exaggerated 
TSH response to TRH test in the presence of normal TSH and FT4; (2) sub-clinical 
hypothyroidism: elevated serum TSH with normal serum FT4 levels; (3) overt (clin-
ical) hypothyroidism: High TSH with low FT4 level and (4) central Hypothyrodism: 
an inappropriately low or normal TSH with a low free T4 level [74]. The lack of 
autoimmune thyroiditis in thalassaemia patients continues to be supported by 
multiple studies [75, 76].
Subclinical hypothyroidisim was found to be the most prevalent thyroid dys-
function in many studies [77, 78]. In a study of 144 thalassaemia patients by by 
Saleem et al., hypothyroidism was found in 31.2% of patients. Subclinical hypo-
thyroidism was found to be the most prevalent thyroid dysfunction (31.2%; 45 
patients), whilst only 6.7% [3] patients were found to have overt hypothyroidism. 
Interestingly, 76% of the patients with subclinical hypothyroidism were in the first 
decade of life [77].
The study conducted by Yassouf et al. demonstrated that out of the 82 cases of 
thalassaemia studied, subclinical hypothyroidism was once again found to be the 
most prevalent thyroid disorder - 29.27% of patients [24] had subclinical hypothy-
roidism while only one patient (1.22%) had overt hypothyroidism. In contrast to 
other studies, no case of central hypothyroidism was found [78].
There is a general consensus that central hypothyroidism is underestimated as 
there are only a handful of studies on the topic currently. The diagnosis of central 
hypothyroidism remains difficult from a clinical perspective, as its non-specific 
symptoms means that symptoms are usually attributed to another cause. From a 
biochemical perspective, central hypothyroidism is diagnosed based on a low to 
normal TSH level, in the presence of low levels of free T4 [74].
De Sanctis et al. explored the prevalence of central hypothyroidism in their 
thalassaemia population (339 patients). They found that central hypothyroidism 
was present in 6% of patients aged less than 21 years old, and 7.9% in patients above 
21 years of age. Delaporta et al. showed that 16% of 114 studied patients (mean age 
20.9 ± 7.8 years) had central hypothyroidism [79].
A prospective study carried out by Soliman et al. followed a total of 48 patients 
over a period of 12 years. In this duration, hypothyroidism was diagnosed in 35% 
[17] of patients - central hypothyrodisim was found in 13/17 (76%) patients [75]. 
Unexpectedly, this paper also found that the mean serum ferritin level did not differ 
significantly between patients with or without central hypothyroidism. This in 
turn did not support the hypothesis that iron overload of the HPA axis had resulted 
in central hypothyroidism thus concluding that the precise underlying aetiology 
of central hypothyroidism was unclear. However, due to the susceptibility of the 
pituitary gland to excess iron, central hypothyroidism due to iron overload of the 
HPA axis still remains a possibility [74].
Belhoul et al. found an increase in prevalence of hypothyroidism in splenect-
omised patients [80]. In non-splenectomised thalassemic patients, the spleen was 
thought to have a scavenging effect on free iron fractions. However, further studies 
are needed to evaluate this hypothesis [74].
Thyroid failure was found to correlate with age at which iron chelation therapy 
started. When iron chelation therapy was started late, thyroid dysfunction was 
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there is a family history of diabetes [30]. Screening is carried out with the oral 
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function was not entirely recovered even after intensive iron chelation. Moreover, 
high transfusion regimes that were not paired with appropriate iron chelation 
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found to occur earlier [74]. A study published in 2018 by Upadya et al. showed that 
of a population of 83 children with thalassaemia, 4.8% had evidence of subclinical 
hypothyroidism. In this study, the mean ferritin level was 3983.0 ± 169,830 ng/ml. 
However, while the severity of thyroid dysfunction was statistically significantly 
associated with higher serum TSH value in children in the second decade of life 
(p = 0.001), it is important to note that no significant correlation was found 
between the severity of thyroid dysfunction and serum ferritin levels [76].
These findings were also echoed in the study conducted by Yassouf et al. They 
found that serum ferritin was directly correlated with TSH levels (r = 0.414; 
p < 0.001). However, there was no correlation between serum ferritin and FT4 lev-
els (r = 0.027; p > 0.05) [78]. This study also demonstrated that the risk of thyroid 
dysfunction was increased by non-compliance of chelation therapy by 6.38 fold as 
compared with compliant patients (RR = 6.385 l 95% CI, 2.40–16.95) [78].
In another study a total of 72 thalassaemia patients were followed for 8 years. 
The study endpoint was defined as the incidence of thyroid dysfunction, and aim 
of the study was to analyse ferritin as a prognostic maker. It found that that patients 
with thyroid dysfunction had higher ferritin levels in contrast to those with normal 
thyroid function (1500 (872–2336)) vs. (513 (370–698) ug/l; P < 0.0001). The study 
also found patients with ferritin values above 1800ug/L had a more rapid progres-
sion towards the endpoint of thyroid dysfunction [81].
However, as a single value, ferritin may not always be reliable. Ferritin, as an 
acute phase protein, is subject to fluctuations caused by other variables such as 
inflammation and malignancy. However, ferritin may still be the most convenient 
way to assess iron overload, especially when used as part of a serial measurement 
[81]. Ferritin may be of value as a prognostic maker and may be used to identify 
patients at risk of developing thyroid dysfunction [81]. This begs the question as to 
whether the value of ferritin in determining the severity of thyroid dysfunction is 
over-appreciated [76].
Currently, the UK Thalassaemia Society Standards for the clinical care of chil-
dren and adults with thalassaemia in the UK (2016) recommend thyroid functions 
tests annually in patients with thalassaemia from age of 12 years, or if there are any 
suggestive symptoms of thyroid deficiency between times [30].
6. Hypoparathyroidism
Hypoparathyroidism, resulting in hypocalcaemia, is a late complication of iron 
overload, typically manifesting after the age of 10 years and with a higher incidence 
in men [46]. The first sign of incipient hypoparathyroidism is loss of the diurnal 
pattern of parathyroid hormone (PTH) secretion [9]. The typical biochemical pro-
file is low serum calcium, low serum PTH, low serum vitamin D and elevated serum 
phosphate levels [82]. Clinical signs of the disorder are most frequently noted from 
the second decade of life onwards [15].
A recent survey of clinicians by the International Network of Clinicians for 
Endocrinopathies in Thalassemia and Adolescence Medicine (ICET-A) published in 
2018 reported a prevalence of 6.8% among 3023 thalassaemia major patients from 17 
centres [83]. 42.2% of hypoparathyroid patients in this study were described as asymp-
tomatic at diagnosis. The most common presenting symptom was paraesthesia and/or 
cramping seen in 37.6% patients [83]. In the ICET-A study, 49.8% of [83] hypoparath-
ryoid individuals were also noted to have serum ferritin level > 2.500 ng/ml8. Chirico 
and colleagues also noted a significant association between elevated ferritin and 
incidence of hypoparathyroidism in thalassaemia major, proposing its use a prognostic 
marker for development of endocrinopathy [84].
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Inconsistencies in case definition of hypoparathyroidism have complicated 
estimates of prevalence. In a cohort of transfusion-dependent thalassaemia major 
patients, 13.5% were shown to have hypoparathyroidism, characterised by low 
serum PTH, total and ionised calcium levels [85]. In contrast, a multicentre study 
in Italy, encompassing 25 units, showed the prevalence to be 3.6% [46]. A French 
study from 1993 showed the prevalence of hyperparathyroidism to be as high as 
22.5% [86]; similarly Aleem and colleagues reported a prevalence of 20% [87]. 
Shamshirsaz and colleagues showed a prevalence of 7.6% [1] with male:female 
ratio of 4:1, a higher ratio than has been described elsewhere [46, 83]. Further 
studies in Iran by Bordbar et al. and Bazi et al. reported prevalences of 13.2% [88] 
and 18% [89] respectively among their thalassaemia patient cohorts. Interestingly, 
Tangngam and colleagues reported a prevalence of asymptomatic hypoparathyroid-
ism of 38% in their cohort of 66 transfusion-dependent thalassaemia patients, 
with significantly lower serum FGF-23, a major regulator of phosphate, detected in 
hypoparathyroid patients [90].
A small study by Even and colleagues suggests loss of normal diurnal variation 
in PTH secretion in thalassaemia patients, even in individuals with normal daytime 
calcium levels [91].
In the UK, annual screening of parathyroid function and bone profile is rec-
ommended in thalassaemia patients [30]. Limited data [92, 93] shows that early 
supplementation with Vitamin D or calcitriol treatment for three months is suf-
ficient to normalise plasma calcium and phosphate levels. 2016 UKTS guidelines 
recommend treatment with activated vitamin D preparations in the case of primary 
hypoparathyroidism secondary to iron overload. In order to avoid nephrocalcinosis, 
adjusted calcium levels should be targeted towards the lower reference range [30].
With regard to other complications, tetany, seizures or cardiac failure due to 
severe hypocalcaemia is rare and requires immediate correction with intravenous 
administration of calcium. Koutsis and colleagues report a rare case of Fahr’s 
syndrome—striatopallidodentate calcinosis—in a 42 year-old woman with 
thalassaemia major with erratic compliance with oral vitamin D/calcium supple-
mentation. Her hyperkinetic symptoms resolved with resumption of adequate oral 
 supplementation [94].
7. Adrenal dysfunction
Histological and imaging studies have shown that iron deposits in the adrenal 
cortex of thalassaemic patients are mainly confined to the zona glomerulosa with 
rare involvement of the zona fascicularis [95]. Most studies have revealed intact 
pituitary adrenal axis in thalassaemia patients [35, 60, 65, 66, 96]. Prevalence of 
adrenal insufficiency is variable and depends both on the degree of iron overload, 
cut off values for cortisol measurement and diagnostic test used [97, 98].
Poggi et al. used a low dose synacthen test with adrenal insufficiency deter-
mined by cortisol <500 nmol/L and found a prevalence of 13.7% in the study 
population [97]. Huang et al. used a glucagon stimulation test, followed by cortico-
trophin-releasing hormone and found a prevalence of 61% [98].
Raised ACTH levels were found by McIntosh which suggests primary adrenal 
failure [66], however Costin et al. found suppressed ACTH levels and reduced 
adrenal reserve despite the lack of clinical signs [5]. The diminished ability of the 
adrenal cortex to react to further pulses of ACTH may be reflected in the fact that 
baseline serum and urinary cortisol levels are usually normal [99].
Low serum Dihydroepiandrostenedione (DHEA), Dihydroepiandrostenedione 
Sulphate (DHEAS), androstenedione and testosterone levels were found to be 
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caused by the dissociation between androgen, cortisol and aldosterone synthe-
sis. This may be the reason adrenarche is usually absent in these patients [100]. 
Dysfunctions in ACTH secretion circadian patterns but unaffected cortisol and 
aldosterone secretory were seen in these patients [101]. In addition to that, falsely 
low serum cortisol levels may be found in thalassaemic patients with chronic liver 
disease because cortisol is usually bound to cortisol binding globulin (CBG) which 
is produced by hepatocytes [102]. Currently, there are no reports on CBG levels 
in thalassaemic patients. Nonetheless, the role of CBG in adrenal insufficiency is 
excluded by a normal CBG level in the presence of low cortisol. In female patients, 
oestrogen may cause a rise in CBG levels resulting in inaccurate cortisol levels.
Current research shows female gender to be a protective factor [97]. Huang et 
al. have found that there was a significant prevalence of adrenal insufficiency in 
males when compared to females (92% vs. 29%, p = 0.049) in their study cohort 
[98]. Imaging studies by Drakonaki et al. using MRI scan have frequently identified 
adrenal hypointensity without alteration of morphology in thalassaemia patients 
and verified autopsy findings of correlation between adrenal iron and liver iron 
[103]. However a study by Guzelbey et al., found that, on the contrary, there was 
no statistically significant correlation between iron deposition in the adrenal glands 
and liver [104]. Another study suggests that imaging from Cardiac MRI T2 could be 
used as a surrogate of adrenal hypofunction, with a sensitivity of 81% and specific-
ity of 78% [105]. However, despite high sensitivity, histology still remains the gold 
standard for diagnosis of iron deposition.
Currently, routine cortisol monitoring does not form part of the recommended 
routine investigations to screen for adrenal dysfunction in patients with thalassae-
mia [30]. However, the UK standards for thalassaemia guidelines acknowledges 
that annual monitoring of cortisol may allow for trends in decline to be noted, 
but also stress that normal cortisol levels does not exclude partial adrenal insuf-
ficiency when the patient is unwell. While current literature is very contradictory, 
adrenal dysfunction can be life-threatening in an acutely unwell patient. Therefore, 
hydrocortisone supplementation should be considered even before formal proof of 
insufficiency is available, if clinically relevant [30].
8. Osteoporosis
Beta thalassaemia is associated with marrow expansion, osteopaenia with corti-
cal thickening, trabecular coarsening and bone deformity [106]. Osteoporosis—
defined as a microarchietctual deterioration in bone tissue leading to an increased 
fracture risk [107]—is the predominant bone disease in beta thalassaemia. The 
prevalence of osteoporosis in thalassaemia is variably estimated from 13.6–50% 
[108]. In a cohort of well-treated thalassaemia patients, Baldini and colleagues 
reported demineralization—.osteoporotic or osteopaenic bone—in 92.7% [109].
Factors implicated in its cause include hypogonadism, diabetes mellitus, 
hypothyroidism, hypoparathyroidism, iron overload and its treatment [108, 110]. 
Malnutrition, inadequate exercise and absence of adrenal sex hormones during 
adrenarche and gonadal hormones during puberty are other contributory factors 
[111]. Excessive erythropoesis may also impair bone formation [112]. Iron chelation 
therapy is further linked to hypercalciuria, with consequential nephrolithiasis and 
reduced bone mineral density (BMD) [113]. Desferrioxamine is also linked to bone 
dysplasia, independently of osteoporosis [114].
Spine and hip osteoporosis is common in both sexes, with spinal osteoporosis 
more common in women and the lumbar vertebrae and femoral neck affected more 
frequently in men [110]. Osteoporosis is characterised by significant decreases 
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in bone mineral density, both cortical and trabecular. In an Italian case series, 
pathological fractures were reported in 19.7% of transfusion-dependent patients 
with thalassaemia major [115]. With regard to putative mechanisms, significantly 
lower osteoprotegerin/RANKL ratios have been observed in thalassaemia patients. 
Excessive RANKL activity favours osteoclastic bone resorption, leading to reduced 
BMD [116]. Sapunarova and colleagues report 10-fold higher serum levels of 
sclerostin, a secreted glycoprotein with anti-osteoblastic properties, in adults with 
transfusion-dependent beta thalassaemia compared to controls [117]. Given its 
correlation with both lumbar spine/femoral neck Z-scores and incidence of fragil-
ity fractures, it has been proposed to act as a biomarker of severe osteoporosis in 
advanced beta thalassaemia. In Tehran, Shamishiraz et al. [1] demonstrated similar 
prevalence of that osteoporosis and osteopaenia in the lumbar spine (50.7% and 
39.4% respectively) of patients with thalassaemia. In the same cohort, osteoporosis 
and osteopaenia prevalences were 10.8% and 36.9% at the femoral neck. These 
prevalences have been replicated in other cohorts [118, 119]. Jensen amd colleagued 
reported “severely low” bone mass in 51% of thalassaemia patients, with “low 
bone mass” in 45% [110]. Among 31 thalassaemic patients studied by Vogiatzi and 
colleagues (5 of whom with the milder thalassaemia intermedia phenotype), 22.6% 
had reduced bone mass (defined as Z score = −1 to −2 on DXA analysis) and 61.3% 
had a low bone mass (Z score ≤ −2) [93].
Early diagnosis requires accurate estimation of BMD via densitometry. 
Interpretation of dual-energy X-ray absorptiometry (DXA) may be confounded 
in thalassaemia due to short stature and spinal deformities caused by medullary 
expansion, bone dysplasia and the increased rate of degenerative vertebral disc 
disease in TM patients [120, 121]. Artefact from hepatic iron loading might also 
derange DXA analysis [122]. Alternative modalities for assessing bone micro-
architecture in thalassaemia include trabecular bone structure (TBS) analysis—a 
textural assessment derived from DXA images—and quantitative computed tomog-
raphy (QCT). These alternative methods remain limited by the distinctive profile 
of thalassaemia osteopathy and, in the case of QCT, by the amount of vertebral iron 
deposition [121, 123].
Prevention, early diagnosis and effective chelation therapy are most effec-
tive in arresting the progression of bone disease in thalassaemia. Tight adherence 
to recommended chelation treatment is required during childhood to prevent 
desferroximine-asssociated bone pathologies, including “pseudo-rickets” and 
cartilaginous dysplasia [30]. Diets rich in calcium and Vitamin D and exercise can 
improve the outcome [69]. The role of lifestyle interventions is particularly promi-
nent during childhood. If deficient, calcium, vitamin D and zinc supplementation 
are advised, preferably via the oral route [119]. 2016 UKTS guidelines advise that 
many patients will require maintenance vitamin D3 supplementation [30]. Annual 
monitoring of vitamin D levels are recommended from age 2 years, aiming for a 
level of approximately 80 nmol/L. Intramuscular depot injection of vitamin D are 
not recommended by UKTS, nor are activated vitamin D preparations (for example 
alfacalcidol) in the absence of proven hypoparathyroidism secondary to iron 
deposition [30].
In terms of anti-osteoclastic treatments, the human anti-RANKL monoclonal 
antibody denosumab has shown promise in a Phase 2b RCT, increasing both lumbar 
spine and wrist BMD in transfusion-dependent TM patients [119]. Data from both 
Indian and Iranian cohorts suggest a role for zolendronic acid in increasing lumbar 
spine BMD [124, 125]. Alendronate and vitamin D regimen showed promise in 
an Italian Phase 2b RCT [126]. Prior to this, Morabito and colleagues showed that 
daily oral alendronate increased BMD in a two-year study of young adults with 
thalassaemia [127]. A 2016 Cochrane review of both bisphosphonates and zinc 
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caused by the dissociation between androgen, cortisol and aldosterone synthe-
sis. This may be the reason adrenarche is usually absent in these patients [100]. 
Dysfunctions in ACTH secretion circadian patterns but unaffected cortisol and 
aldosterone secretory were seen in these patients [101]. In addition to that, falsely 
low serum cortisol levels may be found in thalassaemic patients with chronic liver 
disease because cortisol is usually bound to cortisol binding globulin (CBG) which 
is produced by hepatocytes [102]. Currently, there are no reports on CBG levels 
in thalassaemic patients. Nonetheless, the role of CBG in adrenal insufficiency is 
excluded by a normal CBG level in the presence of low cortisol. In female patients, 
oestrogen may cause a rise in CBG levels resulting in inaccurate cortisol levels.
Current research shows female gender to be a protective factor [97]. Huang et 
al. have found that there was a significant prevalence of adrenal insufficiency in 
males when compared to females (92% vs. 29%, p = 0.049) in their study cohort 
[98]. Imaging studies by Drakonaki et al. using MRI scan have frequently identified 
adrenal hypointensity without alteration of morphology in thalassaemia patients 
and verified autopsy findings of correlation between adrenal iron and liver iron 
[103]. However a study by Guzelbey et al., found that, on the contrary, there was 
no statistically significant correlation between iron deposition in the adrenal glands 
and liver [104]. Another study suggests that imaging from Cardiac MRI T2 could be 
used as a surrogate of adrenal hypofunction, with a sensitivity of 81% and specific-
ity of 78% [105]. However, despite high sensitivity, histology still remains the gold 
standard for diagnosis of iron deposition.
Currently, routine cortisol monitoring does not form part of the recommended 
routine investigations to screen for adrenal dysfunction in patients with thalassae-
mia [30]. However, the UK standards for thalassaemia guidelines acknowledges 
that annual monitoring of cortisol may allow for trends in decline to be noted, 
but also stress that normal cortisol levels does not exclude partial adrenal insuf-
ficiency when the patient is unwell. While current literature is very contradictory, 
adrenal dysfunction can be life-threatening in an acutely unwell patient. Therefore, 
hydrocortisone supplementation should be considered even before formal proof of 
insufficiency is available, if clinically relevant [30].
8. Osteoporosis
Beta thalassaemia is associated with marrow expansion, osteopaenia with corti-
cal thickening, trabecular coarsening and bone deformity [106]. Osteoporosis—
defined as a microarchietctual deterioration in bone tissue leading to an increased 
fracture risk [107]—is the predominant bone disease in beta thalassaemia. The 
prevalence of osteoporosis in thalassaemia is variably estimated from 13.6–50% 
[108]. In a cohort of well-treated thalassaemia patients, Baldini and colleagues 
reported demineralization—.osteoporotic or osteopaenic bone—in 92.7% [109].
Factors implicated in its cause include hypogonadism, diabetes mellitus, 
hypothyroidism, hypoparathyroidism, iron overload and its treatment [108, 110]. 
Malnutrition, inadequate exercise and absence of adrenal sex hormones during 
adrenarche and gonadal hormones during puberty are other contributory factors 
[111]. Excessive erythropoesis may also impair bone formation [112]. Iron chelation 
therapy is further linked to hypercalciuria, with consequential nephrolithiasis and 
reduced bone mineral density (BMD) [113]. Desferrioxamine is also linked to bone 
dysplasia, independently of osteoporosis [114].
Spine and hip osteoporosis is common in both sexes, with spinal osteoporosis 
more common in women and the lumbar vertebrae and femoral neck affected more 
frequently in men [110]. Osteoporosis is characterised by significant decreases 
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lower osteoprotegerin/RANKL ratios have been observed in thalassaemia patients. 
Excessive RANKL activity favours osteoclastic bone resorption, leading to reduced 
BMD [116]. Sapunarova and colleagues report 10-fold higher serum levels of 
sclerostin, a secreted glycoprotein with anti-osteoblastic properties, in adults with 
transfusion-dependent beta thalassaemia compared to controls [117]. Given its 
correlation with both lumbar spine/femoral neck Z-scores and incidence of fragil-
ity fractures, it has been proposed to act as a biomarker of severe osteoporosis in 
advanced beta thalassaemia. In Tehran, Shamishiraz et al. [1] demonstrated similar 
prevalence of that osteoporosis and osteopaenia in the lumbar spine (50.7% and 
39.4% respectively) of patients with thalassaemia. In the same cohort, osteoporosis 
and osteopaenia prevalences were 10.8% and 36.9% at the femoral neck. These 
prevalences have been replicated in other cohorts [118, 119]. Jensen amd colleagued 
reported “severely low” bone mass in 51% of thalassaemia patients, with “low 
bone mass” in 45% [110]. Among 31 thalassaemic patients studied by Vogiatzi and 
colleagues (5 of whom with the milder thalassaemia intermedia phenotype), 22.6% 
had reduced bone mass (defined as Z score = −1 to −2 on DXA analysis) and 61.3% 
had a low bone mass (Z score ≤ −2) [93].
Early diagnosis requires accurate estimation of BMD via densitometry. 
Interpretation of dual-energy X-ray absorptiometry (DXA) may be confounded 
in thalassaemia due to short stature and spinal deformities caused by medullary 
expansion, bone dysplasia and the increased rate of degenerative vertebral disc 
disease in TM patients [120, 121]. Artefact from hepatic iron loading might also 
derange DXA analysis [122]. Alternative modalities for assessing bone micro-
architecture in thalassaemia include trabecular bone structure (TBS) analysis—a 
textural assessment derived from DXA images—and quantitative computed tomog-
raphy (QCT). These alternative methods remain limited by the distinctive profile 
of thalassaemia osteopathy and, in the case of QCT, by the amount of vertebral iron 
deposition [121, 123].
Prevention, early diagnosis and effective chelation therapy are most effec-
tive in arresting the progression of bone disease in thalassaemia. Tight adherence 
to recommended chelation treatment is required during childhood to prevent 
desferroximine-asssociated bone pathologies, including “pseudo-rickets” and 
cartilaginous dysplasia [30]. Diets rich in calcium and Vitamin D and exercise can 
improve the outcome [69]. The role of lifestyle interventions is particularly promi-
nent during childhood. If deficient, calcium, vitamin D and zinc supplementation 
are advised, preferably via the oral route [119]. 2016 UKTS guidelines advise that 
many patients will require maintenance vitamin D3 supplementation [30]. Annual 
monitoring of vitamin D levels are recommended from age 2 years, aiming for a 
level of approximately 80 nmol/L. Intramuscular depot injection of vitamin D are 
not recommended by UKTS, nor are activated vitamin D preparations (for example 
alfacalcidol) in the absence of proven hypoparathyroidism secondary to iron 
deposition [30].
In terms of anti-osteoclastic treatments, the human anti-RANKL monoclonal 
antibody denosumab has shown promise in a Phase 2b RCT, increasing both lumbar 
spine and wrist BMD in transfusion-dependent TM patients [119]. Data from both 
Indian and Iranian cohorts suggest a role for zolendronic acid in increasing lumbar 
spine BMD [124, 125]. Alendronate and vitamin D regimen showed promise in 
an Italian Phase 2b RCT [126]. Prior to this, Morabito and colleagues showed that 
daily oral alendronate increased BMD in a two-year study of young adults with 
thalassaemia [127]. A 2016 Cochrane review of both bisphosphonates and zinc 
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supplementation for thalassaemia-associated osteoporosis acknowledges an accre-
tion of evidence in favour of their use, but suggests that further RCT evidence is 
required [128].
Current UKTS guidelines advocate consideration of anti-osteoclastic agents 
for individuals with low age-adjusted BMD or in whom fragility fractures have 
occurred despite appropriate vitamin D/calcium or hormone supplementation. 
Bisphosphonate initiation should occur following consultation with a specialist in 
osteoporosis, given that no definite evidence exists for fracture reductions with 
bisphosphonates in thalassaemia patients, despite the evidence for improved BMD. 
Burden of adverse effects, including atypical femoral fractures and osteonecrosis of 
the jaw, are significant [30].
Hormone replacement therapy is beneficial in patients with concomitant 
osteoporosis and hypogonadism but may not offer complete resolution, due to the 
multifactorial nature of bone pathology in thalassaemia [129, 130]. Patients with 
concomitant hypogonadism require hormone replacement therapy [108].
9. Conclusions
There is a high incidence of endocrinological abnormalities in patients with thal-
assaemia. Thalassaemic patients have been shown to have an elevated frequency of 
endocrinopathies in several research centres. The role of regular follow-up to allow 
early detection and proper management of complications is vital. The care and 
quality of life of thalassaemic patients can be positively impacted by advancements 
in transfusion protocols and chelating therapy. Early recognition of endocrinopa-
thies in patients with thalassaemia is crucial apart from the fact that life expectancy 
is increased, at the same time morbidity and mortality as a result of complications 
can be decreased with routine monitoring, appropriate interventions and follow-up 
in thalassaemia-endocrine join care clinics.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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for individuals with low age-adjusted BMD or in whom fragility fractures have 
occurred despite appropriate vitamin D/calcium or hormone supplementation. 
Bisphosphonate initiation should occur following consultation with a specialist in 
osteoporosis, given that no definite evidence exists for fracture reductions with 
bisphosphonates in thalassaemia patients, despite the evidence for improved BMD. 
Burden of adverse effects, including atypical femoral fractures and osteonecrosis of 
the jaw, are significant [30].
Hormone replacement therapy is beneficial in patients with concomitant 
osteoporosis and hypogonadism but may not offer complete resolution, due to the 
multifactorial nature of bone pathology in thalassaemia [129, 130]. Patients with 
concomitant hypogonadism require hormone replacement therapy [108].
9. Conclusions
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assaemia. Thalassaemic patients have been shown to have an elevated frequency of 
endocrinopathies in several research centres. The role of regular follow-up to allow 
early detection and proper management of complications is vital. The care and 
quality of life of thalassaemic patients can be positively impacted by advancements 
in transfusion protocols and chelating therapy. Early recognition of endocrinopa-
thies in patients with thalassaemia is crucial apart from the fact that life expectancy 
is increased, at the same time morbidity and mortality as a result of complications 
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Abstract
The Duffy group system includes six known antigens that reside on a glycoprotein 
which acts as a receptor for chemokines. It is also a receptor for some malaria 
species. There are significant racial variations in expression of Duffy antigens. 
Approximately 68% of Blacks lack both Fya and Fyb antigens. Individuals with this 
unique phenotype are resistant to two malaria species. Antibodies formed against 
the Duffy antigens are of IgG subclass and are clinically significant as they can be 
implicated in acute and delayed hemolytic transfusion reactions as well as hemo-
lytic disease of fetus and newborn. Patients who form anti-Fya or anti-Fyb must 
receive antigen negative blood units in the future.
Keywords: Duffy, RBC antigens, FYA, FYB, DARC, hemolysis, fetus, HDFN
1. Introduction
The Duffy blood group system, ISBT number 008/symbol (FY), was published for 
the first time in 1950 when anti-Fya was identified in a suspected hemolytic transfu-
sion reaction in a 43-year-old patient with hemophilia who received 3 packed red blood 
cell (PRBC) units for treatment of spontaneous bleeding and who developed jaundice 
1 day after transfusion [1, 2]. Approximately, 1 year later, anti-Fyb was discovered in a 
postpartum blood sample from a patient who gave birth to her third child [3].
Chromosome 1 has both FY and RH gene loci. The FY locus is located on the 
long arm at position 1q22-q23 where it consists of two exons distributed over 1.5 kbp 
of gDNA, whereas RH resides on the short arm. The Duffy system is N-glycosylated 
multi-pass transmembrane glycoprotein (Figure 1) [4] also known as the atypical 
chemokine receptor 1 (ACKR1, CD234). The protein is composed of 336 amino 
acids. There are two possible Duffy mRNAs which are translated from the Duffy 
antigen gene, a less abundant α form (338 amino acids) and a major β form  
(336 amino acids) which differ by 2 amino acids in the N-terminus. Approximately 
6000–13,000 copies of the Duffy protein are found on the surface of RBCs [5].
The Duffy blood group includes six known antigens that differ by amino acid 
sequence. The Duffy antigen prevalence varies between racial groups.
ACKR1 (previously known as DARC) is a receptor for a variety of chemokines, 
including interleukin-8, monocyte chemotactic protein-1, and melanoma growth 
stimulatory activity. Also, this glycoprotein is a receptor for Plasmodium vivax and 
Plasmodium knowlesi; thus red cells with Fy(a-b-) phenotype are resistant to inva-
sion by these malarial species. Antibodies formed against the Duffy antigens show a 
dosage effect and are a cause of both hemolytic transfusion reactions and hemolytic 
disease of fetus and newborn. The Duffy protein is also found on the endothelial 
cells of capillary and postcapillary venules, the epithelial cells of kidney collecting 
ducts, lung alveoli, and Purkinje cells of cerebellum [6].
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2. Duffy antigens
There are six known antigens with four main phenotypes; Fy(a+b+), Fy(a−b+), 
Fy(a+b−), and Fy(a−b−) (Table 1) [5]. The most common antigens are, two poly-
morphic and antithetical, Fya (FY1) and Fyb (FY2) which differ by one amino acid 
at position 42 on the extracellular domain, with glycine resulting in Fya expression 
and aspartic acid resulting in Fyb expression [5, 7]. They are sensitive to destruction 
when RBCs are treated with proteolytic enzymes such as papain or ficin, whereas, 
there is no RBCs destruction with trypsin treatment [8].
Fya antigen has a prevalence of 66% in Caucasians, 10% in Blacks, and 99% in 
Asians. It has been identified on fetal RBCs as early as 6 weeks gestation and reaches 
adult levels in approximately 12 weeks after birth. Fyb has a prevalence of 83% in 
Caucasians, 23% in Blacks, and 18.5% in Asians. It is expressed on cord blood cells. Fy3 
antigen is expressed in 100% of Caucasians, 32% of Blacks, and 99.9% of Asians. It is 
also expressed on cord cells and demonstrates increased expression after birth. Fy5 
antigen is expressed on 32% of Blacks and 99.9% of Caucasians and Asians. It is not 
expressed on Rh null RBCs. Fy6 is expressed in 100% of most populations and 32% of 
Blacks. The Fy(a–b–) phenotype is the major phenotype in approximately 70% Blacks, 
but is very rarely found in other populations. This phenotype is characterized by the 
Figure 1. 
The predicted seven-transmembrane domain structure of the Duffy protein. The amino acid change responsible 
for Fya/Fyb polymorphism, the mutation responsible for Fyx, and the glycosylation sites and the regions where 
Fy3 (and Fy6) map are indicated (reproduced with permission).
Red cell phenotype Prevalence (%) Allele
Caucasians Blacks
Fy (a+b−) 17 9 FY*01/FY*01 or FY*A/FY*A
Fy (a−b+) 34 22 FY*02/FY*02 or FY*B/FY*B
Fy (a+b+) 49 1 FY*A/FY*B




‡Nomenclature pending approval by the ISBT working party on terminology for red cell surface antigens.
Table 1. 
Duffy blood group system phenotypes and prevalence. Reproduced with permission and modification.
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absence of the Fyb antigen on RBCs and its presence on non-erythroid cells. Duffy 
mRNA is not detected in the bone marrow of Fy(a–b–) individuals; however, it is 
detected in other tissues including the colon, lung, and spleen. This unique phenotype 
is caused by a single amino acid substitution at position 46 in the Duffy (Fyb) gene. 
This mutation impairs the promotor activity in erythroid cells by disrupting the binding 
site for GATA1 erythroid transcription factor. Furthermore, some individuals with this 
phenotype do not make anti-Fyb. This is believed to be due to a mutation in the, ery-
throid promoter, GATA-1 binding motif. Interestingly, the same Fy(a–b–) phenotype 
rarely found in Caucasians is characterized by absence of Duffy antigens expression in 
both erythroid and non-erythroid tissues due to possibly presence of mutations which 
prevent formation of Duffy protein. These individuals can form anti-Fy3. The have 
high prevalence antigens; Fy3, Fy5, and Fy6 are conformational epitopes as opposed 
to specific sequence epitopes with Fy5 hypothesized to be a combined conformational 
epitope of Duffy and Rh protein [9–12].
3. Duffy antibodies
Anti-Fya and -Fyb are clinically significant RBC alloantibodies which can cause 
immediate and delayed hemolytic transfusion reactions (HTRs) as well as hemolytic 
disease of the fetus and newborn (HDFN). They often result from previous exposure 
such as after transfusion or pregnancy. They are not usually naturally occurring. The 
Duffy antibodies are predominantly of the IgG subclass whereas the IgM form is rare.
The mechanism of extravascular hemolysis (EH) in both HDFN and HTR is 
similar. In HDFN, the mother lacks a certain red cell antigen which the fetus is 
positive for, thus the mother is allo-immunized (i.e., made a new antibody) during 
the first pregnancy. If she gets exposed to the same antigen in subsequent pregnancy 
(ies), the fetus (es) is/are at risk of HDFN. Similarly, if a patient lacks a certain red 
cell antigen but receives red cell transfusion with a unit that has such antigen, the 
patient is at risk for allo-immunziation after the transfusion and HTR in subsequent 
transfusion (s). EH is typically induced by IgG red cell antibodies. EH consists of 
consumption of antibody and/or C3b-bound red cells by phagocytes in the reticulo-
endothelial system (RES) causing a delayed hemolytic transfusion reaction (DHTR). 
DHTRs can be clinically significant leading to morbidity and possibly mortality. To 
avoid DHTR, patients with known clinically significant antibodies, receive red cell 
units that lack antigen (s) to their the cognate antibody (ies). The Duffy antibodies 
are usually associated with a moderate DHTR and mild HDFN [13].
Anti-Fya is identified more than anti-Fy3, anti-Fy5, or anti-Fyb. Fya is 20 times 
more immunogenic than Fyb. Some of anti-Fya can bind and activate complements 
[14]. Anti-Fy3 is also clinically significant antibody which can cause mild HDFN and 
HTRs. Serologically, it can react with enzyme treated Fy(a+) or Fy(b+) RBCs, but 
fails to react with Fy(a−b−) RBCs [15]. Anti-Fy4 shows lack of consistent test results. 
It was found to be reactive with Fy(a−b−), some Fy(a+b−), some Fy(a−b+) RBCs 
but shows no reaction with Fy(a+b+) RBCs [16]. Anti-Fy5 reacts with enzyme treated 
Fy(a+) or Fy(b+) RBCs with no reaction with Fy(a−b−) RBCs or Rh null RBCS. It has 
been reported in sickle cell patients with delayed HTRs in the presence of other clini-
cally significant alloantibodies [17]. A human anti-Fy6 has not been identified [18].
4. The Duffy glycoprotein as a receptor for chemokines
The Duffy glycoprotein can bind to a variety of chemokines and is known 
commonly as the Duffy antigen receptor for chemokines (DARC) or more recently 
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atypical chemokine receptor 1 (ACKR1). Chemokines are proteins secreted by 
immune cells as a mean to communicate signals to guide their interactions. The 
exact function of DARC is not fully clear. One postulated function is that DARC 
permits erythrocyte to act a chemokine scavenger to limit leukocyte activation. The 
importance of this function in inflammatory diseases is not well established [6, 19].
5. Duffy and malaria
The Duffy glycoprotein plays an important role in malaria transmission by 
acting as the erythroid receptor for Plasmodium vivax through binding to the 
Fy6 epitope (previously known as P. vivax Duffy-binding protein (PvDbp)) and 
for Plasmodium knowlesi. Individuals with Fy(a−b−) phenotype were resistant 
to parasitic invasion in a study performed on 11 volunteers, whereas those who 
contracted malaria were Fy(a+) or Fy(b+). Fy6 is present on all erythroid cells with 
an Fy(a+) or Fy(b+) phenotype. Thus it is absent on red cells with Fy(a−b−) phe-
notype. In west Africa, individuals with Fy(a−b−) phenotype are found in greater 
frequency than in areas where P. vivax is absent. The protective effect of Fy(a−b−) 
phenotype does not extend to P. falciparum which can infect red cells of all Duffy 
phenotype [20].
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atypical chemokine receptor 1 (ACKR1). Chemokines are proteins secreted by 
immune cells as a mean to communicate signals to guide their interactions. The 
exact function of DARC is not fully clear. One postulated function is that DARC 
permits erythrocyte to act a chemokine scavenger to limit leukocyte activation. The 
importance of this function in inflammatory diseases is not well established [6, 19].
5. Duffy and malaria
The Duffy glycoprotein plays an important role in malaria transmission by 
acting as the erythroid receptor for Plasmodium vivax through binding to the 
Fy6 epitope (previously known as P. vivax Duffy-binding protein (PvDbp)) and 
for Plasmodium knowlesi. Individuals with Fy(a−b−) phenotype were resistant 
to parasitic invasion in a study performed on 11 volunteers, whereas those who 
contracted malaria were Fy(a+) or Fy(b+). Fy6 is present on all erythroid cells with 
an Fy(a+) or Fy(b+) phenotype. Thus it is absent on red cells with Fy(a−b−) phe-
notype. In west Africa, individuals with Fy(a−b−) phenotype are found in greater 
frequency than in areas where P. vivax is absent. The protective effect of Fy(a−b−) 
phenotype does not extend to P. falciparum which can infect red cells of all Duffy 
phenotype [20].
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Haemolytic post-transfusion reaction is caused by accelerated destruction of 
erythrocytes by immunological incompatibility between the donor and the recipi-
ent. It also occurs for non-immunological reasons: thermal, osmotic or mechanical 
damage and bacterial infection. Haemolysis can be endogenous (usually acute) 
and exogenous with macrophages in the reticuloendothelial system of spleen or 
liver (delayed). The pathophysiology: antibody binding erythrocyte antigens, 
antibody-coated erythrocytes interaction with monocytes/macrophages activating 
phagocytosis or antibody-dependent cytotoxicity and the production of inflamma-
tory mediators. Antibodies destroying transfused blood cells are called clinically 
relevant antibodies that are active in vitro at 37°C. An interesting mechanism is the 
“bystander immune cytolysis”.
Keywords: haemolytic reaction, haemolysis, transfusion reaction, HTR
1. Introduction
Haemolytic transfusion reaction (HTR) is the result of accelerated destruc-
tion of red blood cells. The most common cause is immunological incompatibility 
between a donor and a blood recipient. It is mainly haemolysis that is responsible 
for the destruction of transfused donor blood cells by antibodies present in the 
recipient, but in rare cases, destruction may be caused in recipient blood cells 
by donor antibodies present in transfused plasma or platelet concentrate [1]. 
Haemolysis may also occur due to non-immunological reasons, such as thermal, 
osmotic or mechanical damage to the transfused blood; bacterial infection or 
extremely rare and blood transfusion from a donor with congenital haemolytic 
anaemia due to deficiency of glucose-6-phosphate dehydrogenase [2].
2. The incidence of haemolytic transfusion reactions
Currently, the incidence of haemolytic transfusion reactions is difficult to 
estimate. Most data come from retrospective studies that do not include reactions 
not reported by clinicians. In contrast, prospective studies also contain errors due to 
reaction symptoms often remaining unrecognised or masked by associated diseases, 
for example, bleeding or liver disease [1]. The frequency of reporting haemolytic 
transfusion reactions may also depend on other factors, such as patient population, 
transfusion response reporting system and medical staff education. Historical 
research results indicate that the frequency of haemolytic transfusion reactions falls 
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between 1:10,000 and 1:50,000 transfused blood components [3, 4]. In contrast, 
the incidence for patients receiving a transfusion is estimated to be higher (about 
1:500–1:800 patients) because most recipients receive more than one blood unit. 
It is worth noting that the estimation of the frequency of haemolytic reactions 
depends on the number of transfusions in a given centre. Thus, in large clinical cen-
tres, where severely ill patients are treated, more of these events are recorded [4]. A 
report issued by the Quebec Haemovigilance System covering 5 years of observation 
described 47 ABO incompatibility reactions, 55 cases of acute haemolytic transfu-
sion reaction and 91 cases of delayed transfusion reaction in reference to 7059 all 
reported transfusion reactions. It was estimated that the frequency of reactions 
resulting from the ABO incompatibility was 1:27,318, acute haemolytic transfusion 
reactions 1:14,901 and delayed haemolytic transfusion reactions 1:9313 per unit of 
transfused red blood cell concentrate [5].
The most common reaction among the acute (approximately 30%) was haemol-
ysis resulting from ABO incompatibility [5]. In the annual report Serious Hazards 
of Transfusion (SHOT), published in England, in 2017, 42 haemolytic transfusion 
reactions were reported in reference to 3230 of all reactions observed following 
transfusion of blood components, of which 13 cases of acute haemolytic transfusion 
reaction and 29 cases of delayed haemolytic reaction (including 6 cases of hyperhe-
molysis) were reported. The number of reported cases of delayed haemolytic trans-
fusion reaction was higher than in 2016, but comparable with previous years [6]. 
Factors that can affect the increase in the number of delayed haemolytic reactions 
include correctness in carrying out serological tests, longer survival of patients after 
transfusions and an increase in the number of transfused blood components. Since 
most patients receive more than one unit of red blood cell concentrate, the esti-
mated incidence of delayed haemolytic transfusion reactions is from 1:854 to 1:524 
per patient who has been transfused and is higher than per transfused unit [7]. In 
the population, delayed haemolytic transfusion reactions occur with a frequency of 
1.69/100,000 per year [7].
3. Mechanisms of haemolytic transfusion reactions
Red blood cells undergo haemolysis in the intravascular mechanism, in blood 
or extravascular vessels, that is, organs involving cells of the reticuloendothelial 
system, primarily spleen and/or liver. Clinically significant differences between 
the above mechanisms of red blood cells destruction are based on the time of onset 
of haemolysis and the destruction rate of red blood cells. Intravascular haemolysis 
is characterised by the destruction of red blood cells at a rate of about 200 ml of 
transfused cells within 1 h of transfusion. It is manifested by a rapid decrease in 
haemoglobin, haemoglobinemia and haemoglobinuria and can potentially be life 
threatening [2]. In contrast, extravascular haemolysis is less dramatic, with a rate of 
destruction of red blood cells of approximately 0.25 ml/h/1 kg of recipient’s body 
weight. For example, for 70 kg recipient, about 18 ml of transfused red blood cells 
are destroyed per hour. However, it is worth noting that despite the low intensity 
of haemolysis, the survival time of red blood cells after transfusion is significantly 
reduced [2]. In general, intravascular haemolysis is called as an early acute hae-
molytic transfusion reaction. It can occur during transfusion or up to 24 h after 
transfusion of red blood cells. In comparison extravascular haemolysis is called 
delayed haemolytic transfusion reaction and usually occurs 24 h or days after the 
end of the transfusion. The quoted breakdown of reactions is somewhat artificial, 




The occurrence and severity of individual clinical symptoms can vary widely and 
are often non-specific [1, 8].
Red blood cell transfusion can also stimulate the production of alloantibodies 
without the occurrence of haemolysis. This phenomenon is called delayed serologic 
transfusion reaction (DSTR) and should be differentiated from delayed haemolytic 
transfusion reaction [9].
3.1 Intravascular haemolysis
Most often intravascular haemolysis is the result of the destruction of red blood 
cells by the complement system, stimulated by the presence of alloantibodies or 
autoantibodies. Among alloantibodies, such haemolysis is induced by anti-A and 
anti-B, rarely anti-Jka, anti-Jkb, anti-Vel, anti-P, anti-Lea and very unique antibod-
ies with other specificities [10, 11]. In all these cases, haemolysis takes place via the 
classical pathway of complement activation. Its occurrence and severity, in addition 
to the class of antibodies, is also affected by the number of antigenic determinants 
with which the antibodies react. The reaction is most severe in the case of antigens 
A and B, because their number is estimated at about 5 × 105 per cell [12, 13]. In 
contrast, the presence of antigens from the Rh, Kell, Kidd and Duffy systems on the 
surface of red blood cells is determined in the range of 103–104 per cell [12]. Table 1 
shows the number of antigenic determinants on the cell surface for selected red 
blood cell antigens.
Antibodies combined with antigens by triggering the complement cascade lead 
to cell lysis. This mechanism is called the classic pathway for complement activation 
and is shown in Figure 1.
The starting point is the antigen-antibody complex present on the surface of 
the cell membrane [14, 15]. Antibodies of the IgM and IgG class (outside the IgG4 
subclass) bind the C1q protein in the initial stage of activation. The condition for 
complement activation is the binding of the C1q molecule by two Fc fragments of 
adjacent IgG antibodies or by one IgM molecule. It should be noted here that the 
IgM class is more efficient in starting the process of complement activation than the 
IgG class [2, 15]. The C1qrs complex is created and activates the C2 and C4 compo-
nents and their distribution into C2a and C2b as well as C4a and C4b. The C4b2a 
Blood group 
system
Antigens The number of antigenic determinants on the surface of the cell 
membrane
ABO A1 8.5 × 105
A2 2.5 × 105
B 7.5 × 105
Rh D 1–2 × 105
C 7–8 × 104
e 1.8–2.4 × 104
Kell K 6.1 × 103
Duffy Fya 1.7 × 104
Kidd Jka 1.4 × 105
MNSs S 1.2 × 104
Table 1. 
Number of antigenic determinants on the cell surface of the red blood cell (according to [12, 13]).
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complex has proteolytic properties and is called C3 convertase. Convertase breaks 
down molecules of C3 into C3a, C3b, C3c and C3d. The C3b and C3d components 
bind with the red blood cell membrane and in many cases the complement cascade 
process ends. In other cases, the C3b component activates C5 and C5a and C5b 
are formed. C5b binds to C6, then to C7. This creates a complex of three C5b-6-7 
particles, which is partially incorporated into the cell membrane and further binds 
C8. The C5b-8 complexes create holes in the cell membrane that increase when 
exposed to the C9 component. The C5B-C9 complex called membrane attack com-
plex (MAC) creates pores in the cell membrane of a red blood cell that are 1/700 
of its size. Haemoglobin escapes from the cells into the plasma, and the effects of 
haemolysis are visible macroscopically in the plasma of the blood sample [15].
The alternative path of complement activation and the lectin path of comple-
ment activation do not play a role in the destruction of red blood cells. Although the 
mechanism of the lectin route may be the reason for the in vivo ineffectiveness of 
the use of monoclonal and recombinant antibodies, which are thus eliminated from 
the body before they fulfil their function, for example, anti-D Ig for prevention 
purposes in RhD maternal-foetal conflict [16].
However, the complement system does not work specifically. The safety of body 
cells is enabled by factors that regulate complement activity present in plasma and 
on cells of various tissues, including red blood cells. Membrane inhibitor of reactive 
lysis (MIRL) (CD59) and decay accelerating factor (DAF) (CD55) are essential to 
protect red blood cells from haemolysis. The expression of these membrane inhibi-
tors is associated with Cromer group system and CD59. On blood cells with the 
Cromer mull phenotype, known as Inab, DAF inhibitor expression is absent [17, 18]. 
DAF regulates C3a-converting activity. MIRL inhibits membrane attack complex 
[15, 17]. Lack of these particles may increase the susceptibility of red blood cells to 
intravascular haemolysis due to complement activation [19].
3.2 Extravascular haemolysis
In a situation in which, despite activation of the complement system, through 
antigen-antibody reaction, there is no intravascular haemolysis, red blood cells with 
detectable C3b component remain in the circulation. This kind of mechanism of 
red blood cell destruction occurs for IgG antibodies with complement system [13]. 
They may interact with CR1 and CR3 receptors on macrophages and consequently 
undergo phagocytosis. Most of the cells coated by the complement C3b component are 
destroyed by liver macrophages, that is, by Kupffer cells, while the cells coated with 
antibody molecules are mainly destroyed by spleen macrophages. They have surface 
receptors that recognise antibody classes and subclasses, and complement components, 
Figure 1. 




of which the Fc R1 receptor is specific for red cells coated with antibodies [1]. Blood 
cells connected to this receptor are destroyed in the process of antibody-dependent 
cytotoxicity. Red blood cells can be absorbed and completely “digested” inside the 
macrophage. They can also be partially absorbed and then the integrity of the cell 
membrane is disturbed by the loss of proteins and lipids, which changes its osmotic 
properties. Such a blood cell, after being released from the macrophage, circulates 
in the blood as a spherocyte, whose survival is short. The macrophage cytotoxins are 
another mechanism that plays a role in the destruction of red blood cells. As a conse-
quence of antibody-dependent cell-mediated cytotoxicity (ADCC) haemoglobinemia 
and haemoglobinuria may occur similarly to intravascular haemolysis, although the 
antibodies that caused it do not bind complement components.
4.  Mediators of inflammatory reactions in haemolytic transfusion 
reactions
Receptors for complement activation products C3a and C5a are found on many 
cells: monocytes, macrophages, neutrophils, platelets, endothelium and smooth 
muscle. Their release causes an increase in the concentration of oxygen radicals, 
leukotrienes, nitric oxide and cytokines. The increase in cytokine release may also 
be due to the interaction of Fcγ R1 receptors with IgG molecules associated with 
red blood cells. Udani et al. [20] showed in vitro that in the case of ABO incom-
patibility, monocytes are directly involved in the formation of acute haemolytic 
transfusion reaction [15]. Incompatible red blood cells reduce CD14 expression and 
increase CD44 expression on monocytes in whole blood. After 24 incubations with 
incompatible red blood cells, monocytes show a significant increase in CD44 levels. 
The results of these studies indicate a critical role of monocyte activation in the 
development of intravascular haemolytic transfusion reaction [15].
In ABO incompatibility, in which anti-A, anti-B and anti-AB antibodies activate 
complement leading to intravascular haemolysis, a large amount of tumour necrosis 
factor-α (TNF) and interleukins CXCL8 (IL-8) and CCL2 are released into the 
plasma (MCP-1) [19–21]. TNF-α is released first, its elevated concentration is already 
detected within first 2 h. It carries a pro-inflammatory potential that is responsible 
for fever, leukocyte activation, stimulation of procoagulant activity, increased anti-
body production and vascular wall permeability [22]. TNF-α also stimulates endo-
thelial cells to synthesise adhesion molecules and chemotactic cytokines [22]. CXCL8 
and CCL2 produced in the blood during ABO incompatibility will appear later than 
TNF-α in very high concentrations. CXCL8 primarily activates neutrophils, which 
leads to the accumulation of leukocytes in the lung vessels of small diameter and 
damage to the endothelium of blood vessels and their higher permeability [1, 12]. 
CCL2 is mainly a chemotactic and activating factor for monocytes [1, 12].
In incompatibility, in which non-complement IgG antibodies cause extravascu-
lar haemolysis, cytokines belonging to two categories differing in response rates are 
produced: (1) synthesised at a concentration higher than 1 μg/ml within 24 h and 
(2) synthesised at a concentration of about 100 pg/ml. Low concentration cytokines 
include IL-1β, IL-6 and TNF-α. CXCL8 concentration is similar to that in intravas-
cular haemolysis, whereas TNF-α is synthesised at low concentration, estimated 
at <100 pg/ml [1, 2]. IL-1ra (receptor antagonist) is produced in extravascular 
haemolysis, which is an IL-1 receptor antagonist. Its presence to some extent affects 
some clinical differences between extravascular and intravascular haemolysis [23]. 
IL-1β concentration and IL-6 produced by monocytes in response to red blood 
cells coated with IgG antibodies increase progressively within 24 h to a concentra-
tion of 100 pg/ml. Since IL-1β and IL-6 affect proliferation and differentiation 
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of β-lymphocytes, the synthesis of these two cytokines enhances the synthesis 
of allo- and autoantibodies, which are often involved in the formation of delayed 
haemolytic transfusion reaction [1, 24, 25].
5. Complications of haemolytic transfusion reactions
5.1  Disseminated intravascular coagulation associated with haemolytic 
transfusion reaction
The key pathogenetic phenomenon in DIC is excessive thrombin generation in 
the tissue factor (TF)-dependent pathway and activated factor VII (FVIIa-activated 
factor VII) [26]. In the pathogenesis of DIC, interactions between the blood coagu-
lation system and mediators of the inflammatory response are also of great impor-
tance [27]. Proinflammatory cytokines affect blood coagulation and fibrinolysis, 
for example, TNF-α and IL-1 increase TF expression and inhibit thrombomodulin 
(TM) expression on vascular endothelial cells [28]. On the one hand, these pro-
cesses lead to the production of a large amount of thrombin that converts fibrinogen 
to fibrin. Fibrin creates blood clots in the light of small vessels trapping the plate-
lets. If the activation of coagulation is not timely inhibited, the resulting clots will 
block the blood supply to vital organs, which will be manifested in their failure. On 
the other hand, the formation of a large amount of blood clots will “consume” blood 
coagulation factors and platelets, which will manifest as a haemorrhagic diathesis. 
In addition, their degradation products (fibrinogen/fibrin degradation products 
(FDP)) resulting from the breakdown of fibrinogen and fibrin exhibit anticoagu-
lant properties, inhibit platelet function, act as cytotoxic vascular endothelium and 
increase capillary permeability, further disrupting haemostasis mechanisms [26].
Clinically, this is manifested by unexpected bleeding and/or a decrease in blood 
pressure. The course is acute, dynamic, with thrombocytopenia, increased concen-
tration of fibrin degradation products, prolonged prothrombin time (PT), extended 
partial thromboplastin time after activation (activated partial thromboplastin time 
(APTT)) and hypofibrinogenaemia. Table 2 presents the point algorithm for the 
diagnosis of acute disseminated intravascular coagulation.
However, this complication is rare and predominantly accompanies intravascu-
lar haemolysis, but in recipients who have received non-compliant blood in the ABO 
system, it occurs even in 25% of cases [1].
5.2 Hypotension and shock
Hypotension occurs in about 1 in 10 cases of intravascular haemolytic trans-
fusion reaction, but is also sometimes observed in extravascular haemolysis. 
Complement activation appears to be the most important determining factor 
in these cases. During the haemolytic reaction, C3a, C4a, C5a and C5a-des-arg 
anaphylatoxins are released. Furthermore, consumption of a C1-esterase inhibitor 
contributes to the activation of the kinin pathway associated with the release of bra-
dykinin [32]. In addition, tumour necrosis factor (TNF) and interleukin-1 (IL-1), 
released by phagocytes during haemolytic transfusion reaction may also contribute 
to hypotension and shock [32].
5.3 Impaired renal function
Impaired renal function is observed in both intravascular and extravascular 




intravascular. The severity of this abnormality varies greatly—from asymptomatic 
increase in urea (BUN) and serum creatinine up to complete anuria. Concomitant 
hypotension and intravascular coagulation syndrome may increase renal impair-
ment. Blood clots that form in the renal arterioles cause cortical kidney attacks. 
Haemoglobin released from red blood cells also reacts nephrotoxically with nitric 
oxide (NO), damaging the epithelial cells of the renal tubules and the stroma that 
remains after their breakdown [33, 34].
Intravascular haemolysis modulates blood pressure and local blood flow through 
changes in the metabolism of the physiological vasodilator—nitric oxide (NO). NO 
can bind to thiol groups and haemoglobin haeme [35]. The connection of NO with 
haeme Fe2+ impairs oxygen transport through Hb. The presence of O2 leads to oxida-
tion of NO to NO3 and oxidation of Fe2+ to Fe3+ and the formation of methaemoglo-
bin. The interaction between Hb and NO is regulated by the allosteric transition of 
haemoglobin R (oxyHb) to the T form (deoxyHb). In oxyHb, cysteine is exposed 
at position 93 of the haemoglobin amino acid chain (Cys 93β). It is known that a 
significant proportion of NO does not immediately bind to HbFe2+ heme, instead 
it binds to cysteine, resulting in the formation of the S-nitrosothiol derivative Hb 
(SNO-Hb). This process is reversible, so SNO-Hb releases NO, which is transported 
to endothelial receptors, where it participates in the regulation of vascular wall tone 
and blood flow. In the case of haemolysis of red blood cells, the free haemoglobin 
released from them reacts with NO much faster and more strongly than Hb inside 
cells [35]. The effect of intravascular haemolysis described above may be very simi-
lar to the side effect caused by transfusion of first-generation stromal haemoglobin 
solutions. This has been tested for its use as a substitute for red blood cells. It had 
vasoconstrictive and, as a result, hypertensive effect. This effect is largely attributed 
to the binding nitric oxide by free haemoglobin (NO) [36].
6. Clinical symptoms of transfusion haemolytic reactions
Intravascular haemolysis is accompanied by haemoglobinaemia and usu-
ally also haemoglobinuria, whereas extravascular haemolysis can only be 
Test Result Score
Platelet count (×109/l) >100 0
>50, ale ≤ 100 1
≤50 2







Prothrombin time extended o < 3 s 0
o ≥ 3 s, ale < 6 s 1
o ≥ 6 s 2
Fibrinogen concentration (g/l) >1.0 0
≤1.0 1
DIC acute diagnosis ≥5
Table 2. 
Point algorithm for the diagnosis of acute disseminated coagulation Intravascular [29–31].
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accompanied by anaemia. In both cases, the patient’s serum bilirubin increases, 
but it depends on the degree of haemolysis as well as liver function [1]. Elevated 
LDH is always observed with intravascular haemolysis, not always with extra-
vascular haemolysis. Reduced haptoglobin levels usually occur in both types 
of haemolysis. Drop in blood pressure is much more common in patients with 
intravascular than extravascular haemolysis. Renal failure and DIC are also more 
commonly associated with intravascular haemolysis. Some patients may experi-
ence organ failure such as the pancreas, heart and even multiple organ failure that 
threatens the patient’s life.
In unconscious patients and patients under general anaesthesia, it may be 
difficult to recognise a haemolytic transfusion reaction, as some symptoms may 
go unnoticed (e.g. pain and nausea). Pain, which is described as a symptom of 
haemolytic reactions, is located at the puncture site, back, chest, groin and head. 
The occurrence of pain in the haemolytic transfusion reaction is not clear. It is 
probably the result of direct stimulation of nociceptive nerves in perivascular tissue 
by bradykinin, which, in turn, is released during sudden activation of complement 
[37]. Clinical manifestations are shown in Table 3.
7. Causes of haemolytic transfusion reactions
7.1 Haemolytic transfusion reactions caused by alloantibodies
The most common cause of haemolytic transfusion reactions is the immunologi-
cal destruction of red blood cells resulting from the reaction of antibodies in the 
recipient’s blood and the antigens present on the transfused donor’s blood cells to 
which these antibodies are made.
Antibodies capable of destroying transfused blood cells are called clinically 
relevant antibodies, and the transfusion reaction in the event of immunological 
incompatibility depends on: (1) specificity of antibodies; (2) thermal amplitude 
of the antibodies; (3) IgG classes and IgG subclasses; (4) number, density and 
spatial configuration of antigenic sites on red blood cells; (5) the ability of anti-
bodies to activate the complement system; (6) plasma concentrations of antibod-
ies and (7) volumes of transfused red blood cells. A very important feature of all 
antibodies responsible for causing a haemolytic transfusion reaction is its in vitro 
activity at 37°C.







Decrease in RR and/or tachycardia
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disseminated intravascular coagulation (DIC)
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Antibodies detected at a lower temperature are not considered clinically rel-
evant, for example, anti-A1, anti-M and anti-P1, whose optimal reaction is usually 
at low temperature, but if detected at 37°C, they can cause destruction of red blood 
cells with the appropriate antigen. They then become clinically significant.
Features of antibodies (specificity, class and heat amplitude) and antigens (den-
sity of antigenic sites and their distribution) against which the antibodies directed 
are interconnected. In different people, antibodies with a particular specificity most 
often occur in the same class of immunoglobulins and have a similar heat ampli-
tude, for example, anti-A, anti-B and anti-AB from the ABO system often belong 
to both IgM and IgG classes, they bind complement and have an extended thermal 
amplitude of up to 37°C.
A and B antigens are highly immunogenic. Anti-A, anti-B and anti-AB anti-
bodies are involved in causing an early intravascular transfusion reaction, and 
transfusion of incompatible blood in the ABO system poses a threat to the recipi-
ent’s life, especially when group A red blood cells are transfused to a patient with 
group O. Sixty-one (61%) of all haemolytic transfusion-related fatal reactions are 
associated with the ABO incompatibility [38, 39]. A contrasting example is the Lua 
antigen and anti-Lua antibodies. They are usually IgM molecules, are rarely active 
at 37°C and usually do not bind complement. Lua antigens have uneven distribu-
tion on red blood cells and are weakly immunogenic. No cases of acute haemolytic 
reaction caused by anti-Lua antibodies have been reported, delayed transfusion 
haemolytic reaction is rare and occurs only in mild form.
Not all detectable alloantibodies that react with red blood cells can cause a 
haemolytic reaction. The specificity of the antibodies potentially responsible for 
intravascular and extravascular haemolysis is shown in Table 4.
Similar reactions to anti-A and anti-B come from anti-PP1Pk, anti-P1 and 
anti-Vel. Other antibodies cause intravascular haemolysis, but sometimes they 
may be accompanied by intravascular haemolysis. Such reactions were observed in 
the following blood group systems: Rh, MNSs, Lutheran, Kell, Duffy, Diego and 
Lewis. The mechanism of appearance of intravascular symptoms has not been fully 
explained, because although some of the antibodies bind complement components, 
Blood group 
system
Intravascular haemolysis Extravascular 
haemolysis
ABO, H Anti-A, -B, -AB, -H in the Bombay phenotype
Rh All
Kell Anti-K All
Kidd Anti-Jka Anti-Jka, -Jkb, -Jk3
Duffy Anti-Fya, -Fyb








Specificity of selected antibodies associated with haemolytic transfusion reactions.
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their reactions end with C3 components. Only in the case of rare haemolytic reac-
tions due to anti-Lea it was shown that the coated cells are destroyed by the spleen 
macrophages very slowly and in the event of transfusion of large volumes of red 
blood cells, they become inefficient. Then intravascular haemolysis coincides with 
visible haemoglobinuria [40, 41]. Interesting clinical point of view are antibodies 
from the Kidd system. They activate the complement system to the stage of binding 
of the C3b component, causing extravascular haemolysis. However, the symptoms 
in some recipients, or the occurrence of a reaction already during a blood transfu-
sion and haemoglobinuria, indicate that the destruction of blood cells also takes 
place inside the vessel. In the laboratory setting, anti-Jka antibodies are called 
“insidious” antibodies because they are often difficult to detect due to their low 
concentration, and yet they can cause a severe haemolytic complication [41].
Patients with antibodies found to be clinically insignificant may theoretically be 
given a blood transfusion from a donor with the antigen to which they are directed. 
In clinical practice, however, such antibodies can sometimes destroy donor blood 
cells. Therefore, if possible, blood without this antigen should be selected [41].
Another cause for haemolytic transfusion reaction may be a secondary immune 
response in patients who have developed alloantibodies during previous transfu-
sions of blood components or pregnancy. This is called delayed haemolytic trans-
fusion reaction (DHTR) in which current blood transfusion stimulates memory 
lymphocytes and stimulates the production of alloantibodies directed at incompati-
ble antigen found on transfused blood cells [21, 42]. In approximately 50% of cases, 
alloantibodies produced after transfusion or pregnancy cease to be detected after 
a few months, and this period of time depends on the specificity of the antibodies 
and the individual characteristics of the immune system. Schonewille et al. found 
that, using current laboratory methods, 25% of red blood cell antibodies become 
indeterminate on average after about 10 months from production [43]. Therefore, 
pre-transfusion tests may not always detect the presence of antibodies. Antibodies 
stimulated for synthesis may cause symptoms of haemolysis after 3–10 days, usually 
very mild and their presence can be detected after 10–21 days. Table 5 presents fea-
tures of delayed haemolytic transfusion reaction and the time of their occurrence.
Antibodies that cause a delayed haemolytic transfusion reaction are IgG mole-
cules that are binding or non-binding for complementary components. Their speci-
ficity is most often directed to the antigens of the Rh, Kidd, Duffy, MNS and Kell 
systems [14]. In approximately 11% of cases, more than one antibody specificity is 
Time (days) Occurrence Explanation
0 Negative pre-transfusion test Antibody titres below detection threshold
1 Red blood cell transfusion
3–10 Clinical symptoms of haemolysis Acceleration of transfused blood cells 
destruction
10–21 Post-transfusion testing of blood samples: 
DAT and screen of antibodies positive
Increase in antibody titre; donated blood 
cells coated with antibodies
>21 DAT can be negative Destruction of donor blood cells in 
reticuloendothelial system and/or liver
>21–300 DAT may be positive, eluate testing 
may show presence of alloantibodies or 
panagglutination
Alloantibodies not specifically associated 








detected. In rare cases, the result of transfusion alloimmunity in DHTR may be the 
production of autoantibodies (warm IgG autoantibodies or cold autoagglutinins). 
This phenomenon occurs in patients with sickle cell disease [44–46].
7.2  Haemolytic transfusion reactions due to passive transmission of 
alloantibodies in blood components or in blood products
Transfusion of plasma, platelet or granulocyte concentrate from donors 
incompatible in the ABO system with the recipient may lead to acute haemolytic 
transfusion reaction and even death. The severity of the reaction depends on the 
titre of anti-A and/or anti-B antibodies in the transfused plasma or in the blood 
component containing the plasma, and on its volume [47–49]. Tests on the ABO 
system titre in group O apheresis concentrates of platelets show that 26% of samples 
have an anti-A or anti-A, B antibody titre of 64 or higher. This concentration may be 
responsible for causing a haemolytic reaction [50]. In turn, the results of studies by 
Coolig et al. [51] carried out in pooled platelet concentrates of whole blood groups 
showed that 60% of them had anti-A titres of at least 64 [51]. Repeated transfu-
sions of ABO incompatible platelet concentrate may lead to accumulation of anti-A 
antibodies in the recipient’s plasma, which may result in severe haemolytic reactions 
[52]. Unfortunately, despite many studies, it has not been possible to determine 
the critical titre of anti-A and/or anti-B antibodies that would be safe in the event 
of transfusion of ABO incompatible platelet concentrates, and in many countries, 
proprietary haemolysis prevention programs have been developed for recipients of 
incompatible platelets [48–50, 53].
Haemolytic transfusion reactions due to passively transferred anti-A and/or 
anti-B antibodies have also been observed in patients after intravenous immu-
noglobulin administration [54]. Spath et al. [55] analysed reports available in 
the literature describing cases of haemolysis in patients treated with intravenous 
immunoglobulins [55]. They showed that the haemolytic reaction is induced by IgG 
anti-A/B antibodies present in immunoglobulin products. The reaction generally 
occurs in high-dose IVIG recipients [55].
7.3 Haemolytic reaction associated with the “bystander immune cytolysis”
The haemolytic transfusion reactions may have a different immunological origin 
than the reactions of antibodies in the recipient’s blood and the antigen present 
on the donor’s blood cells. This additional mechanism occurs when recipient’s red 
blood cells are destroyed by a reaction called “bystander immune cytolysis”. It is 
defined as the immunological destruction of red blood cells by antibodies whose 
specificity corresponds to antigens found on other cells/blood cells (e.g. HLA anti-
gens found on leukocytes and plasma proteins), while red blood cells are only close 
to this immunological “confusion” [56]. They are destroyed by the complement 
system, although they did not participate directly in the antigen-antibody reaction. 
One of the reasons for this haemolytic reaction is the binding of the C567 comple-
ment complex, activated in an immune reaction, to the membrane of red blood 
cells not participating in the reaction but located in the vicinity [56]. Blood cells are 
destroyed as a result of the activation of the binding of the remaining components 
of C8 and C9 complement and the formation of the MAC complex on the blood 
cells [56]. The mechanism of “bystander” haemolysis is similar to the destruction 
of blood cells in patients with paroxysmal nocturnal haemoglobinuria [57, 58]. A 
characteristic feature of the cell membrane of these blood cells is the lack or weak 
expression of the CD55 (DAF) and CD 59 (MIRL) proteins, which are complement 
inhibitors. This makes the subject more susceptible to haemolysis. It was found that 
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their reactions end with C3 components. Only in the case of rare haemolytic reac-
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when red blood cells became the “bystander” of leukocyte reactions and antibodies 
directed to them, they underwent haemolysis. The reaction of anti-HLA antibodies 
with leucocytes caused complement activation, which resulted in haemolysis of 
the patient’s red blood cells sensitive to the complement [59]. It is noteworthy that 
in patients with a haemolytic reaction associated with the immune cytolysis of the 
“bystander” not only transfused red blood cells but also autologous blood cells of 
the patient were destroyed.
8. Differentiation
Early haemolytic transfusion reactions should be differentiated with septic 
shock due to bacterial contamination of the blood component, as well as anaphy-
laxis and bleeding. In addition, immune haemolysis of nocturnal paroxysmal hae-
moglobinuria or autoimmune anaemia should also be considered. The cause of an 
early haemolytic reaction may also be congenital haemolytic anaemia, for example, 
glucose-6-phosphate dehydrogenase deficiency or microangiopathic haemolytic 
• Alloantibodies responsible for haemolysis
• Delayed serological transfusion reaction
• Autoimmune haemolytic anaemia
• Cold agglutinins disease
• Non-immune haemolysis
 ○ use of inappropriate fluids
 ○ improper storage of blood components
 ○ defects in the blood-heating devices
 ○ needle diameter too small, haematocrit of transfused red blood cells too high
 ○ an inappropriate method of freezing/thawing red blood cells
 ○ using the wrong infusion pumps
 ○ bacterial infection of blood components
 ○ mechanical damage to blood cells, artificial valves
• Congenital haemolytic anaemia
• Haemoglobinopathies
• Drug-induced haemolysis of red blood cells
• Microangiopathic haemolytic anaemia
 ○ thrombocytopenic thrombosis (TTP)
 ○ haemolytic uremic syndrome
 ○ HELLP syndrome
• Bleeding
• Nocturnal paroxysmal haemoglobinuria
• Polyagglutination
• Infections








anaemia (TTP, HUS and HELLP). In differential diagnosis, attention should also be 
paid to non-immune reasons related to improper blood storage, transfusion of red 
blood cells through a small needle diameter, etc.
Differential diagnosis of delayed haemolytic transfusion reactions includes 
latent sources of infection, autoimmune haemolytic anaemia, cold agglutinin 
disease, nocturnal paroxysmal haemoglobinuria, bleeding, mechanical destruction 
of red blood cells, for example, artificial heart valves and TTP.
It should be noted that an increase in body temperature and white blood cell 
count, typical for DHTR, can be interpreted as a sign of infection. In some patient 
groups, it may be difficult to recognise a delayed haemolytic transfusion reaction. 
Patients with liver failure are a special problem. Haemoglobinemia is not diagnosed 
in the serum of these patients due to jaundice, often direct antiglobulin reaction 
(DTA) is positive and elevated bilirubin and LDH are found.
Another group are patients with absorbing haematomas. They may be similar 
to delayed haemolytic reactions. Elevated unbound bilirubin, LDH and decreased 
haptoglobin are observed. The presence of fibrinogen degradation products from an 
absorbing haematoma can be interpreted as a DIC symptom. DHTR can be identi-
fied in these patients by the presence of antigen on the transfused red blood cells to 
which the antibodies may be directed. Table 6 presents the differential diagnosis of 
haemolytic transfusion reactions.
9. Diagnosis of transfusion haemolytic reactions
If a haemolytic transfusion reaction is suspected, medical personnel should 
immediately stop transfusing a blood component. The blood unit should be checked 
at the patient’s bedside, whether it was properly administered. Often, the clinical 
manifestations of haemolytic reactions are not clear, and the cause of the complica-
tion should be differentiated with bacterial infection. Therefore, prior to conduct-
ing laboratory tests of donor blood, bacteriological examination of the component 
remaining after the transfusion cessation should be conducted.
9.1 Tests carried out in case of suspected early hemolytic transfusion reaction
Laboratory tests—mainly serological—are crucial for the diagnosis of an early 
haemolytic reaction. The type of laboratory tests performed for early transfusion 
haemolytic reactions is shown in Table 7.
The basic serological examination consists of direct antiglobulin testing (DAT); 
determination of blood group and RhD in donor and recipient; repetition of the 
serological compliance test. A test should be performed for the presence of antibod-
ies in the recipient before and after the transfusion. Positive DAT indicates haemoly-
sis of red blood cells of immunisation origin. A negative DAT result does not exclude 
haemolysis, it may mean that the transfused blood cells have been destroyed by 
alloantibodies or the method used is not very sensitive. Alvarez et al. [60] compared 
the sensitivity of DAT performed by technique using monospecific IgG antiglobulin, 
flow cytometry and antibody elution. The study showed that DAT could only indi-
cate 10% of antibody coated cells [61]. Performing DAT in the red blood cell eluate, 
its sensitivity was 1%. Flow cytometry proved to be a similarly sensitive method.
The re-determination of the ABO and RhD blood group of the recipient before 
and after the transfusion and in the donors’ blood will exclude errors in the identifi-
cation of the recipient or blood sample (wrong blood in tube (WBIT)). Test results 
carried out by Biomedical Excellence for Safer Transfusion Working Party of The 
International Society for Blood Transfusion in 10 countries with 62 institutions, 
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which examined a total of 690,000 blood samples, showed that the frequency of 
WBIT is 1 in 165. In two countries, Sweden and Finland, which have implemented 
national identification systems, this frequency was 1 for 1986 samples [61].
All-antibody screening for recipients is generally performed using routine testing 
on standard blood cells. A panel of standard cells should contain clinically impor-
tant antigens in a homozygous form to detect the presence of weak antibodies. The 
test should be performed on serum/plasma samples taken before and after transfu-
sion. If positive results indicate alloantibodies are present, they should be identified. 
Detection of a specific antigen on the donor’s blood cells is the confirmation that the 
detected alloantibodies were responsible for the haemolytic transfusion reaction. 
If negative results are obtained, additional tests should be performed, for example, 
PTA PEG, polybrene test and PTA NaCl test. If negative results persist, the test 
should be repeated after a week and after 2 weeks, as in some patients, the antibod-
ies may have been consumed to destroy transfused incompatible red blood cells.
Laboratory tests that help to differentiate haemolysis include determination of 
free haemoglobin in the blood and urine, haptoglobin and lactate dehydrogenase 
(LDH) and bilirubin. While interpreting the obtained test results, it should be 
kept in mind that haemolysis or shortening the survival time of red blood cells can 
be caused by non-immunological factors, for example, adding hypotonic fluids to 
red blood cells, inefficient heating or freezing devices, etc. [62]. Table 8 presents 
changes in laboratory indicators in transfusion haemolytic reactions [56].
9.2  Tests carried out in case of suspected delayed haemolytic transfusion 
reaction
Laboratory tests show anaemia, increased LDH and bilirubin, decreased hapto-
globin and higher white blood cell counts in post-transfusion haemolytic reactions. 
Bilirubin concentration depends on the severity of haemolysis and liver function.
Laboratory indicators Frequency (%)
Low haptoglobin 92 92
Positive DAT 89*
Increased bilirubin concentration medium/slow 80
The presence of haemoglobin in plasma and/or urine 88 vs. 52**
*Negative DAT mainly associated with HTR in ABO incompatibility.
**IHTR vs. DHTR.
Table 8. 
Changes in laboratory indicators in haemolytic transfusion reactions [56].
Blood product Confirm ABO, Rh
Confirm other antigen types, if indicated
Blood bank laboratory Direct antiglobulin test (DAT)
Confirm ABO, RH, antibody screen and identification
Post-transfusion haemolysis check
Clinical laboratory Complete blood count, platelet count
Urinalysis for haemoglobin
Serum bilirubin, creatinine, urine quantitation, coagulation profile
DIC evaluation
Table 7. 




Serological tests show positive DAT and the presence of all red blood cell anti-
bodies that were not detected prior to transfusion. This means that after transfusion 
of red blood cells, the production of alloantibodies directed to the antigen found on 
the transfused blood cells occurs.
Positive DAT with anti-IgG reagents or with anti-IgG and anti-C3 reagents is 
generally seen as two red blood cell populations. It has been observed that in some 
patients, the coating of blood cells includes not only transfused, but also autologous 
red blood cells. Positive DAT with anti-IgG and anti-C3d reagents may persist for 
several months [9].
Alloantibody testing should be performed in the intermediate antiglobulin test 
(IAT) and enzyme test. In both methods, in addition to the reference blood cells, 
the patient’s autologous blood cells should be included. Depending on the specific-
ity, alloantibodies responsible for the delayed transfusion reaction activate in char-
acteristic tests, for example, antibodies from the Rh system react in an enzymatic 
test, often also in anti-globulin testing. In contrast, anti-K, anti-Fya antibodies react 
in an anti-globulin test. Positive reactions with allogeneic blood cells are accompa-
nied by positive auto control of the patient’s red blood cells. Ness et al. [9] showed 
that the formation of warm autoantibodies after the onset of DHTR is relatively 
common. Approximately one-third of patients who were examined 25 days after 
the onset of the reaction presented a positive DAT due to autoantibodies with broad 
specificity [9]. The incidence of autoantibodies after DHTR may be even higher 
because autoantibodies may mimic the specificity of alloantibodies.
Usually, plasma alloantibodies are detectable at 4–7 days after the transfusion 
and reach maximum activity between 10 and 15 days after the transfusion. When 
examining recipient red blood cells using a diagnostic reagent with a specificity 
corresponding to alloantibodies detected in the patient, mixed agglutination is 
observed, which indicates the presence of two blood cell populations in the patient’s 
circulation. One of them, which does not react with diagnostic antibodies, is the 
recipient’s autologous blood cells, the other population is antigenically incompatible 
transfused donor cells, not yet removed from the recipient’s circulation.
10. Treatment of transfusion haemolytic reactions
Treatment of early haemolytic transfusion reactions depends mainly on the 
patient’s condition, which must be closely monitored. It is most important to 
observe the clinical symptoms of the recipient and stop the blood transfusion at the 
right moment. Particular attention should be paid to the patient’s circulation. In the 
event of a marked decrease in blood pressure, make-up fluids should be transfused 
and pressure amines should be administered. However, it is important to avoid 
overloading the circulation with fluids, especially in patients with heart or kidney 
failure. Catheterisation of the pulmonary artery helps to monitor the situation.
In some cases, an exchange transfusion should be considered, bearing in mind 
that the haemolysis intensity depends mainly on the volume of incompatible blood 
transfused. For exchange transfusion, red blood cells without an antigen should be 
used against which the patient has developed alloantibodies. The decision to carry 
it out must be balanced and the course carefully monitored. It should be empha-
sised that in patients with an early reaction due to ABO incompatibility, exchange 
transfusion may reduce the risk of serious complications or death. For patients 
with ongoing haemorrhage choosing a blood for transfusion may be difficult. 
However, it should be remembered that these difficulties must not cause risk of 
haemorrhage. Often the way out of this situation is transfusion of O RhD negative 
red blood cells.
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haemorrhage. Often the way out of this situation is transfusion of O RhD negative 
red blood cells.
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The prevention of renal failure is aided by an early prevention of hypotension. 
A fluid balance should be maintained, the use of dehydrating agents (mannitol and 
furosemide) is helpful, but their oliguria should be closely monitored. Low doses of 
dopamine (1–5 μg/kg/min) may be used to maintain renal circulation, but this may 
not be effective.
Treatment and prevention of DIC during haemolytic transfusion reaction is 
controversial. Heparin is recommended because it additionally acts as an inhibitor 
of the complement activity and limits haemolysis. However, there is a danger of 
bleeding. Another method of treating early haemolytic transfusion reaction is to use 
a high dose of 0.4/kg intravenous immunoglobulin per 24 h after blood transfusion.
Delayed haemolytic transfusion reactions are well tolerated by most patients. 
Additional fluid and diuretic therapy are usually not necessary. Depending on the 
severity of the anaemia, transfusion of blood components should be avoided until 
the antibodies responsible for the reaction have been identified and the appropri-
ate selection of blood cells has been made. Attempts have been made to use high 
doses of intravenous immunoglobulins to prevent haemolytic reactions in patients 
who have been immunised for winter and for whom compatible red blood cells 
have not been selected [63]. The main procedure for subsequent transfusions is to 
select red cells that do not contain the antigen for which all antibodies have been 
detected. Table 9 summarises the treatment options used in haemolytic transfusion 
reactions.
11. Prevention of haemolytic transfusion reactions
Data on the incidence of haemolytic transfusion reactions vary from country to 
country and change over time. There are several causes. One of them was the use of 
improved techniques for detecting clinically relevant alloantibodies, which reduce 
the number of haemolytic transfusion reactions observed in blood recipients. 
In addition, the widespread introduction of automation and computerisation to 
Therapeutic intervention Indication Typical dose
Hydration Prevent renal impairment
Maintain urine output
>100 ml/h
Normal saline and/or 5% dextrose 
200 ml/m2/h
Alkalinisation of urine Prevent renal impairment
Maintain urine pH > 7.5
NaH2CO3 40–70 mEq
Diuresis Prevent renal impairment Mannitol 20% 100 ml/m2
Furosemide 40–80 mg
Vasodilation Increase renal blood flow Dopamine 1–5 μg/kg/min
Anticoagulant Treat DIC Heparin 5–10 u/kg/h
Red cells exchange transfusion Decrease load of 
incompatible red cells
Exchange of one estimated red 
cells mass
Plasma or platelet transfusion Treat haemorrhagic 
complications of DIC
Platelet—1 unit platelet/10 kg or 1 
unit apheresis platelet
FFP—10 ml/kg





DIC—disseminated intravascular coagulation; FFP—fresh frozen plasma.
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pre-transfusion studies, which significantly limits the possibility of errors in serol-
ogy laboratories and blood banks.
The above improvements, however, did not significantly affect the elimination 
of mistakes made in hospitals leading to transfusion of inappropriate blood to 
the patient. These include, among others, errors in collecting blood samples from 
patients and blood transfusions to a wrong patient. These errors are the most com-
mon cause of ABO incompatible transfusions, threatening the patient’s life.
The introduction of haemovigilance transfusiological surveillance systems has 
enabled the analysis of all fatal and severe transfusion reactions. It allows to identify 
malfunctioning procedures leading to transfusion reactions. It enforces the intro-
duction of procedures eliminating further errors.
12. Summary
Preventing haemolytic transfusion reactions by focusing on advances in serol-
ogy and transfusion medicine has significantly reduced their incidence. Progress in 
understanding reaction pathophysiology has helped clinically assess patients and 
treat them effectively. It is possible that technological progress enabling modifica-
tion of red blood cells and the use of red blood cell substitutes will significantly 
change transfusion practice in the future and eliminate the occurrence of haemo-
lytic transfusion reactions. But until then, HTRs will remain the most important 
adverse post-transfusion reaction.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Abstract
The ABO and Rhesus blood group systems are the most clinically relevant blood 
group systems from haemolytic disease of the foetus and newborn (HDFN) and 
haemolytic transfusion reaction (HTR) perspectives. Other clinically relevant 
blood group systems include the Kell, Duffy, Kidd and MNSs blood group systems. 
The clinical relevance of a blood group system depends on the ability of antibodies 
of the system to cause HDFN and HTR. This chapter discusses the distribution 
of ABO, Rhesus and other clinically relevant red cell antigens among Nigerians 
and implications for HDFN and HTR. There are several challenges associated 
with the management of Rhesus negative pregnancies, pregnancies associated 
with clinically significant alloantibodies, implementation of policy on routine 
antenatal anti-D prophylaxis (RAADP), management of Rhesus negative women 
that require termination of pregnancy (TOP), provision of antigen negative blood 
for certain patient groups and the management of pregnant and non-pregnant 
patients with clinically significant alloantibodies. This chapter highlights the need 
for Nigeria and other African countries to implement best practices to optimize the 
care offered to pregnant women as well as patients in whom red cell transfusion is 
indicated.
Keywords: clinically relevant blood group antigens, Nigerians,  
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1. Introduction
1.1 History of Nigeria
Nigeria often referred to the giant of Africa is the largest Black nation in 
Africa. It is a country located in West Africa bordered by Cameroon in the East, 
Benin Republic in the West, Niger Republic to the North and Chad Republic to the 
North East. It is a federation consisting of 36 states with Abuja the Federal Capital 
territory as the capital. It is located on the Gulf of Guinea with a total area of 
923,768 km2 (356,669 sq. miles). It is the world’s 32nd-largest country. Nigeria got 
her independence from the British on 1st of October 1960. It has an estimated popu-
lation of over 200 million people. The United Nations estimated the population in 
2016 to be 185,989,640 distributed as 51.7% rural and 48.3% urban with a popula-
tion density of 167.5 persons per square kilometre. Although the official language is 
English, there are more than 250 ethnic groups with well over 500 different native 
languages and diverse cultures. There are 3 major ethnic groups in Nigeria (Hausa/
Fulani, Igbo and Yoruba). Nigeria is a religiously diverse nation divided into a pre-
dominantly Christian South and Muslim North and a minority groups of traditional 
African religion. Nigeria is a mixed economy dependent and an emerging market. 
As at 2014 Nigeria was the fastest growing and largest economy in Africa. She is 
blessed with abundant natural resources and a developing communication, finan-
cial, legal and transportation sector. Nigeria is the 12th largest producer of oil in the 
world, the 8th largest exporter, has the 10th largest proven reserves and supplies 
a fifth of its oil to the United States of America. Oil plays a significant role in the 
Nigerian economy and accounts for 40% of GDP and 80% of all government earn-
ings. Healthcare delivery is the responsibility of the 3 tiers of government (federal, 
state and local government). There is a number of health-related challenges in 
Nigeria (HIV/AIDS, malaria, polio, poor access to potable and clean water, lack of 
proper sanitation system, high infant and maternal mortality rates). Although the 
recurrent expenditure on health in Nigeria has increased over the years, healthcare 
delivery and infrastructural endowment remains suboptimal with health tourism 
on the increase [1]. The Nigerian health care system is continuously faced with a 
number of challenges; shortage of healthcare workers [2] predominantly due to 
significant emigration of skilled medical personnel to developed economies of the 
world (brain drain), suboptimal funding, decaying infrastructure, inter-profes-
sional conflict, perennial strike actions by healthcare professionals, lack of political 
will as well as bureaucratic bottlenecks in public health care delivery in Nigeria [3].
2.  UHC and the WHO model lists as governmental obligations to 
implement before 2030
Nigeria is a party to the United Nation (UN) General Assembly adopted 2030 
agenda for Sustainable Development and the UN High-Level Meeting (UN HLM) 
Universal Health Coverage (UHC) UHC2030. In September 2015, the UN General 
Assembly adopted the 2030 Agenda for Sustainable Development that included 17 
Sustainable Development Goals (SDGs) ensuring that all persons are carried along 
and that no one is left behind [4]. The agenda laid emphasis a holistic approach 
aimed at achieving sustainable development for all. The 17 sustainable development 
goals (SDGs) included; no poverty, zero hunger, good health and well-being, quality 
education, gender equality, clean water and sanitation, affordable and clean energy, 
decent work and economic growth, industrial innovation and infrastructure, 
reduced inequality, sustainable cities and communities, responsible consumption 
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and production, climate action, life below water, life on land, peace and justice 
strong institutions and partnerships to achieve goal. On September 23rd 2019, a 
high-level meeting on universal health coverage held at the United Nations General 
Assembly. The meeting focussed on Universal Health Coverage: Moving Together 
to Build a Healthier World (UHC2030) and brought together heads of state, politi-
cal and health leaders, policy-makers, and universal health coverage champions 
to advocate for health for all. The meeting agreed on Key Asks from the UHC 
Movement aimed at accelerating progress toward Universal Health Coverage (UHC) 
[4]. Among others, UHC2030 advocates that countries should; ensure political 
leadership beyond health (that all countries to ensure healthy lives and wellbe-
ing for all at all stages as a social contract), leave no one behind (pursue equity in 
access to quality health services with financial protection), regulate and legislate 
(create a strong, enabling regulatory and legal environment responsive to people’s 
needs), uphold the quality of care (build high-quality health systems that people 
and communities trust), invest more and better (increased domestic investment 
and allocation of more public financing for health through equitable and manda-
tory resource) and move together (establishing multi-stakeholder mechanisms for 
engaging the whole of society for a healthier world). Nigeria is a party to the global 
commitment ensuring the well-being, universal health coverage and access to qual-
ity healthcare when and where they need it, without facing financial hardship [5]. 
There is general expectation among Nigerians for the government to mix word with 
action by ensuring that all Nigerians in both rural and urban communities have 
access and can use the promotive, preventive, curative, rehabilitative and palliative 
health services they require, that is of sufficient quality and affordable [6].
3. Current situation in Nigeria
3.1 Distribution of ABO and other clinically significant blood groups
The human red blood cell membrane is complex and contains a number of 
clinically relevant blood group antigens, the most relevant being the ABO and the 
Rhesus blood group antigens. Apart from the ABO and Rhesus blood group systems, 
thirty-four other blood group systems have been identified as at November 2014 [7]. 
In addition to the ABO and Rhesus blood group antigens, 364 other red cell antigens 
have been identified serologically. The clinical relevance of a blood group system 
depends on the distribution of antigens of the blood group system in the popula-
tion, ability of antibodies of the blood group system to cause haemolytic transfu-
sion reaction (HTR) and haemolytic disease of the foetus and newborn (HDFN) 
[8]. The ABO blood group system is one of the most clinically relevant blood group 
systems [9]. It was first discovered by Karl Landsteiner in 1901 [10]. The ABO blood 
group system has three main antigens (A, B and H). Four major ABO groups exist 
(A, B, AB and O). The ABO blood group system is based on the A and B antigens 
occurring singly as A or B, doubling as AB or the absence of both as O. Individuals 
who have lack the A or B antigens on their red cells have the group specific antibody 
in their serum or plasma. Antibodies of the system are predominantly IgM origi-
nally thought to be naturally occurring but are now known to occur in the first years 
of life as a result of sensitization to ABO-like antigen and environmental substances 
that occur in nature such as bacteria, viruses and food. Evidence has shown that 
these antibodies are not present at birth and that animals kept in a sterile room from 
birth do not produce these antibodies. The ABO blood group system is important in 
transfusion medicine, HDFN and in organ transplant. Transfusion of ABO incom-
patible unit can cause severe HTR. Similarly, an immune response can also occur 
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following ABO incompatible organ transplant. ABO blood group incompatibilities 
between the mother and child does not normally cause HDFN because antibodies 
of the ABO blood group system are usually of the large molecular weight IgM type, 
which do not cross the placenta. However, mothers who were previously sensitised 
(previous incompatible transfusion and pregnancy) can potentially have IgG ABO 
antibodies that can potentially cause ABO HDFN. The distribution of ABO blood 
groups varies across the world according to the population. There are also variations 
in blood type distribution within human subpopulations.
Nigeria is a significantly varied nation in terms of ethnicity. The gene frequency 
of ABO and Rh blood group varies significantly within the six geopolitical zones 
in Nigeria [11–18]. Previous studies in most parts of Nigeria indicates that the 
ABO blood group distribution is in the order O > A > B > AB [19]. Studies from 
the United States, Mauritania, Morocco, Cameroun, Tunisia, Ethiopia and Iran 
reported same order (O > A > B > AB) [20–26]. However, study in Madagascar and 
Guinea reported a contrary trend (O > B > A > AB) [27, 28]. This observation in 
Nigeria is also at variance with reports from India and Bangladesh where preva-
lence of B is highest followed by O and the least was AB (B > O > A > AB) [29, 30]. 
Reports from Turkey and Colombia indicates an order A > O > B > AB [31, 32].
A multi race/ethnic study in the United States reported that blood type O is the most 
prevalent (46.6%) with White non-Hispanic, Hispanic, Black non-Hispanic, Asian 
and North American Indian having varying percentage of 45.5, 56.5, 50.2, 39.8 and 
54.6 respectively [21]. Other studies in Turkey, Mauritania, Iran, Ethiopia, Colombia, 
Cameroun, Bangladesh, Madagascar, Morocco, Guinea and Northern India have 
reported varying percentage in ABO and Rh blood types [20–23, 25–32].
Phenotypic distribution of Rh(D) in Nigeria varies from one part of the coun-
try to the other; Kwara (4.5%) [17], Jos Plateau State (4.32) [14], FCT (4.3) [33], 
Minna (3.3%0) [11], Lagos (3.0, 6, 6.86%) [16, 34, 35], Ogun (6.65 and 2.9%) [36, 37], 
Osun (6.3%) [38], Oyo (3.3, 6.68, 4.8, 5.89%) [12, 14, 18, 39], Ekiti (4.3%) [40], Akwa 
Ibom (5.7%) [41], Bayelsa (2%) [42], Delta (1.8%) [43], Benin (6.0%) [13], Rivers (3.2, 
7, 8.3%) [44–46], Kano (5.2%) [47], Sokoto (1.55%) [14], Zamfara (1.2%) [48], Enugu 
(4.49%) [14], Abia (5.3%) [49], Ebonyi (4.2%) [50], Borno (1.92%) [14], Adamawa 
(4.6%) [51], Yobe (4.6%) [52]. The prevalence of Rhesus negativity varies from one 
zone to the other; 4.4, 3.1, 6.0, 4.3, 3.9 and 3.1% respectively for the South East, North 
East, South, South, South West, North Central and North West zone respectively.
The overall average prevalence of Rhesus negativity is 5.1%. The distribution 
of Rh(D) in Nigeria is in agreement with others parts of the world [20, 23, 25–28, 
30, 31]. Blacks have been found to have a lower frequency of Rhesus D negative 
 phenotype (3–5%) [34, 42, 44] compared to the general Caucasian population 
(15%) [21, 53]. The lower prevalence of Rh(D)− in Nigeria and other developing 
is important and a blessing in disguise because clinical situations like fetomaternal 
haemorrhage during the course of pregnancy can give arise through Rh incompat-
ibility and HDFN. In Nigeria and many of these developing countries RAADP 
and other anti-D HDFN related prevention strategies are not being implemented. 
Table 1 shows the prevalence of Rhesus D group among Nigerians based on zones.
The Kell blood group is the third most clinically relevant blood group system 
after ABO and Rhesus. Individuals without Kell antigens (K0) who are transfused 
with Kell positive donor red cells or Kell negative pregnant women exposed to 
the Kell positive red cells of their baby carry the risk of developing Kell antibody 
which can cause HDFN [54]. In the developed world all pregnant women and 
non-pregnant women of child bearing age are transfused with Kell negative blood. 
Also, patients with other antibodies are transfused with Kell negative and red cells 
also lacking the antigen to which their alloantibody is specific. This is to prevent 
them from potentially developing anti-Kell antibody. Kell sensitization is the third 
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most common cause of HDFN after Rh and ABO. Anti-Kell has been shown to cause 
severe foetal anaemia by suppressing foetal RBC synthesis [55]. HDFN-associated 
anaemia in Anti-Kell-related HDFN is caused by the ability of anti-K to cause the 
suppression of foetal production of RBCs [56]. Unlike Rh and ABO, Kell antigens 
are expressed on the surface of RBC precursors, and anti-K promotes the immune 
destruction of Kell positive erythroid early progenitor cells by macrophages in the 
foetal liver rather than only mature foetal RBCs [55]. There are few Kell prevalence 
studies in Nigeria. Among their cohort of pregnant women in Sokoto, North 
Western Nigeria, Erhabor and Colleagues [57] obtained a Kell antigen prevalence of 
2%. Similarly, Ugboma and Nwauche [58] in Port Harcourt investigated the preva-
lence of Kell antigen among their patients and reported a Kell antigen prevalence 
of 2%. The prevalence of Kell antigen among a multi-ethnic cohort of 302 healthy 
Nigerian individuals indicated a zero prevalence of K antigen [59]. Racial differ-
ences seem to exist in Kell blood group antigen distributions [60, 61]. The Nigerian 
government and governments in other African countries will need to implement 
this strategy in a bid to reducing Kell-related sensitization and the effect of HDFN.
The prevalence of other clinically significant red cell antigens has been deter-
mined among Nigerians. The prevalence of Lewis, Kidd, Duffy, Kell and M blood 
group antigens among blood donors in Aminu Kano Teaching Hospital, Kano, 
Nigeria [62] were as follows: Lea: 26.4%, Leb: 15.1%, M: 20.8%, k (cellano): 21.7%. 
The Duffy (anti Fya, anti Fyb) and Kidd (anti Jka anti Jkb) antigens were not 
detected among the donors. Out of the 162 pregnant women tested for their Duffy 
antigens status indicated Fya, Fyb and Fya (a+b+) prevalence of 7 (4.3%), 9 (5.6%) 
and 1 (0.61%) respectively [63]. Kidd blood group phenotypes were determined 
among pregnant women in Sokoto, North Western Nigeria [63]. The distribution 
of Kidd antigens among subjects studied indicated a prevalence of Jka, Jkb and 
Jk(a+b+) of 8 (4.9%), 13 (8.0%) and 0 (0.0%), respectively. There is need for the 
phenotyping of donor’s blood for clinically significant red cell antigens. There is 
also the need to routinely screen all pregnant women for alloantibodies to facilitate 
the selection of antigen negative units for those with clinically significant alloanti-
bodies who require a red cell transfusion. This can potentially optimise the obstetric 
management of HDFN.
The prevalence of Rh c and e phenotype among 200 pregnant women attending 
antenatal clinic (ANC) in Usmanu Danfodiyo University Teaching Hospital Sokoto 
was determined. The prevalence of Rh c was 92% while Rh e was 98.5% [64]. 
The frequencies of Rh blood group antigens and phenotypes of the Ibibio, Efik, 
and Ibo ethnic nationalities in Calabar municipality, Nigeria, were determined 
using standard serologic techniques. Of the 720 Calabar individuals tested, the 
frequencies of the Rh antigens within the nationalities were c (100%), e (96.38%), 
Zone of 
Nigeria








Prevalence of Rhesus D group among Nigerians based on zones.
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Jk(a+b+) of 8 (4.9%), 13 (8.0%) and 0 (0.0%), respectively. There is need for the 
phenotyping of donor’s blood for clinically significant red cell antigens. There is 
also the need to routinely screen all pregnant women for alloantibodies to facilitate 
the selection of antigen negative units for those with clinically significant alloanti-
bodies who require a red cell transfusion. This can potentially optimise the obstetric 
management of HDFN.
The prevalence of Rh c and e phenotype among 200 pregnant women attending 
antenatal clinic (ANC) in Usmanu Danfodiyo University Teaching Hospital Sokoto 
was determined. The prevalence of Rh c was 92% while Rh e was 98.5% [64]. 
The frequencies of Rh blood group antigens and phenotypes of the Ibibio, Efik, 
and Ibo ethnic nationalities in Calabar municipality, Nigeria, were determined 
using standard serologic techniques. Of the 720 Calabar individuals tested, the 
frequencies of the Rh antigens within the nationalities were c (100%), e (96.38%), 
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D (96.38%), E (15.22%), and C (3.62%) for the Ibibios; c (100%), e (95.60%), D 
(96.70%), E (21.98%), and C (0%) for the Efiks; and c (100%), e (94.29%), D 
(91.43%), E (28.57%), and C (2.86%) for the Ibos. The overall frequencies of the 
Rh antigens in these 720 individuals were c (100%), e (95.56%), D (94.44%), 
E (18.89%), and C (2.78%). Forty (5.56%) were found to be D−, while all were 
found to possess the c antigen. The most frequently occurring Rh phenotype was 
Dccee, with a frequency of 73.61%. The alternative allele, C, did not appear in 
homozygous form (CC) in the population tested [65]. Of the 374 pregnant women 
studied in Port Harcourt, Nigeria, the frequencies of the Rh antigens within the 
population were D (89.0%), c (82.0%), e (54.0%), C (24.3%), E (20.1%). The 
frequencies of the Rh antithetical antigens were DD/Dd (91.2%), Cc (19.5%), cc 
(84.5%), Ee (13.9%), ee (54.3%), CC (25.1%), EE (19.8%) and dd (10.4%). Seven 
(1.9%) were found to be Rhnull, sixteen (4.3%) were found to be D− or exalted 
D. Phenotypes without RhD reactivity were -c- (2.9%), -Cc (0.3%), -C- (0.3%), 
-Ee (0.5%) and -E- (0.3%) [66]. A multi-ethnic cohort of healthy Nigerian 
individuals were studied. The antigen status of these individuals for Rh was 
determined. The prevalence of the Rh antigens in the study cohort was found to 
be: D (92.7%), C (20.5%), c (97.7%), E (19.5%), and e (97.4%). Dce was the most 
common Rh phenotype (53.3%) [59]. Few countries in sub-Saharan Africa have 
systematic testing for antigens C, c, E, and e of the Rh and Kell system antigens 
in the donor and recipient, thereby exposing transfused patients to the risk of 
 developing antibodies that can cause HTR and HDFN. Among 651 blood donors 
tested in Abidjan for antigens of the Rh blood group system, the antigen frequen-
cies of D, c, e, C, and E were; 92.93, 99.85, 99.85, 21.97, and 13.82% respectively.  
K antigen is was found in 0.77% of donors [67].
3.2  Universal donor phenomenon: the need to implement a policy of universal 
haemolysin testing of group O donor units
ABO blood group system is one of the most clinically relevant blood group 
systems. Individuals above the age of 6 months have clinically significant anti-A 
and/or anti-B in their serum particularly if they lack the corresponding antigens on 
their red cells. Whole blood transfusion still thrives in Nigeria despite the advan-
tages of component therapy and challenges associated with whole blood transfu-
sion (development of febrile transfusion reactions, graft-versus-host disease, 
alloimmunization to leukocyte antigens, immunomodulatory effects, transmission 
of diseases such as cytomegalovirus, Human T-Lymphotrophic Virus I/II and 
Epstein Barr (EBV) for which leukocytes may be the vector) [68]. Blood group O 
donor blood is the most common blood group among Nigerian blood donors [69] 
and their red cells are commonly used as universal donor units for transfusion to A, 
B and AB recipient particularly in emergency situations. Blood group O individu-
als lack the A and B antigens on their red cells and thus are inappropriately called 
Universal donors. These individuals have anti A and Anti B in the plasma. Due to 
the absence of A and B on their red cell, their red cells could be given to A, B, and 
AB individuals. This is quite useful particularly in Nigeria and other developing 
countries where there is inadequate supply of donor blood. However, some group 
O individuals have potentially lytic anti-A and lytic anti-B in their plasma that bind 
to antigens A and B on the surface of erythrocytes in recipients and potentially 
activate the complement cascade resulting in acute intravascular haemolysis. To 
avoid this, all blood group O donor units intended for transfusion to non-O patient 
must be tested for the presence of these anti-A and lytic anti-B haemolysis. Those 
donors found negative can have their blood given to non-O patients while those 
that test positive are reserved for group O recipients only. Haemolysin testing to 
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identify the presence of haemolytic anti-A and anti-B antibodies has emerged as 
a useful screening in most countries to identify high levels of anti-A and/or anti-B 
antibodies to prevent HTRs. Routine haemolysis testing of blood group O donor 
units intended for transfusion to A, B or AB recipient is not routinely carried out 
in most settings in Nigeria despite the high prevalence of haemolysins observed 
among Nigerians in previous studies [70–75]. The Nigeria government can learn 
from evidenced-based best practices in most developed settings [76, 77] and imple-
ment a policy to routinely test all group O donor units for haemolysins in other to 
identify group O donors with high titre of IgG anti A and/or anti B whose blood 
should be reserved only for transfusion to group O recipient while those that test 
negative can be transfused to A, B or AB individual as a way to maximising the use 
of our limited allogeneic stock.
3.3 Screening for clinically significant alloantibodies
Alloantibodies are antibodies produced in a patient as a result of exposure 
to foreign red cell antigen via transfusion, pregnancy or transplantation. In 
countries such as Nigeria, there are multiple ethnic groups and racial or genetic 
heterogeneity among the population. This can often be associated with a wide 
variation of alloantibodies [78]. Other common factors that facilitate alloanti-
body formation in the recipient include: the immune competence, the dose of 
the antigen the recipient is exposed to, the route of exposure and how immuno-
genic the foreign antigen is [79, 80]. Development of alloantibodies can lead to 
difficulty in finding compatible blood for transfusion or it can result in severe 
delayed haemolytic transfusion reaction if the antibody titre is low, undetected, 
missed and if antigen positive units is transfused [81]. Evidenced-based best 
practice in the developing world requires that alloantibody testing is carried out 
as part of pre-transfusion testing of patients who require a red cell transfusion 
as well as pregnant women presenting to antenatal clinic at booking [82, 83]. 
The aim of this test is to detect the presence of unexpected red cell antibody 
in the patient’s serum [84, 85]. Once these antibodies are detected during the 
alloantibody screening, every effort must be made to identify the specificity of 
the alloantibody by doing a panel test. The aim of identifying the specificity of 
the alloantibody in a patient that requires a red cell transfusion is to enable the 
Medical Laboratory or Biomedical Scientist to select antigen negative donor unit 
for appropriate crossmatch (indirect antiglobulin test) for such patient [86]. The 
aim of a panel test in the case of a pregnant women coming for antenatal booking 
is to identify the alloantibody, determine whether the antibody can potentially 
cause HDFN [87] and to allow the monitoring of the titre or quantification of 
the antibody every 4 weeks from booking until 28 weeks’ gestation and every 
2 weeks thereafter until delivery [88]. The obstetrician requires this information 
to determine to what extent the developing foetus is affected by HDFN, decide 
whether to monitor the baby for anaemia using Doppler ultrasound, determine 
whether the baby will require intrauterine transfusion and to make an informed 
decision to possibly deliver the baby earlier. These evidence-based best practices 
are not being implemented in many settings in Nigeria. Testing of donor units 
for other clinically relevant red cell antigens other than ABO and Rhesus D is not 
routinely carried out. Also, donor units particularly those intended for transfu-
sion to pregnant women and neonates are also not routinely screened for CMV 
and Hepatitis E virus like it is routinely done in more advanced part of the world. 
This is a complete failure in stewardship by the Nigerian government and can 
compromise the transfusion service delivery to pregnant women and patients 
that require red cell transfusion.
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4. Challenges for the future
4.1  Absence of universal access to prophylactic anti-D through the routine 
antenatal anti-D prophylaxis (RAADP) program
RAADP or routine antenatal anti-D prophylaxis is a recommended treatment 
option for all Rhesus D negative pregnant women who are not known to be sensi-
tised previously to the RhD antigen. The D antigen is the most immunogenic and 
most clinically relevant of the Rhesus antigens. A mother who is RhD negative and 
married to a homozygous or heterozygous D positive husband has a 100 and 50% 
chance respectively of carrying a D positive baby. During such pregnancies as a 
result of feto maternal haemorrhage (FMH) following potentially sensitising events 
[abdominal trauma, abortion or termination of pregnancy, antepartum haemor-
rhage (APH), amniocentesis, chorionic villus sampling, external cephalic version 
(ECV) and miscarriages] during pregnancy, small amounts of foetal blood can 
enter into the maternal circulation. The foetal RhD-positive cells can irreversibly 
sensitise the mother to produce alloantibody D. The risk of sensitisation occurring 
is dependent on a number of factors; ABO blood group of the developing foetus 
(there is a higher risk if there is ABO compatibility between mum and baby), dose 
of foetal cells entering the maternal circulation, immune competence of the mother 
and type of pregnancy (risk is significantly higher in the first decreasing in the 
subsequent pregnancies. The antibody produced is immune IgG antibody that is a 
low molecular weight antibody and can potentially cross the placenta barrier. The 
maternal immune anti-D are small molecular weight IgG immunoglobulin and can 
pass through the placenta in subsequent D positive pregnancy and destroy the foetal 
red cells with increased production of bilirubin a product of red cell breakdown 
(HDFN). While in womb the mother manages the bilirubin on behalf of the baby 
by production of glucoronyl transferase enzyme which break down (conjugate) 
the bilirubin to water soluble forms that can be excreted in the urine. However, 
after delivery, the excess bilirubin released from the breakdown of the foetal red 
cells leads to jaundice. With the baby’s liver poorly developed and not producing 
enough glucoronyl transferase enzyme to conjugate the bilirubin to excretable form, 
the level can potentially rise above the blood brain barrier and cause kernicterus 
(permanent brain damage) with attendant neurodevelopmental problems (cerebral 
palsy, deafness neuromotor and speech delay). Routine antenatal anti-D prophy-
laxis (RAADP) is a program under which Rhesus D negative non-sensitised preg-
nant women are universally offered anti-D prophylaxis at 28–34 weeks’ gestation 
with the aim of preventing the sensitization of Rh D-negative women and by exten-
sion prevent anti-D HDFN in subsequent pregnancy [89]. The aim of the RAADP 
programme is the reduction in the incidence of anti-D related HDFN; improve 
the survival of the children delivered by Rhesus D negative women, reduce the 
incidence of disability and health-related quality of life of children and mortality in 
children delivered by Rhesus D negative women who would have developed anti-D 
related-HDFN if mothers were not offered prophylaxis. The RAADP program is 
based on offering either two doses of at least 500 IU at 28- and 34-weeks’ gestation 
or a single dose of at least 1500 IU at 28 weeks gestation followed by a further dose 
of at least 1500 IU within 72 h of delivery of a Rh D positive baby. The dose offered 
post-delivery is dependent on the result of feto maternal haemorrhage testing 
result (flow cytometry of Kleihauer testing). Both methods quantify in millilitres 
the amount of foetal red cells that has entered maternal circulation to facilitate the 
administration of adequate dose of prophylactic anti-D. As a general rule 1 25 IU 
of anti-D is administered to clear 1 ml of foetal red cells from maternal circula-
tion. The introduction of anti-D prophylaxis using Rhesus D immunoglobulin 
121
Distribution of Clinically Relevant Blood Group Antigens among Nigerians…
DOI: http://dx.doi.org/10.5772/intechopen.90372
(given intramuscular or intravenous administration) has led to a significant fall in 
the number of women becoming sensitised and by extension reduced the incidence 
and severity of this condition. The anti D immunoglobulin used as prophylaxis 
is prepared from plasma of male Rhesus D negative donors who have high levels 
of plasma anti-D due to deliberate or intentional immunisation with D positive 
red cells. Anti D is also administered to Rhesus D negative women following a 
potentially sensitising events during pregnancy. The anti-D facilitates the clearance 
of foetal red cells from the maternal circulation to prevents active immunisation, 
thus preventing the production of alloantibody D. Prior to the availability and 
widespread use of anti-D prophylaxis for Rhesus negative pregnant women, the 
incidence of Rh D sensitization among Rhesus D negative women following two 
deliveries of D positive and ABO-compatible, infants was approximately 16% and 
haemolytic disease of the foetus and newborn (HDFN) due to immune anti-D was 
a significant cause of morbidity and mortality [90]. Following the implementation 
of anti-D prophylaxis, the rate of sensitization has declined significantly to approxi-
mately 2%. With the implementation of RAADP by providing anti-D prophylaxis 
in the 3rd trimester between 28 and 34 weeks gestation, there has been a further 
remarkable reduction in the sensitisation rate to 0.17–0.28% [91]. Mortality from 
D-related HDFN related has also declined significantly from 46/100,000 births to 
1.6/100,000 births [89]. Evidence from best practice implementation in England 
and Wales indicates that RAADP has reduced the incidence of sensitisation and 
hence of HDFN [92]. Conservative estimate indicates that it cost £2–£3.5 million for 
England and Wales to provide RAADP to all her Rh D-negative pregnant women. 
The Nigerian government can learn from this evidence-based best practice by 
implementing RAADP program for her population of Rhesus D negative pregnant 
population with the hope of reducing sensitization, incidence and severity of anti-D 
related HDFN and mortality in Nigeria.
4.2  Absence of facility for foetal genotype testing for D, K and other clinically 
relevant red cell antigens
Rhesus D grouping is relevant for blood donors, transfusion recipients and for 
women of child bearing age including pregnant women. This is because the Rh 
blood group antigens particularly D is significantly immunogenic. Rh D negative 
individuals often lack the D antigens on their red cells and can potentially be sen-
sitised when exposed to D antigen positive red cells during pregnancy and blood 
transfusion. Such antibodies are often capable of causing a haemolytic transfusion 
reaction (HTR) and haemolytic disease of the foetus and newborn (HDFN). Since 
the introduction of prophylactic anti-D and implementation of evidence based 
best practice of careful management and monitoring of D negative pregnant 
women for all the potentially sensitising events that occur during pregnancy, the 
prevalence of HDFN because of Rh D incompatibility between the mother and 
baby has declined significantly [90]. In order to prevent Rhesus D negative women 
who are not previously sensitised from developing alloantibody D, these women 
are offered prophylactic anti-D during pregnancy under the Routine Antenatal 
Anti-D Prophylaxis program between 28 and 34 weeks’ gestation. The half-life of 
the administered anti-D is 12 weeks. The anti-D prevents the mother from being 
sensitised by micro foetal maternal haemorrhage that can occur as a result of 
potentially sensitising events that occur during pregnancy. These women should 
have a fetomaternal haemorrhage testing following any potentially sensitising 
events that occur after from 20 weeks’ gestation. This test quantifies the amount 
of foetal red cells that entered the maternal circulation to allow for the adminis-
tration of adequate dose of anti-D to clear the fotal cells and prevent them from 
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individuals often lack the D antigens on their red cells and can potentially be sen-
sitised when exposed to D antigen positive red cells during pregnancy and blood 
transfusion. Such antibodies are often capable of causing a haemolytic transfusion 
reaction (HTR) and haemolytic disease of the foetus and newborn (HDFN). Since 
the introduction of prophylactic anti-D and implementation of evidence based 
best practice of careful management and monitoring of D negative pregnant 
women for all the potentially sensitising events that occur during pregnancy, the 
prevalence of HDFN because of Rh D incompatibility between the mother and 
baby has declined significantly [90]. In order to prevent Rhesus D negative women 
who are not previously sensitised from developing alloantibody D, these women 
are offered prophylactic anti-D during pregnancy under the Routine Antenatal 
Anti-D Prophylaxis program between 28 and 34 weeks’ gestation. The half-life of 
the administered anti-D is 12 weeks. The anti-D prevents the mother from being 
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of foetal red cells that entered the maternal circulation to allow for the adminis-
tration of adequate dose of anti-D to clear the fotal cells and prevent them from 
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sensitising the mother. Anti-D (125 IU) is required to remove 1 ml of foetal red 
cells from maternal circulation. RhD alloimmunisation is still a significant cause 
of foetal and neonatal morbidity and mortality particularly in Nigeria and other 
developing countries [93–95] because of absence of evidence-based best practices 
and non-implementation of Rh D prophylaxis during pregnancy. This often result 
in a significant number of unfortunate women developing alloantibody D through 
no fault of theirs but rather as a result of failure in stewardship by the Nigerian 
government. Also, non-invasive foetal blood group genotyping (DNA) testing of 
maternal plasma to determine the antigen status of the developing foetus carried 
by an alloimmunised pregnant women is vital as it provides useful information 
as to whether a foetus is carrying the group specific antigen and in fact at risk of 
HDFN. This will help prevent the need for extensive laboratory testing (titration 
and quantification of antibody every 4 weeks from booking till 28 weeks’ gestation 
and every 2 weeks from 28 weeks to delivery) and clinical monitoring in antigen 
negative cases. Molecular testing of maternal plasma for foetal DNA can be per-
formed during the second trimester. DNA probes for the most common antigens 
associated with HDFN are now available [96]. Knowledge of the molecular basis 
of the blood group systems has facilitated the development of assays for blood 
group genotyping. Foetal Rhesus D genotyping can potentially tell at 16 weeks’ 
gestation through the analysis of amniotic fluid or through maternal plasma 
the foetal D genotype of the developing foetus. In previously sensitised alloim-
munised pregnant women, knowledge of the foetal D antigen status is beneficial 
to enable obstetricians optimally manage these women [95]. In non-sensitised 
Rhesus negative pregnant women, the knowledge of the foetal D antigen status 
is quite important for several reasons; prevent us from exposing the mother to a 
prophylactic anti-D (a human blood product that even though significantly virally 
tested for TTIs) she does not need, allow for the optimal utilisation of the product 
in patients in whom it is indicated and spare the woman the pain of the product 
being administered intramuscularly. RHD genotyping of foetuses carried by Rh 
D-negative women using foetal DNA obtained invasively through amniocentesis 
or chorionic villus sampling used to be critical to the clinical management of these 
women. Technological advances now allows for accurate determination of foetal 
Rh D genotype using cell-free foetal DNA from maternal blood, thus overcoming 
the invasive procedures [97]. Rh D genotyping are based on polymerase chain reac-
tion using non-invasive blood sample from the mum are quite sensitive with low 
incidence of false positive result [98, 99]. Although there are cases of D-negative 
genomes possessing fragments of mutated Rh D genes, the most notable of which 
is the Rh D pseudogene found in Africans. Rh D genotyping tests have been devel-
oped to differentiate these alleles and thus enhance the diagnosis in a multi-ethnic 
population [100].
Foetal blood group genotype of a developing foetus can also be determined for 
Rh C, c, E and Kell (K) using cffDNA from maternal plasma [101]. Many European 
Union countries have suggested the mass application of foetal genotyping for all 
foetuses carried by D-negative women. This advocacy is based on clear benefit of 
conserving anti-D stocks and prevention of unnecessary administration of this 
human-derived blood product that has associated risk [102, 103]. In Denmark 
and the Netherlands this evidenced-based best practice of foetal Rh D testing for 
all non-sensitised D negative pregnant women have been introduced [104]. Also, 
non-invasive foetal blood group genotyping (DNA) testing of maternal plasma to 
determine the antigen status of the developing foetus carried by an already alloim-
munised pregnant women is vital as it provides useful information as to whether 
a foetus is carrying the group specific antigen and in fact at risk of haemolytic 
disease. This will help prevent the need of extensive laboratory (titration and 
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quantification of antibody every 4 weeks till 28 weeks’ gestation and every 2 weeks 
from 28 weeks to delivery) and clinical monitoring in antigen-negative cases.
4.3  Absence of facility for intrauterine transfusion for children with HDFN that 
are severely anaemic in utero
The maternal alloantibody D produced as a result of sensitization of the Rh 
D negative mother to the Rhesus D positive foetal red cells are low molecular 
weight IgG antibody. This antibody can potentially cross the placenta barrier into 
the foetal circulation and can destroy the foetal red cells resulting in anaemia, 
heart failure, hydrops foetalis (fluid retention and swelling) and intrauterine 
death. In utero the diagnosis of foetal anaemia used to be made by carrying out 
ultrasound guided foetal blood sampling for analysis of the foetal haemoglobin 
and haematocrit or amniocentesis-an invasive ultrasound guided procedure with 
a significant 2% risk of foetal loss associated with entering the amniotic sac and 
obtaining amniotic fluid which is analysed for product of haemoglobin break-
down. However, non-invasive diagnosis of foetal anaemia can now be made using 
non-invasive Doppler ultrasound technology by measuring the middle cerebral 
artery peak systolic velocities (MCA PSV). The foetal anaemia can be managed 
with intrauterine blood transfusions. Intrauterine transfusion is associated with a 
number of risks; foetal bradycardia, foetal death, cord haematoma, haemorrhage 
from the puncture site, miscarriage, preterm labour and vessel spasm. The blood 
used for such transfusions must meet certain requirements; gamma irradiated red 
cells to prevent transfusion-associated graft-versus-host disease, haemoglobin S 
negative, CMV negative and significantly high PCV (0.70–0.85) [105, 106], unit 
must be C-, D-, E- and K-, leucocyte depleted to less than 1 × 106 leucocytes per 
unit, less than 5 days old, free from clinically significant irregular blood group 
antibodies and negative for high-titre anti-A and anti-B haemolysin. If the mother 
has other alloantibodies apart from D, it is vital that suitable unit negative for the 
specific antigens to which those maternal alloantibodies are specific are selected. 
Once the baby is delivered, intensive phototherapy and IV immunoglobulin along 
with antiglobulin (DAT) test should be carried out. There should also be continu-
ous monitoring of the haemoglobin, haematocrit and bilirubin level. A positive 
DAT is diagnostic of HDFN and the baby sample should be sent for elution to 
identify if the antibody coating the foetal red cell is maternal alloantibody. If the 
bilirubin is not responsive to intensive phototherapy and continues to rise, the 
associated neonatal anaemia and hyperbilirubinemia can be managed by carrying 
our exchange blood transfusion (EBT) to prevent bilirubin encephalopathy by 
removing a significant number of maternal antibodies-coated foetal red cells and 
excess bilirubin and replacing it with donor red cells. The red cell product used for 
EBT must meet certain requirements; group O or ABO compatibility (mum and 
baby), compatible with any maternal antibody, gamma irradiated, collected in 
saline, adenine, glucose and mannitol (SAGM), fresh less than 5 days old, have high 
haematocrit (0.5–0.55) to prevent of post-exchange anaemia and polycythaemia 
and negative for high titre haemolysins. A number of these evidenced-based best 
practices; facility for intrauterine blood transfusion, facilities for diagnosis of 
foetal anaemia in utero, maternal alloantibody testing, elution testing, facility for 
gamma irradiation of blood, CMV testing of donors units, testing of donor units 
for other clinical significant red cell antigens apart from ABO and Rhesus D, SAGM 
units and leucodepletion of donor units are often not available in Nigeria and most 
developing countries. This failure in stewardship by government in these countries 
limits the delivery of best possible care in the management of HDFN and appropri-
ate transfusion in these patients.
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quantification of antibody every 4 weeks till 28 weeks’ gestation and every 2 weeks 
from 28 weeks to delivery) and clinical monitoring in antigen-negative cases.
4.3  Absence of facility for intrauterine transfusion for children with HDFN that 
are severely anaemic in utero
The maternal alloantibody D produced as a result of sensitization of the Rh 
D negative mother to the Rhesus D positive foetal red cells are low molecular 
weight IgG antibody. This antibody can potentially cross the placenta barrier into 
the foetal circulation and can destroy the foetal red cells resulting in anaemia, 
heart failure, hydrops foetalis (fluid retention and swelling) and intrauterine 
death. In utero the diagnosis of foetal anaemia used to be made by carrying out 
ultrasound guided foetal blood sampling for analysis of the foetal haemoglobin 
and haematocrit or amniocentesis-an invasive ultrasound guided procedure with 
a significant 2% risk of foetal loss associated with entering the amniotic sac and 
obtaining amniotic fluid which is analysed for product of haemoglobin break-
down. However, non-invasive diagnosis of foetal anaemia can now be made using 
non-invasive Doppler ultrasound technology by measuring the middle cerebral 
artery peak systolic velocities (MCA PSV). The foetal anaemia can be managed 
with intrauterine blood transfusions. Intrauterine transfusion is associated with a 
number of risks; foetal bradycardia, foetal death, cord haematoma, haemorrhage 
from the puncture site, miscarriage, preterm labour and vessel spasm. The blood 
used for such transfusions must meet certain requirements; gamma irradiated red 
cells to prevent transfusion-associated graft-versus-host disease, haemoglobin S 
negative, CMV negative and significantly high PCV (0.70–0.85) [105, 106], unit 
must be C-, D-, E- and K-, leucocyte depleted to less than 1 × 106 leucocytes per 
unit, less than 5 days old, free from clinically significant irregular blood group 
antibodies and negative for high-titre anti-A and anti-B haemolysin. If the mother 
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specific antigens to which those maternal alloantibodies are specific are selected. 
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with antiglobulin (DAT) test should be carried out. There should also be continu-
ous monitoring of the haemoglobin, haematocrit and bilirubin level. A positive 
DAT is diagnostic of HDFN and the baby sample should be sent for elution to 
identify if the antibody coating the foetal red cell is maternal alloantibody. If the 
bilirubin is not responsive to intensive phototherapy and continues to rise, the 
associated neonatal anaemia and hyperbilirubinemia can be managed by carrying 
our exchange blood transfusion (EBT) to prevent bilirubin encephalopathy by 
removing a significant number of maternal antibodies-coated foetal red cells and 
excess bilirubin and replacing it with donor red cells. The red cell product used for 
EBT must meet certain requirements; group O or ABO compatibility (mum and 
baby), compatible with any maternal antibody, gamma irradiated, collected in 
saline, adenine, glucose and mannitol (SAGM), fresh less than 5 days old, have high 
haematocrit (0.5–0.55) to prevent of post-exchange anaemia and polycythaemia 
and negative for high titre haemolysins. A number of these evidenced-based best 
practices; facility for intrauterine blood transfusion, facilities for diagnosis of 
foetal anaemia in utero, maternal alloantibody testing, elution testing, facility for 
gamma irradiation of blood, CMV testing of donors units, testing of donor units 
for other clinical significant red cell antigens apart from ABO and Rhesus D, SAGM 
units and leucodepletion of donor units are often not available in Nigeria and most 
developing countries. This failure in stewardship by government in these countries 
limits the delivery of best possible care in the management of HDFN and appropri-
ate transfusion in these patients.
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4.4  Absence of facility to monitor the antibody titre and quantification in 
pregnant women who have developed HDFN causing alloantibody during 
pregnancy
Haemolytic Disease of the Foetus and Newborn (HDFN) is the destruction of 
foetal and newborn red cells by maternally derived alloantibody directed against a 
red cell antigen often inherited from the father and expressed on foetal cells. These 
maternal IgG antibodies are low molecular weight and can pass through the pla-
centa barrier into the foetal circulation and bind to the corresponding foetal red cell 
antigen. The resultant maternal IgG-coated cells interact with foetal macrophages 
in resulting in their removal by the foetal spleen. This often results in anaemia, 
erthroblastosis with compensatory erythropoiesis resuming in the foetal liver and 
spleen, resulting in hepatosplenomegaly and portal hypertension. Maternal 
antibody screening is undertaken to detect clinically significant antibodies, which 
might affect the foetus and/or newborn, and to detect antibodies that may cause 
problems with the provision of compatible blood products for the woman and for 
the foetus/newborn. Approximately 1% of pregnant women are found to have 
clinically significant red cell antibodies [107–109]. The detection of clinically 
significant antibodies among antenatal women plays an important role in transfu-
sion safety and preventing HDFN. A previous study among antenatal multiparous 
women in Jammu region of India indicated that the commonly observed alloanti-
bodies were anti-D, anti-E, anti-C and anti-K [110]. Once an antibody has been 
detected, it is identified by carrying out a panel test. If the antibody specificity is 
one that has the potential to cause HDFN, the titre/quantification must be carried 
out periodically. Antibody quantification and titration is performed on patients’ 
samples, to support the prediction and management of HDFN and ABO mis-
matched organ transplant. Antibody quantification of anti-D, and anti-c for 
management of HDFN. Antibody titration in ABO mismatched transplant is 
carried out to allow clinical assessment of the possibility of carrying out an ABO 
mismatched transplant, and monitoring of treatment to reduce antibody titre in 
preparation for ABO mismatched transplant. All clinically significant maternal 
antibodies detected during antenatal booking or follow up visit must be referred to 
the reference laboratory for confirmation of specificity, determination of the 
possibility of the antibody to cause HDFN and for and titre/quantification to allow 
for the monitoring of antibody. Evidence based best practice in developed countries 
requires the monitoring of women with red cell antibodies of specificities known to 
have potential to cause significant HDFN (anti-D, anti-c and anti-K), covering 
frequency of testing (every 4 weeks from booking until 28 weeks and every 2 weeks 
there after till delivery), measurement of antibody concentration (by quantifica-
tion or titration as appropriate), referral to a foetal medicine specialist and follow-
up required post-delivery. Antibodies that require quantification include anti-c, 
anti D, anti c + D, and anti-c + E. The antibodies that require titration include 
Anti-e, c, E, C+ e, G, CW, Fya, Fyb, K, k, Kpa, Kpb, Jsa, Jsb, M, S, and s. Antibody 
titration (ABT) is a semi quantitative method used to detect the strength of an 
alloantibody/antibodies present in the patient’s plasma [111]. Antibody titration is 
used prenatally to screen for risk of HDFN, haemolytic transfusion reactions and 
assessment in solid organ or haematopoietic stem cell transplant. To assess risk for 
HDFN, the titre of the clinically significant alloantibody is performed. When the 
antibody and the titre strength are identified, ABT is periodically performed 
throughout pregnancy, whereby plasma samples are compared in parallel with the 
previously frozen samples to determine if the titre or strength of the antibody is 
static, decreasing or increasing. Obstetricians can use this information in conjunc-
tion with middle cerebral artery Doppler assessment to determine the extent to 
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which the developing infant is affected, the presence of foetal anaemia, decision to 
carry out intrauterine transfusion as well as decision on whether to deliver the baby 
earlier to allow for a better and less risky physical management rather than ultra-
sound-guided in utero management [112]. Colour Doppler ultrasonography a 
non-invasive technique is currently being used to assess cerebral artery blood flow 
[113]. Increased cerebral artery blood flow is an indicator of foetal anaemia [114]. 
Invasive procedures such as amniocentesis or cordocentesis, with subsequent 
analysis of amniotic fluid and foetal blood sampling obtained by ultrasonography 
guided procedure are invasive and significantly risky with potential attendant 
negative effect to the foetus. Accepted titration methodologies include the tube and 
gel column technology method [115]. A difference of 2 dilutions or a score of 10 is 
usually an indication of significant change in antibody production. The antibody 
titre/quantification often rises as a result of re-exposure of the maternal immune 
system to red cell antigen following the initial sensitising events that occur during 
pregnancy. Every re-exposure to the initial offending antigen from the foetus to the 
mother’s immune system often becomes booster doses. These booster doses often 
result in more antibody production, attendant increase in the titre and quantifica-
tion. Antibody titration is also commonly used for screening blood products, 
particularly platelets and plasma as well as group O donor blood intended for 
transfusion to blood group A, B and AB patients. This is to decrease the risk of 
haemolytic transfusion reactions due to passive anti-A/anti-B antibodies. The titre 
of group O products is determined and those with high titers [51, 114] are labelled 
and used for group O individuals only while those negative for HT haemolysin can 
be given to A, B and AB individuals [116]. Also, ABT also has a potential role in 
preventing graft rejection in ABO-incompatible solid organ transplants (heart, 
liver, and lung) [117] as well as in erythroid engraftment after haematopoietic 
progenitor cell transplants [118]. Previous report indicates that the performance of 
antenatal titrations by column agglutination technology (CAT) is at least as sensi-
tive as the performance by the indirect antiglobulin test (IAT) tube method. CAT 
was found to show greater sensitivity than IAT tube when dealing with anti-c 
compared to titrating Anti-K. The CAT method also appears to be more sensitive 
for detecting samples that require referral to the obstetrician [119]. Evidenced-
based best practice requires that all pregnant women are tested for the presence of 
alloantibodies and its titers/quantification during pregnancy as a way of calculating 
the risk of developing HDFN [120]. Guidelines of the British Committee for 
standards in Haematology requires that, all pregnant women should be ABO and D 
antigen typed and screened for presence of alloantibodies at booking and at the 
28th week of gestation [121]. Similarly, in the Netherlands, it has been mandatory 
to screen all pregnant females for presence of alloantibodies [122]. The aim of 
periodic antibody titration and quantification (every 4 weeks from detection at 
booking till 28 weeks and every 2 weeks thereafter until delivery) is to determine 
whether the titre/quantification is static, decreasing or increasing. A static titre/
quantification shows that there is no increase in severity over time, a dropping 
titre/quantification indicate a low risk for HDFN while a rising titre/quantification 
is an indication of a potentially severe HDFN. For anti-D quantification a level of 
4–15 IU indicates a moderate risk while a level > 15 IU indicates a high risk for 
HDFN. For anti-c a level > 7.5 IU indicates a high risk of HDFN. For anti-K, a titre 
of 1:32 or greater is indicative of HDFN risk. Generally, a 4-fold increase in the titre 
of an HDFN-associated alloantibody is an indication of a significant risk for HDFN 
[68]. In Nigeria and some other African countries alloantibody testing at booking 
and at 28 weeks gestation is not available, facilities for alloantibody identification 
and titration/quantification is not available. A number of pregnant women have 
alloantibodies without knowing and the risk of mortality from HDFN is high. 
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which the developing infant is affected, the presence of foetal anaemia, decision to 
carry out intrauterine transfusion as well as decision on whether to deliver the baby 
earlier to allow for a better and less risky physical management rather than ultra-
sound-guided in utero management [112]. Colour Doppler ultrasonography a 
non-invasive technique is currently being used to assess cerebral artery blood flow 
[113]. Increased cerebral artery blood flow is an indicator of foetal anaemia [114]. 
Invasive procedures such as amniocentesis or cordocentesis, with subsequent 
analysis of amniotic fluid and foetal blood sampling obtained by ultrasonography 
guided procedure are invasive and significantly risky with potential attendant 
negative effect to the foetus. Accepted titration methodologies include the tube and 
gel column technology method [115]. A difference of 2 dilutions or a score of 10 is 
usually an indication of significant change in antibody production. The antibody 
titre/quantification often rises as a result of re-exposure of the maternal immune 
system to red cell antigen following the initial sensitising events that occur during 
pregnancy. Every re-exposure to the initial offending antigen from the foetus to the 
mother’s immune system often becomes booster doses. These booster doses often 
result in more antibody production, attendant increase in the titre and quantifica-
tion. Antibody titration is also commonly used for screening blood products, 
particularly platelets and plasma as well as group O donor blood intended for 
transfusion to blood group A, B and AB patients. This is to decrease the risk of 
haemolytic transfusion reactions due to passive anti-A/anti-B antibodies. The titre 
of group O products is determined and those with high titers [51, 114] are labelled 
and used for group O individuals only while those negative for HT haemolysin can 
be given to A, B and AB individuals [116]. Also, ABT also has a potential role in 
preventing graft rejection in ABO-incompatible solid organ transplants (heart, 
liver, and lung) [117] as well as in erythroid engraftment after haematopoietic 
progenitor cell transplants [118]. Previous report indicates that the performance of 
antenatal titrations by column agglutination technology (CAT) is at least as sensi-
tive as the performance by the indirect antiglobulin test (IAT) tube method. CAT 
was found to show greater sensitivity than IAT tube when dealing with anti-c 
compared to titrating Anti-K. The CAT method also appears to be more sensitive 
for detecting samples that require referral to the obstetrician [119]. Evidenced-
based best practice requires that all pregnant women are tested for the presence of 
alloantibodies and its titers/quantification during pregnancy as a way of calculating 
the risk of developing HDFN [120]. Guidelines of the British Committee for 
standards in Haematology requires that, all pregnant women should be ABO and D 
antigen typed and screened for presence of alloantibodies at booking and at the 
28th week of gestation [121]. Similarly, in the Netherlands, it has been mandatory 
to screen all pregnant females for presence of alloantibodies [122]. The aim of 
periodic antibody titration and quantification (every 4 weeks from detection at 
booking till 28 weeks and every 2 weeks thereafter until delivery) is to determine 
whether the titre/quantification is static, decreasing or increasing. A static titre/
quantification shows that there is no increase in severity over time, a dropping 
titre/quantification indicate a low risk for HDFN while a rising titre/quantification 
is an indication of a potentially severe HDFN. For anti-D quantification a level of 
4–15 IU indicates a moderate risk while a level > 15 IU indicates a high risk for 
HDFN. For anti-c a level > 7.5 IU indicates a high risk of HDFN. For anti-K, a titre 
of 1:32 or greater is indicative of HDFN risk. Generally, a 4-fold increase in the titre 
of an HDFN-associated alloantibody is an indication of a significant risk for HDFN 
[68]. In Nigeria and some other African countries alloantibody testing at booking 
and at 28 weeks gestation is not available, facilities for alloantibody identification 
and titration/quantification is not available. A number of pregnant women have 
alloantibodies without knowing and the risk of mortality from HDFN is high. 
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Nigerian and most of these countries can afford to provide the best possible 
antenatal care for their pregnant population like it obtains in the developed world. 
However, lack of political will, failure in stewardship and endemic corruption and 
misappropriation of the people’s resources remains a major challenge to the effec-
tive management of the women. African government must rise to the responsibili-
ties and do what is right by implementing evidence-based practice to allow for the 
effective management of pregnancies associated with clinically significant alloanti-
bodies and its associated HDFN.
4.5  Challenge associated with use of anti-D immunoglobulin for the prevention 
of haemolytic disease of the foetus and newborn
Alloantibody-D are produced in a woman of child bearing age either as a result 
of Rhesus D incompatible transfusion (deliberate or erroneous transfusion of D 
positive donor red cells to Rhesus D negative women) or as a result of prior Rhesus 
D incompatibility between the mother and the developing foetus. These sensitiza-
tions are often as a result of fetomaternal haemorrhage during pregnancy or during 
delivery. This is often associated with D positive red cells entering into the maternal 
circulation to sensitise the mother to produce these immune antibody D. This 
immune D is an IgG class antibody and can potentially cross the placenta in subse-
quent D positive pregnancies to cause D HDFN. If a Rhesus D negative woman is 
married to Rh D positive men who are either homozygous or heterozygous for blood 
group antigen D, there is a 100 and 50% chance respectively of potentially carry-
ing a Rhesus D positive foetus. In such pregnancies the risk of sensitization of the 
mother during the first pregnancy as a result of fetomaternal haemorrhage (during 
pregnancy or delivery) of D positive foetal red cell into maternal circulation is high. 
The recommend that prophylaxis be provided as soon as possible and always within 
72 h of the following potentially sensitising event taking place in Rh D negative 
pregnant women (Amniocentesis, chorionic villus biopsy and cordocentesis, APH, 
PV bleed during pregnancy, ECV, Abdo trauma (sharp/blunt, open/closed, ectopic 
pregnancy, evacuation of molar, pregnancy, IUFD, intrauterine intervention during 
pregnancy (transfusion, surgery, insertion of shunts and laser), miscarriages, TOP, 
delivery (normal, instrument or C/S) and intraoperative cell salvage) to prevent 
sensitization and anti-D-related HDFN in subsequent pregnancy. Evidence-based 
best practice in most developed countries is to prevent this sensitization from 
taking place by the implementation of the Routine Antenatal Anti-D Prophylaxis 
(RAADP) programme. This program is alloimmunization prevention where all 
Rh D negative women are universally offered anti prophylaxis during pregnancy 
(28 weeks gestation) and following the delivery of a Rhesus positive baby. The 
implementation of this program has significantly reduced the number of residual 
alloimmunization from 16% to less than 0.1% [123]. The justification for this 
implementation is based of scientific evidence that 92% of women who develop an 
alloantibody-D during pregnancy do so at or after 28 weeks gestation [124, 125].
This implementation has significantly reduced the number of women who are 
sensitised and by extension the number of D HDFN. However, in countries like 
Nigeria and some other developing countries where this policy has not been imple-
mented, a significant 14% of unfortunate foetuses are born dead while 50% of those 
who are born alive suffer from brain injury and neonatal death [126]. This cases of 
preventable death of Nigerian and African children is a humanitarian emergency 
that require urgent attention and good will by the Nigerian, African government 
and people of good will across to globe. Rho(D) immune globulin (RhIG) is a medi-
cation that can be given to non-sensitised Rhesus D negative pregnant women to 
prevent Rh D sensitization. The medication is often administered intramuscularly 
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or intravenously and has a half-life of 12 weeks. Rho(D) immune globulin used for 
prophylaxis is a human derived fractionated plasma product produced from blood 
donors who have high levels of anti-D Ig either due to previous sensitization or 
intentional immunisation of Rh D negative men to produced immune D. This prod-
uct is significantly virally tested (HBsAg, anti-HIV and HCV RNA) and includes 
viral inactivation steps in order to further reduce the risk of viral transmission. 
There is still a small unquantifiable possibility of transmitting prion particularly 
vCJD or other infectious agents. Product safety data submitted by manufacturers 
to National Institute of Health and Clinical Excellence technical appraisal guidance 
156 (National Institute for Health and Clinical Excellence [127]) indicates a very 
low rate of adverse event (less than one non-serious per 80,000 doses of anti-D 
administered) [89]. There is no evidence till date to suggest that prophylactic anti-D 
administered to Rhesus D negative women during pregnancy is harmful to the 
foetus. Child birth or delivery is a potential sensitising event that can potentially 
expose the mother to the Rhesus D positive cells of the baby. Following delivery in 
these women, the cord blood is tested for ABO, Rh D group and DAT. If the infant 
is Rhesus D positive, the mother sample taken within 72 h is tested for fetomaternal 
haemorrhage (flow cytometry of Kleihauer-Betke test). These tests quantify the 
number of foetal cells that has entered the maternal circulation and thus facilitates 
the determination of the optimal dosage of prophylactic anti-D to be administered. 
As a general rule 125iu of anti-D is required to clear 1 ml of foetal cells from mater-
nal circulation. A dose of 300 μg or 1500 IU is often sufficient to prevent alloim-
munization after delivery in 99% of cases [128]. If the D-type of a newborn or 
stillborn is unknown or cannot be determined, a dose of anti-D prophylaxis should 
be administered. However, if the infant is found Rhesus D negative, prophylaxis 
will not be required. Evidenced-based best practices in most developed countries as 
part of their HDFN prevention program recommend the following [92].
In Nigeria and many countries in Africa, these recommendations and best prac-
tices are not being implemented. Government in these countries will need to rise 
up to their responsibilities by implementing these recommendations to prove the 
sincerity of their resolve to offer their people particularly Rhesus negative women 
the best possible health care delivery.
4.6 Unaffordability due to high cost of prophylactic anti-D
Anti-D related HDFN often result from the transplacental passage of maternal 
allo-antibodies directed against foetal red cell antigens inherited from the father 
affects the foetus or neonate. Majority of the mothers becomes sensitised following 
small feto-maternal haemorrhages during pregnancy and at delivery of the first Rh 
D-positive infant. These antibodies can potentially cause HDFN in successive Rh 
D-positive infants. Implementation of universal access to prophylactic anti-D given 
during antenatal and post-partum period following the delivery of a Rh D positive 
baby can help prevent primary Rh D immunisation and risk of HDFN in subsequent 
pregnancies [129]. It is recommended that routine antenatal anti-D prophylaxis 
(RAADP) is offered to all non-sensitised pregnant women who are Rh D negative to 
reduce the risk of sensitization and by extension D-related HDFN [130]. The World 
Health Organisation (WHO) recommends that antenatal prophylaxis with anti-D 
immunoglobulin should be given to non-sensitised Rh-negative pregnant women 
at 28 and 34 weeks of gestation to prevent Rh D alloimmunization. It is estimated 
that single dose of anti-D can cost around US$ 50 (500 IU) to US$ 87 (1500 IU), 
depending on the brand and local taxes. Therefore, the cost of antenatal prophy-
laxis for two 500 IU doses could be as much as US$ 100 per woman. Additional 
costs will include screening for blood typing in settings where Rh blood tests are not 
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or intravenously and has a half-life of 12 weeks. Rho(D) immune globulin used for 
prophylaxis is a human derived fractionated plasma product produced from blood 
donors who have high levels of anti-D Ig either due to previous sensitization or 
intentional immunisation of Rh D negative men to produced immune D. This prod-
uct is significantly virally tested (HBsAg, anti-HIV and HCV RNA) and includes 
viral inactivation steps in order to further reduce the risk of viral transmission. 
There is still a small unquantifiable possibility of transmitting prion particularly 
vCJD or other infectious agents. Product safety data submitted by manufacturers 
to National Institute of Health and Clinical Excellence technical appraisal guidance 
156 (National Institute for Health and Clinical Excellence [127]) indicates a very 
low rate of adverse event (less than one non-serious per 80,000 doses of anti-D 
administered) [89]. There is no evidence till date to suggest that prophylactic anti-D 
administered to Rhesus D negative women during pregnancy is harmful to the 
foetus. Child birth or delivery is a potential sensitising event that can potentially 
expose the mother to the Rhesus D positive cells of the baby. Following delivery in 
these women, the cord blood is tested for ABO, Rh D group and DAT. If the infant 
is Rhesus D positive, the mother sample taken within 72 h is tested for fetomaternal 
haemorrhage (flow cytometry of Kleihauer-Betke test). These tests quantify the 
number of foetal cells that has entered the maternal circulation and thus facilitates 
the determination of the optimal dosage of prophylactic anti-D to be administered. 
As a general rule 125iu of anti-D is required to clear 1 ml of foetal cells from mater-
nal circulation. A dose of 300 μg or 1500 IU is often sufficient to prevent alloim-
munization after delivery in 99% of cases [128]. If the D-type of a newborn or 
stillborn is unknown or cannot be determined, a dose of anti-D prophylaxis should 
be administered. However, if the infant is found Rhesus D negative, prophylaxis 
will not be required. Evidenced-based best practices in most developed countries as 
part of their HDFN prevention program recommend the following [92].
In Nigeria and many countries in Africa, these recommendations and best prac-
tices are not being implemented. Government in these countries will need to rise 
up to their responsibilities by implementing these recommendations to prove the 
sincerity of their resolve to offer their people particularly Rhesus negative women 
the best possible health care delivery.
4.6 Unaffordability due to high cost of prophylactic anti-D
Anti-D related HDFN often result from the transplacental passage of maternal 
allo-antibodies directed against foetal red cell antigens inherited from the father 
affects the foetus or neonate. Majority of the mothers becomes sensitised following 
small feto-maternal haemorrhages during pregnancy and at delivery of the first Rh 
D-positive infant. These antibodies can potentially cause HDFN in successive Rh 
D-positive infants. Implementation of universal access to prophylactic anti-D given 
during antenatal and post-partum period following the delivery of a Rh D positive 
baby can help prevent primary Rh D immunisation and risk of HDFN in subsequent 
pregnancies [129]. It is recommended that routine antenatal anti-D prophylaxis 
(RAADP) is offered to all non-sensitised pregnant women who are Rh D negative to 
reduce the risk of sensitization and by extension D-related HDFN [130]. The World 
Health Organisation (WHO) recommends that antenatal prophylaxis with anti-D 
immunoglobulin should be given to non-sensitised Rh-negative pregnant women 
at 28 and 34 weeks of gestation to prevent Rh D alloimmunization. It is estimated 
that single dose of anti-D can cost around US$ 50 (500 IU) to US$ 87 (1500 IU), 
depending on the brand and local taxes. Therefore, the cost of antenatal prophy-
laxis for two 500 IU doses could be as much as US$ 100 per woman. Additional 
costs will include screening for blood typing in settings where Rh blood tests are not 
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currently performed [131]. However, providing anti-D prophylaxis universally to all 
Rh D negative non-sensitised pregnant women is not cheap. The cost benefit analy-
sis of preventing sensitization, HDFN and its related physical disabilities, mental 
retardation and death of affected children supports investing in the implementation 
of this policy by responsible government who believes that every life count. Routine 
antenatal anti-D prophylaxis provides a cost effective intervention for preventing 
HDFN in non-sensitised Rh D-negative pregnant women [132]. Health economic 
model indicates a significant cost per quality-adjusted life-year (QALY) gained by 
the implementation of RAADP given to Rh D-negative primigravidae versus no 
RAADP is between £9000 and £15,000, and for RAADP given to all RhD-negative 
women rather than to Rh D-negative primigravidae only is between £20,000 and 
£35,000. It is suggested that a programme of routine prophylaxis would be cost 
saving if HDFN were eradicated by its implementation [130]. The National Institute 
for Health and Clinical Excellence reported that when RAADP for all Rh D-negative 
women was compared with that for primigravidae, the additional cost per incident 
of sensitisation prevented ranged from £2900 to £8200 depending on the regimen 
used. The cost per HDFN-associated foetal loss avoided was £42,000–120,000. It 
does make economic sense for African government to rise to their responsibilities 
by proving universally anti-D prophylaxis to all non-sensitised Rhesus D negative 
women. There is also potential to significantly reduce the cost of implementing 
RAADP by these governments investing on facilities to non-invasive determination 
of foetal D genotyping for all non-sensitised Rh D negative pregnant women. This 
will help identify women who are carrying Rhesus D negative mothers who will 
not require the prophylaxis. Also, because the prevalence of Rh D negative status is 
significantly lower among Nigerians (6%) [133] compared to the West ≥15% [134], 
it is likely to cost African countries a lot less to implement universal access to anti-D 
prophylaxis [135].
4.7  Challenges associated with the provision of antigen negative red cells to 
patients with clinically significant red cell antibodies
Evidenced based best practice in management of patients including pregnant 
women requires that patients are transfused with red cells lacking the group 
specific antigens to which the recipient alloantibody is specific [136]. This aim 
of this implementation is to prevent immune mediated destruction of the donor 
red cells containing the offending antigen [137, 138]. For example, pregnant 
women who have alloantibody Kell should be given K-negative donor units. The 
provision of antigen negative blood units for these patients is a special challenge 
particularly in Nigeria and many other countries in Africa [139]. Although these 
countries have national blood transfusion services, majority of them are often 
not fit for purpose. Majority of them test blood donors only for their ABO and 
Rhesus antigen status [139]. Routine testing of blood donors for other clinically 
significant red sell antigens are not routinely done. This has a significant implica-
tion on haemolytic transfusion reaction and HDFN. In the alloimmuned pregnant 
women who have low molecular weight immune IgG antibodies, IAT crossmatch-
ing should ideally be carried out using donor red cells suspended in low ionic 
strength saline preferably using highly sensitive column agglutination technique 
instead of the conventional less sensitive tube methods. Many of these technolo-
gies are often not available in most settings in Nigeria and other African countries. 
Transfusion of antigen positive donor red cells to patient with the group specific 
antibodies like it potentially happens in Nigeria and some other African countries 
have significant negative consequences [140]. These antibodies can cause clini-
cally significant haemolytic transfusion reactions, difficulty in cross-matching 
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blood and getting compatible blood in future, cause decrease in RBC survival and 
thus negate the aim of red cell transfusion of managing anaemia, improving the 
quality of life and improving the oxygen carrying capacity of the recipient’s blood 
[141]. Also, there is also the effect of managing donor red cell clearance and the 
product of red cell breakdown due to haemolysis which often results in multiple 
organ failure, electrolyte perturbations, coagulopathy and in some severe cases, 
death [142]. Nigerians and citizens of other African countries deserve the best 
quality transfusion service like their counterparts in the West. It is the responsi-
bility of African government to work smartly and effectively by avoiding waste 
and eradicating corruption to ensure that citizens get the best quality health care 
they deserve.
4.8 Lack of facilities for feto-maternal haemorrhage testing
The accurate detection and quantification of foetal red blood cells (RBCs) in the 
maternal circulation are necessary for the prevention of Rhesus D alloimmuniza-
tion among D-negative women because of FMH. It is critical to the administration 
of adequate amount of anti-D prophylaxis are necessary for the prevention of 
Rhesus D alloimmunization. As a result of D incompatibility between mother 
(Rhesus D negative and foetus (D-positive), foetal red cells can enter into maternal 
circulation and sensitise the mother to produce anti-D alloantibody. These anti-
D alloantibodies (small molecular weight IgG antibodies) can pass through the 
placenta barrier in subsequent D positive pregnancies cause HDFN (haemolysis, 
foetal anaemia, hydrops foetalis, kernicterus or even death). FMH testing helps 
obstetrician to determine that a potential sensitising event has taken place and 
facilitate the administration of adequate amount of prophylactic anti-D (125 IU 
per 1 ml bleed of foetal red cells into maternal circulation). The widespread use of 
FMH testing in the evidenced-based provision of adequate immunoprophylaxis 
with anti-D immunoglobulin has resulted in a significant reduction in the incidence 
of anti-D related HDFN mortality. Evidence-based best practice implementation 
of FMH test and provision of immunoprophylaxis with anti-D immunoglobulin 
in England and Wales has brought about a significant reduction in the number of 
infants affected with HDFN from affected in 1.2 per 1000 births in 1970 to 0.02 
per 1000 births by 1989. There are several methods available for FMH testing 
(Quantitative and qualitative). Three qualitative methods (micro Du, rosette test, 
and PEG Du) and two quantitative methods (acid elution and Flow Cytometry) 
for assessing FMH were evaluated with particular attention given to PEG Du and 
FC. Of the qualitative techniques, the micro Du test was the least sensitive with 
20% false-negative results occurring at 0.5% foetal cells. The PEG Du test was only 
slightly more sensitive and offered no clinical advantage. The rosette test was the 
most sensitive, consistently detecting foetal cells at concentrations of 0.25% or 
greater. Flow Cytometry and acid elution showed similar results, with good corre-
lation obtained between measured and expected quantities of foetal cells (r = 0.99 
and 0.96, respectively). One of 26 postpartum samples was positive by all screening 
techniques; acid elution and FC detected 0.3% concentrations of fetal cells and 
0.17% [143, 144]. The rosette screen is a highly sensitive in qualitatively detecting 
10 mL of foetal whole blood in the maternal circulation. As the screen is reliant on 
the presence of the D antigen to distinguish foetal from maternal cells, it cannot 
be used to detect FMH in D-positive mothers or in D-negative mothers carrying a 
D-negative fetus. The Kleihauer-Betke acid-elution test, the most widely used con-
firmatory test for quantifying FMH, relies on the principle that foetal RBCs contain 
mostly foetal haemoglobin (HbF), which is resistant to acid-elution whereas adult 
haemoglobin is acid-sensitive. Although the Kleihauer-Betke test is inexpensive 
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mostly foetal haemoglobin (HbF), which is resistant to acid-elution whereas adult 
haemoglobin is acid-sensitive. Although the Kleihauer-Betke test is inexpensive 
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and requires no special equipment, it lacks standardisation and precision, and may 
not be accurate in conditions with elevated F-cells. Flow cytometry is a promising 
alternative, although its use is limited by equipment and staffing costs. The two 
well-established confirmatory tests are the Kleihauer-Betke acid-elution assay and 
flow cytometry. The rosette screen is a highly sensitive FDA approved method 
to qualitatively detect 10 mL or more of foetal whole blood, or 0.2% foetal cells 
(volume/volume) in the maternal circulation [143]. The principle is based upon the 
formation of microscopic foetal D+ aggregates upon incubation of foetal cells with 
enzyme0-treated group O D-positive indicator RBCs and reagent anti-D serum. 
The foetal cells must be D-positive and the maternal cells D-negative for the test to 
be valid. In summary the maternal blood sample is first incubated with anti-D and 
then washed. The indicator D-positive RBCs are added and the sample is examined 
under a light microscope. In the presence of anti-D coated foetal D-positive cells, 
the indicator cells will form aggregates (or rosettes) around the foetal cells. The 
main limitation of this method is that falsely positive result may occur is the mum 
has a variant of the D antigen and falsely negative if the foetus or neonate is weak 
D. Also, mothers that have a positive direct antiglobulin test (DAT) or an autoan-
tibody can produce a false positive result due to the agglutination of the mother’s 
antibody coated red cells.
A positive rosette test is indicative of FMH > 10 mL. In a negative rosette test 
administration of is 300 μg (1500 IU) of Rh Ig is sufficient to prevent immunisation 
in 99% of patients. If the rosette test is positive quantification of the FMH by either 
the Kleihauer-Betke acid elution test or flow cytometry is indicated to determine 
the optimal dose of prophylactic anti-D immunoglobulin to be administered. The 
Kleihauer-Betke acid-elution test is an inexpensive method and requires no spe-
cial equipment and thus can possibly be implemented in developing country like 
Nigeria and other resource-limited settings. The method is based on the principle 
that foetal RBCs containing foetal haemoglobin (HbF) to resist acid elution whereas 
adult haemoglobin does not. When a peripheral smear prepared from a EDTA anti-
coagulated maternal blood sample is exposed to an acid buffer such as Shepherds 
stain, haemoglobin in the cytoplasm of maternal red cells are eluted while HbF in 
the foetal red cells resist acid elution. Subsequent counterstaining with haema-
toxylin results in red cell containing foetal haemoglobin staining pink while the 
maternal adult haemoglobin containing red cells appear as ghost. Figure 1 shows 
a positive Kleihauer-Betke test. To calculate the number of foetal cells in maternal 
circulation using Kleihauer-Betke test, get a stained thin film on a microscope and 
replace one of the objectives of the microscope with a graticule (Miller square) 
(Figure 2). Focus the microscope making sure the graticule is on the top left-hand 
corner. Select the ×40 lens and count at least 50 fields of the area of the film where 
the red cells are just touching each other. For each field count all the foetal cells in 
the large and small square. Count all the maternal cells in the small square. Count 
fields with at least 25–30 maternal cells. To calculate the total number of maternal 
cells, add the total number of maternal cells together and multiply by 9. Also add 
the total number of foetal cells from the 50 fields. The calculation of FMH is done 
using Mollison’s rule.
Mollison’s rule = 2400 × number of foetal cells ÷ number of maternal cells
For example, if the number of foetal red cells is 20 and the maternal cells is 
2000, the FMH = number of maternal cells = 2000 × 9 = 18,000
25 × 2400/18,000 = 3.3 mls bleed.
Calculation of dose of anti-D. Anti-D administered is calculated by giving 125 IU 
per ml of FMH. For a 3.3 ml bleed you will have to administer 3.3 × 125 IU = 413 IU 
of anti-D.
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The Kleihauer-Betke method is a labour intensive and subjective method. The 
accuracy and precision of this method is hampered by lack of standardisation 
which can potentially lead to slight variations in result (thickness of blood smear, 
pipetting skill of analyst, pH variations in the buffer used, inter analyst varia-
tions). Over- and underestimation of FMH using the Kleihauer-Betke test has 
been reported [145, 146]. The disadvantages of this method include; laborious to 
perform, lacks standardisation, is imprecise and may not be accurate in conditions 
associated with elevated haemoglobin F containing red cells. However, standardisa-
tion of the Kleihauer-Betke test can make the result potentially comparable to result 
from flow cytometry [147]. Haemoglobin F containing red cells are increased in 
haemoglobinopathies including sickle cell disease and β-thalassemia and hereditary 
persistence of foetal haemoglobin (HPFH). In 25% of pregnant women, HbF tend 
to be increased and can cause false positive results [148, 149]. In pregnant women 
with conditions such as sickle cell disease, thalassaemia and HPFH an alternative 
method for FMH testing such as flow cytometry should be employed. Despite its 
limitations, a good correlation has been reported between the Kleihauer-Betke test 
and flow cytometry for both small and large FMH [150, 151].
Flow cytometry involves using a flow cytometer using monoclonal antibodies 
directed against. Flow cytometric determination of FMH is superior to Kleihauer-
Betke test for a number of reasons; cytometric methods can accurately distinguish 
adult foetal haemoglobin containing red cells from foetal RBCs, flow cytometers 
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its quantitative accuracy and flow cytometry is automated non-subjective and has 
greater reproducibility. The only disadvantage is that it requires trained staff to 
perform test coupled with the fact that it is it is expensive and may not be affordable 
in low-resource settings.
5. Conclusions
There is paucity of data on the distribution of clinically significant blood group 
antigens apart from ABO and Rhesus D among Nigerians. Management of Rhesus D 
negative pregnancies and pregnancies associated with clinically significant alloan-
tibody is suboptimal. This failure in stewardship by the Nigerian government has a 
significant implication for Haemolytic Disease of the Foetus and Newborn and hae-
molytic transfusion reaction. There is need to introduce routine screening of pregnant 
women in Nigeria for clinically significant red cell antibodies to facilitate the effective 
management of HDFN as well as prevent HTR by enabling the selection of antigen 
negative red cells for women who have alloantibodies and require a red cell transfusion.
5.1 Recommendations
We recommend that the Nigerian government should implement the following 
evidence-based best practices (British Committee for Standards in Haematology 
[152–155].
1. That the Nigerian government should fulfil her obligations under goal 3.8 of 
the Universal Health Coverage initiative and the Sustainable Development goal 
3.b which emphasises the need for access to safe, effective, quality and afford-
able essential medicines for all by implementing universal access to anti-D 
prophylaxis for previously unsensitized Rhesus D negative pregnant women.
2. Screen donor units for clinically significant antigen status to facilitate the 
selection of antigen negative donor units for transfusion to patients with a 
clinically significant alloantibody.
3. Routinely screening all blood group O donors whose units are intended for 
transfusion to non-O recipients for high titre haemolysin.
4. Anti-D immunoglobulin should be available in cases of potentially  sensitising 
events such as amniocentesis, cordocentesis, antepartum haemorrhage, 
vaginal bleeding during pregnancy, external cephalic version, abdominal 
trauma,  intrauterine death and stillbirth, in utero therapeutic interventions, 
 miscarriage, and therapeutic termination of pregnancy.
5. All Rhesus D negative women having a termination of pregnancy (abortion) 
must be tested for Rhesus D group and those found to be Rhesus D negative 
must be offered prophylaxis following the procedure.
6. Routine foetal genotyping using non-invasive testing of maternal sample to 
identify Rhesus negative pregnant women who are carrying Rhesus negative 
infants for whom prophylaxis is not indicated.
7. Facilities for intrauterine transfusion of infants who become anaemic in utero 
as a result of HDFN and require a red cell transfusion. Facilities to test donor 
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red cells to ensure that they meet the requirements for intrauterine, exchange 
and top up transfusion.
8. Facilities for the implementation of alloantibody titration and quantification 
should be provided for pregnant women with a clinically significant, HDFN 
causing alloantibody.
9. There is need for the provision of facilities for fetomaternal haemorrhage test-
ing to facilitate the administration of optimal amount of anti-D prophylaxis 
following a sensitising event to prevent HDFN.
10. Knowledge of anti-D prophylaxis and management of women with  clinically 
significant antibodies among Obstetricians, Laboratory of Biomedical 
 Scientist, Midwives, Traditional Birth Attendants, Pharmacists and Nurses in 
Nigeria and other countries in Africa needs to be improved. This will facilitate 
quality antenatal and postnatal care offered particularly to Rh-negative preg-
nant women and those with clinically significant alloantibodies.
11. That anti-D prophylaxis be provided in Rhesus D negative pregnant preg-
nancies <12 weeks gestation, following ectopic pregnancy, molar pregnancy, 
therapeutic termination of pregnancy. FMH haemorrhage (FMH) testing is 
often not required for sensitising events at <12 weeks gestation.
12. That for all potentially sensitising events occurring between 12- and 20-weeks’ 
gestation, prophylaxis should be administered within 72 h of the event without 
need for FMH testing.
13. That for potentially sensitising events after 20 weeks gestation,  prophylaxis 
should be administered within 72 h of the event along with testing for 
FMH. This is to determine if additional dose of anti-D Ig is required for a 
significant bleed.
14. That in the event of an intrauterine foetal death (IUFD), where no sample can 
be obtained from the baby or foetus, an appropriate dose of prophylactic anti-
D should be administered to Rhesus D negative, previously non-sensitised 
women within 72 h of the diagnosis of IUFD, irrespective of the time of subse-
quent delivery.
15. That following intra-operative cell salvage (ICS) during Caesarean section in 
D negative, previously non-sensitised women, and where cord blood group 
is confirmed as D positive (or unknown), a minimum dose of 1500 IU pro-
phylactic anti-D should be administered following the re-infusion of salvaged 
red cells. Also, the maternal sample should be taken for estimation of FMH 
30–45 min after reinfusion to confirm if a further dose of anti-D Ig is required.
16. That in cases of therapeutic termination of pregnancy (abortion), whether by 
surgical or medical methods, and regardless of gestational age, all previously 
non-sensitised D negative women should receive a dose of prophylactic anti-D 
within 72 h of having the procedures.
17. That anti-D prophylaxis should be administered to all cases of ectopic preg-
nancy in previously non-sensitised, D negative women regardless of the mode 
of management.
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18. That there is significant potential for sensitisation in cases of molar pregnancy. 
Anti-D prophylaxis should be administered to all cases of molar pregnancy in 
previously non-sensitised, D negative women.
19. That D negative women presenting with continual uterine bleeding between 
12- and 20-weeks’ gestation should be offered anti-D prophylaxis at a mini-
mum of 6 weekly intervals.
20. That under normal circumstances, D negative platelets should be transfused to 
D negative females or women of child bearing age, who need a platelet trans-
fusion. Occasionally, if the appropriate product is not available or its avail-
ability is likely to cause unacceptable delay and harm, it may be necessary to 
transfuse D positive platelets. In these situations, prophylaxis against possible 
sensitisation by the D positive red cells contaminating the platelet product 
should be given. A dose of 250 IU anti-D immunoglobulin is sufficient to cover 
up to five adult therapeutic doses of D positive platelets given over a 6-weeks 
period.
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Abstract
Acquired aplastic anemia (AA) is characterized by partial or total bone marrow 
(BM) destruction resulting in pancytopenia. Most of the acquired AA is the result 
of autoimmune condition the imbalance between T-regulatory cells (Treg), abnor-
mal cytokines production and cytotoxic T cells activation, leading to the hemato-
poietic stem cells (HSCs) death. The first-line treatment is given by HSC transplant, 
but some patients did not respond to the treatment. Therefore, new technologies 
need to treat AA nonresponder patients. Studies are in progress to test the efficacy 
of stem cell-based therapeutic as mesenchymal stem cells (MSCs), which confer 
low immunogenicity and are reliable allogeneic transplants in refractory severe AA 
cases. Furthermore, MSCs comprise the BM stromal niche and have an important 
role in supporting hematopoiesis by secreting regulatory cytokines, providing 
stimulus to natural BM microenvironment. In addition, MSCs have immunomodu-
latory property and are candidates for efficient supporting AA therapy.
Keywords: allogeneic transplant, mesenchymal stem cell,  
immune-mediated aplastic anemia, paracrine effects, immunomodulation
1. Introduction
Aplastic anemia (AA) is a rare disease, caused by bone marrow (BM) aggression 
resulting in hypo or aplastic BM with precocious fat replacement and consequently 
to peripheral blood pancytopenia [1, 2]. The autoimmunity process in AA occurs 
due to the activation of the oligoclonal cytotoxic T cells that will lead the hemato-
poietic cells to apoptosis. Its triggering occurs by the imbalance between CD8 +,  
CD4 +, T-Helper (Th), Th type 1 (Th1), Th type 2 (Th2), Th17 type (Th17), Natural 
Killer (NK) and T-regulatory cells (Treg). Besides, there is also an abnormal produc-
tion of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), 
interferon-gamma (IFN-γ) and transformed growth factor (TGF) [3–7].
For severe cases, immunosuppressive therapy is accepted as the first-line treat-
ment option and the allogeneic transplantation of BM and hematopoietic stem cells 
(HSCs). However, 30–40% of patients with severe aplastic anemia (SAA) remain 
pancytopenia following the treatment. The transplant option still has a restricted 
number of compatibility between suitable donors. Additionally, patients aged 
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Abstract
Acquired aplastic anemia (AA) is characterized by partial or total bone marrow 
(BM) destruction resulting in pancytopenia. Most of the acquired AA is the result 
of autoimmune condition the imbalance between T-regulatory cells (Treg), abnor-
mal cytokines production and cytotoxic T cells activation, leading to the hemato-
poietic stem cells (HSCs) death. The first-line treatment is given by HSC transplant, 
but some patients did not respond to the treatment. Therefore, new technologies 
need to treat AA nonresponder patients. Studies are in progress to test the efficacy 
of stem cell-based therapeutic as mesenchymal stem cells (MSCs), which confer 
low immunogenicity and are reliable allogeneic transplants in refractory severe AA 
cases. Furthermore, MSCs comprise the BM stromal niche and have an important 
role in supporting hematopoiesis by secreting regulatory cytokines, providing 
stimulus to natural BM microenvironment. In addition, MSCs have immunomodu-
latory property and are candidates for efficient supporting AA therapy.
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1. Introduction
Aplastic anemia (AA) is a rare disease, caused by bone marrow (BM) aggression 
resulting in hypo or aplastic BM with precocious fat replacement and consequently 
to peripheral blood pancytopenia [1, 2]. The autoimmunity process in AA occurs 
due to the activation of the oligoclonal cytotoxic T cells that will lead the hemato-
poietic cells to apoptosis. Its triggering occurs by the imbalance between CD8 +,  
CD4 +, T-Helper (Th), Th type 1 (Th1), Th type 2 (Th2), Th17 type (Th17), Natural 
Killer (NK) and T-regulatory cells (Treg). Besides, there is also an abnormal produc-
tion of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), 
interferon-gamma (IFN-γ) and transformed growth factor (TGF) [3–7].
For severe cases, immunosuppressive therapy is accepted as the first-line treat-
ment option and the allogeneic transplantation of BM and hematopoietic stem cells 
(HSCs). However, 30–40% of patients with severe aplastic anemia (SAA) remain 
pancytopenia following the treatment. The transplant option still has a restricted 
number of compatibility between suitable donors. Additionally, patients aged 
>50 years are not eligible for transplant [8].
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A new viable alternative for the treatment of AA has been sought and the use 
of mesenchymal stem (MSCs) therapy may be a promising therapeutic candidate 
mainly because of their hypoimmunogenicity and the lack of rejection after trans-
plants and immunomodulatory effects, which may promote decreasing the symp-
toms of the disease [9, 10]. These benefits are attributed to the paracrine effects, 
above all by its ability to regulate the immune system [11].
Actually, is known that MSCs have wide therapeutically potential attributed 
by paracrine effects and the past decades have seen explosion research directed to 
understand better these MSCs mechanism and function [12]. One of the main and 
most important features of MSCs is the low expression of human leukocyte antigen 
(HLA) class I, with no expression of HLA class II. This feature allows the cell to 
be characterized as hypoimmunogenic, since it does not stimulate the patient’s 
immune system and can be used safely in transplants [13]. More recently, the stud-
ies showed that the main cause of AA is autoimmunity. Through the secretion of 
bioactive molecules, MSCs have the capacity of regulating immune responses. The 
mechanism of MSCs may decrease secretion of proinflammatory cytokines such as 
transforming growth factor (TGF), IFN-γ TNF-α, interleukin (IL)-17 and increase 
secretion of many soluble mediators, including anti-inflammatory cytokines stimu-
lation that inhibit antigen-presenting cells (APCs) functions, which are capable to 
decrease proliferation of dendritic cells (DCs) and regulate macrophage activity by 
polarizing proinflammatory phenotype (M1) to anti-inflammatory phenotype (M2) 
[14, 15]. Therefore, the decrease of B cells proliferation and antibodies production 
and adjustment of T cells activities as well as inhibit the proliferation of cytotoxic T 
cells and stimulate Treg activity [16].
MSCs therapy has gained space due to its vast therapeutic potentials such as 
immunomodulation mechanisms and main safety as bioproduct. Thus, this chapter 
will discuss the challenges of allogeneic MSCs as an alternative for an efficient 
therapeutic in AA immune-mediated treatment.
2. Aplastic anemia: general features
AA is a disorder characterized by BM hypocellularity, and peripheral blood 
pancytopenia due to a deficit of HSCs. It affects mostly children, young adults, and 
adults, over 60 years of age [17]. This condition can be similar to other hematologic 
disorders, however, in most cases, the AA is caused by reduced HSCs function, an 
increase in HSCs apoptosis level, consequently, the decreased of HSCs and hemato-
poietic progenitors and lastly, microenvironment fat replacement [18, 19].
Following the patient diagnosis, AA can be considered as moderate or severe. 
The patients with pancytopenia may present symptoms of anemia purpura or 
skin hemorrhage, and in most of the cases there is an infection association, that 
may worsen the symptoms [20]. Three main criteria are used for the diagnostic: 
neutrophil count lower than 0.5 × 109 cells/L, reticulocyte count lower than 1% and 
platelet count lower than 20 × 109 cells/L [21]. To confirm acquired AA, the clinical 
case must be differentiated from other hematological diseases, as well as from the 
signs of malignant cell transformation or myelodysplasia [22].
Normally the first AA etiology is uncertain and for this reason, the disorder is 
considered heterogeneous in origin and characterized as idiopathic [23]. AA is asso-
ciated with exposures to chemical agents (pesticides and benzene), cytotoxic drugs 
(antineoplastics, antibiotics, non-steroidal anti-inflammatory drugs), active viral 
infections exposure (Epstein Barr, hepatitis virus, human immunodeficiency virus 
parvovirus) and radiation exposure [18, 24, 25]. However, these causes considered 
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secondary etiologies, since the studies are directed to the primary etiology of AA 
to autoimmunity [26, 27]. AA pathogenesis involves an immunity dysfunction, 
initially provoked by the activated T cells [23], which leads to an abnormal hemato-
poietic microenvironment, destruction of hematopoietic stem/progenitor cell and 
differentiation deficiency. These findings suggest that the immune system plays an 
important role in the pathogenesis of AA.
2.1 AA pathophysiology
Currently, the studies of AA etiology are focused on the immune mechanism of 
hematopoietic cells destruction. Many researchers [28, 29–31] have demonstrated 
that the dysfunction of T cells might be a key factor in recent characterization as 
an autoimmune disease [28]. Most of the acquired AA is the result of an immune-
mediated process as an imbalance between CD8+ and CD4+ T cells, including Th1, 
Th2, Treg and Th17 cells, NK, and natural killer T cells (NK T) that leads to apopto-
sis of BM cells triggered by cytotoxic T cells activation [6, 17].
The abnormal immunoregulatory cell functions observed in AA can be attribut-
able to abnormal antigen stimulation and some inappropriate T cells activation 
[28]. Studies demonstrated that patients with AA have a significantly increased 
proportion of Th1 cells, and showed a reduced fraction of natural killer T cells and 
regulatory T cells, together with an increased level of TNF-α, a consequent eleva-
tion of IL-6, IL-8, and IL17 productions [18]. Additionally, there is also an abnormal 
production of proinflammatory cytokines including IFN-γ and TGF [4, 5, 28, 32]. 
The new T cells subset was characterized as Th17 and currently is known that both 
Th17 cells and the cytokine IL-17, which is secreted by Th17 cells, also is in an asso-
ciation with AA pathogenesis [31]. Studies showed that AA patients who presented 
an increase in the frequency of Th17 cells had a positive correlation with an increase 
in the IFN- γ and IL-17 expression. Autoimmunity promotes inflammatory Th17 
immune responses that contributed to disease pathophysiology [29].
Otherwise, AA is attributed to inappropriate antigen stimulation and abnormal 
APCs activation [28], resulting in the priming of T cells specific for hematopoietic 
cells [33, 34]. APCs exhibit a significant increase in the expression of major histocom-
patibility class 2 (MHCII), increasing the recognition of CD4+ T cells. In AA, T cells 
are also stimulated by unknown antigens or abnormal APC activation as DCs and 
macrophages, which trigger a series of immune responses. Studies have shown that 
immunoregulatory cell dysfunction leads to a corresponding immune tolerance disor-
der and renders the body unable to recognize autologous hematopoietic cells [28].
Although the definitive mechanism has not been identified, some genetic factors 
are the targets of ongoing research, such as the molecular basis of the aberrant 
immune response and hematopoietic cell deficiency, telomere repair gene muta-
tions in the target cells and unregulated T cell activation pathways and cytokine 
genes polymorphisms [9, 26, 28]. These changes in the nucleotide sequence and 
gene regulation are associated with an increased immune response and suggest a 
genetic basis for aberrant T cells activation in BM failure [35].
2.2 AA treatment
The treatment depends on the severity of the disease, once for moderate 
cases are based on red blood cell (RBC) transfusions, on platelet transfusions to 
prevent bleeding, and on supportive care in association with antibiotic aiming to 
reestablish blood cell volume and prevent secondary infections [17]. However, the 
pancytopenia of many moderate cases may progress to severe [21]. For severe cases, 
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immunosuppressive therapy is accepted as a first-line treatment option. However, 
30–40% of patients with SAA remain pancytopenia following the treatment. 
Patients with SAA, which are refractory or have a relapse after immunosuppres-
sive treatment, may undergo allogeneic hematopoietic stem cells transplantation 
(HSCT). However, about one-third of patients do not have a suitable donor for 
HSCT. Additionally, patients aged >50 years are not eligible for transplant [8].
Furthermore, the immunosuppressive drug treatment has several side effects 
on patients. On the other hand, the patients often do not respond adequately to 
the therapies and are not suitable for life treatment (refractory patients) [24]. 
Therefore, immunosuppressive drugs are considered supporting AA treatment, 
once it does not promote the cure [20].
2.3 Allogeneic transplantation and alternative methods for AA treatment
Generally, patients are treated with allogeneic HSCs or whole BM transplanta-
tions, which replace since HSCs, hematopoietic precursors, until differentiated 
bloodstream cells and immune system cells. However, in all types of transplants, 
the treatment involves a combination of immunosuppressive agents or radiation 
therapy to prevent and to eliminate residual host BM [24]. The transplantation 
success varies according to risk factors, such as age and mainly histocompat-
ibility allogeneic HLA-matched sibling donors, which are rare for the majority of 
patients. Despite being well established for many years, the transplanted patients 
can trigger late complications, such as the development of graft versus host disease 
(GVHD) and infections, especially in patients who have received hematopoietic 
grafts from HLA antigen matched donor [36, 37]. Studies show that the incidence 
of GVHD after unrelated donor transplantation can achieve ∼14%, and overall 
survival index was 57% for all 8 HLA-loci matched transplants and 39% for 1-loci 
mismatched transplant [38]. Thus, for BM and HSCT, the immediate challenge is 
the extension of stem cell therapies to all patients, regardless of age, with a histo-
compatible sibling [24].
Since then a new viable alternative for the treatment of AA has been sought 
and the use of MSCs transplantation becomes of choice. The MSCs therapy may 
be a promising therapeutic candidate mainly because of their hypoimmunoge-
nicity, the lack of rejection after transplants and immunomodulatory effects, 
which may promote decreasing the symptoms of the disease [39]. These benefits 
are attributed to MSCs paracrine effects, above all to their ability to regulate the 
immune system. MSCs may help for AA treatment, especially for autoimmune 
type [11].
3. Mesenchymal stem cell: general features
MSCs are multipotent progenitors, which were first isolated from an adult 
organism by Friedenstein and colleagues in 1968, and described years later by 
Caplan and colleagues [40, 41]. These cells include firstly an inherent autocrine 
effect, as self-renewal and differentiation potential for a variety of cell types, as 
main adipocytes, osteoclasts, and chondrocytes [42], depending on the surround-
ing microenvironment conditions [43]. Currently, such cells have shown to be 
isolated from many postnatal and adult tissues, such as adipose tissue, umbilical 
cord, placenta, dental pulp, and others [44, 45].
Initially, the mechanism therapeutic potential of the MSCs was based only 
on the potential for regeneration through cellular self-renewal and its plasticity. 
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Further studies have shown low engraft of MSCs in injured areas that questioned 
the hypothesis that MSCs repair tissue damage by replacing cell loss with newly 
differentiated cells [46, 47].
3.1 MSC: paracrine effects
It is known that MSCs have wide therapeutically potential attributed to paracrine 
effects and the past decades explosion research was directed to understand better 
these MSCs mechanism and function [12]. Although the therapeutic mechanisms of 
MSCs are not yet well characterized, it is possible to say that their paracrine effects 
consist in the secretion of bioactive molecules such as a variety of cytokines and 
growth factors as like anti-inflammatory, anti-apoptotic and angiogenic [46–51].
MSCs can to migrate to the lesion site through signals from specific chemokines. 
This process called homing consists of the steps of activating adhesion molecules, 
rolling to the endothelium, adhesion, and migration to the tissue that is the source 
of chemokine inflammation production [52, 53]. The current hypothesis is that 
paracrine factors secreted by MSCs promote protective microenvironment and 
repair by local tissue-resident progenitor populations, favoring the hypothesis of 
detecting favorable effects even in the absence of the cells at lesion sites [54].
3.2 MSC: immunogenic effect and safety for transplantation
One of the main and most important features of MSC is the low expression of 
HLA class I, with no expression of HLA class II. Also, MSCs do not appear to express 
the co-stimulatory molecules CD80 or CD86 required for effector T cell induction 
[55]. The absence of co-stimulatory molecules implies that any residual engagement 
of the T cell receptor on Th cells would result in absence of the normal immune 
response to a particular antigen and contribute to tolerance rather than allogeneic 
responses. This feature allows the cell to be characterized as hypoimmunogenic, 
since it does not stimulate the patient’s immune system and can be used safely in 
transplants [113]. As well, MSCs have properties attributed to immune functions, 
indicating their ability to immunomodulatory activity. Studies indicated that MSCs 
can regulate immune responses during chronic inflammation through the innate and 
adaptive immune system, regulating the recruitment and their function [56, 57].
3.3 MSC: immunomodulatory potential
The paracrine effects of MSCs may have great importance in the treatment of 
autoimmune diseases. Through the secretion of bioactive molecules, MSCs have the 
capacity of regulating immune responses. These cells can regulate adaptive immune 
responses through multiple redundant pathways, interacting with various immune 
cells and secreting soluble mediators such as IL-6, IL-10, prostaglandin E2 (PGE2), 
nitric oxide (NO), transforming growth factor-β1 (TGF-β1), and hepatocyte 
growth factor (HGF), indoleamine-pyrrole 2, 3-dioxygenase (IDO) [58, 59]. They 
can regulate APCs activity, decreasing maturation and proliferation of DCs [14]. 
MSC also may regulate macrophage activity by polarizing its pro-inflammatory 
phenotype (M1) to its anti-inflammatory phenotype (M2) [15]. Therefore, suppress 
T cell proliferation and activation and regulate the differentiation of Th cells and 
act on the humoral response by inhibiting of B cell activation and antibody produc-
tion [60]. MSCs may also reduce pro-inflammatory cytokines proliferation, such 
TNF-α, which has an important role of the pathogenesis of autoimmune diseases 
and chronic inflammation (Figure 1) [14, 16, 61].
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4. MSC mechanism in AA treatment
The first paracrine effect, showed for MSCs, was the capacity to support HSCs 
growth in vitro. Afterward, adipose tissue (AT) – derived MSCs also supported HSCs 
growth in vitro [62, 63]. Therefore, the most successful clinical application of  
MSCs is involved in the hematological disease.
At BM microenvironment, MSCs niche supports hematopoietic cells and 
produce factors recruiting HSCs and supporting hematopoiesis [64]. This mecha-
nism occurs through chemokine secretion of C-X-C motif chemokine ligand 12 
(CXCL12), which acts on the homing regulation of HSCs, regulating the stages of 
adhesion, expansion and migration [65, 66]. The secretion of other factors is also 
important in the proliferation of HSCs mechanisms such as Flt-3 ligand (FLT3LG) 
[67], thrombopoietin (TPO) [68] and IL-6 [17]. That despite being a proinflamma-
tory cytokine in general, when IL-6 is secreted in BM microenvironment, is capable 
to stimulate hematopoiesis [69, 70].
More recently, the studies showed that the main cause of AA is autoimmunity. 
This process occurs in the result of an imbalance between CD8 + and CD4 + T 
cells, including Th1, Th2, Th17, NK, leading to the death of hematopoietic cells 
and their precursors [28]. Many studies have hypothesized that the onset of the 
immune imbalance in AA begins by stimulating APCs through an unknown antigen 
resulting in the T cells activation [71]. Another important mechanism of MSCs is 
the immunomodulation mechanism. MSCs can act directly on AA imbalance by T 
cells suppression, inhibiting activation and proliferation of T cells [72]. MSCs also 
inhibit the secretion of two important cytokines present in the pathology of AA, the 
Figure 1. 
Benefits of MSCs paracrine effect (immunomodulatory) on immune cells imbalance. MSCs secrete many 
soluble mediators, including anti-inflammatory cytokines stimulation that regulates APCs functions capable 
to decrease proliferation of DCs and regulate macrophage activity by polarizing proinflammatory phenotype 
(M1) to anti-inflammatory phenotype (M2). Therefore, they are responsible for humoral response regulation 
by the decrease of B cells proliferation and antibodies production. The APCs are also capable to regulate 
the T cell activities as well as inhibit cytotoxic T cell proliferation and upregulation and increase of Treg 
cells. MSCs may also promote the decrease of proinflammatory cytokines secretion. And act on the homing 
regulation of HSCs mechanism on stages of adhesion, expansion, and migration through chemokine and 
other factors secretion.
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INF-γ and TNF-α and stimulate the proliferation of Treg, promoting the production 
of the anti-inflammatory cytokine IL-10 Table 1 [73, 74]. In addition, some studies 
also show that MSCs also acts through its anti-apoptotic effects [75].
5. Biodistribution and engraftment of allogeneic MSC in BM
In the last years, several studies have been exploring intravenous administrations 
(IV) due to being safe and do not present morbidity risk for patients. However, still 
lack the data about the biodistribution mechanism of MSCs and about how these 
cells engraftment on the target organ, which is essential for the success of clinical 
studies. It is known that the biodistribution is influenced in vivo and in vitro condi-
tions. Stromal cell-derived factor 1 (SDF-1) (also known as CXCL12) is upregulated 
at sites of injury and acts as a chemoattractant to recruit circulating or residing 
MSCs expressing its cognate receptor CXC chemokine receptor 4 (CXCR4). It has 
been demonstrated that the CXCR4-SDF-1 axis is critical for BM homing [76]. 
Diverse studies demonstrate that some in vitro conditions may influence the expres-
sion of adhesion molecules [77, 78]. For instance, long expansion periods [79] and 
cells culturing at high density may reduce CXCR4 cell expression; the cells cultured 
at higher confluence secrete more metalloproteinase inhibitor 3, which decreases 
migration of MSCs when compared to those cultured at the low confluence [80]. 
Hypoxia condition may increase CXCR4 expression; on the other hand, hypoxia 
may decrease matrix metalloproteinase-2 secretion and an increase in membrane-
type 1 matrix metalloproteinase [81].
In vivo engraftment is influenced by interactions of MSCs with different types 
of immune cells that depend on their ability to respond to signals from the immune 
AA disorders x MSC benefits
Aberrant secretion of pro-inflammatory 
cytokines ↑IFN-γ ↑TNF-α ↑IL-17 ↑IL-2;
Immunomodulatory effect: Decreased secretion of 
proinflammatory cytokines, ↓IFN-γ ↓TNF-α ↓IL-17 ↓IL-2;
Imbalance between CD8+ and CD4+
T cells; ↑ Cytotoxic T cell ↓Treg
Regulation of T cell activity and Treg cell proliferation
↓ Cytotoxic T cell ↑Treg
Apoptosis of HSC and progenitor cells
↑ Apoptosis
Protect BM by antiapoptotic properties
↓ Apoptosis
BM hypoplasia Recovery of BM
↑ Hematopoiesis improvements
↑ CXCL12 ↑FLT3LG ↑TPO ↑IL-6
Abnormal APC activation
↑ DCs ↑ Macrophage
Regulate APCs functions
↓ DCs maturation and proliferation and
↓ Macrophages M1 activation







Irregular activity of NK cells
↑ Cytotoxicity of NK cells
↓ Cytotoxicity of NK cells
MSC can decrease secretion of pro-inflammatory cytokines such as TGF, IFN-γ TNF-α, IL-17, regulate T cell activity, 
inhibit proliferation of cytotoxic T cells and stimulate Treg activity. MSC has anti-apoptotic properties, protects 
BM environment and recovery BM through cytoprotective effect and stimulates macrophages M2 activation and 
hematopoiesis improvements. MSCs may also regulate APCs functions, humoral response, and cytotoxicity of NK cells.
Table 1. 
Table shows disorders characterized in AA and the mechanism of action of MSCs in AA pathology.
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4. MSC mechanism in AA treatment
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(CXCL12), which acts on the homing regulation of HSCs, regulating the stages of 
adhesion, expansion and migration [65, 66]. The secretion of other factors is also 
important in the proliferation of HSCs mechanisms such as Flt-3 ligand (FLT3LG) 
[67], thrombopoietin (TPO) [68] and IL-6 [17]. That despite being a proinflamma-
tory cytokine in general, when IL-6 is secreted in BM microenvironment, is capable 
to stimulate hematopoiesis [69, 70].
More recently, the studies showed that the main cause of AA is autoimmunity. 
This process occurs in the result of an imbalance between CD8 + and CD4 + T 
cells, including Th1, Th2, Th17, NK, leading to the death of hematopoietic cells 
and their precursors [28]. Many studies have hypothesized that the onset of the 
immune imbalance in AA begins by stimulating APCs through an unknown antigen 
resulting in the T cells activation [71]. Another important mechanism of MSCs is 
the immunomodulation mechanism. MSCs can act directly on AA imbalance by T 
cells suppression, inhibiting activation and proliferation of T cells [72]. MSCs also 
inhibit the secretion of two important cytokines present in the pathology of AA, the 
Figure 1. 
Benefits of MSCs paracrine effect (immunomodulatory) on immune cells imbalance. MSCs secrete many 
soluble mediators, including anti-inflammatory cytokines stimulation that regulates APCs functions capable 
to decrease proliferation of DCs and regulate macrophage activity by polarizing proinflammatory phenotype 
(M1) to anti-inflammatory phenotype (M2). Therefore, they are responsible for humoral response regulation 
by the decrease of B cells proliferation and antibodies production. The APCs are also capable to regulate 
the T cell activities as well as inhibit cytotoxic T cell proliferation and upregulation and increase of Treg 
cells. MSCs may also promote the decrease of proinflammatory cytokines secretion. And act on the homing 
regulation of HSCs mechanism on stages of adhesion, expansion, and migration through chemokine and 
other factors secretion.
155
Alternative Immune-Mediated-Based Methods in the Aplastic Anemia Treatment
DOI: http://dx.doi.org/10.5772/intechopen.89090
INF-γ and TNF-α and stimulate the proliferation of Treg, promoting the production 
of the anti-inflammatory cytokine IL-10 Table 1 [73, 74]. In addition, some studies 
also show that MSCs also acts through its anti-apoptotic effects [75].
5. Biodistribution and engraftment of allogeneic MSC in BM
In the last years, several studies have been exploring intravenous administrations 
(IV) due to being safe and do not present morbidity risk for patients. However, still 
lack the data about the biodistribution mechanism of MSCs and about how these 
cells engraftment on the target organ, which is essential for the success of clinical 
studies. It is known that the biodistribution is influenced in vivo and in vitro condi-
tions. Stromal cell-derived factor 1 (SDF-1) (also known as CXCL12) is upregulated 
at sites of injury and acts as a chemoattractant to recruit circulating or residing 
MSCs expressing its cognate receptor CXC chemokine receptor 4 (CXCR4). It has 
been demonstrated that the CXCR4-SDF-1 axis is critical for BM homing [76]. 
Diverse studies demonstrate that some in vitro conditions may influence the expres-
sion of adhesion molecules [77, 78]. For instance, long expansion periods [79] and 
cells culturing at high density may reduce CXCR4 cell expression; the cells cultured 
at higher confluence secrete more metalloproteinase inhibitor 3, which decreases 
migration of MSCs when compared to those cultured at the low confluence [80]. 
Hypoxia condition may increase CXCR4 expression; on the other hand, hypoxia 
may decrease matrix metalloproteinase-2 secretion and an increase in membrane-
type 1 matrix metalloproteinase [81].
In vivo engraftment is influenced by interactions of MSCs with different types 
of immune cells that depend on their ability to respond to signals from the immune 
AA disorders x MSC benefits
Aberrant secretion of pro-inflammatory 
cytokines ↑IFN-γ ↑TNF-α ↑IL-17 ↑IL-2;
Immunomodulatory effect: Decreased secretion of 
proinflammatory cytokines, ↓IFN-γ ↓TNF-α ↓IL-17 ↓IL-2;
Imbalance between CD8+ and CD4+
T cells; ↑ Cytotoxic T cell ↓Treg
Regulation of T cell activity and Treg cell proliferation
↓ Cytotoxic T cell ↑Treg
Apoptosis of HSC and progenitor cells
↑ Apoptosis
Protect BM by antiapoptotic properties
↓ Apoptosis
BM hypoplasia Recovery of BM
↑ Hematopoiesis improvements
↑ CXCL12 ↑FLT3LG ↑TPO ↑IL-6
Abnormal APC activation
↑ DCs ↑ Macrophage
Regulate APCs functions
↓ DCs maturation and proliferation and
↓ Macrophages M1 activation







Irregular activity of NK cells
↑ Cytotoxicity of NK cells
↓ Cytotoxicity of NK cells
MSC can decrease secretion of pro-inflammatory cytokines such as TGF, IFN-γ TNF-α, IL-17, regulate T cell activity, 
inhibit proliferation of cytotoxic T cells and stimulate Treg activity. MSC has anti-apoptotic properties, protects 
BM environment and recovery BM through cytoprotective effect and stimulates macrophages M2 activation and 
hematopoiesis improvements. MSCs may also regulate APCs functions, humoral response, and cytotoxicity of NK cells.
Table 1. 
Table shows disorders characterized in AA and the mechanism of action of MSCs in AA pathology.
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system. On the other hands, the MSCs biodistribution and homing depend on 
the host niche. Interesting the MSCs migration and homing to target tissue can be 
influenced positively by irradiation. It has been demonstrated an increased absolute 
number of human MSCs in the brain, heart, bone marrow, and muscles after total 
body irradiation and MSCs IV administrations in mice, when compared to the 
untreated control [82].
Some animal studies evidence that MSCs can engraftment in BM after systemic 
administration [83]. Studies in patients showed MSCs engraftment into BM 30 days 
after the second MSCs IV administration. Although, after MSCs infusion was 
observed no recovery of hematopoietic tissue, interstitial hemorrhage, edema, and all 
adipocytic necrosis disappeared in BM [84]. Other studies indicate the engraftment 
due to myeloid and plated recovery after HSCs and MSCs transplantation [85, 86].
6. MSC use in clinical studies
6.1 Clinical potential and market of MSC in hematopoietic disorders
MSCs have been implicated in immunomodulatory therapy, in particular, in 
GVHD treatment and as an adjunct to hematopoietic stem cell transplantation 
(HSCT) to help enhance engraftment [87, 88]. The first major clinical trial of MSCs 
(Prochymal) was for the treatment of steroid-refractory of GVHD (NCT00366145) 
[89, 90]. The primary endpoint of the study was complete remission at day 28 
after allogeneic BM-MSCs infusion but was not significantly increased compared 
to placebo [89, 91]. In 2012, MSCs have bens conditional approval to treat children 
GVHD in Canada, based on subset analysis that suggested children with GVHD 
were responsive to MSCs [89, 92, 93]. Many new studies have been developed in 
recent years; however, a few of them have attempted to look at biological correlates 
of response to therapy. Isolated studies reported serum biomarkers of GVHD 
severity including IL-2, tumor necrosis factor receptor 1 (TNFR1), regenerating 
islet-derived protein 3 alpha (Reg3a), and levels of inflammatory cytokines, which 
not clearly correlate with the response in humans. More studies are needed to obtain 
correlative research data [94, 95]. This outcome results in the first Food and Drug 
Administration (FDA) approved MSCs product in the United States [96, 97].
6.2  Clinical studies with MSC in combination to HSCT transplantation for  
treat AA
Cotransplantation of HSCs with (umbilical cord) UC-MSCs has been performed 
to study whether the last will be able to support hematopoiesis, enhance the 
engraftment of HSCs, and reduce the incidence of GVHD following HSCT  
[98–100]. These studies include adult and children in AA patients [101, 102]. Stem 
cells application was mainly intravenous. In some of the studies multiple (five) 
infusions were used. All clinical protocols have been developed in the presence of 
traditional immunosuppressive protocol to prevent GVHD manifestation [98–102].
One pioneer study, where the conditioning of patients was myeloablative or 
reduced, followed BM-MSCs treatment together with allogeneic HSCT. This study 
showed that co-transplantation of MSCs resulted in fast engraftment of absolute 
neutrophil count and platelets and 100% donor chimerism [87]. In turn, Yamei and 
co-workers (2014) demonstrate prolonged survival (follow up of 78 months) in 80.9% 
patients after cotransplantation of the culture-expanded third party donor-derived 
UC-MSCs in 21 young people with SAA undergoing haplo-HSCT [103]. Even so, the 
patients did not show infusion toxicity. This study showed that MSCs support in vivo 
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normal hematopoiesis and display potent immunosuppressive effects. The other 
metacentric study shows that cotransplantation of BM-MSCs and haplo-HSCT could 
reduce the risk of graft failure and severe GVHD in SAA [104]. Similar data were 
obtained in a study that used cotransplantation of haploidentical HSCs and BM-MSCs 
into children with SAA without an HLA-identical sibling donor. It was shown that such 
cotransplantation seems to be safe and may improve survival rates and reduce the risk 
of graft failure [105]. Another multicenter study, which explored cotransplantation 
of BM-MSCs with allo-HSCT, reported that such treatment could ameliorate clinical 
outcomes of a GVHD, viremia, and survival in allo-HSCT for AA patients [106].
6.3 Clinical studies with MSC for treat AA
Nowadays there a few clinical studies using only MSCs single to treat AA. All 
studies used MSCs isolated from BM s and adult patients with severe or non-severe 
AA and refractory. The via of MSCs administration used was IV and the number of 
administrations was 2 until 5 depending on study in combination with conventional 
immunosuppressive therapy.
The study development by Pang et al. showed, six of 18 patients (33.3%) achieved 
a complete response or a partial response to MSCs treatment [107]. In six patients, 
two achieved a complete response including recovery of three hematopoietic cell lines 
after MSCs therapy. Similar results was achieved by Cle et al. 2015 using MSCs being 
22% of all patients (18 patients) presents hematologic response at 6 months after 
MSCs transplantation [108]. One clinical trial phase II conducted in China evaluated 
the MSC overall response rate and safety using a significant number of refractory 
AA younger patients (n = 72). The study performed full quality control of BM-MSCs 
production, which includes counts, viability, morphology, endotoxin, aseptic culture, 
immunophenotype. It was the first clinical study that showed significant results in 
BM functional recovery. The rate response of patients was 28.4% being that 6.8% 
complete response and 21.6% partial response after MSCs transplantation. Among 
patients with hematologic response, ten patients had normalization of cellularity BM 
followed for more than 1 year MSCs transplantation. Seven patients got adverse events 
such as fever and headaches. No other adverse events were observed in the study. At 
the follow-up endpoint, nine patients died. One patient with RAEB-II died of disease 
progression, two patients died of intracranial hemorrhages, and six patients died of 
serious infection [107]. In other two studies were reported adverse events such as, 
fever, hypoxemia, mild dyspnea and diarrhea during MSCs administration or some 
hours after MSCs injection, this phenomenon occurs in 2 of 16 patients [107] and 7 of 
the 18 patients [108]. None major adverse effects were reported in all studies during 
months of follow-up of each respective study. Fuillard et al., 2003 reported one death 
due to fungal infection and Cle et al. 2015 four patients died in consequence result of 
heart failure and bacterial or invasive fungal infections and none of the deaths in both 
studies were directly attributable to MSCs infusions [84, 108].
These preliminary studies support the concept that MSCs replacement can 
improve BM stroma and may alleviate symptoms severe and non-severe AA 
patients. However, larger studies with a significant number of patients are needed to 
evaluate the utility of MSCs further.
7. Conclusion and future perspectives
The progress in dissecting the underlying and complex pathophysiology of AA 
has been gain space over the past years in the hematology research community [26]. 
In addition to that, the need for an optimal alternative of a targeted treatment for 
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due to myeloid and plated recovery after HSCs and MSCs transplantation [85, 86].
6. MSC use in clinical studies
6.1 Clinical potential and market of MSC in hematopoietic disorders
MSCs have been implicated in immunomodulatory therapy, in particular, in 
GVHD treatment and as an adjunct to hematopoietic stem cell transplantation 
(HSCT) to help enhance engraftment [87, 88]. The first major clinical trial of MSCs 
(Prochymal) was for the treatment of steroid-refractory of GVHD (NCT00366145) 
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reduced, followed BM-MSCs treatment together with allogeneic HSCT. This study 
showed that co-transplantation of MSCs resulted in fast engraftment of absolute 
neutrophil count and platelets and 100% donor chimerism [87]. In turn, Yamei and 
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of BM-MSCs with allo-HSCT, reported that such treatment could ameliorate clinical 
outcomes of a GVHD, viremia, and survival in allo-HSCT for AA patients [106].
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studies used MSCs isolated from BM s and adult patients with severe or non-severe 
AA and refractory. The via of MSCs administration used was IV and the number of 
administrations was 2 until 5 depending on study in combination with conventional 
immunosuppressive therapy.
The study development by Pang et al. showed, six of 18 patients (33.3%) achieved 
a complete response or a partial response to MSCs treatment [107]. In six patients, 
two achieved a complete response including recovery of three hematopoietic cell lines 
after MSCs therapy. Similar results was achieved by Cle et al. 2015 using MSCs being 
22% of all patients (18 patients) presents hematologic response at 6 months after 
MSCs transplantation [108]. One clinical trial phase II conducted in China evaluated 
the MSC overall response rate and safety using a significant number of refractory 
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production, which includes counts, viability, morphology, endotoxin, aseptic culture, 
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BM functional recovery. The rate response of patients was 28.4% being that 6.8% 
complete response and 21.6% partial response after MSCs transplantation. Among 
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studies were directly attributable to MSCs infusions [84, 108].
These preliminary studies support the concept that MSCs replacement can 
improve BM stroma and may alleviate symptoms severe and non-severe AA 
patients. However, larger studies with a significant number of patients are needed to 
evaluate the utility of MSCs further.
7. Conclusion and future perspectives
The progress in dissecting the underlying and complex pathophysiology of AA 
has been gain space over the past years in the hematology research community [26]. 
In addition to that, the need for an optimal alternative of a targeted treatment for 
Human Blood Group Systems and Haemoglobinopathies
158
this disorder. It is too soon to place the conventional AA treatment methods, but 
MSCs have gained space for demonstrating positive results in several AA clinical 
studies and other hematological diseases. The hypoimmunogenicity advantages, 
ensuring the absence of rejection in patients due to no expression of MHC class II, 
prevention and treatment of GVHD traditional transplants, and mainly immuno-
modulatory action presented [109]. Essential in the environment imbalance pro-
voked by own immune system in people committed by the AA disorder. The MSCs 
are able in a modulating way to relieve the BM self-attack [110].
Contemporary, personalized therapies are famous in the whole scientific world. 
The MSCs may fit into this class due to their paracrine effects. These cells can assist 
in diverse situations such as: migration, injury recovery, stimulates cells renewal, 
death cell prevention, anti-inflammatory and modulation of the immune system to 
control the autoimmune environment [111]. Thus, MSCs have the heterogeneous 
capacity in varied therapies field. And the patient may have alternative use accord-
ing to their needs.
In that event, the current way is providing the MSCs safety and acceptance by 
regulatory agencies as new biological product [112], which has already been proven 
to be more efficient than synthetic industries products [113]. And finally, imple-
ment the MSCs as ideal allogeneic transplant model, even for adequacy periods used 
as support for other established therapies.
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voked by own immune system in people committed by the AA disorder. The MSCs 
are able in a modulating way to relieve the BM self-attack [110].
Contemporary, personalized therapies are famous in the whole scientific world. 
The MSCs may fit into this class due to their paracrine effects. These cells can assist 
in diverse situations such as: migration, injury recovery, stimulates cells renewal, 
death cell prevention, anti-inflammatory and modulation of the immune system to 
control the autoimmune environment [111]. Thus, MSCs have the heterogeneous 
capacity in varied therapies field. And the patient may have alternative use accord-
ing to their needs.
In that event, the current way is providing the MSCs safety and acceptance by 
regulatory agencies as new biological product [112], which has already been proven 
to be more efficient than synthetic industries products [113]. And finally, imple-
ment the MSCs as ideal allogeneic transplant model, even for adequacy periods used 
as support for other established therapies.
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Professionalism is the current hallmark of biobanks [1], which are driven by 
standards and best practices. A biobank is “an entity that receives, stores, processes, 
and/or distributes specimens, as needed. It encompasses the physical location as 
well as the full range of activities associated with its operation [2].” Different types 
of biobanks have been proposed [3], although the definitive model will be the result 
of the activities performed in support of the particular needs of attended projects, 
including real or virtual collection, processing, conservation, and distribution.
Biobanks have been involved in large quality-assured prospective studies based 
on validated and standardized sample handling and storage protocols [4, 5]. When 
a prospective multicenter research project is designed, multiple variables must be 
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well as the full range of activities associated with its operation [2].” Different types 
of biobanks have been proposed [3], although the definitive model will be the result 
of the activities performed in support of the particular needs of attended projects, 
including real or virtual collection, processing, conservation, and distribution.
Biobanks have been involved in large quality-assured prospective studies based 
on validated and standardized sample handling and storage protocols [4, 5]. When 
a prospective multicenter research project is designed, multiple variables must be 
considered such as the number and type of donations, recruitment sites and ana-
lytical laboratory locations, pre-analytical requirements of samples and derivatives 
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obtained, and processing and storage facilities. Attending to the complexity of the 
project, a specific workflow is implemented after process definition identifying 
every factor involved in (site, staff, equipment, method, materials, samples and 
transferences) and their corresponding checkpoints.
2. Harmonization of sample collection and derivative preservation
To guarantee the integrity of biomarkers to be tested and to avoid bias, pre-ana-
lytical variables must be carefully considered [6]. In fact, many studies are being 
conducted to elucidate the effects of pre-analytical variables on analytical profiles. 
In this sense, a study has been recently published to determine acceptable delays to 
fixation for formalin-fixed paraffin-embedded (FFPE) tissue samples [7]. In order 
to mitigate their impact in the complex frame of multicenter projects, biobanks 
contribute through supervised materials and sample handling and continuous and 
overlapped checkpoints.
2.1  Centralized preparation of consumables for sample collection, processing 
and preservation
With the objective to ensure the consistency in sample collection, stabilization, 
and preservation, specific kits with the consumables necessary for only a donation 
are defined in function of pre-analytical requirements of obtaining samples and 
derivatives (Figure 1). A careful selection of collection devices is critical here since 
differences in biomarker testing have been reported [8, 9]. Consumables such as 
modified cards (IsoCode cards or FTA cards) for blood spot collection, in addition 
to multibarrier pouches with desiccant packs for room-temperature transportation 
and future conservation, could be also included for traceability purposes [10]. For 
Figure 1. 
Consumables included for sample collection, stabilization, and preservation in representative kits, classified by 
the corresponding protocol and derivatives obtained.
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noninvasive samples (nails, stool, etc.), kits targeted to donors may be designed for 
a more accessible collection at home, with the appropriate consumables to guar-
antee the integrity of samples until they are receipted by the biobank or analytical 
laboratory. When processing is performed by a different center from the recruit-
ment site, two kits are prepared in independent boxes for collection and processing, 
especially when the sample collection is made by the donor on his own.
Materials included in the kits are classified in several bags according with the 
downstream protocol. Expiration date and batch numbers for consumables must be 
considered during the purchasing process in relation with the recruitment rates and 
the validity of the results, respectively. Additionally, expiration date is identified for 
each kit according to the most recent expiration date from the consumables, and it 
is used as a reference to track and replace expired consumables by the biobank when 
the recruitment rate is not the expected.
2.2 Sample processing and quality controls
Evidence-based standard operating procedures (SOPs) are elaborated for sample 
processing taking the sample requirements provided by the testing laboratories into 
consideration. The number and volume of samples necessary for analytical assays 
and the type of derivative, anticoagulant or preservative must be identified in order 
to choose the most appropriate and approachable option of prospective collection 
of samples providing high-quality biomarkers useful for downstream applications 
[11]. Additional requirements from guides [12] or previous scientific publications 
[13] are also taken into account in relation with specific sample collection and 
derivative stabilization. Preservation delay and resources available for long-term 
storage will influence the selection of the collection device as well. In fact, room-
temperature storage alternatives have been proposed [14]. When the same sample 
allows obtaining different derivatives (i.e., blood for plasma, buffy coat, and 
RBCs), protocols will adjust the number and type of collection tubes or devices 
to minimize the quantity of sample collected from the donor. On the other hand, 
the number of aliquots of liquid samples must be set in function of the different 
analyses to be performed avoiding unnecessary freeze-thaw cycles.
These pre-analytical conditions of samples and derivatives will determine where 
each process (collection, initial sample processing, provisional cryopreservation 
of derivatives, long-term storage, testing) will be performed depending on the 
recruitment site, the biobank, and the analytical laboratory locations and facilities. 
Accordingly, transportation of samples at the corresponding temperature should be 
organized [15] following the international recommendations.
Obtaining of specific derivatives such as nucleic acid isolation may be central-
ized in the biobank or testing laboratories in order to avoid bias. In the same sense, 
reactive batches must be controlled. When possible, automation of processes must 
be implemented to avoid traceability errors and decreasing hands on time. Samples 
should be handled following validation of standard operating protocols by using 
samples not belonging to the particular project, specifically collected and approved 
for this purpose by an ethical committee.
The quality of samples must be evaluated after processing by means of a 
comprehensive analysis of quality indicators [16]. Because of the current lack of 
qualification tools for each type of derivative and pre-analytical variable, numerous 
studies are trying to identify new markers to assess the fitness-for-purpose of sam-
ples. Thus, new scores and indicators have been proposed for the quality of samples 
in relation with the impact derived from the pre-analytical phase [17–23]. In the 
same way, participation in external quality assurance (EQA) schemes like the EQA 
program developed by the International Society for Biological and Environmental 
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Repositories (ISBER) focused on sample processing and testing evaluation [24]; it is 
a highly recommended complementary tool for the internal quality control (IQC). 
Biobank collaboration through international working groups focused on standard-
ization of sample processing, and biological sample quality control will contribute 
to the implementation of the last innovations in the field as well.
2.3 Monitored storage of biological samples and distribution
In relation with sample conservation, derivatives are long-term stored in the 
most appropriate conditions to maintain their original characteristics, being very 
important for the sample stability the selection of the temperature storage [15]. 
When samples are receipted in the storage facilities, aliquots are immediately 
revised to check the shipment temperature; the number, integrity, and volume of 
each aliquot regarding the expected; and incidents reported, maintaining the cold 
chain. Racks and boxes are previously prepared to directly store the derivatives in a 
reduced and optimized space within the conservation equipment classified by the 
type of container. In addition, derivatives are preferably stored separately in differ-
ent equipment and preservation rooms as a safety measure.
So, long-term storage facilities may be located in one or more rooms or buildings 
and may even be assumed by several institutions when transportation of samples 
and temperature variations are minimized. In any case, sample handling and 
positions must be under control and restricted access. Both the preservation rooms 
and storage equipment are constantly controlled through a monitoring system 
that records critical parameters such as temperature, humidity, CO2, and O2 levels 
(where necessary) and the proper functioning of equipment (compressors, battery 
power, display) (Figure 2). The system triggers an alarm when any parameter is out 
of the established range, thus activating an emergency plan. Briefly, warnings are 
received by specifically dedicated staff available for 24 h who analyze and classify 
the failure to initiate the defined corrective actions. In case it could not be repaired, 
samples are evacuated to backup equipment.
If previous instructions are followed, samples could be preserved in good condi-
tions for a long time. However, the specific period of time will depend on the type 
of sample but, most importantly, on the biomarker to be detected by a particular 
methodology, with a range from minutes to years [15]. In this sense, fitness-for-pur-
pose procedures should be validated and established when a prospective workflow 
is designed, taking into consideration the general good practices that do allow the 
most use of samples [2, 12]. Independently, other approaches have been reviewed 
for the conservation of samples at room temperature by biobanks [25].
Figure 2. 
Representative graph of a monitoring system showing a temperature of an ultra-freezer at −80°C.
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Before sending of samples to analytical laboratories from the storage facilities, 
a checkpoint is introduced to guarantee that each aliquot is compliant with the cor-
responding study or with the necessary volume of sample to thus supplement with 
additional aliquots. Additional quality controls should be performed when incidents 
during the sample conservation occur or after a non-validated long-term storage. 
The remaining precious samples may be again received for long-term storage from 
the testing laboratories followed by a new quality control.
3. Traceability of biological samples
3.1 Electronic database
The electronic database used by biobanks allows the integral management 
of multicenter prospective projects with a maximum level of security through 
restricted access. Donors, biological samples, and associated information, as 
well as the ethical-legal documentation associated to the project, are recorded. 
In detail, the system allows an exhaustive control of collaborating centers and 
researchers, preparation of sample collection kits maintaining the traceability 
of all materials used, donor and clinical information, informed consent forms, 
ethical and scientific committees’ approvals, agreements, sample handling by 
different sites (reception, processing, storage and shipments), quality incidents, 
and even the project monitoring by using any recorded information, for example, 
the recruitment rates from each clinical site. The electronic database may be also 
connected to external databases incorporating additional information such as 
temperature information from storage equipment. So, traceability is achieved 
from all the processes.
Figure 3. 
Identification of samples and materials with structured codes and representative box map with pre-coded 
tubes.
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different sites (reception, processing, storage and shipments), quality incidents, 
and even the project monitoring by using any recorded information, for example, 
the recruitment rates from each clinical site. The electronic database may be also 
connected to external databases incorporating additional information such as 
temperature information from storage equipment. So, traceability is achieved 
from all the processes.
Figure 3. 
Identification of samples and materials with structured codes and representative box map with pre-coded 
tubes.
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3.2 Identification of materials and samples
Unique standardized codes are generated by the electronic database to identify 
each donation, sample, and material included in its corresponding collection kit, 
thanks to label printing (Figure 3). Therefore, samples (and associated informa-
tion) are de-identified in compliance with applicable laws. Records included in the 
kit are also identified in relation with donations.
Commercially available pre-coded tubes are selected to prepare derivative 
aliquots so that specific pre-coded tubes are pre-assigned to each type of sample 
for a donation during the kit preparation by using the electronic database, support-
ing the traceability of samples (Figure 3). Similarly, racks for the pre-coded tubes 
included in the kits are identified as well. The process of generation of a new dona-
tion code to the positions of aliquots within the storage equipment is recorded in the 
electronic database. Code generation and identification also accompany manual or 
automated sample processing to identify the samples by using code readers.
4. Quality management system
A variety of quality standards can be implemented by laboratories, being 
requirements from ISO 9001 for the quality management system (QMS) the most 
widely used [26]. Briefly, ISO 9001 is characterized by a process-based approach 
following the plan-do-check-act cycle, not only focused on the quality of a prod-
uct or service or the satisfaction of its users but on the way to obtain them. This 
QMS involves the definition and systematic management of the processes and the 
interactions between them in order to meet the legal, regulatory, and users’ require-
ments and to achieve the expected results by continuously improving efficiency. 
Specifically for biobank activities, the ISO 20387:2018 Biotechnology-Biobanking-
General Requirements for Biobanking has been launched under which other more 
specific standards will be additionally developed [27]. Next, quality assurance tools 
related with the harmonization and traceability of samples in multicenter prospec-
tive studies are shown.
4.1 Protocols, records, and other documents
The definition of processes (strategic, key, and support) involves identifying 
every factor involved (staff, equipment, method) with the objective of describing 
them through procedures and keeping them well controlled. Strict adherence to 
procedures by each stakeholder involved in the multicenter projects is mandatory to 
avoid pre-analytical deviations. A scheme summarizing the project workflow may 
be useful to clearly represent the responsibilities of all the stakeholders (Figure 4).
Clear and schematic protocols are developed for each type of collection device 
included in the kits in order to make easier the procedure interpretation (Figure 5).  
This action is especially critical when kits are targeted to donors for collection at 
home. The protocols include associated records to be filled with pre-analytical 
information of donations or samples, to report any incident that occurred during 
collection and preservation, even rack maps as guide for derivatives aliquoting into 
the specific tubes.
After centralized derivatives are obtained, a technical report specifying the 
sample processing features is accompanied in the shipments to analytical labora-
tories. Once all the samples for a study are sent from storage facilities to analyti-
cal laboratories, a final report is prepared with the missing samples, because of 
insufficient quantity of aliquots or any incident reported, and with the remaining 
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material for the study. Transaction forms specifying the samples included are 
necessary to declare the derivative shipment to the next facility involved in the 
project workflow.
Figure 4. 
Biobank-supported workflow for sample handling.
Figure 5. 
Representative schematic protocol for derivative stabilization and preservation.
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4.2 Risk management tool
As part of the quality assurance tools, the processes of prospective sample col-
lection, stabilization and processing, conservation, and distribution in multicenter 
research studies are managed under a global approach based on risk analysis, aimed 
at preventing undesired results. Since incidents are treated in the format of correc-
tive and preventative action (CAPA) and root cause analysis (RCA) documentation, 
these records are used as reference.
So, the implementation by the biobanks of a comprehensive quality control for 
sample collection kits before shipment to recruitment sites is a result from this risk 
analysis. The potential consequences (inadequate preservation of samples due to 
inappropriate devices, containers, or additives, lower amount of derivatives for 
analysis, or loss of traceability) and costs of this process (new shipment of replace-
ment kits and time of technician dedicated to kit checking), in addition to the num-
ber of nonconforming kits detected, have been evaluated. Quality control of kits is 
performed with a checklist, and follow-up of kit preparation and shipments is made 
with a specific record. Similarly, a checklist for the recruitment sites is included to 
track the reception of kits.
In addition, a training activity for the staff from the recruitment sites is orga-
nized before initializing the donors’ recruitment to present the procedures for 
sample handling and the kit composition and usage. On the other hand, a pilot 
in a recruitment site is necessary to validate the model designed and to propose 
improvement measures.
5. Conclusions
The biobank-supported workflow, specifically designed and implemented for 
each research study, allows obtaining prospective, harmonized, and quality samples 
avoiding pre-analytical bias and contributing to the validity of the analytical 
results. Through biobanking processes and continuous and overlapped checkpoints, 
quality derivatives are obtained based on common and evidence-based standard 
operating procedures and supervised materials, with associated traceability infor-
mation in relation with their collection, processing, conservation, and distribution. 
The effective workflow established is valid for large and complex multicenter 
projects.
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Abstract
Sickle cell anemia is a serious disease with manifestations and complications that
directly affect the patient’s quality of life and his entourage. This is not a shameful
disease on the contrary; it is linked to a mutation that arose for us to defend against
severe forms of malaria. It is due to the so-called selective pressure that has enabled
AS carriers to resist severe forms of malaria. This advantage explains among other
things why, although cosmopolitan, sickle cell disease predominates in Africa and
its geographical distribution is superimposed on the malaria one. In the Democratic
Republic of the Congo (DRC), it is estimated that there are 25–30% heterozygous
healthy carriers (AS) and about 50,000 homozygous newborns (SS) each year,
equating to 2% of newborns. Therefore, an effective medical care is very indispens-
able. The management of any pathology implies the appropriate choice of
techniques and technologies. Unfortunately, very often in sub-Saharan countries,
there is a lack of global strategy to providing effective solution. The choice of
equipment performed after an objective needs analysis enables to optimize the
acquiring process, to ensure the quality of reported results, and to provide more
accessible costs to target populations that are generally poor. Biomedical engineers
may enhance health by assessing and managing health technologies.
Keywords: sickle cell anemia, project management, biomedical equipment,
planning
1. Introduction
By way of introduction, the quotation below significantly translates the problem
of sickle cell disease both in the Democratic Republic of the Congo and in most
countries of sub-Saharan Africa:
“Sickle cell disease is a genetic inherited disorder where hemoglobin (Hb) normal A
(HbA) is replaced by another abnormal, HbS.”
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disease contrary; it is linked to a mutation that arose for us to defend against severe
forms of malaria. It is due to the so-called selective pressure that has enabled AS
carriers to resist severe forms of malaria. This advantage explains among other
things why, although cosmopolitan, sickle cell disease predominates in Africa and
its geographical distribution is superimposed on the malaria one.
There are four major outbreaks of sickle cell disease based on genetic markers called
haplotypes: Arabo-Indian, Beninese, Senegalese, and Central African or Bantu.
Among Bantu haplotype carriers, the clinical expression of the sickle cell disease is
more severe because of, among other things, the relatively low rate of the fetal
hemoglobin (HbF) and other genetic factors.
According to WHO estimates, approximately 300–500,000 children are born
each year with hemoglobinopathy; 80% of them are born in developing countries,
particularly in Africa. The sickle cell anemia is a hemoglobin disorder most common
in Africa, where every year about 200,000 newborns with sickle cell disease are
diagnosed and 80% will not reach the age of 5 years.
In the Democratic Republic of the Congo (DRC), it is estimated that there are
25–30% heterozygous healthy carriers (AS) and about 50,000 homozygous newborns
(SS) each year, equating to 2% of newborns [1].
Sickle cell disease is particularly common among people from sub-Saharan
Africa, India, Saudi Arabia, and Mediterranean countries. Migration has increased
the frequency of the offending gene in the Americas. In parts of sub-Saharan Africa,
sickle cell disease affects up to 2% of newborns. More broadly, the prevalence of
sickle cell disease (healthy carriers that inherited the mutant gene from only one
parent) in equatorial Africa is 10–40%, compared to only 1–2% on the coast of
North Africa and less than 1% in South Africa. This distribution reflects the fact that
the sickle cell trait confers an advantage in terms of survival against malaria and
that the selection pressure due to malaria has made the mutant gene more frequent,
especially in areas with high malaria transmission. In West African countries such
as Ghana and Nigeria, the rate of trafficking is 15–30%, while in Uganda, where
marked tribal variations are observed, it is 45% among the Bahamas of west of the
country [2].
2. Problems of financing of health systems and their corollary in the DR
Congo
2.1 Deficit in sources of health-care funding
A country’s problem of access to health care depends on its ability to finance the
required health systems. This presupposes that the country concerned can offer
structures, viable infrastructures, and competent personnel. However, low-income
countries are struggling to find adequate budget balances to effectively meet the
ever-growing health needs of their populations [3], and this is the case of the DR
Congo and many other countries in sub-Saharan Africa.
Indeed, the current sources of financing useful for universal health coverage are
essentially public expenditure, donor funding, and compulsory contributions to
social health insurance [4]. Since under current conditions household contributions
to health care remain relatively low, with a few exceptions when community initia-
tives are organized [5] or when the state is effectively involved, only two sources
are secure: public spending and donor funding.
With regard to public expenditure, the state budget is low, often well below
Abuja’s commitments (15%) [6]. In 2013, for example, the Congolese state allocated
only 4.3% of its budget to health, while all projections for spending in 2020 are
below 3%. Worse still, this state contribution has only decreased from 2013 to date.
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It just so happens that a large part of the financing of the health system relies
heavily on donor funding. And in order to cover all needs, donors will theoretically
have to continually increase their contribution in proportion to the decrease in the
state budget.
But is such a hypothesis sustainable? Logically, the answer is negative, since
donors cannot set themselves up as substitutes for failing health systems. Indeed,
the study of the financing mechanism supported by the World Bank Group shows
that “the health sector in the DRC suffers from several ills: low budget allocation;
excessive household expenditure; dependence on external financing; available
resources are poorly spent; budget execution is weak; governance problems; and the
decentralization process is partly theoretical.” [7] The same study shows that a
decrease in external financing is observed from 2017, just as the projections predict
that the deficit financing observed since 2019 will have to continue until 2030.
2.2 Attempt to address the funding gap for the management of sickle cell
disease
In the specific case of the management of sickle cell disease, are there other ways
of compensating for this financial situation?
The first way already present in the field is that of the actions of charitable
associations. The contribution of several nongovernmental organizations involved
in the management of specific pathologies such as sickle cell disease is very signif-
icant and constitutes a major support, especially for the most deprived populations.
The action is perceptible not only in the DR Congo but also in other countries of
sub-Saharan Africa [8]. But these efforts remain insignificant compared to the
magnitude of the disease, and a country’s health policy cannot be based on impulses
that are difficult to predict.
The second way is the frequent use of donated second-hand equipment to
reduce the costs they (the equipment) represent in the health-care chain. This
resource can make a great contribution if best practices for donors and donors’
applicants are rigorously observed [9]. Unfortunately, very often this is not the
case. Many donations still arrive in Africa without observing the prerequisites,
which very often makes them either ineffective or unusable. On the other hand,
recourse to donations of second-hand equipment should remain ad hoc, without
becoming structural.
The third way is that of optimizing the use of the means available to approach
the objectives set. At the international level, donors have understood the challenge
of structured and well-executed health financing. This obliges the partners to
accompany for decades the countries receiving aid through specific national
programs in order to reduce deficits and achieve the objectives.
In the DR Congo, it is through the national health development program that the
government and its partners express their willingness to provide effective and
realistic solutions to the health problems of the DR Congo’s populations. This is
generally applied for a period of 5 years, iteratively after evaluation.
The partners in the health field remain practically the same for African coun-
tries, and their health problems are very similar: the fight against epidemics, mal-
nutrition, and hereditary diseases. This probably explains why almost all countries
in sub-Saharan Africa each develop a national health development plan, with virtu-
ally the same content except for a few differences. Examples include the DR Congo,
Mali, Côte d’Ivoire, Burkina Faso, Benin, and Kenya. Therefore the methods applied
by the partners for health support to the different countries will be very similar.
In the national health development plans drawn up in many sub-Saharan African
countries since 2000 to date, the improvement of infrastructures and the strength-
ening of the capacities of the medical technical platforms, including the expression of
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needs, acquisition, and maintenance of the systems acquired, are among the issues
addressed. These topics involve a lot of money that will have to be put to good use;
otherwise they can be a source of conscious or unconscious waste of scarce resources.
In the case of the DR Congo, a reflection carried out on the medical technical
platform shows that the objectives assigned to medical infrastructure and equipment
through national programs are never achieved and the situation is getting more
complicated every year. And yet, after evaluation, the same programs continue with
the same objectives and use practically the same methods [10]. In order to minimize
procurement costs, the WHO proposes a strategic procurement approach to achieve
universal health coverage [11]. The illustration below is more explicit.
This diagram raises fundamental questions that need to be answered if we are to
succeed in our efforts. Indeed, countries cannot simply spend their money on
universal health coverage. They must master purchasing, define the relationships
between suppliers and buyers, define a purchasing strategy on the basis of useful
data before disbursement, and finally move from passive purchasing to strategic
purchasing.
The fourth path, a corollary to the third, consists of mobilizing and structuring
human skills, each in its own sector, to boost the strategic purchasing process. Since
the problem of strategic purchasing concerns all sectors, what can the biomedical
engineer’s contribution be as far as it is concerned?
From this point of view, the biomedical engineer can play an important role as
a technical interface between the hospital, suppliers, and industry to make the
right choices, as he is considered responsible for the research and development,
architecture, selection, management, and safe use of all types of medical devices
including single-use, reusable, prosthetic, implantable, and bionic devices, among
others [12].
For several decades, a developed country like France has been efficiently
involving biomedical engineers in the medical equipment procurement process
[13]. It organizes hospital purchasing, where biomedical engineers play a leading
role in the purchasing function that has developed in companies over the last 30
years or so [14]. Better still, it is developing a purchasing policy that, among other
things, brings together the skills of biomedical engineers to offer end customer
equipment negotiated at attractive prices through group purchasing [15].
But in the Democratic Republic of the Congo in particular and in sub-Saharan
Africa in general, the biomedical engineering component does not seem to be
sufficiently integrated at its best in the administrative and technical response
mechanisms for improving health care. This aspect of things can only lead to a
waste of funds when the actors at this stage do not master the equipment.
3. Situation of medical equipment dedicated to the analysis of
hemoglobinopathies
In the field there are currently different types of electrophoresis equipment.
However, to date, it is difficult to determine their number, origins, and brands,
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given the country’s size, diverse supply methods, and ineffective control
mechanisms. Nevertheless, some facilities stand out from the others in terms of
their number, mainly for historical and geographical, economic, and commercial
reasons.
Historically and geographically, sickle cell disease was first discovered in black
populations in Africa and in the Arabian Peninsula; to date it remains more frequent
in these geographical areas. Initially, this disease, which later turned out to be
hereditary, did not directly affect the Indo-European populations.
However, due to massive immigration, countries with well-organized preven-
tion programs are now faced with the problems of uninformed couples of
allochthonous origin, as well as variations in specific population characteristics,
which is rare among indigenous populations [16].
In the early 1970s, screening tests were launched in the United States, and the
American population of African origin was indeed very affected. In 1981, an exper-
imental neonatal screening program began in the French Antilles and metropolitan
France. It is set up by the Association Française pour le Dépistage et la Prévention
du Handicap (AFDPHE). It was only in 2000 that neonatal screening for sickle cell
disease was, this time, extended in whole France [17].
As a result of the above, electrophoresis systems are initially more equipped with
routine programs dedicated to serum protein analysis; programs for the analysis of
hemoglobinopathies will gradually come into operation. Indeed, the implementa-
tion of new programs involves significant costs that the manufacturer cannot incur
without a guaranteed return on investment.
Since the greatest need for sickle cell disease management is in Africa, countries
with strong historical ties to the continent will find it easier to sell their technologies
to this potential market. Among them we will mention the most prominent firms
such as HELENA, TITAN, BECKMAN SEBIA, and BIORAD.
In financial terms, the choice of equipment for routine needs will focus more on
technical solutions that offer good results at lower cost. From this point of view, for
the analysis of hemoglobinopathies, there is an established correlation between
agarose gel electrophoresis on the one hand and capillary electrophoresis on the
other [18]. On the other hand, high-performance liquid chromatography (HPLC)
and capillary techniques are complementary and can be used routinely, knowing
that capillary diagrams are easier to read and interpret than those obtained in HPLC.
Even better, the development of the capillary technique for the characterization of
hemoglobin variants suggested that it would become the first method of choice for
screening in many clinical laboratories [19].
This trend is confirmedwith regular innovations from certainmanufacturers, and
this is the case of SEBIA,which has added to its range for the screening of hemoglobin-
opathies [20]. In addition, the capillary technique ismore sensitive than theHPLC
technique for the detection of certain variants such as hemoglobinNewYork [21].
On the commercial level, thanks to their historical links with Africa, the first
companies are more easily organized and set up local representations of their firms
to facilitate the sale of their products. Among the first to obtain country-level
representation are HELENA and BECKMAN.
But for almost two decades, we have been observing the rise of the SEBIA com-
pany, which offers different models of equipment according to the needs and which
regularly innovates its products. Today, this firm, now a world leader in the field of
electrophoresis, is among those with a large number of distributors in Africa.
Apart from the abovementioned brands, it is worth noting a slow penetration of
products of Asian origin in the field. However, while the financial offer is attractive,
distribution is still struggling to be structured in terms of regularity, reliability, and
operation.
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distribution is still struggling to be structured in terms of regularity, reliability, and
operation.
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In the present case of the management of sickle cell disease and in order to make
his contribution relevant and effective, the biomedical engineer must make an
inventory of the existing situation in the field, evaluate the technologies in the state
of the art, and propose material solutions that present a better compromise between
technical and technological contributions and optimization of the financial aspect.
4. Analysis of onboard techniques on electrophoresis systems
The following theories are drawn mainly from the book Appliances and Methods
in Biochemistry and Molecular Biology, whose pedagogical approach seems clearer.
4.1 General principles of electrophoresis
Electrophoresis has established itself over time as the method of choice for the
qualification and quantification of different fractions in the management of hemo-
globinopathy. It involves methods often embedded in laboratory materials. We
review below the most common methods in electrophoresis of hemoglobin.
4.1.1 Definitions
Electrophoresis is a physical method of separating molecules based on their
difference in mobility, under the effect of an electric field. Zone electrophoresis,
carried out on a solid support, is used to essentially separate the ionizable biological
macromolecules, that is to say proteins, nucleic acids, and certain polyosides and
proteoglycans.
Liquid vein electrophoresis, currently capillary electrophoresis, is also applied to
small molecules, organic or mineral, and not necessarily ionizable. In the most
common case, the movement of the molecule depends on several intrinsic (due to
the molecule itself) and extrinsic parameters, in particular linked to migration
buffers which play the role of solvent [22].
4.1.2 Zone electrophoresis
This is the electrophoresis whose migration medium is stabilized by a real or
sometimes virtual porous support as in the density gradient. In the case of a porous
substrate, it is soaked with a buffer solution that both ensures conductivity and
stabilizes the pH at the desired value. The molecules separate according to their
different mobility in the system (they appear as migration zones) and will be
visualized in a second time (“revelations”); we can even isolate them from the
support for the preparatory purpose.
Zone electrophoresis is mainly applied to the separation of macromolecules.
4.1.2.1 Characteristics
These electrophoreses are often characterized by strong electroosmotic currents
and sometimes intense Joule effect. The most common electroosmotic current is the
electroendosmosis current, especially in polyosidic supports used at pH alkaline: the
walls are negatively ionized as the macromolecules to be separated; positive buffer
charges are attracted to the cathode and create a current that is in the opposite
direction of electrophoretic migration.
Another electroosmosis phenomenon is related to the structure of the support,
which can be assimilated to a capillary network; the friction forces are greater on the
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edges of the support, and the center moves faster, distorting the migration band.
Finally, the Joule effect heats the substrate and therefore evaporates the solvent; this
is gradually replaced by the liquid of the vessels which rises in the support by
capillary action, opposite both ends of the support, and annulling in the middle [23].
4.1.2.2 Supports
The supports must be chemically inert (low adsorbent) and homogeneous (reg-
ular microporous structure), have good mechanical resistance (handling), and
possibly allow densitometric reading [24].
4.1.2.2.1 Paper
Paper is a natural cellulose; it is no longer used much because it is not homoge-
neous. Paper electrophoresis provides a strong electroendosmosis current and is a
source of parasitic adsorptions (added chromatography), resulting in poor resolu-
tion; the Joule effect is important with heating, evaporation, and even electrolysis of
the buffer. At high pressure (1000–3000 V), paper electrophoresis is mainly used to
separate peptides and amino acids.
4.1.2.2.2 Cellulose acetate
Cellulose acetate is much more homogeneous than paper; this support allows
densitometric reading, but the electroendosmosis current remains high. The appli-
cations of cellulose acetate are mainly found in medical biology, allowing a quanti-
tative densitometric reading of the protein fractions rather roughly separated
(plasma and urinary proteins, lipoproteins, and hemoglobins), or finer (isoen-
zymes), applying the potential gradients of the order of 30 V cm1. Resolution is
poor, and reproducibility is average.
However, at alkaline pH (typically pH 8.6), Hb A2, Hb C, Hb E, and Hb O
migrate to the same area, and Hb S, Hb D, and Hb G migrate at the same rate. In the
case of suspicions of such hemoglobin abnormalities, an additional technique should
therefore be considered [25].
4.1.2.2.3 Starch gel (cross-linked starch)
Starch gel is a polyoside; electrophoresis on this gel allows the separation of
complex or heterogeneous oligomeric protein associations. Starch gel is little used
because it is opaque, fragile, and not very reproducible.
4.1.2.2.4 Agarose gel
Agarose is desulfonated agar (purified agar); removal of sulfonates greatly limits
the flow of electroendosmosis; agarose gels between 0.5 and 2% are not very vis-
cous. They make it possible to carry out native electrophoresis as with the previous
supports, that is, without denaturation of the macromolecules. Potential gradients
up to 50 V cm1 are usable for protein separation; agarose gel is gradually replacing
cellulose acetate in most biomedical applications because agarose improves resolu-
tion and remains colorless, allowing a good densitometric reading. The agarose gel is
also very homogeneous, thus ensuring good reproducibility, and is well adapted to
zymographic reading [23].
The distinction between the different variants Hb A2, Hb C, Hb E, and Hb O, as
well as Hb S, Hb D, and Hb G, is most often made by electrophoresis on agarose gel
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In the present case of the management of sickle cell disease and in order to make
his contribution relevant and effective, the biomedical engineer must make an
inventory of the existing situation in the field, evaluate the technologies in the state
of the art, and propose material solutions that present a better compromise between
technical and technological contributions and optimization of the financial aspect.
4. Analysis of onboard techniques on electrophoresis systems
The following theories are drawn mainly from the book Appliances and Methods
in Biochemistry and Molecular Biology, whose pedagogical approach seems clearer.
4.1 General principles of electrophoresis
Electrophoresis has established itself over time as the method of choice for the
qualification and quantification of different fractions in the management of hemo-
globinopathy. It involves methods often embedded in laboratory materials. We
review below the most common methods in electrophoresis of hemoglobin.
4.1.1 Definitions
Electrophoresis is a physical method of separating molecules based on their
difference in mobility, under the effect of an electric field. Zone electrophoresis,
carried out on a solid support, is used to essentially separate the ionizable biological
macromolecules, that is to say proteins, nucleic acids, and certain polyosides and
proteoglycans.
Liquid vein electrophoresis, currently capillary electrophoresis, is also applied to
small molecules, organic or mineral, and not necessarily ionizable. In the most
common case, the movement of the molecule depends on several intrinsic (due to
the molecule itself) and extrinsic parameters, in particular linked to migration
buffers which play the role of solvent [22].
4.1.2 Zone electrophoresis
This is the electrophoresis whose migration medium is stabilized by a real or
sometimes virtual porous support as in the density gradient. In the case of a porous
substrate, it is soaked with a buffer solution that both ensures conductivity and
stabilizes the pH at the desired value. The molecules separate according to their
different mobility in the system (they appear as migration zones) and will be
visualized in a second time (“revelations”); we can even isolate them from the
support for the preparatory purpose.
Zone electrophoresis is mainly applied to the separation of macromolecules.
4.1.2.1 Characteristics
These electrophoreses are often characterized by strong electroosmotic currents
and sometimes intense Joule effect. The most common electroosmotic current is the
electroendosmosis current, especially in polyosidic supports used at pH alkaline: the
walls are negatively ionized as the macromolecules to be separated; positive buffer
charges are attracted to the cathode and create a current that is in the opposite
direction of electrophoretic migration.
Another electroosmosis phenomenon is related to the structure of the support,
which can be assimilated to a capillary network; the friction forces are greater on the
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edges of the support, and the center moves faster, distorting the migration band.
Finally, the Joule effect heats the substrate and therefore evaporates the solvent; this
is gradually replaced by the liquid of the vessels which rises in the support by
capillary action, opposite both ends of the support, and annulling in the middle [23].
4.1.2.2 Supports
The supports must be chemically inert (low adsorbent) and homogeneous (reg-
ular microporous structure), have good mechanical resistance (handling), and
possibly allow densitometric reading [24].
4.1.2.2.1 Paper
Paper is a natural cellulose; it is no longer used much because it is not homoge-
neous. Paper electrophoresis provides a strong electroendosmosis current and is a
source of parasitic adsorptions (added chromatography), resulting in poor resolu-
tion; the Joule effect is important with heating, evaporation, and even electrolysis of
the buffer. At high pressure (1000–3000 V), paper electrophoresis is mainly used to
separate peptides and amino acids.
4.1.2.2.2 Cellulose acetate
Cellulose acetate is much more homogeneous than paper; this support allows
densitometric reading, but the electroendosmosis current remains high. The appli-
cations of cellulose acetate are mainly found in medical biology, allowing a quanti-
tative densitometric reading of the protein fractions rather roughly separated
(plasma and urinary proteins, lipoproteins, and hemoglobins), or finer (isoen-
zymes), applying the potential gradients of the order of 30 V cm1. Resolution is
poor, and reproducibility is average.
However, at alkaline pH (typically pH 8.6), Hb A2, Hb C, Hb E, and Hb O
migrate to the same area, and Hb S, Hb D, and Hb G migrate at the same rate. In the
case of suspicions of such hemoglobin abnormalities, an additional technique should
therefore be considered [25].
4.1.2.2.3 Starch gel (cross-linked starch)
Starch gel is a polyoside; electrophoresis on this gel allows the separation of
complex or heterogeneous oligomeric protein associations. Starch gel is little used
because it is opaque, fragile, and not very reproducible.
4.1.2.2.4 Agarose gel
Agarose is desulfonated agar (purified agar); removal of sulfonates greatly limits
the flow of electroendosmosis; agarose gels between 0.5 and 2% are not very vis-
cous. They make it possible to carry out native electrophoresis as with the previous
supports, that is, without denaturation of the macromolecules. Potential gradients
up to 50 V cm1 are usable for protein separation; agarose gel is gradually replacing
cellulose acetate in most biomedical applications because agarose improves resolu-
tion and remains colorless, allowing a good densitometric reading. The agarose gel is
also very homogeneous, thus ensuring good reproducibility, and is well adapted to
zymographic reading [23].
The distinction between the different variants Hb A2, Hb C, Hb E, and Hb O, as
well as Hb S, Hb D, and Hb G, is most often made by electrophoresis on agarose gel
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at acidic pH (pH 6.0), which allows to separate Hb C, from Hb E and Hb O, as well
as Hb S, from Hb D and Hb G. On the other hand, Hb E and Hb O, as well as Hb D
and G, still cannot be differentiated by combining these two electrophoretic
methods (cellulose acetate, agarose gel). In addition, these techniques have the
disadvantage of consuming time and labor.
In addition, they lack precision for the quantification of hemoglobin in low
concentrations, such as Hb A2, and for the detection of fast-migrating variants,
such as Hb H or Hb Bart’s. It is even now accepted that the quantification of variants
by densitometry lacks precision and that these two electrophoresis techniques must
be used for qualitative purposes. They are therefore most often used today in
combination with another method, mainly high-performance liquid chromatogra-
phy, which has a much higher accuracy.
A 1999 study by the College of American Pathologists showed a coefficient of
variation (CV) of 33.6% for the quantification of Hb A2 at a concentration of 2.41%
by densitometry from electrophoretic gels. By HPLC, the CV was 4.3% for Hb A2 at
a concentration of 3.47%. Thus, the combination of these electrophoresis techniques
with HPLC allows the identification and quantification of hemoglobin, the latter
being performed by HPLC only [26].
4.1.2.2.5 Polyacrylamide
It is a polymer of acrylamide and N,N0-methylene-bisacrylamide (Bis), the
acrylamide gel polymerization being obtained in the presence of a catalyst (ammo-
nium persulfate) and a cross-linking agent (N,N,N0,N0-tetramethyl-ethylene-
diamine [TEMED]). The porosity of gels can be very precise; it depends on the
relative concentrations of acrylamide and Bis.
The polymer obtained is very hydrophilic although insoluble in water and easy
to mold even under small thicknesses (<1 mm); it is thermostable, not fragile,
transparent, and inert chemically. There is almost no electroendosmosis flow and no
macromolecules are absorbed. The resolutive power is generally superior to that of
polyosidic gels using gradients of similar potential. The main disadvantage is that
the acrylamide in solution is neurotoxic but also that the resulting porosities are
very poorly adapted to very large molecules [27].
4.1.2.3 Zone electrophoresis methods
4.1.2.3.1 Native electrophoresis (without denaturation)
It is made on paper, starch, cellulose acetate, agarose gel, and sometimes poly-
acrylamide whenever we do not want to touch the tertiary and quaternary struc-
tures of macromolecules, thus their biological activities. This method without
denaturation is a priori applicable to all types of macromolecules, both in vertical
and horizontal tanks [27].
4.1.2.3.2 Isoelectrofocusing
Isoelectrofocusing, carried out on agarose gel or polyacrylamide gel, separates
hemoglobin in a pH gradient according to their isoelectric point. To do this,
ampholytes are introduced into the gel in order to create a continuous pH gradient
under the effect of an electric field. The different hemoglobins contained in the
sample to be analyzed will migrate to the region where the pH is equal to their
isoelectric pH. At this position, the net load is zero, and the hemoglobin ceases to
migrate and focuses into a narrow band.
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This technique, capable of separating hemoglobin variants with isoelectric
points different from 0.02 pH units, has excellent resolution and is very useful for
detecting abnormal hemoglobin in the newborn. In fact, it allows a good separation
of hemoglobins F, A, and S. Moreover, the electrical isofocusing is perfectly adapted
to the analysis of large series. On the other hand, the main limitations of this
method are a long and complex implementation. Therefore, its use is almost
reserved for neonatal screening of hemoglobinopathies [28, 29].
4.1.3 Liquid vein electrophoresis
4.1.3.1 Characteristics
Typically, capillary electrophoresis is performed in a fused silica capillary coated
with a polyamide layer of 20–200 μm of internal diameter and 20–200 cm of length.
The capillary, placed in a thermostatization system, is filled with a buffer solution
and plunges into two tanks containing the same solution. Each tank is connected to
an electrode connected to a current generator. A large potential difference (several
thousand volts) is applied to the terminals of each capillary to separate the
molecules on the basis of their charge/mass ratio [30].
The use of a capillary has a double advantage: increases the sensitivity of the
detection since a reading window in the capillary allows an absorbance reading with
a very small optical path and increases the resolution by applying the potential
difference of more than 10,000 V since it is easy to regulate the capillary in
temperature [31].
4.1.3.2 Support
In this method, the buffer solution in contact with the two tanks of the system
constitutes the support. Since liquid has no specific form, the buffer uses the capillary
as a solid support, contributing also to electroendosmosis current production.
4.1.3.3 Liquid vein electrophoresis methods
There are several methods used in capillary electrophoresis including capillary
zone electrophoresis (CZE), capillary gel electrophoresis (CGE), and micellar elec-
trokinetic chromatography (MECC) [32]. In this study, we will limit ourselves to
capillary zone electrophoresis which is the most exploited for hemoglobinopathy.
This method can be performed on a single-fused silica capillary in which an
electroosmotic flux develops. It causes the negative molecules to the cathode where
the detection is carried out, the injection being anodic.
The electroosmotic flux depends on the temperature, the ionic force, and the
concentration of organic solvent.
4.2 Facilities
We will limit ourselves here to the most common routine techniques for the
analysis of hemoglobinopathies in the Democratic Republic of the Congo in
particular and in sub-Saharan Africa in general. They are often affected by accessi-
bility during acquisition, ease of commissioning, operation, maintenance and
supply, and cost.
On one side, our analysis is based globally on equipment meeting international
standards such as ISO, FDA, and CE certification. Field experience shows that such
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at acidic pH (pH 6.0), which allows to separate Hb C, from Hb E and Hb O, as well
as Hb S, from Hb D and Hb G. On the other hand, Hb E and Hb O, as well as Hb D
and G, still cannot be differentiated by combining these two electrophoretic
methods (cellulose acetate, agarose gel). In addition, these techniques have the
disadvantage of consuming time and labor.
In addition, they lack precision for the quantification of hemoglobin in low
concentrations, such as Hb A2, and for the detection of fast-migrating variants,
such as Hb H or Hb Bart’s. It is even now accepted that the quantification of variants
by densitometry lacks precision and that these two electrophoresis techniques must
be used for qualitative purposes. They are therefore most often used today in
combination with another method, mainly high-performance liquid chromatogra-
phy, which has a much higher accuracy.
A 1999 study by the College of American Pathologists showed a coefficient of
variation (CV) of 33.6% for the quantification of Hb A2 at a concentration of 2.41%
by densitometry from electrophoretic gels. By HPLC, the CV was 4.3% for Hb A2 at
a concentration of 3.47%. Thus, the combination of these electrophoresis techniques
with HPLC allows the identification and quantification of hemoglobin, the latter
being performed by HPLC only [26].
4.1.2.2.5 Polyacrylamide
It is a polymer of acrylamide and N,N0-methylene-bisacrylamide (Bis), the
acrylamide gel polymerization being obtained in the presence of a catalyst (ammo-
nium persulfate) and a cross-linking agent (N,N,N0,N0-tetramethyl-ethylene-
diamine [TEMED]). The porosity of gels can be very precise; it depends on the
relative concentrations of acrylamide and Bis.
The polymer obtained is very hydrophilic although insoluble in water and easy
to mold even under small thicknesses (<1 mm); it is thermostable, not fragile,
transparent, and inert chemically. There is almost no electroendosmosis flow and no
macromolecules are absorbed. The resolutive power is generally superior to that of
polyosidic gels using gradients of similar potential. The main disadvantage is that
the acrylamide in solution is neurotoxic but also that the resulting porosities are
very poorly adapted to very large molecules [27].
4.1.2.3 Zone electrophoresis methods
4.1.2.3.1 Native electrophoresis (without denaturation)
It is made on paper, starch, cellulose acetate, agarose gel, and sometimes poly-
acrylamide whenever we do not want to touch the tertiary and quaternary struc-
tures of macromolecules, thus their biological activities. This method without
denaturation is a priori applicable to all types of macromolecules, both in vertical
and horizontal tanks [27].
4.1.2.3.2 Isoelectrofocusing
Isoelectrofocusing, carried out on agarose gel or polyacrylamide gel, separates
hemoglobin in a pH gradient according to their isoelectric point. To do this,
ampholytes are introduced into the gel in order to create a continuous pH gradient
under the effect of an electric field. The different hemoglobins contained in the
sample to be analyzed will migrate to the region where the pH is equal to their
isoelectric pH. At this position, the net load is zero, and the hemoglobin ceases to
migrate and focuses into a narrow band.
186
Human Blood Group Systems and Haemoglobinopathies
This technique, capable of separating hemoglobin variants with isoelectric
points different from 0.02 pH units, has excellent resolution and is very useful for
detecting abnormal hemoglobin in the newborn. In fact, it allows a good separation
of hemoglobins F, A, and S. Moreover, the electrical isofocusing is perfectly adapted
to the analysis of large series. On the other hand, the main limitations of this
method are a long and complex implementation. Therefore, its use is almost
reserved for neonatal screening of hemoglobinopathies [28, 29].
4.1.3 Liquid vein electrophoresis
4.1.3.1 Characteristics
Typically, capillary electrophoresis is performed in a fused silica capillary coated
with a polyamide layer of 20–200 μm of internal diameter and 20–200 cm of length.
The capillary, placed in a thermostatization system, is filled with a buffer solution
and plunges into two tanks containing the same solution. Each tank is connected to
an electrode connected to a current generator. A large potential difference (several
thousand volts) is applied to the terminals of each capillary to separate the
molecules on the basis of their charge/mass ratio [30].
The use of a capillary has a double advantage: increases the sensitivity of the
detection since a reading window in the capillary allows an absorbance reading with
a very small optical path and increases the resolution by applying the potential
difference of more than 10,000 V since it is easy to regulate the capillary in
temperature [31].
4.1.3.2 Support
In this method, the buffer solution in contact with the two tanks of the system
constitutes the support. Since liquid has no specific form, the buffer uses the capillary
as a solid support, contributing also to electroendosmosis current production.
4.1.3.3 Liquid vein electrophoresis methods
There are several methods used in capillary electrophoresis including capillary
zone electrophoresis (CZE), capillary gel electrophoresis (CGE), and micellar elec-
trokinetic chromatography (MECC) [32]. In this study, we will limit ourselves to
capillary zone electrophoresis which is the most exploited for hemoglobinopathy.
This method can be performed on a single-fused silica capillary in which an
electroosmotic flux develops. It causes the negative molecules to the cathode where
the detection is carried out, the injection being anodic.
The electroosmotic flux depends on the temperature, the ionic force, and the
concentration of organic solvent.
4.2 Facilities
We will limit ourselves here to the most common routine techniques for the
analysis of hemoglobinopathies in the Democratic Republic of the Congo in
particular and in sub-Saharan Africa in general. They are often affected by accessi-
bility during acquisition, ease of commissioning, operation, maintenance and
supply, and cost.
On one side, our analysis is based globally on equipment meeting international
standards such as ISO, FDA, and CE certification. Field experience shows that such
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equipment can operate for about 7 years, if the manufacturer’s operating recom-
mendations are followed.
On the other hand, high-performance liquid chromatography has been developed
to allow both the detection and confirmation of hemoglobinopathy in newborns with
high sensitivity and specificity. In fact, its good sensitivity to the major variants
involved in pathology and its speed of completion (about 3 min per sample), allowing
the analysis of a large number of samples, have made HPLC a particularly suitable
method for screening for hemoglobin abnormalities [33].
However, we will not discuss this technique in this study because, since its
performance is comparable to that of the HPLC method, capillary electrophoresis
quickly became the method of choice, just like HPLC, for the study of hemoglobin-
opathy. In addition, it is of economic interest: although the material cost is compa-
rable to that of the HPLC, the expenditures on reagents are much lower. Indeed, the
price of a capillary is much lower than that of a chromatography column, and the
volumes of buffer used are much lower, about 1000 times less [34].
4.2.1 Manual systems
4.2.1.1 Offer
Manual systems for native electrophoresis (on cellulose acetate and agarose gel)
or isoelectrofocusing offer the best acquisition possibility both in terms of cost and
operational constraints. Their limits both in the separation and in the identification
of hemoglobin variants will be used for the routine forms to be specified by the
customer (identification of the electrophoretic profile, identification of specific
variants).
The coupling of these methods to the reading system (densitometers) makes it
possible to quantify the separate variants. And from this point of view, agarose gel
electrophoresis offers better performance than cellulose acetate. On the other hand,
the reagents are in the form of combs which often require a minimum of seven
samples. Such a constraint requires, for economic reasons, to launch the samples in
series of seven, which requires a consequent sizing and proper holding wire.
4.2.1.2 Facilities
For native electrophoresis the system is usually composed of a current generator
and a migration tank. For isoelectrofocusing, the system consists of a stabilized
supply, an isoelectrofocusing, unit, and a circulating cryostat.
The devices typically contain conventional electronic parts and boards, used in
the manufacture of power generators. These components are often not complex,
and do not require advanced technical repair. In addition, it has been found that
when equipment actually meets ISO, FDA, or CE marking standards, it works well
and lasts for a long time.
4.2.1.3 Use
These systems can be used in very small laboratories, without large volume flow
of samples, for the screening of hemoglobinopathies, by planning a periodic opera-
tion. Indeed, the pre-analytical phase requires a lot of sample preparation time and
immobilizes the staff for quite a long time. They can also be used in medium
laboratories as a backup system.
The isoelectrofocusing system will be more targeted for newborn screening
because it allows for a good separation of the Hb F, Hb A, and Hb S fractions, which
assumes that the system is usually installed near a maternity ward.
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4.2.2 Semiautomatic systems
4.2.2.1 Offer
Semiautomatic systems for native electrophoresis on cellulose acetate or agarose
gel offer the possibility of processing large series of samples. Although the cost of
the system is still high for a large number of health facilities, the manual routine is
clearly improved. Semiautomatic systems (on cellulose acetate or agarose gel) are
embedded on compact systems generally comprising a migration and coloring
modules, which considerably reduce user handling.
The reading system, often equipped with advanced post-processing software, can
be incorporated or remote. Nevertheless, the results obtained show the same limits as
in the case of manual methods because the operating principles of the migration and
coloring units taken separately are the same as those of the manual system.
4.2.2.2 Facilities
The semiautomatic system is generally composed of a compact unit comprising a
thermoregulated migration module connected to a current generator and a fluidic
module for coloring migrated gels. Technologically, an intelligent electronic unit
manages the high voltage of the migration module, the fluidics of the coloring
module, and the application programs for the two modules.
Generally, devices typically contain conventional electronic parts and boards.
The process control is often ensured by position and temperature sensors. As their
complexity is not great, maintenance can be easily carried out by a duly trained
biomedical technician.
4.2.2.3 Use
These systems can equip medium-sized laboratories by planning either periodic
operation or continuous operation, depending on the flow of samples. They are
fairly widespread in the private laboratories which can obtain them and some public
hospital laboratories often on behalf of specific programs. User maintenance mon-
itoring must be ensured to guarantee proper functioning, and periodic annual




Automatic techniques (only capillary zone electrophoresis) are the best offer,
both in terms of flexibility of use and technical performance. Prices are still very
high for many customers in Africa. Nevertheless, a good expression of needs and
an adequate exploitation planning can allow a return on investment in an acceptable
time.
4.2.3.2 Facilities
These techniques are carried out on compact systems, generally comprising
capillaries at the ends plunging into reservoirs of buffer solution, themselves
connected to the current generator. The apparatus also includes a detection system,
most often a UV–visible spectrophotometer, linked to the wavelength of specific
absorption of hemoglobin at 415 nm.
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equipment can operate for about 7 years, if the manufacturer’s operating recom-
mendations are followed.
On the other hand, high-performance liquid chromatography has been developed
to allow both the detection and confirmation of hemoglobinopathy in newborns with
high sensitivity and specificity. In fact, its good sensitivity to the major variants
involved in pathology and its speed of completion (about 3 min per sample), allowing
the analysis of a large number of samples, have made HPLC a particularly suitable
method for screening for hemoglobin abnormalities [33].
However, we will not discuss this technique in this study because, since its
performance is comparable to that of the HPLC method, capillary electrophoresis
quickly became the method of choice, just like HPLC, for the study of hemoglobin-
opathy. In addition, it is of economic interest: although the material cost is compa-
rable to that of the HPLC, the expenditures on reagents are much lower. Indeed, the
price of a capillary is much lower than that of a chromatography column, and the
volumes of buffer used are much lower, about 1000 times less [34].
4.2.1 Manual systems
4.2.1.1 Offer
Manual systems for native electrophoresis (on cellulose acetate and agarose gel)
or isoelectrofocusing offer the best acquisition possibility both in terms of cost and
operational constraints. Their limits both in the separation and in the identification
of hemoglobin variants will be used for the routine forms to be specified by the
customer (identification of the electrophoretic profile, identification of specific
variants).
The coupling of these methods to the reading system (densitometers) makes it
possible to quantify the separate variants. And from this point of view, agarose gel
electrophoresis offers better performance than cellulose acetate. On the other hand,
the reagents are in the form of combs which often require a minimum of seven
samples. Such a constraint requires, for economic reasons, to launch the samples in
series of seven, which requires a consequent sizing and proper holding wire.
4.2.1.2 Facilities
For native electrophoresis the system is usually composed of a current generator
and a migration tank. For isoelectrofocusing, the system consists of a stabilized
supply, an isoelectrofocusing, unit, and a circulating cryostat.
The devices typically contain conventional electronic parts and boards, used in
the manufacture of power generators. These components are often not complex,
and do not require advanced technical repair. In addition, it has been found that
when equipment actually meets ISO, FDA, or CE marking standards, it works well
and lasts for a long time.
4.2.1.3 Use
These systems can be used in very small laboratories, without large volume flow
of samples, for the screening of hemoglobinopathies, by planning a periodic opera-
tion. Indeed, the pre-analytical phase requires a lot of sample preparation time and
immobilizes the staff for quite a long time. They can also be used in medium
laboratories as a backup system.
The isoelectrofocusing system will be more targeted for newborn screening
because it allows for a good separation of the Hb F, Hb A, and Hb S fractions, which
assumes that the system is usually installed near a maternity ward.
188
Human Blood Group Systems and Haemoglobinopathies
4.2.2 Semiautomatic systems
4.2.2.1 Offer
Semiautomatic systems for native electrophoresis on cellulose acetate or agarose
gel offer the possibility of processing large series of samples. Although the cost of
the system is still high for a large number of health facilities, the manual routine is
clearly improved. Semiautomatic systems (on cellulose acetate or agarose gel) are
embedded on compact systems generally comprising a migration and coloring
modules, which considerably reduce user handling.
The reading system, often equipped with advanced post-processing software, can
be incorporated or remote. Nevertheless, the results obtained show the same limits as
in the case of manual methods because the operating principles of the migration and
coloring units taken separately are the same as those of the manual system.
4.2.2.2 Facilities
The semiautomatic system is generally composed of a compact unit comprising a
thermoregulated migration module connected to a current generator and a fluidic
module for coloring migrated gels. Technologically, an intelligent electronic unit
manages the high voltage of the migration module, the fluidics of the coloring
module, and the application programs for the two modules.
Generally, devices typically contain conventional electronic parts and boards.
The process control is often ensured by position and temperature sensors. As their
complexity is not great, maintenance can be easily carried out by a duly trained
biomedical technician.
4.2.2.3 Use
These systems can equip medium-sized laboratories by planning either periodic
operation or continuous operation, depending on the flow of samples. They are
fairly widespread in the private laboratories which can obtain them and some public
hospital laboratories often on behalf of specific programs. User maintenance mon-
itoring must be ensured to guarantee proper functioning, and periodic annual




Automatic techniques (only capillary zone electrophoresis) are the best offer,
both in terms of flexibility of use and technical performance. Prices are still very
high for many customers in Africa. Nevertheless, a good expression of needs and
an adequate exploitation planning can allow a return on investment in an acceptable
time.
4.2.3.2 Facilities
These techniques are carried out on compact systems, generally comprising
capillaries at the ends plunging into reservoirs of buffer solution, themselves
connected to the current generator. The apparatus also includes a detection system,
most often a UV–visible spectrophotometer, linked to the wavelength of specific
absorption of hemoglobin at 415 nm.
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More sophisticated technology includes a capillary thermoregulation system, a
control system comprising various sensors that manage optics, robotics, pneu-
matics, and detection, and a set of intelligent electronic cards capable of communi-
cating with each other. Unlike previous methods, this method allows both to launch
samples in an emergency without restriction and to process large series of samples.
In view of the complexity of its technology, management requires competent
personnel who are regularly trained by the manufacturer. Water quality and user
maintenance of equipment are of paramount importance to ensure the quality of
results. This assumes that the supplier provides user training for the best care.
4.2.3.3 Use
Thanks to their flexibility in the work organization, these automated systems can
equip laboratories with small volumes of samples, as well as those which process large
volumes. Indeed, there are small and large models of automata to cover all these
needs. Because of their high prices, these automata are acquired in public hospitals on
the basis of research projects and specific programs. Private clinics acquire them for
routine because of their performance. However they do have a few requirements that
must be observed: the operating environment must be less dusty, the quality of
electricity flawless, the quality of pure water, and regular maintenance.
We present in Table 1 a summary of different devices that we have reviewed.
5. Discussion on the choice to be made for equipment acquisition
For better use of data in Table 1, it will be broken down below with two sub-
sidiaries: Tables 2 and 3.
The information contained in Table 2 will highlight the performance of the
equipment according to different migration or embedded media available, while
those in Table 3 will compare the systems sold compared to hardware, installation
constraints, execution time, and cost.
A cursory reading shows that the most efficient migration support remains one of
the capillary methods (liquid vein): this support brings in itself the best return for the
resolution, reproducibility, discrimination, and quantification, while the parasitic
effects are almost nonexistent. But medical needs and health goals differ from one
level to another and do not require in all cases the acquisition of such technology.
For routine screening for sickle cell disease, for example, the performance of
migration on cellulose acetate amply suffices needs. This assumes that the precise
separation variants like Hb A2, Hb C, Hb E, and Hb O are not a need first. On the
other hand, as part of the requirements to cover, the effective separation of Hb S and
Hb C variant is needed, and migration on agarose gel will best meet this requirement.
If, during treatment, abnormal forms of hemoglobin are associated, then the
choice of medium will be directed towards agarose gel for a qualitative indication or
the liquid vein for a quantitative indication of Hb A2. Indeed, abnormally low Hb A
and abnormally high Hb A2 correlate with the presence of some abnormal forms of
hemoglobin (alpha or beta thalassemia, etc.).
If precise separation and precise quantification of the variants HbA2, Hb C, Hb E,
andHbOare required, then the liquid vein (capillary) support should be readily chosen.
Depending on work previously defined criteria, this table can guide the choice of
performance basis based migration media.
But the only performance criteria are not sufficient to make a choice of appro-
priate materials. It will also take into account industrial supply in terms of existing
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systems, the materials that make up, their costs, and maintenance requirements.
Below we provide a table that can guide us in assessing the choices to be made.
The line “migration support” is added in order to link Tables 2 and 3.
The analysis of the table shows that as the system moves from manual to fully
automated, the necessary hardware is gradually being integrated into a compact
module. From this point of view, this development provides an appreciable response
to the ergonomic problems that are becoming very frequent in laboratories.
On the other hand, we observe that the installation constraints are more
demanding when the analysis module becomes more compact. Indeed, in addition
to the quality of the electrical ground line and voltage which greatly affect the
operation of systems provided, the environment requires better temperature con-








Nonnative electrophoresis ✓ ✓
Native electrophoresis ✓ ✓ ✓ ✓
Separation of amino acids and peptides ✓ ✓ ✓ ✓
Homogeneity ✓
(poor)
✓ (medium) ✓ (good) ✓
Separation of plasma and urine proteins, lipoproteins,
hemoglobin, and isoenzymes
— ✓ ✓ ✓
Resolution ✓
(bad)
✓ (poor) ✓ ✓
Separation of Hb A2 from Hb C, Hb E, and Hb O — x (migrate in
the same area)
✓ ✓
Separation of Hb C from Hb E and Hb O — x ✓ ✓
Separation of Hb S and Hb from Hb D and G — x (migrate at
the same rate)
✓ ✓
Separation of Hb S and Hb O — x x ✓
Separation of Hb D and Hb G — x x ✓
Rapidity Low Good Good Fast
Quantification of hemoglobin with low concentration
(Hb A2)
— x x ✓
Detection of fast-migrating variants (Hb H, Hb Bart’s) — x x ✓
Precise quantification of hemoglobin fractions — x x ✓




Joule effect ✓ — — —
Pest adsorption ✓ x x x
Reproducibility — ✓ (medium) ✓ ✓
Water quality Normal Normal Normal High
Demanding environment Normal Normal Normal High
Table 2.
Performance comparison based on migration support.
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The time required to perform the analyses is a very important parameter in the
choice of equipment. On the one hand, it allows better management of the patient
queue, and on the other hand, it ensures the management of reagents and consum-
ables with a limited life. When the volume of samples to be treated in a routine
manner is small, manual systems are suitable for both patient satisfaction and
reactive management. If the volume of samples to be processed requires more than
1 day of work, the semiautomated system should be considered to resolve the
queue. Finally, if the volume of samples increases further, the fully automated
system will better meet expectations.
The management of reagents in the laboratory depends heavily on two impor-
tant parameters that should be noted: this is the expiry date and the stability time
after opening of the reagent. The expiry date indicated on the label is usually the
date after which the manufacturer no longer guarantees the validity of the results,
while the stability time after opening of the reagent indicates the period after which
the manufacturer no longer guarantees its reliability after the first use.
Since the stability time is shorter than the expiry date itself, it will be necessary
to ensure that each open reagent is consumed before that time. For example, the use
of a reagent that has a stability time of 60 days and can analyze 1000 samples in a
laboratory that receives only 10 samples per day is a waste. The use of this reagent
before maturity requires an average daily rate of 20 samples, considering that the
laboratory operates 6 days a week. Ten samples/day instead of 20 samples/day will
theoretically cause the damage of half the reagent.
The level of maintenance, and in turn cost, follows the same trend: more com-
pact system is provided and the higher level of maintenance.
Since the cost of acquiring systems increases with the complexity of the tech-
nology, it is important to ask good questions, find good answers, and make good
choices based on real needs, to achieve savings. As an example, is it necessary to
acquire a semiautomatic agarose gel system when, taking into account the medical
needs and the volume of samples to be treated, the manual system on agarose




































Maintenance level Bas Moyen Haut
Table 3.
Comparison of systems in terms of hardware, installation constraints, acquisition cost, and maintenance level.
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non-justified expenditure of 8000€. Worse still, such equipment oversizing com-
promises a substantial depreciation because it will be under-utilized.
6. Conclusion
The management of any pathology implies the appropriate choice of techniques
and technologies. Indeed, beyond the medical needs that are priority, a control
equipment acquisition cost is one of the major parameters providing effective
support to strategies put in place.
Very often in sub-Saharan countries, the aspect of the consequent acquisition of
the necessary technology is not always thorough, and this can lead a poor quality of
reported results, the inaccessible test cost for the poorest people, and the delicate
operation of projects being implemented.
The choice of equipment performed after an objective needs analysis enables to
optimize the process of acquiring, to ensure the quality of reported results, and to
provide more accessible costs to target populations generally poor.
According to WHO recommendations, technology assessment, device evalua-
tion, needs planning, selection and acquisition, installation, commissioning, and
finally monitoring should be part of a successful acquisition procedure [35].
Such an approach should involve all stakeholders, namely, doctors, managers,
biomedical engineers, and users.
In the case of sickle cell anemia, the inventory of installed park shows that
beside manual methods, diagnostic techniques most common in the Democratic
Republic of the Congo and even in sub-Saharan Africa are phenotypic techniques.
These include the electrophoresis at different pH, the isoelectrofocusing, the capillary
electrophoresis, and the high-pressure liquid chromatography. The first three mentioned
are most used for their reliability, flexibility, ease of installation, and maintenance.
The prices of the equipment listed in the table remain indicative. We have taken
into account only good-quality equipment commonly used in the DR Congo and by
extension in other countries of sub-Saharan Africa.
For low-income countries, the costs of such facilities are still high overall. Indeed,
the increase in health expenditure, which represents 10% of the world’s gross
domestic product (GDP), is faster than the growth of the world economy. According
to a new World Health Organization report on global health spending, it is increas-
ing rapidly, particularly in low- and middle-income countries, where spending is
increasing at an average of 6% per year, compared to 4% in high-income countries.
Health expenditure is assumed by governments, by individuals who pay for their
own care (out-of-pocket payments), and by other entities such as voluntary health
insurance schemes, employer-sponsored schemes, and nongovernmental organiza-
tions. On average, 51% of a country’s health expenditure is assumed by general
government and more than 35% by individuals in the form of direct expenditure.
One of the consequences of this situation is that every year 100 million people are
plunged into extreme poverty [36].
For the countries concerned, the acquisition of these health technologies
requires new upstream procurement strategies to meet acquisition and operating
costs. And from this point of view, some developed countries such as France are
now developing group procurement procedures in public hospitals.
According to a recent study conducted in the Democratic Republic of the Congo
on an investment in capillary electrophoresis equipment for a project on sickle cell
disease, this can contribute to improve quality and low cost of tests, if a complete
analysis of needs is carried out upstream.
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In this study, for an equipment activity extending over a period of 7 years, the
cost of acquisition and maintenance cost represent, respectively, 11.4% and 5.0% of
the total life cycle cost.
But when the activity of the same equipment is done over a period of 2 years, the
cost of acquisition and maintenance cost represent, respectively, 31.0% and 3.9% of
the total life cycle cost.
Added to this, for the same annual rate, the minimum unit test cost is € 3.9
for a 7-year activity cycle, whereas it costs € 5 if the activity cycle is reduced to
2 years [37].
Therefore, it should be noted that when operating conditions remain the same,
amortization of equipment carried on shorter lead times significantly increases the
cost of the test at the expense of patients.
Even though this example only concerns electrophoresis capillary equipment,
extrapolating conclusions on agarose gel equipment is possible for the following
reasons: installation, operation, and maintenance are less demanding than for cap-
illary technology.
While sub-Saharan Africa is the most affected region in the world for sickle cell
disease, research and care are relatively slow.
At its 60th session held in Malabo from 30 August to 3 September 2010, the
WHO was already raising the option of a strategy for its African region. Nine years
after the effects are hardly noticeable.
The management improvement of this pathology solicits several challenges,
including the one concerning the technical platform necessary for diagnosis. The
costs of acquiring and operating equipment often require significant fundraising,
which is often lacking. The missing financial means are often one of the first
obstacles to the launching of the relevant programs.
The study mentioned above proves that it is possible to optimize the available
resources, however modest they may be, in order to obtain good and lasting results.
In the case of biomedical equipment, it is sufficient to involve the right people to
achieve the expected results. Policymakers in sub-Saharan African countries must
therefore integrate the skills of biomedical engineers into the design and start-up of
medical projects so that they, in turn, contribute effectively to improve the quality
of medical care populations.
196
Human Blood Group Systems and Haemoglobinopathies
Author details
Vincent Mulunda-a-Mulunda1*, Pierre Kouam2 and Taty Oke Ingwen3
1 Institut Supérieur de Techniques Appliquées (ISTA), Kinshasa,
Democratic Republic of Congo
2 Groupe Hospitalier Nord Essonne, Lonjumeau, France
3 Wagenia Sarl, Kinshasa, Democratic Republic of Congo
*Address all correspondence to: vp_amulunda@yahoo.fr
© 2020TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
197
Contribution of Biomedical Equipment Management to Better Management of Sickle Cell Disease…
DOI: http://dx.doi.org/10.5772/intechopen.92546
In this study, for an equipment activity extending over a period of 7 years, the
cost of acquisition and maintenance cost represent, respectively, 11.4% and 5.0% of
the total life cycle cost.
But when the activity of the same equipment is done over a period of 2 years, the
cost of acquisition and maintenance cost represent, respectively, 31.0% and 3.9% of
the total life cycle cost.
Added to this, for the same annual rate, the minimum unit test cost is € 3.9
for a 7-year activity cycle, whereas it costs € 5 if the activity cycle is reduced to
2 years [37].
Therefore, it should be noted that when operating conditions remain the same,
amortization of equipment carried on shorter lead times significantly increases the
cost of the test at the expense of patients.
Even though this example only concerns electrophoresis capillary equipment,
extrapolating conclusions on agarose gel equipment is possible for the following
reasons: installation, operation, and maintenance are less demanding than for cap-
illary technology.
While sub-Saharan Africa is the most affected region in the world for sickle cell
disease, research and care are relatively slow.
At its 60th session held in Malabo from 30 August to 3 September 2010, the
WHO was already raising the option of a strategy for its African region. Nine years
after the effects are hardly noticeable.
The management improvement of this pathology solicits several challenges,
including the one concerning the technical platform necessary for diagnosis. The
costs of acquiring and operating equipment often require significant fundraising,
which is often lacking. The missing financial means are often one of the first
obstacles to the launching of the relevant programs.
The study mentioned above proves that it is possible to optimize the available
resources, however modest they may be, in order to obtain good and lasting results.
In the case of biomedical equipment, it is sufficient to involve the right people to
achieve the expected results. Policymakers in sub-Saharan African countries must
therefore integrate the skills of biomedical engineers into the design and start-up of
medical projects so that they, in turn, contribute effectively to improve the quality
of medical care populations.
196
Human Blood Group Systems and Haemoglobinopathies
Author details
Vincent Mulunda-a-Mulunda1*, Pierre Kouam2 and Taty Oke Ingwen3
1 Institut Supérieur de Techniques Appliquées (ISTA), Kinshasa,
Democratic Republic of Congo
2 Groupe Hospitalier Nord Essonne, Lonjumeau, France
3 Wagenia Sarl, Kinshasa, Democratic Republic of Congo
*Address all correspondence to: vp_amulunda@yahoo.fr
© 2020TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
197
Contribution of Biomedical Equipment Management to Better Management of Sickle Cell Disease…
DOI: http://dx.doi.org/10.5772/intechopen.92546
References
[1] Tshilolo L, Aïssi LM. Guide pratique
de diagnostic précoce et de prise en
charge de la drépanocytose en RD
Congo. CEFA; 2009. p. 7
[2] Available from: http://apps.who.
int/gb/archive/pdf_files/WHA59/A59_
9-fr.pdf











[5] Stasse S et al. Improving financial
access to health care in the Kisantu
district in the Democratic Republic of
Congo: Acting upon complexity. DOI:
10.3402/gha.v8.25480









[8] Available from: https://www.fonda
tionpierrefabre.org/fr/programmes-en-
cours/lutte-contre-la-drepanocytose/
[9] Medical Devices Donation:
Consideration for Solicitation and
Provision. Geneva: WHO; 2011. p. 10
[10] Mulunda-a-Mulunda V, Kouam P.
Réflexion sur le plateau technique
médical en République Démocratique du
Congo. Irbm News. 2019;40(4):162-174




[12] Human Resources for Medical
Devices, The Role of Biomedical
Engineers. Geneva: World Health




[13] Broun G. Biomedical engineers in
public hospitals: Observations and
hypotheses. ITBM-RBM News. 2006;
27(4):384
[14] Decouvelaere M. Hospital
procurement organization:
Opportunities and perspectives for
biomedical and hospital engineering.
IRBM News. 2013;34(5–6):114
[15] Available from: http://ageps.aphp.fr
[16] Giordano PC. Carrier Screening and
Prevention of Hemoglobinopathies by
Capillary Electrophoresis. Lisses: Sebia
Laboratories; 2007. p. 7
[17] Available from: http://www.apipd.
fr/wp-content/uploads/2015/05/
historique-drepanocytose-new-logo.pdf
[18] Chen FA, Liu C-M, Hsieh Y-Z,
Sternberg JC. Capillary electrophoresis,
a new clinical tool. Clinical Chemistry.
1991;37(1):14-19
[19] Keren DF. Comparison of sebia
capillarys capillary electrophoresis with
the primus high-pressure liquid
chromatography in the evaluation of
hemoglobinopathies. American
Journal of Clinical Pathology. 2008;130:
824-883
[20] Vesseron S et al. Euromedlab: Etat
de l’art en biologie médicale. IRBM
News. 2019:5
198
Human Blood Group Systems and Haemoglobinopathies
[21] Li Y-Q, Huang H-P, Chen Z-Z,
Zhao L, Liang L, Qin G-F, et al.
Comparison of capillary electrophoresis
and high performance liquid
chromatography for detection and
quantification of hemoglobin. Clinical
Chemistry and Laboratory Medicine.
2016;54(1):91-95
[22] HainqueB et al. Appareils etméthodes
enBiochimie etBiologieMoléculaire. Paris:
Flammarion; 2008. p. 274
[23] Hainque B et al. Appareils et
méthodes en Biochimie et Biologie
Moléculaire. Paris: Flammarion; 2008.
p. 276
[24] Hainque B et al. Appareils et
méthodes en Biochimie et Biologie
Moléculaire. Paris: Flammarion; 2008.
pp. 276-277
[25] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. p. 22
[26] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. pp. 22-23
[27] Hainque B et al. Appareils et
méthodes en Biochimie et Biologie
Moléculaire. Paris: Flammarion; 2008.
p. 277
[28] Tshilolo L, Aïssi LM. Guide pratique
de diagnostic précoce et de prise en
charge de la drépanocytose en RD
Congo. Pafoved; 2014. p. 24
[29] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. p. 24
[30] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. p. 32
[31] Hainque B et al. Appareils et
méthodes en Biochimie et Biologie
Moléculaire. Paris: Flammarion; 2008.
p. 285
[32] Hainque B et al. Appareils et
méthodes en Biochimie et Biologie
Moléculaire. Paris: Flammarion; 2008.
p. 286
[33] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. p. 25
[34] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. p. 34
[35] WHO Library. Procurement
Process: A Practical Guide. Geneva;
2012. p. 7
[36] WHO. Press Release. 20






[37] Mulunda-a-Mulunda V et al.
Pérennisation des investissements en
équipements biomédicaux dans les
projets scientifiques. IRBM News. 2018;
39(4–5):80-89
199
Contribution of Biomedical Equipment Management to Better Management of Sickle Cell Disease…
DOI: http://dx.doi.org/10.5772/intechopen.92546
References
[1] Tshilolo L, Aïssi LM. Guide pratique
de diagnostic précoce et de prise en
charge de la drépanocytose en RD
Congo. CEFA; 2009. p. 7
[2] Available from: http://apps.who.
int/gb/archive/pdf_files/WHA59/A59_
9-fr.pdf











[5] Stasse S et al. Improving financial
access to health care in the Kisantu
district in the Democratic Republic of
Congo: Acting upon complexity. DOI:
10.3402/gha.v8.25480









[8] Available from: https://www.fonda
tionpierrefabre.org/fr/programmes-en-
cours/lutte-contre-la-drepanocytose/
[9] Medical Devices Donation:
Consideration for Solicitation and
Provision. Geneva: WHO; 2011. p. 10
[10] Mulunda-a-Mulunda V, Kouam P.
Réflexion sur le plateau technique
médical en République Démocratique du
Congo. Irbm News. 2019;40(4):162-174




[12] Human Resources for Medical
Devices, The Role of Biomedical
Engineers. Geneva: World Health




[13] Broun G. Biomedical engineers in
public hospitals: Observations and
hypotheses. ITBM-RBM News. 2006;
27(4):384
[14] Decouvelaere M. Hospital
procurement organization:
Opportunities and perspectives for
biomedical and hospital engineering.
IRBM News. 2013;34(5–6):114
[15] Available from: http://ageps.aphp.fr
[16] Giordano PC. Carrier Screening and
Prevention of Hemoglobinopathies by
Capillary Electrophoresis. Lisses: Sebia
Laboratories; 2007. p. 7
[17] Available from: http://www.apipd.
fr/wp-content/uploads/2015/05/
historique-drepanocytose-new-logo.pdf
[18] Chen FA, Liu C-M, Hsieh Y-Z,
Sternberg JC. Capillary electrophoresis,
a new clinical tool. Clinical Chemistry.
1991;37(1):14-19
[19] Keren DF. Comparison of sebia
capillarys capillary electrophoresis with
the primus high-pressure liquid
chromatography in the evaluation of
hemoglobinopathies. American
Journal of Clinical Pathology. 2008;130:
824-883
[20] Vesseron S et al. Euromedlab: Etat
de l’art en biologie médicale. IRBM
News. 2019:5
198
Human Blood Group Systems and Haemoglobinopathies
[21] Li Y-Q, Huang H-P, Chen Z-Z,
Zhao L, Liang L, Qin G-F, et al.
Comparison of capillary electrophoresis
and high performance liquid
chromatography for detection and
quantification of hemoglobin. Clinical
Chemistry and Laboratory Medicine.
2016;54(1):91-95
[22] HainqueB et al. Appareils etméthodes
enBiochimie etBiologieMoléculaire. Paris:
Flammarion; 2008. p. 274
[23] Hainque B et al. Appareils et
méthodes en Biochimie et Biologie
Moléculaire. Paris: Flammarion; 2008.
p. 276
[24] Hainque B et al. Appareils et
méthodes en Biochimie et Biologie
Moléculaire. Paris: Flammarion; 2008.
pp. 276-277
[25] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. p. 22
[26] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. pp. 22-23
[27] Hainque B et al. Appareils et
méthodes en Biochimie et Biologie
Moléculaire. Paris: Flammarion; 2008.
p. 277
[28] Tshilolo L, Aïssi LM. Guide pratique
de diagnostic précoce et de prise en
charge de la drépanocytose en RD
Congo. Pafoved; 2014. p. 24
[29] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. p. 24
[30] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. p. 32
[31] Hainque B et al. Appareils et
méthodes en Biochimie et Biologie
Moléculaire. Paris: Flammarion; 2008.
p. 285
[32] Hainque B et al. Appareils et
méthodes en Biochimie et Biologie
Moléculaire. Paris: Flammarion; 2008.
p. 286
[33] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. p. 25
[34] Guerard V. Mise en place de
l’électrophorèse capillaire MINICAP®
(Sebia) pour le diagnostic des
hémoglobinopathies au CHU de Nancy.
In: Sciences Pharmaceutiques. 2014;
ffhal-01733413ff. p. 34
[35] WHO Library. Procurement
Process: A Practical Guide. Geneva;
2012. p. 7
[36] WHO. Press Release. 20






[37] Mulunda-a-Mulunda V et al.
Pérennisation des investissements en
équipements biomédicaux dans les
projets scientifiques. IRBM News. 2018;
39(4–5):80-89
199




Accuracy of Blood Group 
Typing in the Management and 
Prevention of Alloimmunization
Emilia Sippert, Evgeniya Volkova and Maria Rios
Abstract
Blood transfusion is an effective therapeutic approach for several hematological  
conditions including sickle cell disease (SCD), thalassaemia, myelodysplastic 
syndrome (MDS), and autoimmune hemolytic anemia. It is also often indicated for 
transplantation and for patients receiving medical treatments for cancer. However, 
transfusion treatment can lead to the red blood cell (RBC) alloimmunization 
when an incompatible antigen is inadvertently present in the transfused blood. 
Alloantibodies can cause RBC destruction and many other complications defeating 
the purpose of the treatment. The risk of development of multiple alloantibodies 
increases with the frequency of transfusions in transfusion-dependent patients and 
can be mitigated by transfusing blood type negative for multiple antigens to prevent 
hemolysis. This chapter discusses the transfusion’s risk of RBC alloimmunization as 
an adverse event; consequences of alloimmunization in patients’ care; approaches to 
prevent and/or mitigate alloimmunization and enhance transfusion efficacy; appli-
cation of RBC genotyping to supplement serology for preventing alloimmunization. 
The currently available techniques for RBC genotyping and the importance of 
reference reagents for determining the genotyping accuracy will also be discussed.
Keywords: blood transfusion, RBC alloimmunization, blood groups,  
blood group genotyping, reference materials
1. Introduction
Blood transfusion saves lives in trauma situations and serves as a unique thera-
peutic treatment of various hematologic disorders where patients require lifelong 
regular transfusions to survive. However, in contrast to therapeutic drugs, blood 
cannot be manufactured and tested for quality control of purity, potency, and 
efficacy. Instead, each donation is a unique batch, most often single use, for which 
all characterization and quality assessment need to be performed individually even 
if several units are used in a single treatment. Since blood is a biological product, 
safety assessment must be done at multiple levels, including donor screening, blood 
collection, testing for infectious agents, blood cell typing and labeling. Checkpoints 
and quality control are also required at the time of transfusion to avoid human 
error and to guarantee that the right blood goes to the right person. Each step has its 
own characteristics and challenges. Screening involves the review of donor history 
that allows assessment for safety; requirements that need to be followed for blood 
collection to assure proper timing, storage, and processing so that the quality of the 
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product is not compromised; testing for infectious agents ensures a second layer of 
screening for pathogens that could be transmitted to the patient with an infected 
blood unit; testing for blood cell typing helps to avoid improper usage of the 
product since non-compatible blood can produce serious consequences and even 
fatalities; lastly, the transfusion process itself requires strict checkpoints to prevent 
the use of an incompatible unit in a given patient.
The scope of this chapter focuses on blood group typing  and approaches to 
achieve better management and prevention of alloimmunization. We will provide 
an overview on the following topics: blood transfusion and risk of RBC alloim-
munization; approaches for prevention of alloimmunization and improvement of 
transfusion therapy; serology and molecular typing methods and their use for RBC 
matching; current technologies for RBC genotyping; and standards for red cell 
antigens typing including scope, importance, and description of reference reagents 
available for use.
2. Blood transfusion and risk of RBC alloimmunization
RBC transfusion is used for therapeutic treatment of various hematologic disor-
ders including SCD, thalassaemia, MDS, autoimmune hemolytic anemia, and others. 
Management of patients may require lifelong regular transfusions for treatment of 
symptomatic anemia and prevention of disease complications. Although transfusion 
safety and donor-patient matching have improved over the years, RBC alloimmuni-
zation, transmission of infections, and iron overload are still a concern [1].
RBC alloimmunization is a serious adverse event of transfusions and can cause 
further clinical problems in the patients including worsening of anemia, develop-
ment of autoantibodies, acute or delayed hemolytic transfusion reactions (DHTR), 
bystander hemolysis, organ failure, and cause serious complications during preg-
nancies. Frequent transfusions can lead to the production of multiple alloantibod-
ies, which is often associated with autoantibodies requiring extensive serological 
workups and additional transfusions for proper treatment, increasing time and 
resources to find compatible RBC units [2].
Antibodies against ABO blood group antigens are naturally produced, IgM class, 
and are capable of rapid induction of intravascular destruction of RBCs by comple-
ment-mediated mechanism. Clinical outcome of a patient transfused with incom-
patible ABO blood can vary from no adverse effects to permanent organ damage 
and death depending on the volume of ABO-incompatible RBC transfused. As for 
non-ABO blood groups, clinically significant antibodies against non-ABO antigens 
are from IgG class and rarely activate complement. Instead, they cause DHTR or 
hemolytic disease of fetus and newborn (HDFN) by extravascular destruction of 
RBCs marked with IgG [3]. DHTR has been ranked as second or third most com-
monly reported cause of fatal transfusion reactions secondary to non-ABO antibod-
ies in many countries including the United States [4–8]. However, experts believe 
that DHTR has been under-recognized or under-reported to biovigilance agencies 
and FDA, possibly because the reactions can be obscured by underlying disease 
(liver disease, massive trauma, and SCD), lack of knowledge among clinicians 
regarding the reactions, or lack of knowledge regarding the mechanism of  
reporting [7].
Reported RBC alloimmunization rates have considerable variations depending 
on the population and disease studied [9]. The rates are estimated between 1 and 
3% in patients that receive episodic transfusions, while for patients who receive 
chronic blood transfusions like patients with SCD and MDS, rates vary between 8 
and 76% [9–12]. Although the most commonly observed alloantibodies of clinical 
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relevance are against antigens belonging to RH (D, C, c, E, e), KEL (K, k, Jsa, Kpa), 
JK (Jka, Jkb), FY (Fya, Fyb), and MNS (M, S, s) blood group systems [9], alloanti-
bodies against Rh variants [13–15] and other rare blood group phenotypes have also 
been implicated in shortened survival of transfused RBCs by causing DHTR [13, 16] 
or HDFN [17]. In addition, some antibodies only have occasional reports of being 
clinically significant, that is, anti-Yta, -Ge, and -N or have no clinical significance 
unless reactive at 37°C, that is, anti-Lea, -Leb, -M, -N, -P1, -Lub, -A1, and -Bg [18].
The development of RBC antibodies is influenced by many factors including 
recipient’s gender, age, and underlying disease. The diversity of the blood group 
antigen expression among the donor and patient populations contribute substan-
tially to the high alloimmunization rates [15]. Other factors that might be associated 
with alloimmunization risk have been actively explored in seeking novel strategies 
for prevention of alloimmunization [19]. Studies in both animal models and SCD 
patients have reported that inflammation is associated with higher likelihood of 
alloimmunization and it is suggested that the extent of the alloimmune response is 
higher when RBCs are transfused in the presence of an inflammatory signal [19–23]. 
Several studies have suggested that genetic variation in immune-related genes such 
as TNFA, IL1B, CTL4, CD81, TRIM21, TLR1/TANK, MALT1 [24–28], and human 
leukocyte antigens (HLA) [24, 29] might be associated with susceptibility to or 
protection from alloimmunization. Importance of unit’s age and blood product 
modifications like leukoreduction or irradiation has also been investigated but their 
impact remains unclear.
3.  Prevention of alloimmunization and improvement of transfusion 
therapy
Prevention of alloimmunization is desirable for any blood transfusion; however, 
for patients not previously transfused or only having episodic blood transfusions, 
matching for all clinically significant antigens is not of great concern, but can 
result in alloimmunization against non-matched antigens. For patients previously 
transfused, particularly transfusion-dependent patients, the alloimmunization risk 
is higher and management of alloimmunized patients is of greater concern. Their 
alloimmunization status, including antigens of low clinical significance, is a critical 
part of their clinical history that may enable health care providers to take measures 
to prevent further alloimmunization.
As of May 2019, the International Society of Blood Transfusion (ISBT) rec-
ognizes 36 blood group systems. Of the 360 identified antigens, 322 have been 
assigned to a specific blood group system. These antigens have variable immunoge-
nicity and not all blood group antigens are involved with the production of clinically 
significant antibodies after blood transfusion or pregnancy. Ideally, every blood 
transfusion should be compatible for the most clinically significant antigens in the 
RH (D, C, E, c, e), KEL (K), FY (Fya, Fyb), JK (Jka, Jkb), and the MNS (S, s) systems 
to prevent alloimmunization; however, the standard pre-transfusion cross-matching 
is only performed for ABO blood group and the Rh(D) antigen; ABO matching is 
performed to avoid acute hemolytic transfusion reactions caused by natural IgM 
antibodies against ABO antigens, and Rh(D) matching is performed because of the 
high immunogenicity of the Rh(D), which is implicated in DHTR and HDFN.
Currently, recommendations for partial and extended donor unit/patient 
matching are limited to specific groups including [1] patients on long-term transfu-
sion protocol (i.e. SCD, MSD, thalassaemia, and aplastic anemia), [2] patients who 
have developed alloantibodies, and [3] patients with warm autoimmune hemolytic 
anemia.
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Verification of compatibility for Rh (D, E, C, c, e) and K, which are the most 
frequent antigens involved in alloimmunization, is considered partial matching. 
Extended matching should include at least RH (D, C, E, c, e), KEL (K), FY (Fya, 
Fyb), JK (Jka, Jkb), MNS (S, s) and, if available, additional antigens.
3.1 Serology typing
Knowledge of the role of blood groups with their antigens and variants in allo-
immunization was pivotal for the development of transfusion practices and medical 
interventions that require blood transfusion such as trauma, hematological diseases 
(e.g. SCD, MDS, thalassaemia, and aplastic anemia) and later for transplantation 
and cancer treatment.
Serology has been considered the gold standard technique for blood group typ-
ing for a long time. Serological methods detect the antigen expressed on the red cell 
using specific antibodies and can be carried out manually or by automated plat-
forms. Typing of blood group antigens using this method is easy, fast, reliable, and 
accurate for most of the antigens. However, serology has limitations, some of which 
cannot be overcome when it is used as a standalone testing platform (Table 1). 
Scarcity of serological reagents for some blood group systems for which there is 
no monoclonal antibody available is a major limitation. In addition, human serum 
samples from different donors vary in reactivity, which is an issue when a nearly 
exhausted batch of reagent needs to be replaced. This is especially problematic 
when an alloantibody for that antigen is suspected to be causing adverse events after 
transfusion. In those circumstances, molecular methods can be used as an alterna-
tive or as a complementary test for identification of genes associated with the blood 
group antigens expression and prediction of antigenic profile (see Table 1).
3.2 Molecular typing
The identification of genes that encode proteins carrying blood group antigens 
and the molecular polymorphisms that result in distinct antigenicity of these 
proteins is possible using molecular typing methods, which facilitate blood typing 
Serology limitation Genotyping application
No available antisera, weak or limited 
antisera (i.e. Doa, Dob, Jsa, Jsb, Kpa, Kpb, V 
and VS)
Blood group typing can be easily performed by single PCR 
and/or high throughput platform
Mixed field caused by the presence of 
donor’s RBCs in patient’s sample (i.e. 
patients with recent blood transfusions)
Presence of interfering antibodies (i.e. 
autoantibodies, multiple antibodies, 
antibodies against high prevalence antigens)
Genotyping is performed with extracted DNA from 
nucleated cells (e.g. leukocytes, epithelial). The presence of 
donor’s RBCs or interfering antibodies in patient’s sample 
does not interfere with the results
Presence of variant antigens (i.e. hybrid 
RH types, FY silencing mutations, MNS 
hybrids)
Detection of genes and molecular mechanisms associated 
with variant antigen expression
Detection of blood type of fetus at risk of 
HDFN without invasive procedure
Detection of blood type and zygosity on DNA extracted from 
maternal plasma
Mass screening for antigen-negative and 
rare RBC phenotypes
Use of high throughput platforms for donor screening allows 
mass scale typing and creation of databases
Table 1. 
Benefits of genotyping over serology.
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resolution in complex cases and overcome limitations of serological techniques 
when dealing with alloimmunized and multitransfused patients. In addition, 
molecular techniques have allowed identification of genes encoding clinically 
relevant antigens for which serological reagents are not available (see Table 1). In 
those instances, genotyping is critical to resolve clinical challenges.
Blood group genotyping is performed to predict blood group antigens by iden-
tifying specific polymorphisms associated with the expression of an antigen. Most 
variations in the blood group antigens are linked to point mutations, but for some, 
other molecular mechanisms are responsible, such as deletion or insertion of a gene, an 
exon or a nucleotide sequence (i.e. ABO, RH, and DO blood group systems), sequence 
duplication, (i.e. RHD gene and GE blood group system), nonsense mutation (i.e. RHD 
gene), and hybrid genes (i.e. RH, MNS, ABO, and CH/RG blood group systems) [30].
In contrast to serology, molecular tests are performed on DNA obtained from 
nucleated cells and are not affected by the presence of donor’s red cells in patient’s 
sample, which is a common occurrence in samples of patients with recent/multiple 
blood transfusions. Thus, RBC genotyping can resolve blood group typing discrep-
ancies in multitransfused patients presenting with mixed field reactions, alloanti-
bodies, or autoantibodies (Table 1). Also, blood group genotyping can substantially 
help patients who were not previously phenotyped and need regular transfusions by 
facilitating management of these patients and preventing alloimmunization [31].
Studies comparing serology and genotyping in multitransfused population such 
as patients with thalassaemia and SCD have shown that genotyping is superior to 
serology for resolving discrepancies [31–35]. Use of genotyped matched units has 
been shown to decrease alloimmunization rates [36], increase hemoglobin levels 
and in vivo RBC survival, and diminish frequency of transfusions [37–39].
3.3 Sickle cell disease
SCD is the most common congenital red blood cell disorder affecting millions of 
people worldwide with high mortality and morbidity rates [40]. It is considered a 
major public health issue by the WHO. Characterized by an abnormal synthesis of 
hemoglobin, this genetic trait is most common among people of African ancestry. 
Abnormal hemoglobin carried in red cells causes these cells to sickle (thus the name 
SCD), which as early symptoms produces swelling of the hands and feet, anemia, 
fatigue, and jaundice. Long-term effects of the disease include serious damage in 
spleen, brain, eyes, lungs, liver, heart, kidneys, bones, and/or skin that can accumu-
late over a person’s lifetime. Patients can survive beyond their 50s, and most fatali-
ties are not associated with chronic organ failure but occur due to an acute episode 
of one of the SCD complications. SCD can be cured by bone marrow transplanta-
tion, but only a few patients get transplant.
Blood transfusion therapy is part of treatment for SCD patients and it is mainly 
indicated for prevention of stroke and vaso-occlusive crisis. However, transfusion 
benefits are limited upon development of alloantibodies, a common adverse event 
of transfusion. The high incidence of RBC alloimmunization in SCD is multifacto-
rial, but lack of blood group compatibility between donor and recipient is a key 
factor. This is more evident in countries where donors’ and patients’ ethnicities 
significantly diverge, that is, in North America, where blood donors are mostly 
Caucasians while SCD patients are predominantly of African descent; thus, SCD 
patients are frequently exposed to foreign antigens and, consequently, have higher 
risk of developing multiple alloantibodies.
Transfusion protocols for management of SCD and prevention of alloimmu-
nization vary among the hospitals and transfusion services. In many centers that 
provide care to SCD patients, transfusions are phenotypically matched for RH  
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Verification of compatibility for Rh (D, E, C, c, e) and K, which are the most 
frequent antigens involved in alloimmunization, is considered partial matching. 
Extended matching should include at least RH (D, C, E, c, e), KEL (K), FY (Fya, 
Fyb), JK (Jka, Jkb), MNS (S, s) and, if available, additional antigens.
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interventions that require blood transfusion such as trauma, hematological diseases 
(e.g. SCD, MDS, thalassaemia, and aplastic anemia) and later for transplantation 
and cancer treatment.
Serology has been considered the gold standard technique for blood group typ-
ing for a long time. Serological methods detect the antigen expressed on the red cell 
using specific antibodies and can be carried out manually or by automated plat-
forms. Typing of blood group antigens using this method is easy, fast, reliable, and 
accurate for most of the antigens. However, serology has limitations, some of which 
cannot be overcome when it is used as a standalone testing platform (Table 1). 
Scarcity of serological reagents for some blood group systems for which there is 
no monoclonal antibody available is a major limitation. In addition, human serum 
samples from different donors vary in reactivity, which is an issue when a nearly 
exhausted batch of reagent needs to be replaced. This is especially problematic 
when an alloantibody for that antigen is suspected to be causing adverse events after 
transfusion. In those circumstances, molecular methods can be used as an alterna-
tive or as a complementary test for identification of genes associated with the blood 
group antigens expression and prediction of antigenic profile (see Table 1).
3.2 Molecular typing
The identification of genes that encode proteins carrying blood group antigens 
and the molecular polymorphisms that result in distinct antigenicity of these 
proteins is possible using molecular typing methods, which facilitate blood typing 
Serology limitation Genotyping application
No available antisera, weak or limited 
antisera (i.e. Doa, Dob, Jsa, Jsb, Kpa, Kpb, V 
and VS)
Blood group typing can be easily performed by single PCR 
and/or high throughput platform
Mixed field caused by the presence of 
donor’s RBCs in patient’s sample (i.e. 
patients with recent blood transfusions)
Presence of interfering antibodies (i.e. 
autoantibodies, multiple antibodies, 
antibodies against high prevalence antigens)
Genotyping is performed with extracted DNA from 
nucleated cells (e.g. leukocytes, epithelial). The presence of 
donor’s RBCs or interfering antibodies in patient’s sample 
does not interfere with the results
Presence of variant antigens (i.e. hybrid 
RH types, FY silencing mutations, MNS 
hybrids)
Detection of genes and molecular mechanisms associated 
with variant antigen expression
Detection of blood type of fetus at risk of 
HDFN without invasive procedure
Detection of blood type and zygosity on DNA extracted from 
maternal plasma
Mass screening for antigen-negative and 
rare RBC phenotypes
Use of high throughput platforms for donor screening allows 
mass scale typing and creation of databases
Table 1. 
Benefits of genotyping over serology.
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resolution in complex cases and overcome limitations of serological techniques 
when dealing with alloimmunized and multitransfused patients. In addition, 
molecular techniques have allowed identification of genes encoding clinically 
relevant antigens for which serological reagents are not available (see Table 1). In 
those instances, genotyping is critical to resolve clinical challenges.
Blood group genotyping is performed to predict blood group antigens by iden-
tifying specific polymorphisms associated with the expression of an antigen. Most 
variations in the blood group antigens are linked to point mutations, but for some, 
other molecular mechanisms are responsible, such as deletion or insertion of a gene, an 
exon or a nucleotide sequence (i.e. ABO, RH, and DO blood group systems), sequence 
duplication, (i.e. RHD gene and GE blood group system), nonsense mutation (i.e. RHD 
gene), and hybrid genes (i.e. RH, MNS, ABO, and CH/RG blood group systems) [30].
In contrast to serology, molecular tests are performed on DNA obtained from 
nucleated cells and are not affected by the presence of donor’s red cells in patient’s 
sample, which is a common occurrence in samples of patients with recent/multiple 
blood transfusions. Thus, RBC genotyping can resolve blood group typing discrep-
ancies in multitransfused patients presenting with mixed field reactions, alloanti-
bodies, or autoantibodies (Table 1). Also, blood group genotyping can substantially 
help patients who were not previously phenotyped and need regular transfusions by 
facilitating management of these patients and preventing alloimmunization [31].
Studies comparing serology and genotyping in multitransfused population such 
as patients with thalassaemia and SCD have shown that genotyping is superior to 
serology for resolving discrepancies [31–35]. Use of genotyped matched units has 
been shown to decrease alloimmunization rates [36], increase hemoglobin levels 
and in vivo RBC survival, and diminish frequency of transfusions [37–39].
3.3 Sickle cell disease
SCD is the most common congenital red blood cell disorder affecting millions of 
people worldwide with high mortality and morbidity rates [40]. It is considered a 
major public health issue by the WHO. Characterized by an abnormal synthesis of 
hemoglobin, this genetic trait is most common among people of African ancestry. 
Abnormal hemoglobin carried in red cells causes these cells to sickle (thus the name 
SCD), which as early symptoms produces swelling of the hands and feet, anemia, 
fatigue, and jaundice. Long-term effects of the disease include serious damage in 
spleen, brain, eyes, lungs, liver, heart, kidneys, bones, and/or skin that can accumu-
late over a person’s lifetime. Patients can survive beyond their 50s, and most fatali-
ties are not associated with chronic organ failure but occur due to an acute episode 
of one of the SCD complications. SCD can be cured by bone marrow transplanta-
tion, but only a few patients get transplant.
Blood transfusion therapy is part of treatment for SCD patients and it is mainly 
indicated for prevention of stroke and vaso-occlusive crisis. However, transfusion 
benefits are limited upon development of alloantibodies, a common adverse event 
of transfusion. The high incidence of RBC alloimmunization in SCD is multifacto-
rial, but lack of blood group compatibility between donor and recipient is a key 
factor. This is more evident in countries where donors’ and patients’ ethnicities 
significantly diverge, that is, in North America, where blood donors are mostly 
Caucasians while SCD patients are predominantly of African descent; thus, SCD 
patients are frequently exposed to foreign antigens and, consequently, have higher 
risk of developing multiple alloantibodies.
Transfusion protocols for management of SCD and prevention of alloimmu-
nization vary among the hospitals and transfusion services. In many centers that 
provide care to SCD patients, transfusions are phenotypically matched for RH  
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(D, C/c, E/e) and K [41], while others provide extended matching including RH (D, 
C, c, E, e), KEL (K, k), FY (Fya, Fyb), JK (Jka, Jkb), and MNS (S, s) in addition to 
the standard ABO and Rh(D). Less frequently, extended matching is performed by 
genotyping [36]. However, a wide range of institutions do not request phenotypi-
cally matched RBC units until the patient has produced an alloantibody [42].
It has been reported that antibodies against Rh antigens are the most frequently 
identified antibodies in multitransfused SCD patients despite transfusion from Rh 
phenotype matched donors [15]. The main reason for that is the high frequency 
of Rh variants in people of African descent. It has been reported that 90% of SCD 
patients and donors of African ancestry have at least one variant RHD or RHCE 
allele [15, 43]. The term “variant” is used when RHD and/or RHCE genes are carry-
ing genetic alterations that may affect the RhD and RhCe protein expression. Variant 
alleles can encode weak and/or altered antigens and serological methods are limited 
in which variant Rh antigens can be identified and might not be reliable [44, 45].
The prophylactic RBC matching performed by serology typing, before expo-
sure to RBC transfusions, can decrease transfusion complications in SCD patients 
substantially, but does not eliminate the occurrence of alloimmunization against 
Rh variants and other non-matched antigens that can cause DHTR [41]. Currently 
available molecular typing methods can predict several blood group antigens allow-
ing a more precise RBC matching and can support transfusion decision-making. 
RHD and RHCE genotype matching particularly benefits SCD patients carrying Rh 
variants. For instance, SCD patients presenting D+ or e+ phenotype can make allo-
antibodies to these antigens despite receiving Rh phenotyped matching RBCs. The 
molecular analysis in such individuals may identify polymorphisms in RH genes 
responsible for the phenotypic alteration, confirming the alloimmune status of the 
antibody. In such cases, provision of RH genotype matched units or units negative 
for the specific antigen would be recommended, because the antibodies produced 
may be clinically relevant [13, 15].
An additional benefit of blood group genotyping on transfusion management of 
SCD patients is the capability of identifying silence mutations like −67T>C in the 
ACKR1 gene (Duffy gene). Patients carrying the mutation can receive Fy(b+) units, 
because the mutation only abolishes expression of Fy(b) on red cells but not in 
other tissues. The detection of this mutation avoids unnecessary use of Fy(b−) and 
increases the chances to find compatible units available even for highly restrictive 
matching.
Extended genotyping including Dombrock: Doa, Dob, Joa, Hy; Kell: Kpa, Kpb, Jsa, 
Jsb; Rh: V, VS; Colton: Coa, Cob; Cartwright: Yta, Ytb; Lutheran: Lua, Lub; Diego: Dia, 
Dib; and Scianna: Sc1, Sc2 may help prevent development of clinically significant 
antibodies that can be potentially life-threatening.
3.4 Thalassaemia
Thalassaemia is an inherited blood disorder associated with a mutation in one 
of the genes involved in hemoglobin production resulting in abnormal form or an 
inadequate amount of hemoglobin. RBCs carrying abnormal hemoglobin do not 
function properly and are destroyed in large numbers leading to anemia. People 
with thalassaemia may have mild or severe anemia depending on the type of 
thalassaemia. Severe anemia requires regular blood transfusions to maintain the 
hemoglobin and RBCs levels, and to suppress the ineffective erythropoiesis but can 
lead to alloimmunization.
The prevalence of alloimmunization in patients with thalassaemia varies among 
geographical locations and may be related to the heterogeneity of population, trans-
fusion exposure frequency, patients age, antigen matching policy, recipient related 
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factors, and other factors [46]. The most common alloantibodies reported in these 
patients are against RH (primarily anti-E and anti-C) and K, followed by antigens 
of the FY, JK, MNS, and other blood group systems. Development of autoantibodies 
is also commonly observed in these patients. A policy for RH and KEL matching 
been introduced worldwide and its effectiveness has been demonstrated by the 
decreasing rates of alloantibody and autoantibody formation [46–48].
The Thalassaemia International Federation guidelines for transfusion-dependent 
thalassaemia published in 2014 recommends that all patients should receive pro-
phylactic ABO, RH (D, C, c, E, e), and KEL (K) matched transfusions identified 
either with serology or genotyping. In addition, it is indicated that antigen typing 
should be performed using molecular rather than serologic testing if the patient had 
received transfusions previously [49]. However, surveys have reported that there 
is still a lack of adherence to recommendations and a large variation in transfu-
sion practices for thalassaemia and SCD patients among the health care systems 
[42]. Some of the challenges for transfusion centers include difficulty in obtaining 
a reliable antibody and transfusion history and the lack of standards regarding 
procedures for phenotyping and transfusion matching [42].
Molecular typing has been introduced in several centers to confirm extended 
blood group profiles obtained through serological methods, however, it is not 
routine yet [31, 32, 42]. This approach is particularly important for thalassaemia 
patients because these patients are transfusion-dependent and, in many circum-
stances, might have received transfusions at hospitals with different transfusion 
matching policies, therefore the phenotyping might not be reliable.
3.5 Rare type blood donor selection
Alloimmunized patients require transfusion of RBCs that are negative for a 
particular antigen. Historically, serology methods, which are labor-intensive and 
time-consuming, have been used to screen for antigen-negative units. However, 
the standard practice is likely to change with the high-throughput platforms for 
blood group genotyping being approved by regulatory bodies and becoming more 
widely used. High-throughput platforms allow identification of a higher number of 
antigens compared with serology, increasing the availability of blood characterized 
for clinically relevant antigens.
The implementation of RBC mass scale genotyping for donor screening has started 
in blood centers, especially in large collecting facilities [50–53]. The successful estab-
lishment of a blood group genotype database has already been accomplished aiming 
to fulfill antigen-negative requests, especially for SCD patients receiving regular 
transfusions, and to create an inventory of frozen red cell units with rare blood types 
[51]. The refereed database comprises 43,066 non-Caucasian blood donors genotyped 
for 32 single nucleotide polymorphisms, related to the expression of 42 blood group 
antigens. The report showed that within 4 years of starting RBC genotyping, the 
blood group antigen database generated on blood donors was fivefold larger than that 
obtained by serology methods over 30 years. In addition, most antigen-negative units 
requests to that center were met using exclusively the genotyping database.
Strategies for finding units to fulfill transfusion requests for SCD patients 
have included RBC genotyping of non-Caucasian blood donors and donors with 
altered Rh antigen expression [54, 55]. The genotyping selection of donors with a 
genetic background similar to that of SCD patients’ increases the chances of finding 
compatible blood for these patients, including RH-genotype matching. However, 
the low percentage of blood donors with African ethnic background combined with 
the cost of genotyping are limiting factors for widespread use of extended RBC 
genotyping matching strategy.
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(D, C/c, E/e) and K [41], while others provide extended matching including RH (D, 
C, c, E, e), KEL (K, k), FY (Fya, Fyb), JK (Jka, Jkb), and MNS (S, s) in addition to 
the standard ABO and Rh(D). Less frequently, extended matching is performed by 
genotyping [36]. However, a wide range of institutions do not request phenotypi-
cally matched RBC units until the patient has produced an alloantibody [42].
It has been reported that antibodies against Rh antigens are the most frequently 
identified antibodies in multitransfused SCD patients despite transfusion from Rh 
phenotype matched donors [15]. The main reason for that is the high frequency 
of Rh variants in people of African descent. It has been reported that 90% of SCD 
patients and donors of African ancestry have at least one variant RHD or RHCE 
allele [15, 43]. The term “variant” is used when RHD and/or RHCE genes are carry-
ing genetic alterations that may affect the RhD and RhCe protein expression. Variant 
alleles can encode weak and/or altered antigens and serological methods are limited 
in which variant Rh antigens can be identified and might not be reliable [44, 45].
The prophylactic RBC matching performed by serology typing, before expo-
sure to RBC transfusions, can decrease transfusion complications in SCD patients 
substantially, but does not eliminate the occurrence of alloimmunization against 
Rh variants and other non-matched antigens that can cause DHTR [41]. Currently 
available molecular typing methods can predict several blood group antigens allow-
ing a more precise RBC matching and can support transfusion decision-making. 
RHD and RHCE genotype matching particularly benefits SCD patients carrying Rh 
variants. For instance, SCD patients presenting D+ or e+ phenotype can make allo-
antibodies to these antigens despite receiving Rh phenotyped matching RBCs. The 
molecular analysis in such individuals may identify polymorphisms in RH genes 
responsible for the phenotypic alteration, confirming the alloimmune status of the 
antibody. In such cases, provision of RH genotype matched units or units negative 
for the specific antigen would be recommended, because the antibodies produced 
may be clinically relevant [13, 15].
An additional benefit of blood group genotyping on transfusion management of 
SCD patients is the capability of identifying silence mutations like −67T>C in the 
ACKR1 gene (Duffy gene). Patients carrying the mutation can receive Fy(b+) units, 
because the mutation only abolishes expression of Fy(b) on red cells but not in 
other tissues. The detection of this mutation avoids unnecessary use of Fy(b−) and 
increases the chances to find compatible units available even for highly restrictive 
matching.
Extended genotyping including Dombrock: Doa, Dob, Joa, Hy; Kell: Kpa, Kpb, Jsa, 
Jsb; Rh: V, VS; Colton: Coa, Cob; Cartwright: Yta, Ytb; Lutheran: Lua, Lub; Diego: Dia, 
Dib; and Scianna: Sc1, Sc2 may help prevent development of clinically significant 
antibodies that can be potentially life-threatening.
3.4 Thalassaemia
Thalassaemia is an inherited blood disorder associated with a mutation in one 
of the genes involved in hemoglobin production resulting in abnormal form or an 
inadequate amount of hemoglobin. RBCs carrying abnormal hemoglobin do not 
function properly and are destroyed in large numbers leading to anemia. People 
with thalassaemia may have mild or severe anemia depending on the type of 
thalassaemia. Severe anemia requires regular blood transfusions to maintain the 
hemoglobin and RBCs levels, and to suppress the ineffective erythropoiesis but can 
lead to alloimmunization.
The prevalence of alloimmunization in patients with thalassaemia varies among 
geographical locations and may be related to the heterogeneity of population, trans-
fusion exposure frequency, patients age, antigen matching policy, recipient related 
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factors, and other factors [46]. The most common alloantibodies reported in these 
patients are against RH (primarily anti-E and anti-C) and K, followed by antigens 
of the FY, JK, MNS, and other blood group systems. Development of autoantibodies 
is also commonly observed in these patients. A policy for RH and KEL matching 
been introduced worldwide and its effectiveness has been demonstrated by the 
decreasing rates of alloantibody and autoantibody formation [46–48].
The Thalassaemia International Federation guidelines for transfusion-dependent 
thalassaemia published in 2014 recommends that all patients should receive pro-
phylactic ABO, RH (D, C, c, E, e), and KEL (K) matched transfusions identified 
either with serology or genotyping. In addition, it is indicated that antigen typing 
should be performed using molecular rather than serologic testing if the patient had 
received transfusions previously [49]. However, surveys have reported that there 
is still a lack of adherence to recommendations and a large variation in transfu-
sion practices for thalassaemia and SCD patients among the health care systems 
[42]. Some of the challenges for transfusion centers include difficulty in obtaining 
a reliable antibody and transfusion history and the lack of standards regarding 
procedures for phenotyping and transfusion matching [42].
Molecular typing has been introduced in several centers to confirm extended 
blood group profiles obtained through serological methods, however, it is not 
routine yet [31, 32, 42]. This approach is particularly important for thalassaemia 
patients because these patients are transfusion-dependent and, in many circum-
stances, might have received transfusions at hospitals with different transfusion 
matching policies, therefore the phenotyping might not be reliable.
3.5 Rare type blood donor selection
Alloimmunized patients require transfusion of RBCs that are negative for a 
particular antigen. Historically, serology methods, which are labor-intensive and 
time-consuming, have been used to screen for antigen-negative units. However, 
the standard practice is likely to change with the high-throughput platforms for 
blood group genotyping being approved by regulatory bodies and becoming more 
widely used. High-throughput platforms allow identification of a higher number of 
antigens compared with serology, increasing the availability of blood characterized 
for clinically relevant antigens.
The implementation of RBC mass scale genotyping for donor screening has started 
in blood centers, especially in large collecting facilities [50–53]. The successful estab-
lishment of a blood group genotype database has already been accomplished aiming 
to fulfill antigen-negative requests, especially for SCD patients receiving regular 
transfusions, and to create an inventory of frozen red cell units with rare blood types 
[51]. The refereed database comprises 43,066 non-Caucasian blood donors genotyped 
for 32 single nucleotide polymorphisms, related to the expression of 42 blood group 
antigens. The report showed that within 4 years of starting RBC genotyping, the 
blood group antigen database generated on blood donors was fivefold larger than that 
obtained by serology methods over 30 years. In addition, most antigen-negative units 
requests to that center were met using exclusively the genotyping database.
Strategies for finding units to fulfill transfusion requests for SCD patients 
have included RBC genotyping of non-Caucasian blood donors and donors with 
altered Rh antigen expression [54, 55]. The genotyping selection of donors with a 
genetic background similar to that of SCD patients’ increases the chances of finding 
compatible blood for these patients, including RH-genotype matching. However, 
the low percentage of blood donors with African ethnic background combined with 
the cost of genotyping are limiting factors for widespread use of extended RBC 
genotyping matching strategy.
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4. Molecular testing: current technologies
Polymerase chain reaction (PCR) and further advancements in molecular meth-
ods such as DNA sequencing and recombinant DNA technology allowed elucidation 
of the molecular basis of most of the blood group antigens and subsequent use of 
molecular techniques employed for blood group genotyping initially as in-house 
assays or laboratory developed tests (LDT) and later as commercially available assays.
While molecular basis for many of the blood group systems is relatively straight-
forward, with two antithetical alleles differing by a single nucleotide polymorphism 
(SNP) and responsible for one of the two possible phenotypes, some blood group 
systems are very complex. RH blood group system has over 50 antigens described 
Name/manufacturer Principle Number of polymorphisms/antigens 
identified
Immucor PreciseType 
HEA Molecular BeadChip 
Test#,$ [56]
BioArray Solutions
Multiplex PCR followed by 
hybridization of amplified DNA 
to probes attached to spectrally 
distinguishable beads and 
elongation
24 polymorphisms associated with 38 
antigens plus phenotypic variants and 
Hemoglobin S
BioArray RHCE and RHD 
BeadChip$ [57]
BioArray Solutions
Multiplex PCR followed by 
hybridization of amplified DNA 
to probes attached to spectrally 
distinguishable beads and 
elongation
35+ RHCE variants; 80+ RHD variants
ID CORE XT#,$ [58]
Progenika Biopharma
Multiplex biotinylating PCR 
followed by hybridization 
to probes on color-coded 
microspheres
29 polymorphisms associated with 37 
antigens and phenotypic variants
ID RHD XT$ [59]
Progenika Biopharma
Multiplex biotinylating PCR 
followed by hybridization to 
probes coupled to color-coded 
microspheres
6 RHD variants and HPA-1
Hemo ID DQS Panel$ 
[60, 61]
Agena Bioscience
Multiplex end-point PCR and 
single base primer extension
101 antigens associated with 
16 systems, and 23 platelet and 
neutrophil antigens, in modules
HIFI Blood 96$ [62]
AXO Science
Automated multiplex PCR and 
microarray-based assay






Automated TaqMan-based assay 70 antigens and phenotypic variants 




PCR-SSP-based assay 16 modules encompassing antigens 
and variant phenotypes within 13 
systems
TaqMan genotyping on 
OpenArray [65, 66]
BioTrove
Nanofluidic TaqMan assays 
performed in OpenArray plates




Real-time allelic discrimination 
PCR





Commercial solutions available for blood group genotyping.
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to date, more than 500 alleles, and 2 highly homologous genes that, in addition to 
SNPs, insertions, and deletions, may have hybrid configurations. Other systems 
with more than 50 alleles currently identified include MNS, Diego, and Kell. 
Genotyping strategies are often based on a SNP altering a restriction site or punc-
tuating otherwise perfectly matched sequence for primers or probe annealing site. 
These approaches may be suboptimal for designing genotyping assays of complex 
systems and fail to reveal rare variants. Next generation sequencing (NGS) is the 
only method that can reliably detect the exact genetic composition of the site 
 making it possible to predict the phenotype.





Denaturation of PCR product followed by 
fragment analysis in polyacrylamide gel
9 polymorphisms associated with 
1 blood group
PCR-RFLP [68–74] Amplification of target sequence followed 
by enzyme digestion (PCR-RFLP)
Varies
PCR-SSP [75–77] Amplification of single alleles using 
allele-specific primers
Singleplex or multiplex
Multiplex-PCR [78, 79] Amplification with multiple primers 
followed by gel electrophoresis
Polymorphisms associated with 6 
exons of RHD
Quantitative multiplex 
PCR of short fluorescent 
fragments (QMPSF) [80]
Amplification of multiple targets using 
both specific and universal-FAM-labeled 
primers detected by electrophoresis




Amplification followed by enrichment 




probe amplification (MLPA) 
[82]
MLPA probes hybridized to DNA 
target sequence followed by fragment 
amplification and detection
48 alleles encoding blood group 




Multiplex PCR followed by single-
nucleotide extension and hybridization to 
complementary oligonucleotides
12 polymorphisms associated 




PCR with gene-specific primers and 
probes followed by melting curve analysis
Various—customized
Single nucleotide primer 
extension minisequencing 
assay (SNaPshot) [86]
Multiplex PCR followed by SNaPshot 
reaction and fragment analysis
Various—customized
Microsphere-based array [87] Multiplex PCR followed by hybridization 
to probes coupled to fluorescent 
microspheres
8 polymorphisms associated with 
6 blood groups
Multiplex PCR and DNA 
microarray hybridization [88]
Chimeric primers (specific-universal 
tag) are used along with fluorescent-label 
universal primers followed by products 
hybridization to a DNA array
Gene fragments of 19 different 
RBC and platelets antigen 
systems
Sanger sequencing [89] Classical DNA sequencing of single 
fragment using dye terminators
Various—customized
Next generation sequencing 
(NGS) [90]
Sequencing of entire genome or specific 
regions. Millions of small fragments of 
DNA are simultaneously sequenced
Various—customized
Table 3. 
Other techniques developed for blood group genotyping.
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4. Molecular testing: current technologies
Polymerase chain reaction (PCR) and further advancements in molecular meth-
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Name/manufacturer Principle Number of polymorphisms/antigens 
identified
Immucor PreciseType 
HEA Molecular BeadChip 
Test#,$ [56]
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Commercial solutions available for blood group genotyping.
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to date, more than 500 alleles, and 2 highly homologous genes that, in addition to 
SNPs, insertions, and deletions, may have hybrid configurations. Other systems 
with more than 50 alleles currently identified include MNS, Diego, and Kell. 
Genotyping strategies are often based on a SNP altering a restriction site or punc-
tuating otherwise perfectly matched sequence for primers or probe annealing site. 
These approaches may be suboptimal for designing genotyping assays of complex 
systems and fail to reveal rare variants. Next generation sequencing (NGS) is the 
only method that can reliably detect the exact genetic composition of the site 
 making it possible to predict the phenotype.
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tag) are used along with fluorescent-label 
universal primers followed by products 
hybridization to a DNA array
Gene fragments of 19 different 
RBC and platelets antigen 
systems
Sanger sequencing [89] Classical DNA sequencing of single 
fragment using dye terminators
Various—customized
Next generation sequencing 
(NGS) [90]
Sequencing of entire genome or specific 
regions. Millions of small fragments of 
DNA are simultaneously sequenced
Various—customized
Table 3. 
Other techniques developed for blood group genotyping.
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Genotyping methodologies vary widely and include labor-intensive techniques 
that are best suited to test individual samples for limited number of polymorphisms 
(i.e. PCR-RFLP and PCR-SSP), high-throughput commercial kits that are relatively 
easy to use (i.e. real-time PCR and arrays), and methods that require specialized 
equipment to differentiate between alleles in multiple blood group systems at once 
(i.e. NGS). Most of assays described to date rely on enzyme-mediated DNA ampli-
fication at some point in their workflow and on sequence-specific primers or probes 
(Tables 2 and 3).
At the time of this writing, several platforms have been commercialized, 
but only two commercial assays have been approved by the US FDA. Immucor 
PreciseType by BioArray Solutions was approved in May 2014 and ID CORE XT 
manufactured by Progenika Biopharma was approved in October 2018. Due to 
less stringent requirements to obtain the European Conformity (CE mark), this 
certification has been granted to most of the commercial devices described here 
(see Table 2). Commercial assays not approved by the FDA can be labeled and 
utilized for research or investigational use only. Some commercial platforms (such 
as OpenArray or GenomeLab SNPStream) are used to run LDT assays to increase 
the throughput (Table 3).
5. Molecular testing: standards for RBC antigens
The use of molecular typing for characterization of blood group genes has been 
steadily increasing in the last few decades due to the transfusion benefits for the 
patients, technological advances in molecular techniques, and expanding availabil-
ity of mass-scale genotyping. While blood group genotyping is becoming increas-
ingly used, typing errors have been documented indicating the need for quality 
control.
International Workshops on Molecular Blood Group Genotyping have reported 
discrepancies between laboratories studying the same samples indicating that there 
is room for improvement [91, 92]. As a genotyping test may only be done once 
in a person’s lifetime, errors can have serious consequences. A major challenge in 
performing routine RBC genotyping is controlling for process variability of molecu-
lar assays that arises due to scarcity of reference materials. This limitation has been 
circumvented by using clinical specimen leftovers from previous testing, which 
lack proper characterization. Reference materials are critical for the development 
and manufacture of testing kits, for test calibration and for monitoring of assay 
performance.
Recommendations on which targets and recommended controls to use for 
prediction of RBC antigens have been published by international societies offering 
proficiency test programs such as INSTAND [93], The Consortium for Blood Group 
Genes (CBGG) [94], College of American Pathologists (CAP), and International 
Society of Blood Transfusion (ISBT) [91, 92] and also by The American Association 
of Blood Banks (AABB) [95] whose focus is on creating guidelines for AABB 
accreditation aiming to certify laboratories that perform molecular testing for red 
cell, platelet, and neutrophil antigens.
Molecular testing laboratories participate in accreditation programs to validate 
their activities. In the US, the requirements for AABB accreditation are described 
in the 4th edition of standards for molecular testing for red cell, platelet, and 
neutrophil antigens (updated in October 2018) [95]. According to the document, 
“laboratories shall use appropriate reference DNA to validate and control the 
reported test” and further, “the reference DNA needs to contain the target poly-
morphisms reported by the laboratory”. The same publication lists the blood group 
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alleles within 17 blood group systems that should be included in the reference DNA 
materials by the lab seeking to meet the minimum requirements for accreditation.
Various preparations have been used as controls to monitor performance of 
blood group genotyping assays, including synthetic DNA (such as PCR prod-
ucts, plasmid-cloned PCR products) and genetic material from human samples 
col¬lected and characterized for that purpose following standard guidelines [96]. 
PCR products and plasmid-cloned PCR products are simple and easy to produce 
and use as controls for SNPs, but they lack the genomic complexity of human 
sample and do not represent the clinical analyte (genomic DNA); moreover, the 
synthetic material can be a source of contamination for the laboratory if not 
carefully handled and well diluted. Although well-characterized human specimens 
are the best representation of clinical samples, they are of limited source and the 
replenishment may not come from the same donor. The alternative to overcome 
source limitation is to transform human cells into immortalized cell lines and use 
those for characterization and formulation of reference reagents. This approach has 
been successfully used to produce reference DNA using B-lymphoblastoid cell lines 
(B-LCLs), which are an appropriate representation of the genetic material of the 
donor [97].
B-LCLs can be generated by Epstein Barr Virus (EBV) infection of peripheral 
mononuclear cells from genetically characterized donors carrying specific blood 
group antigens and variants. The infection leads to proliferation and subsequent 
cell immortalization, providing an unlimited source of donor’s genomic DNA. Once 
the B-LCLs are established, master and working cell banks are maintained in liquid 
nitrogen to ensure long-term survival of the cell line and continuous supply of 
the DNA. To produce the DNA reagent, B-LCLs from the working cell banks are 
expanded for bulk DNA extraction and subsequent DNA lyophilization. Tests on 
the lyophilized reagents are performed for assessment of their stability under accel-
erated degradation conditions and under normal conditions over longer periods of 
time as long-term stability. The material must be validated via collaborative studies 
with laboratories that routinely perform molecular blood typing.
The first DNA reference reagents for blood group genotyping developed 
using B-LCLs were produced in 2013 by the National Institute for Biological 
Standards and Control (NIBSC) and serve as World Health Organization (WHO) 
International Reference Reagents (IRR) for common blood group alleles found in 
ancestral Caucasians and Black African populations. The panel includes four DNA 
samples covering the most clinically important homozygous and heterozygous 
genotypes within RH, FY, KEL, JK, DO, and MNS blood group systems (Table 4). 
The material was validated in an international collaborative study by PCR-ASP or 
PCR-SSP, PCR-RFLP, Multiplex SSP assays, real-time PCR, Immucor Beadchip 
array, Progenika BLOODchip array, Luminex array, and 5′ Nuclease assay [98].
Additional cell lines were produced by CBER-FDA for use as source of genomic 
DNA for development of reference reagents to expand the number of red cell blood 
group polymorphisms represented in the first WHO IRR from 2013 for blood group 
genotyping. The CBER reference panel consists of 18 members, covering genotypes 
associated with 40 polymorphisms within 17 blood group systems, including alleles 
present in the existing WHO IRR-2013 except for RHD*ψ (Table 4). The CBER 
panel was also characterized and validated for additional genotypes belonging to 
systems already included in the WHO IRR-2013 (RH, KEL, FY, JK, DO, and MNS) 
(Table 4), and for additional systems only represented in CBER panel (ABO, LU, 
DI, YT, SC, CO, LW, CR, KN, IN, and OK) (Table 5) [89].
Participants in the international collaborative study to validate the CBER panel 
used traditional molecular techniques and additional genotyping techniques not 
available at the time of the first WHO IRR production. The most common methods 
Human Blood Group Systems and Haemoglobinopathies
210
Genotyping methodologies vary widely and include labor-intensive techniques 
that are best suited to test individual samples for limited number of polymorphisms 
(i.e. PCR-RFLP and PCR-SSP), high-throughput commercial kits that are relatively 
easy to use (i.e. real-time PCR and arrays), and methods that require specialized 
equipment to differentiate between alleles in multiple blood group systems at once 
(i.e. NGS). Most of assays described to date rely on enzyme-mediated DNA ampli-
fication at some point in their workflow and on sequence-specific primers or probes 
(Tables 2 and 3).
At the time of this writing, several platforms have been commercialized, 
but only two commercial assays have been approved by the US FDA. Immucor 
PreciseType by BioArray Solutions was approved in May 2014 and ID CORE XT 
manufactured by Progenika Biopharma was approved in October 2018. Due to 
less stringent requirements to obtain the European Conformity (CE mark), this 
certification has been granted to most of the commercial devices described here 
(see Table 2). Commercial assays not approved by the FDA can be labeled and 
utilized for research or investigational use only. Some commercial platforms (such 
as OpenArray or GenomeLab SNPStream) are used to run LDT assays to increase 
the throughput (Table 3).
5. Molecular testing: standards for RBC antigens
The use of molecular typing for characterization of blood group genes has been 
steadily increasing in the last few decades due to the transfusion benefits for the 
patients, technological advances in molecular techniques, and expanding availabil-
ity of mass-scale genotyping. While blood group genotyping is becoming increas-
ingly used, typing errors have been documented indicating the need for quality 
control.
International Workshops on Molecular Blood Group Genotyping have reported 
discrepancies between laboratories studying the same samples indicating that there 
is room for improvement [91, 92]. As a genotyping test may only be done once 
in a person’s lifetime, errors can have serious consequences. A major challenge in 
performing routine RBC genotyping is controlling for process variability of molecu-
lar assays that arises due to scarcity of reference materials. This limitation has been 
circumvented by using clinical specimen leftovers from previous testing, which 
lack proper characterization. Reference materials are critical for the development 
and manufacture of testing kits, for test calibration and for monitoring of assay 
performance.
Recommendations on which targets and recommended controls to use for 
prediction of RBC antigens have been published by international societies offering 
proficiency test programs such as INSTAND [93], The Consortium for Blood Group 
Genes (CBGG) [94], College of American Pathologists (CAP), and International 
Society of Blood Transfusion (ISBT) [91, 92] and also by The American Association 
of Blood Banks (AABB) [95] whose focus is on creating guidelines for AABB 
accreditation aiming to certify laboratories that perform molecular testing for red 
cell, platelet, and neutrophil antigens.
Molecular testing laboratories participate in accreditation programs to validate 
their activities. In the US, the requirements for AABB accreditation are described 
in the 4th edition of standards for molecular testing for red cell, platelet, and 
neutrophil antigens (updated in October 2018) [95]. According to the document, 
“laboratories shall use appropriate reference DNA to validate and control the 
reported test” and further, “the reference DNA needs to contain the target poly-
morphisms reported by the laboratory”. The same publication lists the blood group 
211
Accuracy of Blood Group Typing in the Management and Prevention of Alloimmunization
DOI: http://dx.doi.org/10.5772/intechopen.90095
alleles within 17 blood group systems that should be included in the reference DNA 
materials by the lab seeking to meet the minimum requirements for accreditation.
Various preparations have been used as controls to monitor performance of 
blood group genotyping assays, including synthetic DNA (such as PCR prod-
ucts, plasmid-cloned PCR products) and genetic material from human samples 
col¬lected and characterized for that purpose following standard guidelines [96]. 
PCR products and plasmid-cloned PCR products are simple and easy to produce 
and use as controls for SNPs, but they lack the genomic complexity of human 
sample and do not represent the clinical analyte (genomic DNA); moreover, the 
synthetic material can be a source of contamination for the laboratory if not 
carefully handled and well diluted. Although well-characterized human specimens 
are the best representation of clinical samples, they are of limited source and the 
replenishment may not come from the same donor. The alternative to overcome 
source limitation is to transform human cells into immortalized cell lines and use 
those for characterization and formulation of reference reagents. This approach has 
been successfully used to produce reference DNA using B-lymphoblastoid cell lines 
(B-LCLs), which are an appropriate representation of the genetic material of the 
donor [97].
B-LCLs can be generated by Epstein Barr Virus (EBV) infection of peripheral 
mononuclear cells from genetically characterized donors carrying specific blood 
group antigens and variants. The infection leads to proliferation and subsequent 
cell immortalization, providing an unlimited source of donor’s genomic DNA. Once 
the B-LCLs are established, master and working cell banks are maintained in liquid 
nitrogen to ensure long-term survival of the cell line and continuous supply of 
the DNA. To produce the DNA reagent, B-LCLs from the working cell banks are 
expanded for bulk DNA extraction and subsequent DNA lyophilization. Tests on 
the lyophilized reagents are performed for assessment of their stability under accel-
erated degradation conditions and under normal conditions over longer periods of 
time as long-term stability. The material must be validated via collaborative studies 
with laboratories that routinely perform molecular blood typing.
The first DNA reference reagents for blood group genotyping developed 
using B-LCLs were produced in 2013 by the National Institute for Biological 
Standards and Control (NIBSC) and serve as World Health Organization (WHO) 
International Reference Reagents (IRR) for common blood group alleles found in 
ancestral Caucasians and Black African populations. The panel includes four DNA 
samples covering the most clinically important homozygous and heterozygous 
genotypes within RH, FY, KEL, JK, DO, and MNS blood group systems (Table 4). 
The material was validated in an international collaborative study by PCR-ASP or 
PCR-SSP, PCR-RFLP, Multiplex SSP assays, real-time PCR, Immucor Beadchip 
array, Progenika BLOODchip array, Luminex array, and 5′ Nuclease assay [98].
Additional cell lines were produced by CBER-FDA for use as source of genomic 
DNA for development of reference reagents to expand the number of red cell blood 
group polymorphisms represented in the first WHO IRR from 2013 for blood group 
genotyping. The CBER reference panel consists of 18 members, covering genotypes 
associated with 40 polymorphisms within 17 blood group systems, including alleles 
present in the existing WHO IRR-2013 except for RHD*ψ (Table 4). The CBER 
panel was also characterized and validated for additional genotypes belonging to 
systems already included in the WHO IRR-2013 (RH, KEL, FY, JK, DO, and MNS) 
(Table 4), and for additional systems only represented in CBER panel (ABO, LU, 
DI, YT, SC, CO, LW, CR, KN, IN, and OK) (Table 5) [89].
Participants in the international collaborative study to validate the CBER panel 
used traditional molecular techniques and additional genotyping techniques not 
available at the time of the first WHO IRR production. The most common methods 
Human Blood Group Systems and Haemoglobinopathies
212
Blood group system WHO IRR [98] CBER RR [89]
Rh RHD positive (zygosity not determined) RHD*01/RHD*01 (RHD homozygous)
RHD*01/RHD*01N.01 (RHD hemizygous)
RHD*01 N.01/RHD*01 N.01 RHD*01 N.01/RHD*01N.01 (homozygous 
RHD deletion)
RHD*01 N.01/RHD*ψ
RHCE*C/RHCE*c RHCE*C/RHCE*c (307T/C; 109 bp intron 
2 ins present)
RHCE*C/RHCE*C RHCE*C/RHCE*C (307T/T; 109 bp intron 
2 ins present)





RHCE c. 122A>G (genotypes A/A; A/G)
RHCE c. 106G>A (genotype G/G)
RHCE c. 733C>G (genotype G/C; G/G; 
C/C)
RHCE c. 1006G>T (genotype G/G)




KEL c. 841C>T (genotypes C/C; C/T; 
T/T)
KEL c. 1790T>C (genotypes T/T; C/T; 
C/C)






FY c. 265C>T (genotypes C/C; C/T)
Kidd JK*01/JK*02 JK*01/JK*02 (838G/A)
JK*01/JK*01 JK *01/JK*01 (838A/A)





DO c. 323G>T (genotypes G/G; G/T)
DO c. 350C>T (genotype C/C; C/T; 
T/T)
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used by the collaborators were PCR-SSP, either single- or multiplex, the HEA (human 
erythrocyte antigen), RHD, and RHCE BeadChip arrays from Immucor, Sanger 
sequencing, PCR-RFLP, and real-time PCR based assays. Less common methods 
included ID-CORE XT and BLOODchip REFERENCE by Progenika, MALDI-TOF-
based assays such as Hemo ID from Agena Bioscience, NGS, RBC-Ready Gene and 
Blood group system WHO IRR [98] CBER RR [89]







GYPB c. 230C>T (genotype C/C)
GYPB c. 270+5G>T (genotype G/G)
Notes: Additional polymorphisms and genotypes included in the CBER panel are in bold; in parentheses are genotypes 
represented in the CBER panel members; descriptions of the polymorphism positions/genotypes are not available for 
WHO panel. For additional details see references [89, 98].
Table 4. 
Alleles or genotypes included in the WHO IRR and CBER RR for the overlapping blood group systems.
Blood group system Gene Polymorphism Genotypes included





c.261delG G/G; G/delG, delG/delG
Lutheran BCAM c.230G>A A/A; G/A; G/G
Diego SLC4A1 c.2561C>T C/T; C/C
Cartwright ACHE c.1057C>A C/C; C/A; A/A
Scianna ERMAP c.169G>A G/G; G/A
Colton AQP1 c.134C>T C/C; C/T; T/T
Landsteiner-Wiener ICAM4 c.299A>G A/A; A/G
Cromer CD55 c.679G>C G/G; G/C
Knops CR1 c.4681G>A G/G; G/A
c.4768A>G A/A; A/G
c.4801A>G A/A; A/G; G/G
Indian CD44 c.137G>C G/G
OK BSG c.274G>A G/G
For additional details, see reference [89].
Table 5. 
Genotypes from additional blood group systems covered by the CBER panel members.
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represented in the CBER panel members; descriptions of the polymorphism positions/genotypes are not available for 
WHO panel. For additional details see references [89, 98].
Table 4. 
Alleles or genotypes included in the WHO IRR and CBER RR for the overlapping blood group systems.
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Diego SLC4A1 c.2561C>T C/T; C/C
Cartwright ACHE c.1057C>A C/C; C/A; A/A
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Cromer CD55 c.679G>C G/G; G/C
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For additional details, see reference [89].
Table 5. 
Genotypes from additional blood group systems covered by the CBER panel members.
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AXO Science, SNaPshot, and high-resolution melting analysis (HRMA) [89].
6. Conclusions
Alloimmunization remains a major risk for transfusion-dependent patients for 
whom transfusion is critical for survival. The transfusion management of patients 
who have already been alloimmunized is still a challenge when rare blood types are 
involved, but for new patients there is a hope that genotyping will help minimize 
exposure, except for those very rare alleles which are hard to find. One approach 
to overcome this limitation is to create a database for rare and very rare RBC alleles 
where donor selection is based on genotyping and the donor pool is constantly 
enhanced and updated. The use of RBC genotyping for both rare donor selection 
and patient care is path forward in transfusion therapy and transfusion safety. The 
development of new assays and high throughput platforms will enable mass-scale 
genotyping at lower cost and rapid pace to select rare and very rare donors. The 
development and availability of reference reagents will allow better quality control 
in assay development and evaluation of performance and proficiency of testing by 
specialized laboratories making patient care easier and safer to provide.
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6. Conclusions
Alloimmunization remains a major risk for transfusion-dependent patients for 
whom transfusion is critical for survival. The transfusion management of patients 
who have already been alloimmunized is still a challenge when rare blood types are 
involved, but for new patients there is a hope that genotyping will help minimize 
exposure, except for those very rare alleles which are hard to find. One approach 
to overcome this limitation is to create a database for rare and very rare RBC alleles 
where donor selection is based on genotyping and the donor pool is constantly 
enhanced and updated. The use of RBC genotyping for both rare donor selection 
and patient care is path forward in transfusion therapy and transfusion safety. The 
development of new assays and high throughput platforms will enable mass-scale 
genotyping at lower cost and rapid pace to select rare and very rare donors. The 
development and availability of reference reagents will allow better quality control 
in assay development and evaluation of performance and proficiency of testing by 
specialized laboratories making patient care easier and safer to provide.
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